mec_id,record_id,molregno,mechanism_of_action,tid,site_id,action_type,direct_interaction,molecular_mechanism,disease_efficacy,mechanism_comment,selectivity_comment,binding_site_comment
13,1343810,1124,Carbonic anhydrase VII inhibitor,11060,,INHIBITOR,1,1,1,,,
14,1344053,675068,Carbonic anhydrase I inhibitor,10193,,INHIBITOR,1,1,1,,,
15,1344649,674765,Carbonic anhydrase I inhibitor,10193,,INHIBITOR,1,1,1,Expressed in eye,,
16,1343255,1085,Carbonic anhydrase I inhibitor,10193,,INHIBITOR,1,1,1,,,
17,1344903,1125,Carbonic anhydrase I inhibitor,10193,,INHIBITOR,1,1,1,Expressed in eye,,
18,1343810,1124,Carbonic anhydrase I inhibitor,10193,,INHIBITOR,1,1,1,,,
19,1343336,378315,Cytochrome b inhibitor,159,,INHIBITOR,1,1,1,,,
20,1343534,674722,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M3 likely involved",,
21,1343271,1102940,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Indicated for overactive bladder, M3 likely responsible",,
22,1343367,230999,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion and overactive bladded, M3 likely involved",,
23,1344039,674857,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Indicated in mydriasis and regulating gastric secretion, M3 likely involved (main form in iris)",,
24,1343841,554127,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M3 likely involved",,
25,1343451,1049461,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M3 likely involved",,
26,1344767,674831,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M3 likely involved",,
27,1343131,674430,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Indicated in irritable bowel, M3 likely involved",,
28,1343595,594843,Muscarinic acetylcholine receptor M3 agonist,219,,AGONIST,1,1,1,"Indicated for urinary retention, M3 likely responsible",,
29,1344400,453573,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M3 likely involved",,
30,1343115,1418097,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Indicated for mydriasis and regulating gastric secretion, M3 likely involved (main form in iris)",,
31,1344620,445395,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Indicated for mydriasis and regulating gastric secretion, M3 likely involved (main form in iris)",,
32,1343683,674555,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Indicated for mydriasis, M3 likely involved (main form in iris)",,
33,1343522,674754,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Indicated for overactive bladder, M3 likely responsible",,
34,1344268,674886,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,Indicated for overactive bladder,M3 selective,
35,1679369,562404,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Indicated for COPD, M3 likely responsible",,
36,1344179,674715,Muscarinic acetylcholine receptor M3 agonist,219,,AGONIST,1,1,1,"Indicated for diagnosis of broncoconstriction, M3 likely responsible",,
37,1343247,1927030,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Indicated for COPD, M3 likely responsible",,
38,1344980,675716,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Indicated for overactive bladder, M3 likely responsible",,
39,1343371,674424,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Indicated for mydriasis, M3 likely involved (main form in iris)",,
40,1343937,195974,Muscarinic acetylcholine receptor M3 agonist,219,,AGONIST,1,1,1,"Indicated for miosis, M3 likely involved (main form in iris)",,
41,1343881,892,Muscarinic acetylcholine receptor M3 agonist,219,,AGONIST,1,1,1,"Indicated for miosis, M3 likely involved (main form in iris)",,
42,1343853,14406,Muscarinic acetylcholine receptor M3 agonist,219,,AGONIST,1,1,1,"Indicated for miosis, M3 likely involved (main form in iris)",,
43,1344828,674281,Muscarinic acetylcholine receptor M3 agonist,219,,AGONIST,1,1,1,"Indicated for miosis, M3 likely involved (main form in iris)",,
44,1343806,1449190,Muscarinic acetylcholine receptor M3 agonist,219,,AGONIST,1,1,1,"Role in regulating gastric secretion, M3 likely involved",,
45,1343921,674901,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M3 likely involved",,
46,1344831,1406675,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Role in regulating nasal secretion, M3 likely involved",,
47,1344460,778083,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M3 likely involved",,
48,1344417,229058,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Indicated for overactive bladder, M3 likely responsible",,
49,1343474,170395,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Indicated for overactive bladder, M3 likely responsible",,
50,1344265,674842,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M3 likely involved",,
51,1343958,674978,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M3 likely involved",,
52,1343107,674298,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M3 likely involved",,
53,1344421,1594639,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Indicated for overactive bladder, M3 likely responsible",,
54,1344312,2197385,DNA topoisomerase I inhibitor,62,,INHIBITOR,1,1,1,,,
55,1344993,675418,Vascular endothelial growth factor A antagonist,187,,ANTAGONIST,1,1,1,"It's an aptamer, a pegylated modified oligonucleotide",Selective,
56,1390835,675776,Vascular endothelial growth factor A inhibitor,187,,INHIBITOR,1,1,1,,,
57,1392866,1121853,Vascular endothelial growth factor A inhibitor,187,,INHIBITOR,1,1,1,,,
58,1344998,675483,Vascular endothelial growth factor A inhibitor,187,,INHIBITOR,1,1,1,,,
59,1343494,675815,Glucagon-like peptide 1 receptor agonist,11758,,AGONIST,1,1,1,,,
60,1344847,390990,Glucagon-like peptide 1 receptor agonist,11758,,AGONIST,1,1,1,,,
61,1343760,674777,Inositol-1(or 4)-monophosphatase 1 inhibitor,111,,INHIBITOR,1,1,1,,,
62,1343236,1376008,Inositol-1(or 4)-monophosphatase 1 inhibitor,111,,INHIBITOR,1,1,1,,,
63,1343137,675409,Vasopressin V2 receptor agonist,112,,AGONIST,1,1,1,,,
64,1344266,227437,Vasopressin V2 receptor antagonist,112,,ANTAGONIST,1,1,1,,,
65,1343462,675059,Vasopressin V2 receptor antagonist,112,,ANTAGONIST,1,1,1,,,
66,1725024,1592399,Somatostatin receptor 5 agonist,11265,,AGONIST,1,1,1,,Non-selective but type 5 receptor is overexpressed in Cushing's disease,
67,1343995,675135,Somatostatin receptor 5 agonist,11265,,AGONIST,1,1,1,,,
68,1344772,500007,Parathyroid hormone receptor agonist,160,,AGONIST,1,1,1,It's a recombinant protein of the parathyroid hormone for the treatment of postmenopausal women with osteoporosis,,
69,1344722,675370,Parathyroid hormone receptor agonist,160,,AGONIST,1,1,1,,,
70,1344246,293438,Gastric lipase inhibitor,10073,,INHIBITOR,1,1,1,,,
71,1344271,21523,Cysteinyl leukotriene receptor 1 antagonist,179,,ANTAGONIST,1,1,1,,,
72,1343358,674632,Cysteinyl leukotriene receptor 1 antagonist,179,,ANTAGONIST,1,1,1,,Selective,
73,1344477,675525,Thrombin inhibitor,11,,INHIBITOR,1,1,1,,Selective,
74,1343618,1376019,Thrombin inhibitor,11,,INHIBITOR,1,1,1,,,
75,1343745,675435,Thrombin inhibitor,11,,INHIBITOR,1,1,1,,,
77,1344521,1038352,Thrombin inhibitor,11,,INHIBITOR,1,1,1,,,
78,1344401,188815,Thrombin inhibitor,11,,INHIBITOR,1,1,1,,,
79,1696566,1381057,Plasminogen activator,12,,ACTIVATOR,1,1,1,,,
80,1696095,1380413,Plasminogen activator,12,,ACTIVATOR,1,1,1,,,
81,1695975,1380151,Plasminogen activator,12,,ACTIVATOR,1,1,1,,,
82,1344191,675518,Plasminogen activator,12,,ACTIVATOR,1,1,1,,,
83,1344651,675554,Plasminogen inhibitor,12,,INHIBITOR,1,1,1,,,
84,1344218,675431,Plasminogen activator,12,,ACTIVATOR,1,1,1,"is TPA, cleaves plasminogen to plasmin",,
85,1344675,73547,Plasminogen inhibitor,12,,INHIBITOR,1,1,1,,,
86,1344137,127755,Plasminogen inhibitor,12,,INHIBITOR,1,1,1,,,
87,1343111,366278,Carbonic anhydrase II inhibitor,15,,INHIBITOR,1,1,1,,,
88,1344698,675113,Carbonic anhydrase II inhibitor,15,,INHIBITOR,1,1,1,,,
89,1343255,1085,Carbonic anhydrase II inhibitor,15,,INHIBITOR,1,1,1,,,
90,1343810,1124,Carbonic anhydrase II inhibitor,15,,INHIBITOR,1,1,1,,,
91,1344546,366279,Carbonic anhydrase II inhibitor,15,,INHIBITOR,1,1,1,,,
92,1344903,1125,Carbonic anhydrase II inhibitor,15,,INHIBITOR,1,1,1,Expressed in eye,,
93,1344649,674765,Carbonic anhydrase II inhibitor,15,,INHIBITOR,1,1,1,Expressed in eye,,
94,1725024,1592399,Somatostatin receptor 2 agonist,117,,AGONIST,1,1,1,,Non-selective but type 5 receptor is overexpressed in Cushing's disease,
95,1343995,675135,Somatostatin receptor 2 agonist,117,,AGONIST,1,1,1,,,
96,1343222,674954,Serotonin 1f (5-HT1f) receptor agonist,279,,AGONIST,1,1,1,,Selective,
97,1344206,674472,Serotonin 1f (5-HT1f) receptor agonist,279,,AGONIST,1,1,1,,Selective,
99,1343568,674596,DNA topoisomerase II alpha inhibitor,63,,INHIBITOR,1,1,1,,,
100,1343685,674426,DNA topoisomerase II alpha inhibitor,63,,INHIBITOR,1,1,1,,,
101,1343998,446279,DNA topoisomerase II alpha inhibitor,63,,INHIBITOR,1,1,1,,,
102,1344690,462435,DNA topoisomerase II alpha inhibitor,63,,INHIBITOR,1,1,1,,,
103,1343508,840903,DNA topoisomerase II alpha inhibitor,63,,INHIBITOR,1,1,1,,,
104,1343788,624185,DNA topoisomerase II alpha inhibitor,63,,INHIBITOR,1,1,1,,,
105,1344229,674927,DNA topoisomerase II alpha inhibitor,63,,INHIBITOR,1,1,1,,,
106,1343398,674962,Angiotensin-converting enzyme inhibitor,69,,INHIBITOR,1,1,1,,,
107,1344427,421317,Angiotensin-converting enzyme inhibitor,69,,INHIBITOR,1,1,1,,,
108,1343213,674485,Angiotensin-converting enzyme inhibitor,69,,INHIBITOR,1,1,1,,,
109,1344299,2197277,Angiotensin-converting enzyme inhibitor,69,,INHIBITOR,1,1,1,,,
110,1343174,189203,Angiotensin-converting enzyme inhibitor,69,,INHIBITOR,1,1,1,,,
111,1343900,1592407,Angiotensin-converting enzyme inhibitor,69,,INHIBITOR,1,1,1,,,
113,1344171,544432,Angiotensin-converting enzyme inhibitor,69,,INHIBITOR,1,1,1,,,
114,1344353,444750,Angiotensin-converting enzyme inhibitor,69,,INHIBITOR,1,1,1,,,
115,1343177,674294,Angiotensin-converting enzyme inhibitor,69,,INHIBITOR,1,1,1,,,
116,1343074,189204,Angiotensin-converting enzyme inhibitor,69,,INHIBITOR,1,1,1,,,
117,1344813,674610,Angiotensin-converting enzyme inhibitor,69,,INHIBITOR,1,1,1,,,
118,1344379,674782,Angiotensin-converting enzyme inhibitor,69,,INHIBITOR,1,1,1,,,
119,1343239,400344,Thyrotropin-releasing hormone receptor agonist,260,,AGONIST,1,1,1,,,
120,1343086,8130,Prostanoid EP1 receptor agonist,261,,AGONIST,1,1,1,,,
121,1344960,11305,Histone deacetylase 1 inhibitor,12697,,INHIBITOR,1,1,1,,,
122,1344246,293438,Pancreatic lipase inhibitor,77,,INHIBITOR,1,1,1,,,
123,1583662,1285395,Erythropoietin receptor agonist,201,,AGONIST,1,1,1,,,
124,1344696,675361,Erythropoietin receptor agonist,201,,AGONIST,1,1,1,,,
125,1344443,675493,Erythropoietin receptor agonist,201,,AGONIST,1,1,1,,,
126,1344162,485738,Inosine-5'-monophosphate dehydrogenase 1 inhibitor,84,,INHIBITOR,1,1,1,,,
127,1343415,675581,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,,,
128,1630655,1328912,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,,,
129,1392966,1121953,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,,,
130,1343218,675130,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,,,
131,1344819,675544,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
132,1343949,2197756,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
133,1344514,674442,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
134,1343370,674448,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
135,1344469,674569,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
136,1343997,550917,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
137,1343663,1926757,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
138,1344352,674589,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
139,1344806,674701,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
140,1344644,674760,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
141,1343557,674912,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
142,1344838,674957,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
143,1344862,1031157,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
144,1344362,551224,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
145,1343062,674483,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
146,1344419,674878,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
147,1344113,110803,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
148,1344818,496910,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
149,1344318,674746,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
150,1344957,699453,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
151,1343875,674918,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
152,1344803,675019,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
153,1343357,2197426,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
154,1343059,2197391,Histamine H1 receptor agonist,127,,AGONIST,1,1,1,Positive control for allegy test,,
155,1344832,674925,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
156,1344408,675698,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
157,1343681,226880,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
158,1343963,1677325,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
159,1344404,674720,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
160,1343579,1676284,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,Activity against other receptors such as 5HT2A and D2 may underlie efficacy of anxiolytic and antipsychotic effects ,,
161,1343489,191342,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
162,1343968,468199,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
163,1344646,490981,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
164,1343433,674343,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
165,1344910,674397,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
166,1343582,674501,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
167,1344728,675141,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
168,1344930,675710,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
169,1344448,447448,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
170,1343356,479129,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
171,1343121,1537769,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
172,1344489,674357,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
173,1343469,1376009,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
174,1343546,674910,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
175,1344509,675040,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
176,1344151,674974,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
177,1344881,674346,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
178,1343270,524710,Histamine H1 receptor agonist,127,,AGONIST,1,1,1,,,
179,1343777,674899,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
180,1344034,675617,TNF-alpha inhibitor,185,,INHIBITOR,1,1,1,,,
181,1390836,675782,TNF-alpha inhibitor,185,,INHIBITOR,1,1,1,,,
182,1344035,675482,TNF-alpha inhibitor,185,,INHIBITOR,1,1,1,,,
183,1343234,675371,TNF-alpha inhibitor,185,,INHIBITOR,1,1,1,,,
184,1390837,675784,TNF-alpha inhibitor,185,,INHIBITOR,1,1,1,,,
185,1344493,44920,Phosphodiesterase 5A inhibitor,3,,INHIBITOR,1,1,1,,Selective,
186,1344513,283529,Phosphodiesterase 5A inhibitor,3,,INHIBITOR,1,1,1,,Selective,
187,1343766,564291,Phosphodiesterase 5A inhibitor,3,,INHIBITOR,1,1,1,,,
188,1583663,1285392,Phosphodiesterase 5A inhibitor,3,,INHIBITOR,1,1,1,,,
190,1344960,11305,Histone deacetylase 3 inhibitor,11208,,INHIBITOR,1,1,1,,,
191,1344923,1536859,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
192,1344877,2197349,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
193,1343055,674902,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
194,1343294,16505,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
195,1344432,674658,Dopamine D2 receptor modulator,72,,MODULATOR,1,1,1,Antiemetic,,
196,1344288,37266,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
197,1343808,872071,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
198,1344159,675038,Dopamine D2 receptor agonist,72,,AGONIST,1,1,1,Long acting,,
199,1344535,738635,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
200,1343543,674805,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
201,1344181,1537268,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
202,1344886,80209,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
203,1343076,675053,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
204,1343144,1926823,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
205,1343887,155006,Dopamine D2 receptor partial agonist,72,,PARTIAL AGONIST,1,1,1,,,
206,1343540,1379630,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
207,1344016,13949,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
208,1344981,675003,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
209,1344810,674891,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
210,1344796,674370,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
211,1344495,468656,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
212,1343298,209829,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
213,1344890,2197695,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
214,1344199,16584,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
215,1343777,674899,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
216,1344172,675489,Calcitonin receptor agonist,119,,AGONIST,1,1,1,,,
217,1343163,2335132,Calcitonin receptor agonist,119,,AGONIST,1,1,1,,,
218,1344647,675410,Calcitonin receptor agonist,119,,AGONIST,1,1,1,,,
219,1583655,1376065,Type-1 angiotensin II receptor antagonist,115,,ANTAGONIST,1,1,1,,Selective,
220,1343628,109797,Type-1 angiotensin II receptor antagonist,115,,ANTAGONIST,1,1,1,,,
221,1343097,421066,Type-1 angiotensin II receptor antagonist,115,,ANTAGONIST,1,1,1,,,
222,1344355,139045,Type-1 angiotensin II receptor antagonist,115,,ANTAGONIST,1,1,1,,,
223,1343948,674621,Type-1 angiotensin II receptor antagonist,115,,ANTAGONIST,1,1,1,,,
224,1343299,674643,Type-1 angiotensin II receptor antagonist,115,,ANTAGONIST,1,1,1,,,
225,1344584,116349,Type-1 angiotensin II receptor antagonist,115,,ANTAGONIST,1,1,1,,,
226,1344693,674938,Type-1 angiotensin II receptor antagonist,115,,ANTAGONIST,1,1,1,,,
227,1344883,116949,Type-1 angiotensin II receptor antagonist,115,,ANTAGONIST,1,1,1,,,
228,1344682,674794,Serotonin 2b (5-HT2b) receptor partial agonist,227,,PARTIAL AGONIST,1,1,1,,,
229,1344739,2197429,Serotonin 2b (5-HT2b) receptor antagonist,227,,ANTAGONIST,1,1,1,,,
230,1344997,675485,Ig epsilon chain C region inhibitor,229,,INHIBITOR,1,1,1,Should be protein complex but not trivial to define,,
231,1344793,421089,Thyroid peroxidase inhibitor,40,,INHIBITOR,1,1,1,,,
232,1344674,421208,Thyroid peroxidase inhibitor,40,,INHIBITOR,1,1,1,,,
233,1344783,675524,Myeloid cell surface antigen CD33 binding agent,81,,BINDING AGENT,1,1,1,targets ozogamicin to cell,,
234,1343620,674699,DOPA decarboxylase inhibitor,83,,INHIBITOR,1,1,1,,,
235,1344456,675684,Macrophage colony stimulating factor receptor inhibitor,12840,,INHIBITOR,1,1,1,,,
236,1343773,450864,Macrophage colony stimulating factor receptor inhibitor,12840,,INHIBITOR,1,1,1,,,
237,1344553,675476,Alpha-1a adrenergic receptor agonist,125,,AGONIST,1,1,1,,,
238,1344154,33307,Alpha-1a adrenergic receptor antagonist,125,,ANTAGONIST,1,1,1,,,
239,1344726,674995,Alpha-1a adrenergic receptor antagonist,125,,ANTAGONIST,1,1,1,,,
240,1344552,674646,Alpha-1a adrenergic receptor agonist,125,,AGONIST,1,1,1,,,
241,1390843,675778,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
242,1344036,675579,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
243,1344174,611647,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
244,1344994,88232,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
245,1343218,675130,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
246,1343545,112655,Dopamine D3 receptor agonist,130,,AGONIST,1,1,1,,,
247,1344886,80209,Dopamine D3 receptor antagonist,130,,ANTAGONIST,1,1,1,,,
248,1344475,84644,Ryanodine receptor 1 antagonist,89,,ANTAGONIST,1,1,1,,,
249,1344088,4941,Enoyl-[acyl-carrier-protein] reductase inhibitor,145,,INHIBITOR,1,1,1,,,
250,1343566,374005,Enoyl-[acyl-carrier-protein] reductase inhibitor,145,,INHIBITOR,1,1,1,Prodrug enzyme: FAD-containing monooxygenase (EthA),,
251,1344743,675530,Luteinizing hormone/Choriogonadotropin receptor agonist,95,,AGONIST,1,1,1,"It's LH, used to stimulate development of a potentially competent follicle and to indirectly prepare the reproductive tract for implantation and pregnancy",,
252,1344697,675508,Luteinizing hormone/Choriogonadotropin receptor agonist,95,,AGONIST,1,1,1,,,
253,1343544,675623,Luteinizing hormone/Choriogonadotropin receptor agonist,95,,AGONIST,1,1,1,,,
254,1343840,675639,Luteinizing hormone/Choriogonadotropin receptor agonist,95,,AGONIST,1,1,1,,,
255,1343509,1376005,Gonadotropin-releasing hormone receptor antagonist,118,,ANTAGONIST,1,1,1,,,
256,1344754,674622,Gonadotropin-releasing hormone receptor agonist,118,,AGONIST,1,1,1,,,
257,1344851,674462,Gonadotropin-releasing hormone receptor agonist,118,,AGONIST,1,1,1,,,
258,1344548,237298,Gonadotropin-releasing hormone receptor antagonist,118,,ANTAGONIST,1,1,1,,,
259,1344440,1341219,Gonadotropin-releasing hormone receptor antagonist,118,,ANTAGONIST,1,1,1,,,
260,1343057,674452,Gonadotropin-releasing hormone receptor agonist,118,,AGONIST,1,1,1,,,
261,1343453,674460,Gonadotropin-releasing hormone receptor agonist,118,,AGONIST,1,1,1,,,
262,1343609,674467,Gonadotropin-releasing hormone receptor agonist,118,,AGONIST,1,1,1,,,
263,1343274,674505,Gonadotropin-releasing hormone receptor agonist,118,,AGONIST,1,1,1,,,
264,1343523,236376,Gonadotropin-releasing hormone receptor antagonist,118,,ANTAGONIST,1,1,1,,,
265,1343580,674726,Gonadotropin-releasing hormone receptor agonist,118,,AGONIST,1,1,1,,,
266,1344490,33679,Steroid 5-alpha-reductase 2 inhibitor,120,,INHIBITOR,1,1,1,,,
267,1344504,9217,Arachidonate 5-lipoxygenase inhibitor,55,,INHIBITOR,1,1,1,,,
268,1344418,674711,Arachidonate 5-lipoxygenase inhibitor,55,,INHIBITOR,1,1,1,,,
269,1344052,986494,Arachidonate 5-lipoxygenase inhibitor,55,,INHIBITOR,1,1,1,,,
270,1344958,33202,Arachidonate 5-lipoxygenase inhibitor,55,,INHIBITOR,1,1,1,,,
271,1343285,674964,Arachidonate 5-lipoxygenase inhibitor,55,,INHIBITOR,1,1,1,,,
272,1343909,1223,Arachidonate 5-lipoxygenase inhibitor,55,,INHIBITOR,1,1,1,,,
273,1344039,674857,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M1 likely involved",,
274,1343107,674298,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M1 likely involved",,
275,1343806,1449190,Muscarinic acetylcholine receptor M1 agonist,61,,AGONIST,1,1,1,"Role in regulating gastric secretion, M1 likely involved",,
276,1344767,674831,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M1 likely involved",,
277,1343367,230999,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M1 likely involved",,
278,1343841,554127,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M1 likely involved",,
279,1344400,453573,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M1 likely involved",,
280,1344290,150389,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Indicated for Parkinson's disease, M1 likely responsible",,
281,1344724,674779,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Indicated for Parkinson's disease, M1 likely responsible",,
282,1344854,674986,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Indicated for Parkinson's disease, M1 likely responsible",,
283,1343451,1049461,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M1 likely involved",,
284,1344346,675018,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Indicated for Parkinson's disease, M1 likely responsible",,
285,1343131,674430,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Indicated in irritable bowel, M3 likely involved",,
286,1343534,674722,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M1 likely involved",,
287,1343115,1418097,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M1 likely involved",,
288,1343333,583519,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Indicated for Parkinson's disease, M1 likely responsible",,
289,1344620,445395,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M1 likely involved",,
290,1343969,426067,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,antiemetic,,
291,1344194,579689,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,antiemetic,,
292,1343384,674377,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Indicated for Parkinson's disease, M1 likely responsible",,
293,1343567,674921,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Indicated for Parkinson's disease, M1 likely responsible",,
294,1343921,674901,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M1 likely involved",,
295,1344460,778083,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M1 likely involved",,
296,1343428,674334,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Indicated for Parkinson's disease, M1 likely responsible",,
297,1343958,674978,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M1 likely involved",,
298,1344265,674842,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"Role in regulating gastric secretion, M1 likely involved",,
300,1344761,675691,Tyrosine-protein kinase ABL inhibitor,8,,INHIBITOR,1,1,1,,,
301,1344476,361469,Tyrosine-protein kinase ABL inhibitor,8,,INHIBITOR,1,1,1,,,
302,1679379,62111,Tyrosine-protein kinase ABL inhibitor,8,,INHIBITOR,1,1,1,,,
303,1679381,1277553,Tyrosine-protein kinase ABL inhibitor,8,,INHIBITOR,1,1,1,,,
304,1343743,485100,Tyrosine-protein kinase ABL inhibitor,8,,INHIBITOR,1,1,1,,,
305,1390865,675783,Thrombopoietin receptor agonist,265,,AGONIST,1,1,1,,,
306,1343468,2197562,Thrombopoietin receptor agonist,265,,AGONIST,1,1,1,,,
307,1344960,11305,Histone deacetylase 6 inhibitor,11307,,INHIBITOR,1,1,1,,,
309,1344114,1279,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
310,1344947,674788,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
311,1343572,674764,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
312,1344658,675066,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
313,1343931,674696,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
314,1343110,896873,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
315,1344396,675128,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
316,1344562,8543,Beta-1 adrenergic receptor partial agonist,50,,PARTIAL AGONIST,1,1,1,,,
317,1344982,674898,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
318,1343201,674369,Beta-1 adrenergic receptor agonist,50,,AGONIST,1,1,1,,,
319,1344209,444077,Beta-1 adrenergic receptor agonist,50,,AGONIST,1,1,1,,,
320,1343142,27570,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
321,1343430,505776,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
322,1344220,1538559,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
323,1344317,546564,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
324,1344496,2197437,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
325,1344570,543228,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,Selective,
326,1344583,674821,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
327,1343910,1533286,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
328,1343068,1355926,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
329,1343513,675682,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
330,1343238,675014,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
331,1343364,8531,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,,,
332,1343627,675464,Sigma opioid receptor agonist,11272,,AGONIST,1,1,1,,,
333,1344363,2197380,Sigma opioid receptor modulator,11272,,MODULATOR,1,1,1,Mixed agonist/antagonist,,
334,1343657,2197381,Sigma opioid receptor modulator,11272,,MODULATOR,1,1,1,Mixed agonist/antagonist,,
335,1344533,705811,Sigma opioid receptor agonist,11272,,AGONIST,1,1,1,,,
336,1344137,127755,Tissue-type plasminogen activator inhibitor,11399,,INHIBITOR,1,1,1,,,
337,1343888,139281,Sodium-(potassium)-chloride cotransporter 2 inhibitor,167,,INHIBITOR,1,1,1,,,
338,1343758,2654,Sodium-(potassium)-chloride cotransporter 2 inhibitor,167,,INHIBITOR,1,1,1,,,
339,1344609,180329,Sodium-(potassium)-chloride cotransporter 2 inhibitor,167,,INHIBITOR,1,1,1,,,
340,1343559,2046,Sodium-(potassium)-chloride cotransporter 2 inhibitor,167,,INHIBITOR,1,1,1,,,
341,1344004,674438,Sodium-(potassium)-chloride cotransporter 2 inhibitor,167,,INHIBITOR,1,1,1,,,
342,1343677,619,Thiazide-sensitive sodium-chloride cotransporter inhibitor,151,,INHIBITOR,1,1,1,,,
343,1344175,73548,Thiazide-sensitive sodium-chloride cotransporter inhibitor,151,,INHIBITOR,1,1,1,,,
344,1343747,92458,Thiazide-sensitive sodium-chloride cotransporter inhibitor,151,,INHIBITOR,1,1,1,,,
345,1344929,674990,Thiazide-sensitive sodium-chloride cotransporter inhibitor,151,,INHIBITOR,1,1,1,,,
346,1343258,62615,Thiazide-sensitive sodium-chloride cotransporter inhibitor,151,,INHIBITOR,1,1,1,,,
347,1344024,674567,Thiazide-sensitive sodium-chloride cotransporter inhibitor,151,,INHIBITOR,1,1,1,,,
348,1344198,428791,Thiazide-sensitive sodium-chloride cotransporter inhibitor,151,,INHIBITOR,1,1,1,,,
349,1343547,453564,Thiazide-sensitive sodium-chloride cotransporter inhibitor,151,,INHIBITOR,1,1,1,,,
350,1344063,2045,Thiazide-sensitive sodium-chloride cotransporter inhibitor,151,,INHIBITOR,1,1,1,,,
351,1344424,515239,Thiazide-sensitive sodium-chloride cotransporter inhibitor,151,,INHIBITOR,1,1,1,,,
352,1343704,583522,Thiazide-sensitive sodium-chloride cotransporter inhibitor,151,,INHIBITOR,1,1,1,,,
353,1343923,134100,Thiazide-sensitive sodium-chloride cotransporter inhibitor,151,,INHIBITOR,1,1,1,,,
354,1343337,134333,Thiazide-sensitive sodium-chloride cotransporter inhibitor,151,,INHIBITOR,1,1,1,,,
355,1344909,453832,Thiazide-sensitive sodium-chloride cotransporter inhibitor,151,,INHIBITOR,1,1,1,,,
356,1344482,1629652,Arabinosyltransferase A inhibitor,152,,INHIBITOR,1,1,1,,,
357,1344950,674727,Calcium sensing receptor positive allosteric modulator,282,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,
358,1343086,8130,Prostanoid EP2 receptor agonist,142,,AGONIST,1,1,1,,,
359,1344345,596044,Nicotinic acetylcholine receptor alpha subunit agonist,5,,AGONIST,1,1,1,,,
360,1344985,364859,"Potassium channel, inwardly rectifying, subfamily J, member 11 opener",285,,OPENER,1,1,1,,,
361,1343137,675409,Vasopressin V1a receptor agonist,134,,AGONIST,1,1,1,,,
362,1343462,675059,Vasopressin V1a receptor antagonist,134,,ANTAGONIST,1,1,1,,,
363,1344464,1510461,Serotonin 1b (5-HT1b) receptor agonist,106,,AGONIST,1,1,1,,,
364,1343935,196215,Serotonin 1b (5-HT1b) receptor agonist,106,,AGONIST,1,1,1,,,
365,1343222,674954,Serotonin 1b (5-HT1b) receptor agonist,106,,AGONIST,1,1,1,,Selective,
366,1344254,1410635,Serotonin 1b (5-HT1b) receptor agonist,106,,AGONIST,1,1,1,,Selective,
368,1344206,674472,Serotonin 1b (5-HT1b) receptor agonist,106,,AGONIST,1,1,1,,Selective,
369,1344987,674552,Serotonin 1b (5-HT1b) receptor agonist,106,,AGONIST,1,1,1,,Selective,
370,1344606,674983,Serotonin 1b (5-HT1b) receptor agonist,106,,AGONIST,1,1,1,,Selective,
371,1343551,27111,Serotonin 1b (5-HT1b) receptor agonist,106,,AGONIST,1,1,1,,Selective,
372,1343552,675101,Serotonin 1b (5-HT1b) receptor agonist,106,,AGONIST,1,1,1,,Selective,
373,1344934,1543375,Serotonin 3a (5-HT3a) receptor antagonist,144,,ANTAGONIST,1,1,1,,Selective,
374,1343394,3183,Serotonin 3a (5-HT3a) receptor antagonist,144,,ANTAGONIST,1,1,1,,Selective,
375,1344077,699431,Serotonin 3a (5-HT3a) receptor antagonist,144,,ANTAGONIST,1,1,1,,,
376,1343612,54547,Serotonin 3a (5-HT3a) receptor antagonist,144,,ANTAGONIST,1,1,1,,,
377,1344040,551486,Serotonin 3a (5-HT3a) receptor antagonist,144,,ANTAGONIST,1,1,1,,,
378,1343173,1675783,Serotonin 3a (5-HT3a) receptor antagonist,144,,ANTAGONIST,1,1,1,,Selective,
379,1344799,674836,Serotonin 3a (5-HT3a) receptor antagonist,144,,ANTAGONIST,1,1,1,,,
380,1344810,674891,Serotonin 3a (5-HT3a) receptor antagonist,144,,ANTAGONIST,1,1,1,,,
381,1344354,674706,Cholecystokinin A receptor agonist,10472,,AGONIST,1,1,1,,,
382,1343246,675133,FK506-binding protein 1A inhibitor,80,,INHIBITOR,1,1,1,,,
383,1344737,923,FK506-binding protein 1A inhibitor,80,,INHIBITOR,1,1,1,,,
384,1344572,1248731,FK506-binding protein 1A inhibitor,80,,INHIBITOR,1,1,1,,,
385,1344224,674637,FK506-binding protein 1A inhibitor,80,,INHIBITOR,1,1,1,,,
386,1344189,2197758,FK506-binding protein 1A inhibitor,80,,INHIBITOR,1,1,1,,,
387,1679381,1277553,Serine/threonine-protein kinase RAF inhibitor,10904,,INHIBITOR,1,1,1,,,
388,1344744,674436,Serine/threonine-protein kinase RAF inhibitor,10904,,INHIBITOR,1,1,1,,,
389,1343376,453578,Adenosine deaminase inhibitor,14,,INHIBITOR,1,1,1,,,
390,1344599,1377883,Succinate semialdehyde dehydrogenase inhibitor,283,,INHIBITOR,1,1,1,,,
391,1343419,1991,Succinate semialdehyde dehydrogenase inhibitor,283,,INHIBITOR,1,1,1,,,
392,1344130,15217,Succinate semialdehyde dehydrogenase inhibitor,283,,INHIBITOR,1,1,1,,,
393,1879208,161281,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
394,1343448,549367,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,reuptake inhibitor,,
395,1344718,674273,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,reuptake inhibitor,,
396,1343314,674661,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,reuptake inhibitor,,
397,1343639,674732,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,reuptake inhibitor,,
398,1344542,345595,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,reuptake inhibitor,,
399,1343063,549372,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,reuptake inhibitor,,
400,1344769,674560,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,reuptake inhibitor,,
401,1343603,675033,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,reuptake inhibitor,,
402,1344303,674546,Serotonin transporter substrate,121,,SUBSTRATE,1,1,1,,,
403,1344520,1038357,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
404,1343377,674749,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
405,1343312,675017,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
406,1343143,674915,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
407,1343950,155045,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
408,1344146,675679,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
409,1343212,674279,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
410,1344311,543658,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
411,1344680,2197716,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
412,1343253,2335035,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
413,1344096,674443,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
414,1344972,675107,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
415,1344632,674283,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
416,1344476,361469,Platelet-derived growth factor receptor beta inhibitor,197,,INHIBITOR,1,1,1,,,
417,1344744,674436,Platelet-derived growth factor receptor beta inhibitor,197,,INHIBITOR,1,1,1,,,
418,1343743,485100,Platelet-derived growth factor receptor beta inhibitor,197,,INHIBITOR,1,1,1,,,
419,1725024,1592399,Somatostatin receptor 1 agonist,12786,,AGONIST,1,1,1,,Non-selective but type 5 receptor is overexpressed in Cushing's disease,
420,1343137,675409,Vasopressin V1b receptor agonist,148,,AGONIST,1,1,1,,,
422,1343224,550857,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,,,
423,1343555,62701,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,,Selective,
424,1343693,666,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,,,
425,1344418,674711,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,,,
426,1344958,33202,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,,,
427,1343285,674964,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,,,
428,1344717,675369,Secretin receptor agonist,147,,AGONIST,1,1,1,,,
429,1344748,675494,Secretin receptor agonist,147,,AGONIST,1,1,1,,,
430,1343352,1592393,Secretin receptor agonist,147,,AGONIST,1,1,1,,,
431,1344942,675696,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,,,
432,1343073,2994,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,,,
433,1344135,28331,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,,,
434,1343446,16415,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,,,
435,1344147,100310,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,,,
436,1343644,1539205,Thioredoxin reductase 1 inhibitor,172,,INHIBITOR,1,1,1,,,
437,1343198,674428,Xanthine dehydrogenase inhibitor,149,,INHIBITOR,1,1,1,,,
438,1343147,647206,Xanthine dehydrogenase inhibitor,149,,INHIBITOR,1,1,1,,,
439,1344205,395607,Xanthine dehydrogenase inhibitor,149,,INHIBITOR,1,1,1,,,
440,1344746,394229,Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor,224,,INHIBITOR,1,1,1,,,
441,1343940,33727,Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor,224,,INHIBITOR,1,1,1,,,
442,1344598,394231,Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor,224,,INHIBITOR,1,1,1,,,
443,1344777,674723,Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor,224,,INHIBITOR,1,1,1,,,
444,1344654,674830,Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor,224,,INHIBITOR,1,1,1,,,
445,1344933,94571,Aldehyde dehydrogenase inhibitor,30,,INHIBITOR,1,1,1,,,
446,1344476,361469,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
447,1344456,675684,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
448,1679381,1277553,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
449,1344744,674436,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
450,1343773,450864,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
451,1343743,485100,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
452,1343762,675138,C-C chemokine receptor type 5 antagonist,10580,,ANTAGONIST,1,1,1,,,
453,1344839,2080,Dihydrofolate reductase inhibitor,70,,INHIBITOR,1,1,1,,,
454,1641035,2197696,Dihydrofolate reductase inhibitor,70,,INHIBITOR,1,1,1,,,
455,1343912,675010,Dihydrofolate reductase inhibitor,70,,INHIBITOR,1,1,1,,,
456,1344075,78303,Histamine H2 receptor antagonist,102,,ANTAGONIST,1,1,1,,,
457,1344932,675002,Histamine H2 receptor antagonist,102,,ANTAGONIST,1,1,1,,,
458,1344334,674900,Histamine H2 receptor agonist,102,,AGONIST,1,1,1,,,
459,1343355,1672366,Histamine H2 receptor antagonist,102,,ANTAGONIST,1,1,1,,,
460,1343933,1382812,Histamine H2 receptor antagonist,102,,ANTAGONIST,1,1,1,,,
461,1343959,1620,Histamine H2 receptor antagonist,102,,ANTAGONIST,1,1,1,,,
462,1343151,1383722,Histamine H2 receptor antagonist,102,,ANTAGONIST,1,1,1,,,
463,1344990,674939,Histamine H2 receptor antagonist,102,,ANTAGONIST,1,1,1,,,
464,1343270,524710,Histamine H2 receptor agonist,102,,AGONIST,1,1,1,,,
465,1702472,377715,Dipeptidyl peptidase IV inhibitor,11140,,INHIBITOR,1,1,1,,,
466,1343735,675125,Dipeptidyl peptidase IV inhibitor,11140,,INHIBITOR,1,1,1,,,
467,1343280,399873,Dipeptidyl peptidase IV inhibitor,11140,,INHIBITOR,1,1,1,,,
468,1344991,675694,Dipeptidyl peptidase IV inhibitor,11140,,INHIBITOR,1,1,1,,,
469,1343146,674350,Serotonin 1a (5-HT1a) receptor partial agonist,51,,PARTIAL AGONIST,1,1,1,,,
470,1344464,1510461,Serotonin 1a (5-HT1a) receptor agonist,51,,AGONIST,1,1,1,,,
471,1344739,2197429,Serotonin 1a (5-HT1a) receptor partial agonist,51,,PARTIAL AGONIST,1,1,1,,,
472,1343887,155006,Serotonin 1a (5-HT1a) receptor partial agonist,51,,PARTIAL AGONIST,1,1,1,,,
473,1344520,1038357,Serotonin 1a (5-HT1a) receptor partial agonist,51,,PARTIAL AGONIST,1,1,1,,,
474,1344970,72873,Cyclophilin A modulator,180,,MODULATOR,1,1,1,,,
475,1344156,675528,Antithrombin-III activator,16,,ACTIVATOR,1,1,1,Inhibits coagulation by activating antithrombin III;  ATIII then binds to F10; It's a low-molecular-weight heparin,,
476,1343310,675454,Antithrombin-III activator,16,,ACTIVATOR,1,1,1,Inhibits coagulation by activating antithrombin III;  ATIII then binds to F10; It's a low-molecular-weight heparin,,
477,1344472,675574,Antithrombin-III activator,16,,ACTIVATOR,1,1,1,Inhibits coagulation by activating antithrombin III;  ATIII then binds to F10; It's a low-molecular-weight heparin,,
478,1344473,675608,Antithrombin-III activator,16,,ACTIVATOR,1,1,1,Inhibits coagulation by activating antithrombin III;  ATIII then binds to F10;,,
479,1344062,675515,Antithrombin-III activator,16,,ACTIVATOR,1,1,1,Inhibits coagulation by activating antithrombin III;  ATIII then binds to F10;,,
480,1344214,675473,Antithrombin-III activator,16,,ACTIVATOR,1,1,1,Inhibits coagulation by activating antithrombin III;  ATIII then binds to F10;,,
481,1343643,675462,Antithrombin-III activator,16,,ACTIVATOR,1,1,1,Inhibits coagulation by activating antithrombin III;  ATIII then binds to F10; It's a low-molecular-weight heparin,,
482,1343511,674595,Antithrombin-III activator,16,,ACTIVATOR,1,1,1,ATIII then binds to F10,Selective,
483,1344735,82983,Thymidylate synthase inhibitor,28,,INHIBITOR,1,1,1,,,
484,1343556,1537653,Thymidylate synthase inhibitor,28,,INHIBITOR,1,1,1,,,
485,1343623,598447,Thymidylate synthase inhibitor,28,,INHIBITOR,1,1,1,,,
486,1344829,368538,Thymidylate synthase inhibitor,28,,INHIBITOR,1,1,1,,,
487,1344007,675627,Insulin-like growth factor I receptor agonist,234,,AGONIST,1,1,1,,,
488,1344486,675637,Insulin-like growth factor I receptor agonist,234,,AGONIST,1,1,1,,,
489,1344211,675577,Interleukin-1 receptor antagonist,198,,ANTAGONIST,1,1,1,,,
490,1344604,675607,Thyroid stimulating hormone receptor agonist,78,,AGONIST,1,1,1,"It's recombinant human thyroid stimulating hormone approved for diagnosis of serum thyroglobulin levels, but also is indicated as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in cancer patients",,
491,1344537,675540,Thyroid stimulating hormone receptor agonist,78,,AGONIST,1,1,1,"It's purified bovine thyroid stimulating hormone approved for diagnosis of serum thyroglobulin levels, but also is indicated as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in cancer patients",,
492,1344900,675393,Melanocortin receptor 2 agonist,154,,AGONIST,1,1,1,,,
493,1343922,675376,Melanocortin receptor 2 agonist,154,,AGONIST,1,1,1,,,
494,1344459,1376054,Melanocortin receptor 2 agonist,154,,AGONIST,1,1,1,,,
495,1344926,675424,Melanocortin receptor 2 agonist,154,,AGONIST,1,1,1,Is corticotropin,,
497,1343440,93895,Dihydroorotate dehydrogenase inhibitor,157,,INHIBITOR,1,1,1,,,
498,1679383,96107,Dihydroorotate dehydrogenase inhibitor,157,,INHIBITOR,1,1,1,,,
499,1343734,674813,Tyrosine 3-hydroxylase inhibitor,39,,INHIBITOR,1,1,1,,,
500,1343202,5638,HERG blocker,165,,BLOCKER,1,1,1,,,
501,1344956,1532645,HERG blocker,165,,BLOCKER,1,1,1,,,
502,1344376,630439,HERG blocker,165,,BLOCKER,1,1,1,,,
504,1344317,546564,HERG blocker,165,,BLOCKER,1,1,1,,,
505,1343627,675464,Glutamate [NMDA] receptor subunit epsilon 1 antagonist,166,,ANTAGONIST,1,1,1,,,
506,1344533,705811,Glutamate [NMDA] receptor subunit epsilon 1 antagonist,166,,ANTAGONIST,1,1,1,,,
508,1343133,328158,Tyrosinase inhibitor,73,,INHIBITOR,1,1,1,,,
509,1343536,13474,Tyrosinase inhibitor,73,,INHIBITOR,1,1,1,,,
510,1344744,674436,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
511,1343773,450864,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
512,1343156,675381,Growth hormone receptor agonist,60,,AGONIST,1,1,1,It's a recombinant protein: methionyl growth hormone approved for the treatment of growth hormone deficiency,,
513,1344919,675591,Growth hormone receptor agonist,60,,AGONIST,1,1,1,It's a recombinant protein approved for the treatment of growth hormone deficiency,,
514,1344284,675474,Growth hormone receptor antagonist,60,,ANTAGONIST,1,1,1,It's a recombinant protein which selectively binds to growth hormone receptor,,
515,1343065,125294,Vitamin D receptor agonist,64,,AGONIST,1,1,1,,,
516,1343895,430124,Vitamin D receptor agonist,64,,AGONIST,1,1,1,,,
517,1343920,674617,Vitamin D receptor agonist,64,,AGONIST,1,1,1,,,
518,1344453,674573,Vitamin D receptor agonist,64,,AGONIST,1,1,1,,,
519,1344395,63252,Vitamin D receptor agonist,64,,AGONIST,1,1,1,,,
520,1344912,1926758,Vitamin D receptor agonist,64,,AGONIST,1,1,1,,,
521,1343707,674761,Vitamin D receptor agonist,64,,AGONIST,1,1,1,,,
522,1344511,453121,Cytochrome P450 19A1 inhibitor,65,,INHIBITOR,1,1,1,,,
523,1344595,337366,Cytochrome P450 19A1 inhibitor,65,,INHIBITOR,1,1,1,,,
524,1344230,374548,Cytochrome P450 19A1 inhibitor,65,,INHIBITOR,1,1,1,,,
525,1343276,674325,Cytochrome P450 19A1 inhibitor,65,,INHIBITOR,1,1,1,,,
526,1344613,6317,Cytochrome P450 19A1 inhibitor,65,,INHIBITOR,1,1,1,,,
527,1344557,674773,Sodium channel protein type V alpha subunit blocker,11480,,BLOCKER,1,1,1,,,
528,1344018,674563,Sodium channel protein type V alpha subunit blocker,11480,,BLOCKER,1,1,1,,,
529,1343499,341382,Sodium channel protein type V alpha subunit blocker,11480,,BLOCKER,1,1,1,,,
530,1343329,675534,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
531,1343099,675609,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
532,1344961,675451,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
533,1343227,675618,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
534,1343330,675526,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
535,1344091,675547,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
536,1344330,675510,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
537,1344275,675534,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
538,1344834,675503,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
539,1343101,675565,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
540,1343705,675542,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
541,1343738,675535,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
542,1343479,675594,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
543,1344833,675436,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
544,1343171,675505,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
545,1344790,675446,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
546,1343100,675541,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
547,1344791,675366,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
548,1344390,675589,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
549,1344092,675615,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
550,1344161,675383,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
551,1344528,675478,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
552,1344329,675595,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
553,1344681,675543,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
554,1343667,675610,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
555,1343331,675536,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
556,1343589,675386,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
557,1344714,675560,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
558,1344907,675373,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
559,1344389,675441,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
560,1344639,675445,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
561,1344640,1376661,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
562,1343812,35271,Isoleucyl-tRNA synthetase inhibitor,139,,INHIBITOR,1,1,1,,,
563,1344986,2197586,Isoleucyl-tRNA synthetase inhibitor,139,,INHIBITOR,1,1,1,,,
565,1343648,674468,Serotonin 1d (5-HT1d) receptor agonist,105,,AGONIST,1,1,1,,,
566,1343162,1590760,Serotonin 1d (5-HT1d) receptor agonist,105,,AGONIST,1,1,1,,,
567,1343222,674954,Serotonin 1d (5-HT1d) receptor agonist,105,,AGONIST,1,1,1,,Selective,
569,1344987,674552,Serotonin 1d (5-HT1d) receptor agonist,105,,AGONIST,1,1,1,,Selective,
570,1343935,196215,Serotonin 1d (5-HT1d) receptor agonist,105,,AGONIST,1,1,1,,,
571,1344206,674472,Serotonin 1d (5-HT1d) receptor agonist,105,,AGONIST,1,1,1,,Selective,
572,1344254,1410635,Serotonin 1d (5-HT1d) receptor agonist,105,,AGONIST,1,1,1,,Selective,
573,1344606,674983,Serotonin 1d (5-HT1d) receptor agonist,105,,AGONIST,1,1,1,,Selective,
574,1343552,675101,Serotonin 1d (5-HT1d) receptor agonist,105,,AGONIST,1,1,1,,Selective,
575,1343551,27111,Serotonin 1d (5-HT1d) receptor agonist,105,,AGONIST,1,1,1,,Selective,
576,1703520,59519,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
577,1344886,80209,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
578,1344072,550303,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
579,1344626,2261,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
580,1344662,674587,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
581,1343313,6216,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
582,1343377,674749,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
583,1343601,1535336,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
584,1344691,152751,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
585,1343887,155006,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
586,1343144,1926823,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
587,1343678,675011,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
588,1344411,675106,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
589,1344270,1038355,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
590,1344981,675003,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
591,1343548,27610,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
592,1344796,674370,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
593,1344096,674443,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
594,1343604,34197,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
595,1343359,2197565,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
596,1344495,468656,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
597,1343540,1379630,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
598,1343562,674420,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
599,1344332,1678284,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
600,1343983,364141,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
601,1343813,7714,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
602,1344273,3859,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
603,1343203,674937,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
604,1344316,2335118,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
605,1344016,13949,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
606,1343767,5970,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
607,1343417,674867,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
608,1343298,209829,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
609,1344890,2197695,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
610,1343976,706035,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
611,1343777,674899,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
612,1343179,799627,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
613,1344176,2197704,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
614,1703520,59519,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
615,1679367,1369607,Serotonin 2c (5-HT2c) receptor agonist,108,,AGONIST,1,1,1,,,
616,1343384,674377,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
617,1344739,2197429,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
618,1343548,27610,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
619,1344096,674443,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
620,1343604,34197,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
621,1343359,2197565,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
622,1344332,1678284,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
623,1343813,7714,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
624,1343767,5970,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
625,1343417,674867,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
626,1343377,674749,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
627,1343976,706035,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
628,1343777,674899,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
629,1343179,799627,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
630,1344176,2197704,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
631,1343601,1535336,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
632,1344886,80209,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
633,1344662,674587,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
634,1344411,675106,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
635,1343678,675011,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
636,1344750,674282,UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor,109,,INHIBITOR,1,1,1,,,
637,1343794,675501,Glucagon receptor agonist,146,,AGONIST,1,1,1,,,
638,1344512,40542,Glucagon receptor agonist,146,,AGONIST,1,1,1,,,
639,1344774,675470,Glucagon receptor agonist,146,,AGONIST,1,1,1,,,
640,1344106,1926908,Renin inhibitor,11225,,INHIBITOR,1,1,1,,,
641,1583661,1285394,Prostanoid FP receptor agonist,140,,AGONIST,1,1,1,,,
642,1344780,132003,Prostanoid FP receptor agonist,140,,AGONIST,1,1,1,,,
643,1344462,674750,Prostanoid FP receptor agonist,140,,AGONIST,1,1,1,,,
644,1344766,674847,Prostanoid FP receptor agonist,140,,AGONIST,1,1,1,,,
645,1343342,674914,Prostanoid FP receptor agonist,140,,AGONIST,1,1,1,,,
646,1343482,699456,Prostanoid FP receptor agonist,140,,AGONIST,1,1,1,,,
647,1343098,674672,Estrogen receptor beta modulator,174,,MODULATOR,1,1,1,Estrogen replacement therapy for prostate cancer,,
648,1343786,674712,Estrogen receptor beta modulator,174,,MODULATOR,1,1,1,Mixed agonist/antagonist,,
649,1343373,158276,Estrogen receptor beta modulator,174,,MODULATOR,1,1,1,Mixed agonist/antagonist,,
650,1343590,675413,Atrial natriuretic peptide receptor A agonist,244,,AGONIST,1,1,1,,,
651,1344216,675008,Renal dipeptidase inhibitor,245,,INHIBITOR,1,1,1,,,
652,1343167,418401,DNA (cytosine-5)-methyltransferase 3A inhibitor,322,,INHIBITOR,1,1,1,,,
653,1343231,675080,DNA (cytosine-5)-methyltransferase 3A inhibitor,322,,INHIBITOR,1,1,1,,,
654,1343167,418401,DNA (cytosine-5)-methyltransferase 1 inhibitor,321,,INHIBITOR,1,1,1,,,
655,1343231,675080,DNA (cytosine-5)-methyltransferase 1 inhibitor,321,,INHIBITOR,1,1,1,,,
656,1344463,626453,Mineralocorticoid receptor antagonist,48,,ANTAGONIST,1,1,1,,,
657,1343378,674493,Mineralocorticoid receptor agonist,48,,AGONIST,1,1,1,,,
658,1343769,674961,Mineralocorticoid receptor agonist,48,,AGONIST,1,1,1,,,
659,1343822,328201,Mineralocorticoid receptor antagonist,48,,ANTAGONIST,1,1,1,,,
660,1344892,674543,Mineralocorticoid receptor agonist,48,,AGONIST,1,1,1,,,
661,1343458,421032,Mineralocorticoid receptor antagonist,48,,ANTAGONIST,1,1,1,,,
662,1343789,365248,Mineralocorticoid receptor antagonist,48,,ANTAGONIST,1,1,1,,,
663,1344373,405365,Mineralocorticoid receptor antagonist,48,,ANTAGONIST,1,1,1,,,
664,1706227,699470,Prostanoid IP receptor agonist,143,,AGONIST,1,1,1,,,
665,1344968,7494,Prostanoid IP receptor agonist,143,,AGONIST,1,1,1,,,
666,1343476,94408,Prostanoid IP receptor agonist,143,,AGONIST,1,1,1,,,
668,1344733,2197566,Adenosine A2a receptor agonist,252,,AGONIST,1,1,1,,,
669,1344936,675434,Granulocyte colony stimulating factor receptor agonist,207,,AGONIST,1,1,1,,,
670,1343688,675363,Granulocyte colony stimulating factor receptor agonist,207,,AGONIST,1,1,1,,,
671,1343374,86042,Equilibrative nucleoside transporter 1 inhibitor,175,,INHIBITOR,1,1,1,,,
672,1344085,252155,Synaptic vesicle glycoprotein 2A modulator,31000,,MODULATOR,1,1,1,,,
673,1390864,675788,Plasma kallikrein inhibitor,23,,INHIBITOR,1,1,1,,,
674,1344651,675554,Plasma kallikrein inhibitor,23,,INHIBITOR,1,1,1,,,
677,1343400,244450,Retinoic acid receptor agonist,105764,,AGONIST,1,1,1,RARG/RXRA are predominant forms in skin,Binds with higher affinity to RARB+RARG,
678,1344577,23522,Fatty acid synthase inhibitor,19909,,INHIBITOR,1,1,1,,,
679,1344124,33809,Vitamin K-dependent gamma-carboxylase inhibitor,19910,,INHIBITOR,1,1,1,,,
680,1343104,430546,Dihydropteroate synthetase inhibitor,325,,INHIBITOR,1,1,1,,,
681,1343389,675007,Dihydropteroate synthetase inhibitor,325,,INHIBITOR,1,1,1,,,
682,1679379,62111,Tyrosine-protein kinase SRC inhibitor,10434,,INHIBITOR,1,1,1,,,
683,1343277,33576,Tyrosine-protein kinase SRC inhibitor,10434,,INHIBITOR,1,1,1,,,
684,1343811,317124,Dopamine transporter inhibitor,155,,INHIBITOR,1,1,1,,,
685,1343365,675143,Dopamine transporter inhibitor,155,,INHIBITOR,1,1,1,,,
686,1344287,674328,Dopamine transporter releasing agent,155,,RELEASING AGENT,1,1,1,,,
687,1344593,543,Dopamine transporter releasing agent,155,,RELEASING AGENT,1,1,1,,,
688,1344804,8838,Dopamine transporter releasing agent,155,,RELEASING AGENT,1,1,1,,,
689,1344610,675686,Dopamine transporter inhibitor,155,,INHIBITOR,1,1,1,,,
690,1343619,545956,Dopamine transporter inhibitor,155,,INHIBITOR,1,1,1,,,
691,1344109,78902,Dopamine transporter inhibitor,155,,INHIBITOR,1,1,1,,,
692,1344586,674338,Dopamine transporter releasing agent,155,,RELEASING AGENT,1,1,1,,,
693,1343125,23199,Dopamine transporter releasing agent,155,,RELEASING AGENT,1,1,1,,,
694,1344859,674733,Dopamine transporter releasing agent,155,,RELEASING AGENT,1,1,1,,,
695,1343296,1926820,Dopamine transporter releasing agent,155,,RELEASING AGENT,1,1,1,,,
696,1343558,2197715,Dopamine transporter releasing agent,155,,RELEASING AGENT,1,1,1,,,
697,1343740,543703,Dopamine transporter inhibitor,155,,INHIBITOR,1,1,1,,,
698,1344227,675129,Dopamine transporter releasing agent,155,,RELEASING AGENT,1,1,1,,,
699,1344279,552883,Dopamine transporter inhibitor,155,,INHIBITOR,1,1,1,,,
700,1344047,49842,Dopamine transporter inhibitor,155,,INHIBITOR,1,1,1,,,
701,1343847,1355754,Dopamine transporter inhibitor,155,,INHIBITOR,1,1,1,,,
702,1343413,674434,Dopamine transporter inhibitor,155,,INHIBITOR,1,1,1,,,
704,1343809,699406,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
705,1343656,2197697,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
706,1343465,548913,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
707,1344808,699416,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
708,1343431,674482,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
709,1343871,674550,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
710,1343116,674616,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
711,1343702,675110,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
712,1344809,30072,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
713,1343646,674841,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
714,1344589,1376014,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
715,1344286,2197587,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
716,1343324,435293,Mu opioid receptor antagonist,129,,ANTAGONIST,1,1,1,,,
717,1344792,547402,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
718,1343668,674776,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
719,1343896,699455,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
720,1343493,2197639,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
721,1344086,1355857,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
722,1343659,675071,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
723,1343772,675721,Mu opioid receptor antagonist,129,,ANTAGONIST,1,1,1,,,
724,1343955,675114,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
725,1343744,19915,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
726,1343492,674768,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
727,1343637,1543312,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
728,1344650,674998,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
729,1343241,518361,Mu opioid receptor partial agonist,129,,PARTIAL AGONIST,1,1,1,,,
730,1343929,674494,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
731,1344995,675728,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
732,1343658,76963,Mu opioid receptor partial agonist,129,,PARTIAL AGONIST,1,1,1,May be mixed agonist/antagonist,,
733,1343316,446784,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
734,1344344,1355867,Mu opioid receptor antagonist,129,,ANTAGONIST,1,1,1,,,
735,1345001,267825,Catechol O-methyltransferase inhibitor,91,,INHIBITOR,1,1,1,,,
736,1343837,92412,Catechol O-methyltransferase inhibitor,91,,INHIBITOR,1,1,1,,,
737,1703356,353902,Acetylcholinesterase inhibitor,93,,INHIBITOR,1,1,1,,,
738,1344374,508667,Acetylcholinesterase inhibitor,93,,INHIBITOR,1,1,1,,,
739,1343722,674884,Acetylcholinesterase inhibitor,93,,INHIBITOR,1,1,1,,,
740,1344331,54149,Acetylcholinesterase inhibitor,93,,INHIBITOR,1,1,1,,,
741,1344805,443255,Acetylcholinesterase inhibitor,93,,INHIBITOR,1,1,1,,,
742,1343459,119717,Acetylcholinesterase inhibitor,93,,INHIBITOR,1,1,1,,,
743,1343918,167875,Acetylcholinesterase inhibitor,93,,INHIBITOR,1,1,1,,,
744,1343466,674318,Acetylcholinesterase inhibitor,93,,INHIBITOR,1,1,1,,,
745,1343199,674465,Acetylcholinesterase inhibitor,93,,INHIBITOR,1,1,1,,,
746,1343859,674492,Acetylcholinesterase inhibitor,93,,INHIBITOR,1,1,1,,,
747,1344139,39624,Acetylcholinesterase activator,93,,ACTIVATOR,1,1,1,reactivates acetylcholinesterase deactivated by organophosphates,,
749,1344815,675667,Follicle stimulating hormone receptor agonist,99,,AGONIST,1,1,1,"It's FSH, for the stimulation of ovarian follicular growth",,
750,1343418,675507,Follicle stimulating hormone receptor agonist,99,,AGONIST,1,1,1,,,
751,1344305,675667,Follicle stimulating hormone receptor agonist,99,,AGONIST,1,1,1,"It's FSH, for the stimulation of ovarian follicular growth",,
753,1699873,1376138,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,"Multi-kinase inhibitor; Cabozantinib (XL184) is a potent inhibitor of MET and VEGFR2 that also inhibits RET, KIT, AXL, and FLT3, all of which have been implicated in tumor pathogenesis (PMID: 21926191)",,
754,1725024,1592399,Somatostatin receptor 3 agonist,11261,,AGONIST,1,1,1,,Non-selective but type 5 receptor is overexpressed in Cushing's disease,
755,1344976,43740,D-alanylalanine synthetase inhibitor,327,,INHIBITOR,1,1,1,,,
756,1343262,675506,Growth hormone-releasing hormone receptor agonist,158,,AGONIST,1,1,1,"It's an analogue of GHRH, which seems to be used as diagnostic of growth hormone deficiency, but also as a replacement therapy in children",,
757,1344786,1383724,Growth hormone-releasing hormone receptor agonist,158,,AGONIST,1,1,1,,,
758,1344613,6317,Cytochrome P450 11A1 inhibitor,32,,INHIBITOR,1,1,1,,,
759,1343254,504310,Cytochrome P450 11A1 inhibitor,32,,INHIBITOR,1,1,1,,,
760,1344798,27229,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
761,1344066,674796,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
762,1344648,675124,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
763,1344517,675700,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
764,1343565,27152,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
765,1343850,374052,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
766,1343594,419622,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
767,1344409,439720,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
768,1344368,641189,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
769,1344612,674446,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
770,1343503,674551,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
771,1344481,674586,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
772,1344294,674713,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
773,1343629,674816,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
774,1343996,674860,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
775,1344057,27370,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
776,1343379,421058,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
777,1343447,674293,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
778,1343300,674335,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
779,1344293,674489,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
780,1344178,1337005,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
781,1343289,675032,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
782,1344145,675060,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
783,1344502,674337,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
784,1343414,674451,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
785,1343517,674496,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
786,1344383,674828,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
787,1343706,674859,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
788,1343405,674919,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
789,1343771,675015,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
790,1344148,27575,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
791,1344367,381691,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
792,1344076,419542,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
793,1344879,508532,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
794,1344891,591037,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
795,1344911,674327,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
796,1344251,674400,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
797,1344677,674513,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
798,1343325,674683,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
799,1343698,674940,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
800,1343304,674965,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
801,1343865,150313,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
802,1344391,187696,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
803,1344659,954312,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
804,1343159,515027,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
805,1343056,674725,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
806,1343507,674829,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
807,1343980,674926,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
808,1343631,675099,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
809,1344946,1347273,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
810,1343120,105252,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
811,1343831,182546,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
812,1343876,313314,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
813,1344337,365281,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
814,1344538,419410,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
815,1344638,487711,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
816,1344010,674568,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
817,1344438,788028,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
818,1343676,674904,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
819,1343439,674963,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
820,1344541,401141,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
821,1344451,712273,Glucocorticoid receptor antagonist,25,,ANTAGONIST,1,1,1,,Selective,
822,1344672,65494,Human immunodeficiency virus type 1 reverse transcriptase inhibitor,228,,INHIBITOR,1,1,1,,,
823,1344685,85233,Human immunodeficiency virus type 1 reverse transcriptase inhibitor,228,,INHIBITOR,1,1,1,,,
824,1343993,390877,Human immunodeficiency virus type 1 reverse transcriptase inhibitor,228,,INHIBITOR,1,1,1,,,
825,1343916,417163,Human immunodeficiency virus type 1 reverse transcriptase inhibitor,228,,INHIBITOR,1,1,1,,,
826,1344228,74911,Human immunodeficiency virus type 1 reverse transcriptase inhibitor,228,,INHIBITOR,1,1,1,,,
827,1343732,374719,Human immunodeficiency virus type 1 reverse transcriptase inhibitor,228,,INHIBITOR,1,1,1,,,
828,1343080,27307,Human immunodeficiency virus type 1 reverse transcriptase inhibitor,228,,INHIBITOR,1,1,1,,,
829,1343079,674570,Human immunodeficiency virus type 1 reverse transcriptase inhibitor,228,,INHIBITOR,1,1,1,,,
830,1344026,4345,Human immunodeficiency virus type 1 reverse transcriptase inhibitor,228,,INHIBITOR,1,1,1,,,
831,1343445,107119,Human immunodeficiency virus type 1 reverse transcriptase inhibitor,228,,INHIBITOR,1,1,1,,,
832,1343281,1051355,Human immunodeficiency virus type 1 reverse transcriptase inhibitor,228,,INHIBITOR,1,1,1,,,
833,1344964,113138,Human immunodeficiency virus type 1 reverse transcriptase inhibitor,228,,INHIBITOR,1,1,1,,,
834,1344547,33986,Human immunodeficiency virus type 1 reverse transcriptase inhibitor,228,,INHIBITOR,1,1,1,"When monophosporylated is incorporates into the DNA, when triphosporylated inhibits the enzymes",,
835,1343779,675093,Monoamine oxidase B inhibitor,104,,INHIBITOR,1,1,1,Irreversible inhibitor,,
836,1343672,674855,Monoamine oxidase B inhibitor,104,,INHIBITOR,1,1,1,Irreversible inhibitor,,
837,1343425,96021,Monoamine oxidase B inhibitor,104,,INHIBITOR,1,1,1,Irreversible inhibitor,,
838,1343708,675480,T-cell surface antigen CD2 inhibitor,196,,INHIBITOR,1,1,1,,,
840,1344456,675684,Tyrosine-protein kinase LCK inhibitor,10140,,INHIBITOR,1,1,1,,,
841,1343309,448986,Pancreatic alpha-amylase inhibitor,10705,,INHIBITOR,1,1,1,Competitive reversible inhibitor,,
842,1344669,442013,Bile acid receptor FXR agonist,11180,,AGONIST,1,1,1,,,
843,1343778,404691,Bile acid receptor FXR agonist,11180,,AGONIST,1,1,1,,,
844,1344741,392195,Oxytocin receptor agonist,116,,AGONIST,1,1,1,,,
845,1344630,674291,Neuraminidase inhibitor,21,,INHIBITOR,1,1,1,,,
846,1345002,373806,Neuraminidase inhibitor,21,,INHIBITOR,1,1,1,,,
847,1343178,549674,Influenza virus A matrix protein M2 inhibitor,22,,INHIBITOR,1,1,1,,,
848,1344882,675697,Dihydrofolate reductase inhibitor,6,,INHIBITOR,1,1,1,,,
849,1344158,1737244,Dihydrofolate reductase inhibitor,6,,INHIBITOR,1,1,1,,,
850,1343556,1537653,Dihydrofolate reductase inhibitor,6,,INHIBITOR,1,1,1,,,
851,1343654,121124,Dopamine D1 receptor agonist,88,,AGONIST,1,1,1,,,
852,1344682,674794,Dopamine D1 receptor antagonist,88,,ANTAGONIST,1,1,1,,,
853,1344015,122901,Ceramide glucosyltransferase inhibitor,286,,INHIBITOR,1,1,1,,,
854,1344476,361469,Ephrin type-A receptor 2 inhibitor,30008,,INHIBITOR,1,1,1,,,
855,1344458,675467,Estrogen receptor alpha agonist,19,,AGONIST,1,1,1,,,
856,1344155,47340,Estrogen receptor alpha modulator,19,,MODULATOR,1,1,1,Mixed agonist/antagonist,,
857,1344478,342897,Estrogen receptor alpha agonist,19,,AGONIST,1,1,1,,,
858,1344327,27626,Estrogen receptor alpha agonist,19,,AGONIST,1,1,1,,,
859,1344720,674381,Estrogen receptor alpha agonist,19,,AGONIST,1,1,1,,,
860,1344629,421038,Estrogen receptor alpha agonist,19,,AGONIST,1,1,1,,,
861,1344554,1675249,Estrogen receptor alpha modulator,19,,MODULATOR,1,1,1,,,
862,1344539,31241,Estrogen receptor alpha agonist,19,,AGONIST,1,1,1,,,
863,1344757,117108,Estrogen receptor alpha agonist,19,,AGONIST,1,1,1,,,
864,1343232,674924,Estrogen receptor alpha agonist,19,,AGONIST,1,1,1,,,
865,1344694,674931,Estrogen receptor alpha agonist,19,,AGONIST,1,1,1,,,
866,1344531,675102,Estrogen receptor alpha agonist,19,,AGONIST,1,1,1,,,
867,1344025,860,Estrogen receptor alpha agonist,19,,AGONIST,1,1,1,,,
868,1344826,674700,Sodium channel protein type IV alpha subunit blocker,18043,,BLOCKER,1,1,1,,,
869,1435097,150882,Sodium channel protein type IV alpha subunit blocker,18043,,BLOCKER,1,1,1,,,
870,1343889,674347,Sodium channel protein type IV alpha subunit blocker,18043,,BLOCKER,1,1,1,,,
871,1343499,341382,Sodium channel protein type IV alpha subunit blocker,18043,,BLOCKER,1,1,1,Competitive reversible inhibitor,,
872,1343497,445681,Maltase-glucoamylase inhibitor,1,,INHIBITOR,1,1,1,,,
873,1343309,448986,Maltase-glucoamylase inhibitor,1,,INHIBITOR,1,1,1,,,
874,1343485,675599,Norepinephrine transporter releasing agent,100,,RELEASING AGENT,1,1,1,,,
875,1343341,1382808,Norepinephrine transporter substrate,100,,SUBSTRATE,1,1,1,accumulates and displaces NE,,
876,1879208,161281,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
877,1344553,675476,Norepinephrine transporter releasing agent,100,,RELEASING AGENT,1,1,1,,,
878,1343434,699486,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,reuptake inhibitor,,
879,1344338,1673434,Norepinephrine transporter substrate,100,,SUBSTRATE,1,1,1,Taken up by transporter and displaces NE from vesicles,,
880,1343456,453532,Norepinephrine transporter releasing agent,100,,RELEASING AGENT,1,1,1,,,
881,1344351,1051125,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,reuptake inhibitor,,
882,1344689,545075,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,reuptake inhibitor,,
883,1344347,624251,Norepinephrine transporter substrate,100,,SUBSTRATE,1,1,1,Taken up by transporter and displaces NE from vesicles,,
884,1343598,289505,Norepinephrine transporter substrate,100,,SUBSTRATE,1,1,1,Taken up by transporter and displaces NE from vesicles,,
885,1343140,547576,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,reuptake inhibitor,,
886,1343181,674863,Norepinephrine transporter releasing agent,100,,RELEASING AGENT,1,1,1,,,
887,1344333,1926755,Norepinephrine transporter releasing agent,100,,RELEASING AGENT,1,1,1,,,
888,1344610,675686,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
889,1344146,675679,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
890,1344109,78902,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
891,1343125,23199,Norepinephrine transporter releasing agent,100,,RELEASING AGENT,1,1,1,,,
892,1344859,674733,Norepinephrine transporter releasing agent,100,,RELEASING AGENT,1,1,1,,,
893,1343296,1926820,Norepinephrine transporter releasing agent,100,,RELEASING AGENT,1,1,1,,,
894,1343558,2197715,Norepinephrine transporter releasing agent,100,,RELEASING AGENT,1,1,1,,,
895,1343740,543703,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
896,1343413,674434,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
897,1344287,674328,Norepinephrine transporter releasing agent,100,,RELEASING AGENT,1,1,1,,,
898,1344680,2197716,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
899,1343950,155045,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
900,1344804,8838,Norepinephrine transporter releasing agent,100,,RELEASING AGENT,1,1,1,,,
901,1343212,674279,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
902,1344593,543,Norepinephrine transporter releasing agent,100,,RELEASING AGENT,1,1,1,,,
903,1343844,2197726,Norepinephrine transporter releasing agent,100,,RELEASING AGENT,1,1,1,,,
904,1343143,674915,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
905,1344632,674283,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
906,1344586,674338,Norepinephrine transporter releasing agent,100,,RELEASING AGENT,1,1,1,,,
907,1343619,545956,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
908,1343253,2335035,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
909,1344047,49842,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
910,1344279,552883,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
911,1344096,674443,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
912,1344972,675107,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
913,1344151,674974,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
914,1344881,674346,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
915,1343843,674675,Norepinephrine transporter releasing agent,100,,RELEASING AGENT,1,1,1,,,
916,1343847,1355754,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
917,1344552,674646,Norepinephrine transporter releasing agent,100,,RELEASING AGENT,1,1,1,,,
918,1344995,675728,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
919,1344311,543658,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
920,1344227,675129,Norepinephrine transporter releasing agent,100,,RELEASING AGENT,1,1,1,,,
921,1343777,674899,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
922,1343312,675017,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
923,1343460,20346,C-X-C chemokine receptor type 4 partial agonist,10473,,PARTIAL AGONIST,1,1,1,,,
924,1696840,1381331,Coagulation factor VIII inhibitor,10210,,INHIBITOR,1,1,1,Activated protein c cleaves clotting factors to inactivate,,
925,1392863,1341084,Bradykinin B2 receptor antagonist,10034,,ANTAGONIST,1,1,1,,,
926,1679379,62111,Tyrosine-protein kinase HCK inhibitor,11785,,INHIBITOR,1,1,1,,,
927,1343255,1085,Carbonic anhydrase XII inhibitor,12209,,INHIBITOR,1,1,1,,,
928,1344903,1125,Carbonic anhydrase XII inhibitor,12209,,INHIBITOR,1,1,1,Expressed in eye,,
929,1344649,674765,Carbonic anhydrase XII inhibitor,12209,,INHIBITOR,1,1,1,Expressed in eye,,
930,1343497,445681,Lysosomal alpha-glucosidase inhibitor,10977,,INHIBITOR,1,1,1,,,
931,1344456,675684,Fibroblast growth factor receptor 3 inhibitor,11926,,INHIBITOR,1,1,1,,,
932,1392856,316787,Glutathione reductase ,12642,,OTHER,1,1,1,,,
933,1343600,10840,Glutathione reductase inhibitor,12642,,INHIBITOR,1,1,1,,,
934,1435100,1158402,Tyrosine-protein kinase JAK1 inhibitor,10919,,INHIBITOR,1,1,1,,,
935,1702651,1378011,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor,11046,,INHIBITOR,1,1,1,,,
936,1435100,1158402,Tyrosine-protein kinase JAK2 inhibitor,10938,,INHIBITOR,1,1,1,,,
937,1344249,675726,Phenylalanine-4-hydroxylase activator,10744,,ACTIVATOR,1,1,1,,,
938,1679389,1369610,Fibronectin proteolytic enzyme,17040,,PROTEOLYTIC ENZYME,1,1,1,It's a recombinant truncated form of human plasmin with proteolytic activity against protein components of the vitreous body and the vitreoretinal interface,,
939,1699828,1376111,Sodium/glucose cotransporter 2 inhibitor,20092,,INHIBITOR,1,1,1,,,
940,1679379,62111,Tyrosine-protein kinase Lyn inhibitor,11842,,INHIBITOR,1,1,1,,,
941,1343954,2197651,Pepsin A inhibitor,12327,,INHIBITOR,1,1,1,,,
942,1344549,425650,Transient receptor potential cation channel subfamily M member 8 opener,103167,,OPENER,1,1,1,,,
943,1345002,373806,Neuraminidase inhibitor,10738,,INHIBITOR,1,1,1,,,
944,1344630,674291,Neuraminidase inhibitor,10738,,INHIBITOR,1,1,1,,,
945,1679374,340684,Human immunodeficiency virus type 1 integrase inhibitor,12456,,INHIBITOR,1,1,1,HIV-1 integrase strand transfer inhibitor,,
946,1344747,470800,Human immunodeficiency virus type 1 integrase inhibitor,12456,,INHIBITOR,1,1,1,,,
947,1344515,438435,Cytochrome P450 17A1 inhibitor,12949,,INHIBITOR,1,1,1,,,
948,1702651,1378011,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,,,
949,1696840,1381331,Coagulation factor V inhibitor,11387,,INHIBITOR,1,1,1,Activated protein c cleaves clotting factors to inactivate,,
950,1344456,675684,Fibroblast growth factor receptor 1 inhibitor,10266,,INHIBITOR,1,1,1,,,
951,1679381,1277553,Fibroblast growth factor receptor 1 inhibitor,10266,,INHIBITOR,1,1,1,,,
952,1344679,674858,3-beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type II inhibitor,11423,,INHIBITOR,1,1,1,,,
953,1344795,22391,Prostanoid EP3 receptor agonist,10329,,AGONIST,1,1,1,,,
954,1699873,1376138,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,"Multi-kinase inhibitor; Cabozantinib (XL184) is a potent inhibitor of MET and VEGFR2 that also inhibits RET, KIT, AXL, and FLT3, all of which have been implicated in tumor pathogenesis (PMID: 21926191)",,
955,1392861,602271,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
956,1343255,1085,Carbonic anhydrase IV inhibitor,12896,,INHIBITOR,1,1,1,,,
957,1343810,1124,Carbonic anhydrase IV inhibitor,12896,,INHIBITOR,1,1,1,,,
958,1344546,366279,Carbonic anhydrase IV inhibitor,12896,,INHIBITOR,1,1,1,,,
959,1344903,1125,Carbonic anhydrase IV inhibitor,12896,,INHIBITOR,1,1,1,Expressed in eye,,
960,1344649,674765,Carbonic anhydrase IV inhibitor,12896,,INHIBITOR,1,1,1,Expressed in eye,,
961,1679368,1369608,Beta-3 adrenergic receptor agonist,226,,AGONIST,1,1,1,,,
962,1679381,1277553,MAP kinase p38 beta inhibitor,10120,,INHIBITOR,1,1,1,,,
963,1343556,1537653,GAR transformylase inhibitor,12291,,INHIBITOR,1,1,1,,,
964,1696132,1380450,Cystic fibrosis transmembrane conductance regulator inhibitor,11540,,INHIBITOR,1,1,1,,,
965,1583659,1331852,Cystic fibrosis transmembrane conductance regulator positive modulator,11540,,POSITIVE MODULATOR,1,1,1,,,"Mode of action is potentiator, so likely allosteric"
966,1344207,674650,Matrix metalloproteinase 7 inhibitor,12738,,INHIBITOR,1,1,1,"It is an antibiotic, however, its primary action, due to the concentration reached in the human body is via metalloproteinases inhibition, which is beneficial in many pathological conditions in which MMP-mediated proteolysis of the extracellular matrix (ECM) contributes to the pathogenesis, such as heart remodeling, tumor invasion, and inflammation",,
967,1344217,1540465,Matrix metalloproteinase 7 inhibitor,12738,,INHIBITOR,1,1,1,"It is an antibiotic, however, its primary action, due to the concentration reached in the human body is via metalloproteinases inhibition, which is beneficial in many pathological conditions in which MMP-mediated proteolysis of the extracellular matrix (ECM) contributes to the pathogenesis, such as heart remodeling, tumor invasion, and inflammation",,
968,1344600,2197611,Matrix metalloproteinase 7 inhibitor,12738,,INHIBITOR,1,1,1,"It is an antibiotic, however, its primary action, due to the concentration reached in the human body is via metalloproteinases inhibition, which is beneficial in many pathological conditions in which MMP-mediated proteolysis of the extracellular matrix (ECM) contributes to the pathogenesis, such as heart remodeling, tumor invasion, and inflammation",,
969,1390855,675772,Fibroblast growth factor receptor 2 agonist,10264,,AGONIST,1,1,1,,,
970,1679381,1277553,Fibroblast growth factor receptor 2 inhibitor,10264,,INHIBITOR,1,1,1,,,
972,1679381,1277553,Tyrosine-protein kinase FRK inhibitor,30012,,INHIBITOR,1,1,1,,,
973,1392861,602271,ALK tyrosine kinase receptor inhibitor,100417,,INHIBITOR,1,1,1,,,
974,1343716,315123,Intermediate conductance calcium-activated potassium channel protein 4 opener,10992,,OPENER,1,1,1,,,
975,1344231,393942,Thymidylate synthase inhibitor,100829,,INHIBITOR,1,1,1,,,
976,1435101,1158403,Voltage-gated N-type calcium channel alpha-1B subunit blocker,10511,,BLOCKER,1,1,1,,,
978,1344207,674650,Matrix metalloproteinase 8 inhibitor,11110,,INHIBITOR,1,1,1,"It is an antibiotic, however, its primary action, due to the concentration reached in the human body is via metalloproteinases inhibition, which is beneficial in many pathological conditions in which MMP-mediated proteolysis of the extracellular matrix (ECM) contributes to the pathogenesis, such as heart remodeling, tumor invasion, and inflammation",,
979,1344217,1540465,Matrix metalloproteinase 8 inhibitor,11110,,INHIBITOR,1,1,1,"It is an antibiotic, however, its primary action, due to the concentration reached in the human body is via metalloproteinases inhibition, which is beneficial in many pathological conditions in which MMP-mediated proteolysis of the extracellular matrix (ECM) contributes to the pathogenesis, such as heart remodeling, tumor invasion, and inflammation",,
980,1344600,2197611,Matrix metalloproteinase 8 inhibitor,11110,,INHIBITOR,1,1,1,"It is an antibiotic, however, its primary action, due to the concentration reached in the human body is via metalloproteinases inhibition, which is beneficial in many pathological conditions in which MMP-mediated proteolysis of the extracellular matrix (ECM) contributes to the pathogenesis, such as heart remodeling, tumor invasion, and inflammation",,
981,1344207,674650,Matrix metalloproteinase 13 inhibitor,11024,,INHIBITOR,1,1,1,"It is an antibiotic, however, its primary action, due to the concentration reached in the human body is via metalloproteinases inhibition, which is beneficial in many pathological conditions in which MMP-mediated proteolysis of the extracellular matrix (ECM) contributes to the pathogenesis, such as heart remodeling, tumor invasion, and inflammation",,
982,1344217,1540465,Matrix metalloproteinase 13 inhibitor,11024,,INHIBITOR,1,1,1,"It is an antibiotic, however, its primary action, due to the concentration reached in the human body is via metalloproteinases inhibition, which is beneficial in many pathological conditions in which MMP-mediated proteolysis of the extracellular matrix (ECM) contributes to the pathogenesis, such as heart remodeling, tumor invasion, and inflammation",,
983,1344600,2197611,Matrix metalloproteinase 13 inhibitor,11024,,INHIBITOR,1,1,1,"It is an antibiotic, however, its primary action, due to the concentration reached in the human body is via metalloproteinases inhibition, which is beneficial in many pathological conditions in which MMP-mediated proteolysis of the extracellular matrix (ECM) contributes to the pathogenesis, such as heart remodeling, tumor invasion, and inflammation",,
984,1343277,33576,Tyrosine-protein kinase BRK inhibitor,30026,,INHIBITOR,1,1,1,,,
985,1344985,364859,"Potassium channel, inwardly rectifying, subfamily J, member 8 opener",10891,,OPENER,1,1,1,,,
986,1344357,91783,Vanilloid receptor opener,10260,,OPENER,1,1,1,,,
987,1344207,674650,Matrix metalloproteinase-1 inhibitor,13000,,INHIBITOR,1,1,1,"It is an antibiotic, however, its primary action, due to the concentration reached in the human body is via metalloproteinases inhibition, which is beneficial in many pathological conditions in which MMP-mediated proteolysis of the extracellular matrix (ECM) contributes to the pathogenesis, such as heart remodeling, tumor invasion, and inflammation",,
988,1344600,2197611,Matrix metalloproteinase-1 inhibitor,13000,,INHIBITOR,1,1,1,"It is an antibiotic, however, its primary action, due to the concentration reached in the human body is via metalloproteinases inhibition, which is beneficial in many pathological conditions in which MMP-mediated proteolysis of the extracellular matrix (ECM) contributes to the pathogenesis, such as heart remodeling, tumor invasion, and inflammation",,
989,1344217,1540465,Matrix metalloproteinase-1 inhibitor,13000,,INHIBITOR,1,1,1,"It is an antibiotic, however, its primary action, due to the concentration reached in the human body is via metalloproteinases inhibition, which is beneficial in many pathological conditions in which MMP-mediated proteolysis of the extracellular matrix (ECM) contributes to the pathogenesis, such as heart remodeling, tumor invasion, and inflammation",,
990,1344085,252155,Voltage-gated N-type calcium channel alpha-1B subunit blocker,10511,,BLOCKER,1,1,1,,,
991,1679381,1277553,Discoidin domain-containing receptor 2 inhibitor,101079,,INHIBITOR,1,1,1,,,
992,1702634,1377999,Serine/threonine-protein kinase B-raf inhibitor,100126,,INHIBITOR,1,1,1,,,
993,1679381,1277553,Serine/threonine-protein kinase B-raf inhibitor,100126,,INHIBITOR,1,1,1,,,
994,1344744,674436,Serine/threonine-protein kinase B-raf inhibitor,100126,,INHIBITOR,1,1,1,,,
995,1392864,691867,Serine/threonine-protein kinase B-raf inhibitor,100126,,INHIBITOR,1,1,1,Indicated for mutated form - V600E,,
997,1343753,543171,Ferriprotoporphyrin IX inhibitor,100262,,INHIBITOR,1,1,1,,,
998,1344067,674852,Ferriprotoporphyrin IX inhibitor,100262,,INHIBITOR,1,1,1,,,
999,1344197,781532,Ferriprotoporphyrin IX inhibitor,100262,,INHIBITOR,1,1,1,prevents crystallisation,,
1000,1344988,90635,Ferriprotoporphyrin IX inhibitor,100262,,INHIBITOR,1,1,1,prevents crystallisation,,
1001,1344875,573926,Ferriprotoporphyrin IX inhibitor,100262,,INHIBITOR,1,1,1,prevents crystallisation,,
1002,1344253,1537155,Ferriprotoporphyrin IX inhibitor,100262,,INHIBITOR,1,1,1,,,
1003,1343785,2335136,Ferriprotoporphyrin IX inhibitor,100262,,INHIBITOR,1,1,1,prevents crystallisation,,
1004,1344365,56095,Ferriprotoporphyrin IX inhibitor,100262,,INHIBITOR,1,1,1,,,
1005,1344184,529987,Ferriprotoporphyrin IX inhibitor,100262,,INHIBITOR,1,1,1,inhibits polymerisation,,
1006,1344162,485738,Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor,12097,,INHIBITOR,1,1,1,,,
1007,1344018,674563,Sodium channel protein type X alpha subunit blocker,18080,,BLOCKER,1,1,1,,,
1008,1701433,1377257,Glucagon-like peptide 2 receptor agonist,102687,,AGONIST,1,1,1,,,
1009,1343679,675085,Chloride channel protein 2 opener,103797,,OPENER,1,1,1,,,
1010,1343066,328153,Progesterone receptor agonist,36,,AGONIST,1,1,1,,,
1011,1344099,428747,Progesterone receptor agonist,36,,AGONIST,1,1,1,,,
1012,1344150,675090,Progesterone receptor agonist,36,,AGONIST,1,1,1,,,
1013,1343302,675097,Progesterone receptor agonist,36,,AGONIST,1,1,1,,,
1014,1344328,34608,Progesterone receptor agonist,36,,AGONIST,1,1,1,,,
1015,1343816,187962,Progesterone receptor agonist,36,,AGONIST,1,1,1,,,
1016,1344185,674799,Progesterone receptor agonist,36,,AGONIST,1,1,1,,,
1017,1344223,674804,Progesterone receptor agonist,36,,AGONIST,1,1,1,,,
1018,1343824,12825,Progesterone receptor agonist,36,,AGONIST,1,1,1,,,
1019,1343828,1380067,Progesterone receptor agonist,36,,AGONIST,1,1,1,,,
1020,1344065,674885,Progesterone receptor agonist,36,,AGONIST,1,1,1,,,
1021,1343084,328164,Progesterone receptor agonist,36,,AGONIST,1,1,1,,,
1022,1343153,429174,Progesterone receptor agonist,36,,AGONIST,1,1,1,,,
1023,1344518,431376,Progesterone receptor modulator,36,,MODULATOR,1,1,1,Mixed agonist/antagonist,,
1024,1343839,674758,Progesterone receptor agonist,36,,AGONIST,1,1,1,,,
1025,1344564,674575,Progesterone receptor agonist,36,,AGONIST,1,1,1,,,
1026,1344451,712273,Progesterone receptor antagonist,36,,ANTAGONIST,1,1,1,,Selective,
1027,1343458,421032,Progesterone receptor agonist,36,,AGONIST,1,1,1,,,
1028,1344474,405364,Progesterone receptor agonist,36,,AGONIST,1,1,1,,,
1030,1583660,460092,Smoothened homolog inhibitor,101400,,INHIBITOR,1,1,1,,,
1031,1344549,425650,Transient receptor potential cation channel subfamily A member 1 opener,101412,,OPENER,1,1,1,,,
1032,1343897,60232,Solute carrier family 22 member 12 inhibitor,102767,,INHIBITOR,1,1,1,,,
1033,1679381,1277553,Tyrosine-protein kinase TIE-2 inhibitor,12913,,INHIBITOR,1,1,1,,,
1034,1343277,33576,Tyrosine-protein kinase TIE-2 inhibitor,12913,,INHIBITOR,1,1,1,,,
1035,1392866,1121853,Placenta growth factor inhibitor,103950,,INHIBITOR,1,1,1,,,
1036,1343127,77474,Solute carrier family 22 member 6 inhibitor,103829,,INHIBITOR,1,1,1,,,
1037,1343127,77474,Solute carrier family 22 member 8 inhibitor,103830,,INHIBITOR,1,1,1,,,
1038,1679388,685974,Glutamate receptor ionotropic AMPA antagonist,104825,,ANTAGONIST,1,1,1,,,
1039,1344546,366279,Glutamate receptor ionotropic AMPA antagonist,104825,,ANTAGONIST,1,1,1,,,
1040,1343869,93617,"Endothelin receptor, ET-A/ET-B antagonist",104833,,ANTAGONIST,1,1,1,,,
1041,1344320,154051,"Endothelin receptor, ET-A/ET-B antagonist",104833,,ANTAGONIST,1,1,1,,,
1042,1343127,77474,Solute carrier family 22 member 11 inhibitor,104618,,INHIBITOR,1,1,1,,,
1043,1344097,675444,Neuronal acetylcholine receptor; alpha4/beta2 agonist,104283,,AGONIST,1,1,1,,,
1044,1343518,115,Neuronal acetylcholine receptor; alpha4/beta2 agonist,104283,,AGONIST,1,1,1,,,
1045,1343475,1355850,Neuronal acetylcholine receptor; alpha4/beta2 agonist,104283,,AGONIST,1,1,1,,,
1046,1679376,1763646,Heat-stable enterotoxin receptor agonist,104277,,AGONIST,1,1,1,,,
1047,1344203,28699,Farnesyl diphosphate synthase inhibitor,71,,INHIBITOR,1,1,1,"Binds to the bone matrix (hydroxyapatite), and when the bone starts to be reabsorbed the compound is released and taken up by osteoclasts, inhibiting protein prenylation of the GTPases involved in the formation of the ruffled border",,
1048,1343652,494630,Farnesyl diphosphate synthase inhibitor,71,,INHIBITOR,1,1,1,"Binds to the bone matrix (hydroxyapatite), and when the bone starts to be reabsorbed the compound is released and taken up by osteoclasts, inhibiting protein prenylation of the GTPases involved in the formation of the ruffled border",,
1049,1344913,83838,Farnesyl diphosphate synthase inhibitor,71,,INHIBITOR,1,1,1,"Binds to the bone matrix (hydroxyapatite), and when the bone starts to be reabsorbed the compound is released and taken up by osteoclasts, inhibiting protein prenylation of the GTPases involved in the formation of the ruffled border",,
1050,1344709,2197440,Farnesyl diphosphate synthase inhibitor,71,,INHIBITOR,1,1,1,"Binds to the bone matrix (hydroxyapatite), and when the bone starts to be reabsorbed the compound is released and taken up by osteoclasts, inhibiting protein prenylation of the GTPases involved in the formation of the ruffled border",,
1051,1344074,2197272,Farnesyl diphosphate synthase inhibitor,71,,INHIBITOR,1,1,1,"Binds to the bone matrix (hydroxyapatite), and when the bone starts to be reabsorbed the compound is released and taken up by osteoclasts, inhibiting protein prenylation of the GTPases involved in the formation of the ruffled border",,
1052,1344871,9495,HMG-CoA reductase inhibitor,24,,INHIBITOR,1,1,1,,,
1053,1343621,674514,HMG-CoA reductase inhibitor,24,,INHIBITOR,1,1,1,,,
1054,1343985,699412,HMG-CoA reductase inhibitor,24,,INHIBITOR,1,1,1,,,
1055,1344848,1449167,HMG-CoA reductase inhibitor,24,,INHIBITOR,1,1,1,,,
1056,1343886,1123018,HMG-CoA reductase inhibitor,24,,INHIBITOR,1,1,1,,,
1057,1343150,30602,HMG-CoA reductase inhibitor,24,,INHIBITOR,1,1,1,,,
1058,1344888,407354,HMG-CoA reductase inhibitor,24,,INHIBITOR,1,1,1,,,
1059,1343830,138562,HMG-CoA reductase inhibitor,24,,INHIBITOR,1,1,1,,,
1060,1343381,150549,Phosphodiesterase 4 inhibitor,104679,,INHIBITOR,1,1,1,,,
1061,1343981,581819,Phosphodiesterase 4 inhibitor,104679,,INHIBITOR,1,1,1,,,
1062,1343275,321696,Phosphodiesterase 4 inhibitor,104679,,INHIBITOR,1,1,1,,Selective,
1063,1343085,381693,Phosphodiesterase 4 inhibitor,104679,,INHIBITOR,1,1,1,,,
1064,1343362,674529,Phosphodiesterase 4 inhibitor,104679,,INHIBITOR,1,1,1,,,
1065,1344201,674826,Phosphodiesterase 4 inhibitor,104679,,INHIBITOR,1,1,1,,,
1066,1343901,794445,Phosphodiesterase 4 inhibitor,104679,,INHIBITOR,1,1,1,,,
1067,1343550,246935,Histone deacetylase inhibitor,104681,,INHIBITOR,1,1,1,,,
1068,1343882,675571,Estrogen receptor agonist,104682,,AGONIST,1,1,1,,,
1069,1344566,675552,Estrogen receptor agonist,104682,,AGONIST,1,1,1,,,
1070,1344090,675621,Estrogen receptor agonist,104682,,AGONIST,1,1,1,,,
1071,1343586,675596,Estrogen receptor agonist,104682,,AGONIST,1,1,1,,,
1072,1701891,1377665,Estrogen receptor modulator,104682,,MODULATOR,1,1,1,Mixed agonist/antagonist,,
1073,1344989,674549,Estrogen receptor agonist,104682,,AGONIST,1,1,1,,,
1074,1343951,675116,Estrogen receptor agonist,104682,,AGONIST,1,1,1,,,
1075,1344020,304798,Estrogen receptor antagonist,104682,,ANTAGONIST,1,1,1,,,
1076,1343799,674626,Estrogen receptor modulator,104682,,MODULATOR,1,1,1,Mixed agonist/antagonist,,
1077,1343491,675576,Integrin alpha-IIb/beta-3 inhibitor,104685,2643,INHIBITOR,1,1,1,,,Beta subunit is binding site
1078,1344232,191902,Integrin alpha-IIb/beta-3 inhibitor,104685,,INHIBITOR,1,1,1,,,
1079,1343798,1678363,Integrin alpha-IIb/beta-3 inhibitor,104685,,INHIBITOR,1,1,1,,,
1080,1344014,419601,Potassium-transporting ATPase inhibitor,104758,2651,INHIBITOR,1,1,1,,,Alpha subunit is likely binding site
1081,1344922,675812,Potassium-transporting ATPase inhibitor,104758,2651,INHIBITOR,1,1,1,,,Alpha subunit is likely binding site
1082,1343525,991212,Potassium-transporting ATPase inhibitor,104758,2651,INHIBITOR,1,1,1,,,Alpha subunit is likely binding site
1083,1343953,674881,Potassium-transporting ATPase inhibitor,104758,2651,INHIBITOR,1,1,1,,,Alpha subunit is likely binding site
1084,1344215,2197430,Potassium-transporting ATPase inhibitor,104758,2651,INHIBITOR,1,1,1,,,Alpha subunit is likely binding site
1085,1343641,5975,Potassium-transporting ATPase inhibitor,104758,2651,INHIBITOR,1,1,1,,,Alpha subunit is likely binding site
1086,1344719,674421,Potassium-transporting ATPase inhibitor,104758,2651,INHIBITOR,1,1,1,,,Alpha subunit is likely binding site
1087,1343932,1418084,Potassium-transporting ATPase inhibitor,104758,2651,INHIBITOR,1,1,1,,,Alpha subunit is likely binding site
1088,1343855,1096,Carbonic anhydrase inhibitor,104764,,INHIBITOR,1,1,1,,,
1089,1344071,675466,Opioid receptors; mu/kappa/delta agonist,104765,,AGONIST,1,1,1,,,
1090,1343087,675465,Opioid receptors; mu/kappa/delta agonist,104765,,AGONIST,1,1,1,,,
1091,1344399,674745,Opioid receptors; mu/kappa/delta agonist,104765,,AGONIST,1,1,1,,,
1092,1344406,21459,Opioid receptors; mu/kappa/delta antagonist,104765,,ANTAGONIST,1,1,1,,,
1093,1344298,675050,Opioid receptors; mu/kappa/delta agonist,104765,,AGONIST,1,1,1,,,
1094,1343496,2335062,Opioid receptors; mu/kappa/delta agonist,104765,,AGONIST,1,1,1,,,
1095,1343207,675100,Opioid receptors; mu/kappa/delta antagonist,104765,,ANTAGONIST,1,1,1,,,
1096,1344461,675083,Opioid receptors; mu/kappa/delta agonist,104765,,AGONIST,1,1,1,may actually be mixed mode of action,,
1097,1344655,675103,Opioid receptors; mu/kappa/delta antagonist,104765,,ANTAGONIST,1,1,1,,,
1098,1343638,551147,Opioid receptors; mu/kappa/delta antagonist,104765,,ANTAGONIST,1,1,1,,,
1099,1343573,2197548,Opioid receptors; mu/kappa/delta agonist,104765,,AGONIST,1,1,1,,,
1100,1392966,1121953,Tubulin inhibitor,104766,2627,INHIBITOR,1,1,1,inhibits polymerisation,,Binds to beta tubulin
1101,1392878,1121865,Tubulin inhibitor,104766,2627,INHIBITOR,1,1,1,,,Binds to beta tubulin
1102,1344721,8062,Tubulin inhibitor,104766,2629,INHIBITOR,1,1,1,,,Binds to beta tubulin
1103,1344343,1927101,Tubulin inhibitor,104766,2629,INHIBITOR,1,1,1,,,Binds to beta tubulin
1104,1343283,1073669,Tubulin inhibitor,104766,2627,INHIBITOR,1,1,1,,,Binds to beta tubulin
1105,1344899,675699,Tubulin inhibitor,104766,2629,INHIBITOR,1,1,1,Stabilises microtubule assembly,,Binds to beta tubulin
1106,1343971,14440,Tubulin inhibitor,104766,2628,INHIBITOR,1,1,1,Inhibits microtubule assembly,,Binds to beta tubulin
1107,1344005,675703,Tubulin inhibitor,104766,2629,INHIBITOR,1,1,1,Stabilises microtubule assembly,,Binds to beta tubulin
1108,1343719,490427,Tubulin inhibitor,104766,2627,INHIBITOR,1,1,1,,,"Binds to beta tubulin, vinca site (PMID: 15057285)"
1109,1344742,564219,Tubulin inhibitor,104766,2627,INHIBITOR,1,1,1,,,"Binds to beta tubulin, vinca site (PMID: 15057285)"
1110,1343653,355917,Tubulin inhibitor,104766,2627,INHIBITOR,1,1,1,,,"Binds to beta tubulin, vinca site (PMID: 15057285)"
1112,1344455,675488,Integrin alpha-4/beta-7 inhibitor,104768,2642,INHIBITOR,1,1,1,,,Alpha subunit is binding site
1113,1343760,674777,Glycogen synthase kinase-3 inhibitor,104772,,INHIBITOR,1,1,1,,,
1114,1343236,1376008,Glycogen synthase kinase-3 inhibitor,104772,,INHIBITOR,1,1,1,,,
1115,1343754,675377,Platelet-derived growth factor receptor agonist,104773,,AGONIST,1,1,1,,,
1116,1344456,675684,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,,,
1117,1679381,1277553,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,,,
1118,1343773,450864,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,,,
1119,1702605,1377978,Bcr/Abl fusion protein inhibitor,104811,,INHIBITOR,1,1,1,,,
1120,1344102,36662,Adrenergic receptor beta antagonist,104700,,ANTAGONIST,1,1,1,,,
1121,1344235,675118,Adrenergic receptor beta antagonist,104700,,ANTAGONIST,1,1,1,,,
1123,1343103,2197392,Adrenergic receptor beta agonist,104700,,AGONIST,1,1,1,,,
1124,1343602,674953,Adrenergic receptor beta antagonist,104700,,ANTAGONIST,1,1,1,,,
1125,1344094,550053,Adrenergic receptor beta agonist,104700,,AGONIST,1,1,1,,,
1126,1344881,674346,Glutamate [NMDA] receptor antagonist,104706,,ANTAGONIST,1,1,1,,,
1127,1343571,1359038,Glutamate [NMDA] receptor antagonist,104706,,ANTAGONIST,1,1,1,,,
1128,1344319,452635,Glutamate [NMDA] receptor antagonist,104706,,ANTAGONIST,1,1,1,Indicated for Parkinson's disease,,
1129,1343574,545974,Glutamate [NMDA] receptor negative allosteric modulator,104706,,NEGATIVE ALLOSTERIC MODULATOR,1,1,1,,,
1130,1344151,674974,Glutamate [NMDA] receptor antagonist,104706,,ANTAGONIST,1,1,1,,,
1131,1343148,150451,Glutamate [NMDA] receptor antagonist,104706,,ANTAGONIST,1,1,1,,,
1132,1344238,550657,Glutamate [NMDA] receptor negative allosteric modulator,104706,,NEGATIVE ALLOSTERIC MODULATOR,1,1,1,,,
1133,1343362,674529,Phosphodiesterase 3 inhibitor,104707,,INHIBITOR,1,1,1,,,
1134,1343128,674710,Phosphodiesterase 3 inhibitor,104707,,INHIBITOR,1,1,1,,,
1135,1343901,794445,Phosphodiesterase 3 inhibitor,104707,,INHIBITOR,1,1,1,,,
1136,1343085,381693,Phosphodiesterase 3 inhibitor,104707,,INHIBITOR,1,1,1,,,
1137,1344435,221962,Melatonin receptor agonist,104733,,AGONIST,1,1,1,,,
1138,1344582,1355848,Adrenergic receptor alpha-2 agonist,104743,,AGONIST,1,1,1,,,
1139,1343944,1378465,Adrenergic receptor alpha-2 agonist,104743,,AGONIST,1,1,1,,Selective,
1140,1343905,674280,Adrenergic receptor alpha-2 agonist,104743,,AGONIST,1,1,1,,,
1141,1343548,27610,Adrenergic receptor alpha-2 antagonist,104743,,ANTAGONIST,1,1,1,,,
1142,1343614,548124,Adrenergic receptor alpha-2 agonist,104743,,AGONIST,1,1,1,,,
1143,1343982,674383,Adrenergic receptor alpha-2 agonist,104743,,AGONIST,1,1,1,,,
1144,1343849,674445,Adrenergic receptor alpha-2 agonist,104743,,AGONIST,1,1,1,,,
1145,1344177,27609,Adrenergic receptor alpha-2 agonist,104743,,AGONIST,1,1,1,,,
1146,1344596,674330,Adrenergic receptor alpha-2 agonist,104743,,AGONIST,1,1,1,,,
1147,1344527,3730,Adrenergic receptor alpha-2 agonist,104743,,AGONIST,1,1,1,,,
1148,1343321,674511,Adrenergic receptor alpha-2 agonist,104743,,AGONIST,1,1,1,,,
1149,1344699,28939,Adrenergic receptor alpha-2 agonist,104743,,AGONIST,1,1,1,,,
1150,1344464,1510461,Dopamine receptor agonist,104842,,AGONIST,1,1,1,,,
1151,1343650,249814,Dopamine receptor agonist,104842,,AGONIST,1,1,1,,,
1152,1343950,155045,Dopamine receptor antagonist,104842,,ANTAGONIST,1,1,1,,,
1153,1343983,364141,Dopamine receptor antagonist,104842,,ANTAGONIST,1,1,1,,,
1155,1344546,366279,Glutamate receptor ionotropic kainate antagonist,104902,,ANTAGONIST,1,1,1,,,
1156,1344143,2096404,"Amylin receptor AMY1, CALCR/RAMP1 agonist",104908,2635,AGONIST,1,1,1,"Is amylin analogue, calcitonin receptor is binding site",,Calcitonin receptor is binding site
1157,1344143,2096404,Amylin receptor AMY3; CALCR/RAMP3 agonist,104909,2637,AGONIST,1,1,1,"Is amylin analogue, calcitonin receptor is binding site",,Calcitonin receptor is binding site
1158,1343777,674899,Adrenergic receptor alpha-1 antagonist,104723,,ANTAGONIST,1,1,1,,,
1159,1343863,1355855,Adrenergic receptor alpha-1 agonist,104723,,AGONIST,1,1,1,,,
1160,1344102,36662,Adrenergic receptor alpha-1 antagonist,104723,,ANTAGONIST,1,1,1,,,
1161,1343432,553490,Adrenergic receptor alpha-1 agonist,104723,,AGONIST,1,1,1,,,
1162,1343095,674512,Adrenergic receptor alpha-1 antagonist,104723,,ANTAGONIST,1,1,1,,,
1163,1344387,675054,Adrenergic receptor alpha-1 agonist,104723,,AGONIST,1,1,1,,,
1164,1343303,1355853,Adrenergic receptor alpha-1 agonist,104723,,AGONIST,1,1,1,,,
1165,1344235,675118,Adrenergic receptor alpha-1 antagonist,104723,,ANTAGONIST,1,1,1,,,
1166,1344837,674412,Adrenergic receptor alpha-1 agonist,104723,,AGONIST,1,1,1,,,
1167,1344906,674290,Adrenergic receptor alpha-1 agonist,104723,,AGONIST,1,1,1,,,
1168,1343592,444191,Adrenergic receptor alpha-1 antagonist,104723,,ANTAGONIST,1,1,1,,,
1169,1343291,674865,Adrenergic receptor alpha-1 antagonist,104723,,ANTAGONIST,1,1,1,,,
1170,1344536,2197433,Adrenergic receptor alpha-1 antagonist,104723,,ANTAGONIST,1,1,1,,,
1171,1679366,2197279,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1172,1343835,16450,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1173,1343332,51056,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1174,1344797,674757,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1175,1344967,675131,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1176,1343686,123693,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1177,1343089,1376006,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1178,1343647,77652,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1179,1343909,1223,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1180,1343587,11674,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1181,1344052,986494,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1182,1344112,161649,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1183,1344568,119162,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1184,1345000,2197547,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1186,1343845,2197625,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1187,1343081,1280,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1188,1344545,674564,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1189,1343952,674755,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1191,1344418,674711,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1192,1343317,173,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1193,1344779,40536,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1194,1344555,16308,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1195,1344870,675075,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1196,1343145,16510,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1197,1343285,674964,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1199,1343387,2197281,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1200,1343796,674414,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1201,1344524,29989,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1202,1344958,33202,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1203,1344707,675092,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1204,1344768,139225,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1205,1344221,12417,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1206,1344127,11968,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1207,1343774,93117,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1208,1344276,16591,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
1209,1343829,68607,DNA topoisomerase II inhibitor,104727,,INHIBITOR,1,1,1,,,
1210,1344386,453046,DNA topoisomerase II inhibitor,104727,,INHIBITOR,1,1,1,,,
1211,1344378,27029,Adenosine A2 receptor antagonist,104729,,ANTAGONIST,1,1,1,,,
1212,1343901,794445,Adenosine receptor antagonist,105024,,ANTAGONIST,1,1,1,,,
1213,1343161,674520,Adenosine receptor antagonist,105024,,ANTAGONIST,1,1,1,,,
1214,1344812,16485,Adenosine receptor antagonist,105024,,ANTAGONIST,1,1,1,,,
1215,1343155,5797,Adenosine receptor agonist,105024,,AGONIST,1,1,1,,,
1216,1343085,381693,Adenosine receptor antagonist,105024,,ANTAGONIST,1,1,1,,,
1217,1343362,674529,Adenosine receptor antagonist,105024,,ANTAGONIST,1,1,1,,,
1218,1344306,37493,Soluble guanylate cyclase activator,105048,2654,ACTIVATOR,1,1,1,,,"Heterodimer, beta (1 or 2) is binding site"
1219,1344028,674640,Soluble guanylate cyclase activator,105048,2654,ACTIVATOR,1,1,1,,,"Heterodimer, beta (1 or 2) is binding site"
1220,1343502,226851,Soluble guanylate cyclase activator,105048,2654,ACTIVATOR,1,1,1,,,"Heterodimer, beta (1 or 2) is binding site"
1221,1343339,263453,Soluble guanylate cyclase activator,105048,2654,ACTIVATOR,1,1,1,,,"Heterodimer, beta (1 or 2) is binding site"
1222,1343864,556,Soluble guanylate cyclase activator,105048,2654,ACTIVATOR,1,1,1,,,"Heterodimer, beta (1 or 2) is binding site"
1223,1344398,386457,Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor,105058,,INHIBITOR,1,1,1,,,
1224,1344255,68396,Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor,105058,,INHIBITOR,1,1,1,,,
1225,1343256,674906,Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor,105058,,INHIBITOR,1,1,1,,,
1226,1344163,36864,Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor,105058,,INHIBITOR,1,1,1,,,
1227,1344201,674826,Phosphodiesterase 7 inhibitor,104918,,INHIBITOR,1,1,1,,,
1228,1344895,674431,Somatostatin receptor agonist,104951,,AGONIST,1,1,1,Long acting,"Selectivity for types 2, 3 and 5",
1229,1343290,51042,"Sulfonylurea receptor 2, Kir6.2 opener",104782,2655,OPENER,1,1,1,,,SUR2 is binding site
1230,1344225,674289,"Sulfonylurea receptor 2, Kir6.2 opener",104782,2655,OPENER,1,1,1,,,SUR2 is binding site
1231,1343576,675463,Adrenergic receptor alpha antagonist,104787,,ANTAGONIST,1,1,1,,,
1232,1344464,1510461,Adrenergic receptor alpha antagonist,104787,,ANTAGONIST,1,1,1,,,
1233,1343162,1590760,Adrenergic receptor alpha agonist,104787,,AGONIST,1,1,1,,,
1234,1344563,548594,Adrenergic receptor alpha agonist,104787,,AGONIST,1,1,1,,,
1235,1344776,674364,Adrenergic receptor alpha agonist,104787,,AGONIST,1,1,1,,,
1236,1344951,674824,Adrenergic receptor alpha antagonist,104787,,ANTAGONIST,1,1,1,,,
1237,1344011,674742,Adrenergic receptor alpha agonist,104787,,AGONIST,1,1,1,"complex action type, partial agonist at alpha-2 receptors",,
1238,1344864,1941483,Adrenergic receptor alpha antagonist,104787,,ANTAGONIST,1,1,1,,,
1239,1344262,674738,Adrenergic receptor alpha antagonist,104787,,ANTAGONIST,1,1,1,,,
1240,1343270,524710,Adrenergic receptor alpha antagonist,104787,,ANTAGONIST,1,1,1,,,
1241,1344784,674846,Monoamine oxidase inhibitor,104789,,INHIBITOR,1,1,1,,,
1242,1343429,674376,Monoamine oxidase inhibitor,104789,,INHIBITOR,1,1,1,,,
1243,1343860,675119,Monoamine oxidase inhibitor,104789,,INHIBITOR,1,1,1,,,
1244,1343252,2197569,Monoamine oxidase inhibitor,104789,,INHIBITOR,1,1,1,,,
1245,1344849,405366,"Sulfonylurea receptor 1, Kir6.2 blocker",104852,,BLOCKER,1,1,1,,,
1246,1343096,5582,"Sulfonylurea receptor 1, Kir6.2 blocker",104852,,BLOCKER,1,1,1,,,
1247,1343407,8516,"Sulfonylurea receptor 1, Kir6.2 blocker",104852,,BLOCKER,1,1,1,,,
1248,1343858,674825,"Sulfonylurea receptor 1, Kir6.2 blocker",104852,,BLOCKER,1,1,1,,,
1249,1343354,139286,"Sulfonylurea receptor 1, Kir6.2 blocker",104852,,BLOCKER,1,1,1,,,
1250,1344660,454070,"Sulfonylurea receptor 1, Kir6.2 blocker",104852,,BLOCKER,1,1,1,,,
1251,1344544,56131,"Sulfonylurea receptor 1, Kir6.2 blocker",104852,,BLOCKER,1,1,1,,,
1252,1343624,248669,"Sulfonylurea receptor 1, Kir6.2 blocker",104852,,BLOCKER,1,1,1,,,
1253,1343927,46727,"Sulfonylurea receptor 1, Kir6.2 blocker",104852,,BLOCKER,1,1,1,,Selective,
1254,1343307,46726,"Sulfonylurea receptor 1, Kir6.2 blocker",104852,,BLOCKER,1,1,1,,,
1255,1344621,17411,"Amiloride-sensitive sodium channel, ENaC blocker",104888,2634,BLOCKER,1,1,1,,,Alpha subunit is binding site
1256,1344857,822010,"Amiloride-sensitive sodium channel, ENaC blocker",104888,2634,BLOCKER,1,1,1,,,Alpha subunit is binding site
1257,1697230,675367,Elongation factor 2 inhibitor,104188,,INHIBITOR,1,1,1,,,
1258,1344274,4730,Ribonucleoside-diphosphate reductase RR1 inhibitor,104791,2658,INHIBITOR,1,1,1,,,M2 subunit is binding site
1259,1344222,581569,Ribonucleoside-diphosphate reductase RR1 inhibitor,104791,2652,INHIBITOR,1,1,1,,,M1 subunit is binding site
1260,1344009,480382,Ribonucleoside-diphosphate reductase RR1 inhibitor,104791,2652,INHIBITOR,1,1,1,,,M1 subunit is binding site
1261,1343956,624161,Ribonucleoside-diphosphate reductase RR1 inhibitor,104791,2652,INHIBITOR,1,1,1,,,M1 subunit is binding site
1262,1344505,674934,Ribonucleoside-diphosphate reductase RR1 inhibitor,104791,2658,INHIBITOR,1,1,1,,,M2 subunit is binding site
1263,1343773,450864,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
1264,1583657,716337,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
1265,1343277,33576,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
1266,1344744,674436,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
1267,1344456,675684,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
1268,1679381,1277553,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
1269,1706068,699483,Voltage-gated L-type calcium channel blocker,104801,,BLOCKER,1,1,1,,,
1271,1343610,486789,Voltage-gated L-type calcium channel blocker,104801,,BLOCKER,1,1,1,,,
1272,1344188,545509,Voltage-gated L-type calcium channel blocker,104801,,BLOCKER,1,1,1,,,
1273,1343725,675680,Voltage-gated L-type calcium channel blocker,104801,,BLOCKER,1,1,1,"Dronedarone reported to have antiarrhythmic properties belonging to all four Vaughan-Williams classes, importance of beta adrenergic receptors and calcium channels disputed in PMID: 23647933",,
1274,1343691,674935,Voltage-gated L-type calcium channel blocker,104801,,BLOCKER,1,1,1,,,
1275,1344407,250508,Voltage-gated L-type calcium channel blocker,104801,,BLOCKER,1,1,1,,,
1276,1343846,419596,Voltage-gated L-type calcium channel blocker,104801,,BLOCKER,1,1,1,,,
1277,1343687,674756,Voltage-gated L-type calcium channel blocker,104801,,BLOCKER,1,1,1,,,
1278,1343826,674353,Voltage-gated L-type calcium channel blocker,104801,,BLOCKER,1,1,1,,,
1279,1344258,674277,Voltage-gated L-type calcium channel blocker,104801,,BLOCKER,1,1,1,,,
1280,1343789,365248,Voltage-gated L-type calcium channel blocker,104801,,BLOCKER,1,1,1,,,
1281,1343784,554892,Voltage-gated L-type calcium channel blocker,104801,,BLOCKER,1,1,1,,,
1282,1344373,405365,Voltage-gated L-type calcium channel blocker,104801,,BLOCKER,1,1,1,,,
1283,1345003,360720,"Hepatitis C virus serine protease, NS3/NS4A inhibitor",104803,,INHIBITOR,1,1,1,,,
1284,1343537,394996,"Hepatitis C virus serine protease, NS3/NS4A inhibitor",104803,,INHIBITOR,1,1,1,,,
1285,1343424,355897,Cholinesterases; ACHE & BCHE inhibitor,104805,,INHIBITOR,1,1,1,,,
1286,1343992,27251,Cholinesterases; ACHE & BCHE inhibitor,104805,,INHIBITOR,1,1,1,,,
1287,1344499,508604,Cholinesterases; ACHE & BCHE inhibitor,104805,,INHIBITOR,1,1,1,,,
1288,1390838,675785,Interleukin-1 beta inhibitor,104335,,INHIBITOR,1,1,1,,,
1289,1390858,675781,Interleukin-1 beta inhibitor,104335,,INHIBITOR,1,1,1,,,
1290,1344319,452635,Matrix protein 2 inhibitor,104398,,INHIBITOR,1,1,1,Antiviral activity,,
1291,1344602,699433,Neuronal acetylcholine receptor; alpha3/beta4 negative allosteric modulator,104288,,NEGATIVE ALLOSTERIC MODULATOR,1,1,1,,,
1292,1344377,742171,Neuronal acetylcholine receptor; alpha3/beta4 antagonist,104288,,ANTAGONIST,1,1,1,,,
1293,1344676,235211,Neuronal acetylcholine receptor; alpha3/beta4 antagonist,104288,,ANTAGONIST,1,1,1,,,
1294,1343491,675576,Integrin alpha-V/beta-3 inhibitor,104292,2645,INHIBITOR,1,1,1,,,Beta subunit is binding site
1295,1344455,675488,Integrin alpha-4/beta-1 inhibitor,104293,2641,INHIBITOR,1,1,1,,,Alpha subunit is binding site
1298,1705068,1379603,Kelch-like ECH-associated protein 1 inhibitor,104593,,INHIBITOR,1,1,1,"Alykylates Keap1 to prevent interaction with Nrf2 (PMID: 22732183, PMID: 23709213, PMID: 18618599)",,
1299,1344475,84644,Ryanodine receptor 3 antagonist,223,,ANTAGONIST,1,1,1,,,
1300,1344488,1926907,Thyroid hormone receptor agonist,104987,,AGONIST,1,1,1,,,
1301,1344560,675070,Thyroid hormone receptor agonist,104987,,AGONIST,1,1,1,,,
1302,2794620,15990,Thyroid hormone receptor agonist,104987,,AGONIST,1,1,1,,,
1303,3130045,433015,Thyroid hormone receptor agonist,104987,,AGONIST,1,1,1,,,
1304,1343091,1376011,Thyroid hormone receptor agonist,104987,,AGONIST,1,1,1,,,
1305,1343251,674633,GABA-B receptor agonist,104988,,AGONIST,1,1,1,,,
1306,1343184,32869,GABA-B receptor agonist,104988,,AGONIST,1,1,1,,,
1307,1343790,281549,4-hydroxyphenylpyruvate dioxygenase inhibitor,123,,INHIBITOR,1,1,1,,,
1308,1343241,518361,Kappa opioid receptor antagonist,137,,ANTAGONIST,1,1,1,,,
1309,1343929,674494,Kappa opioid receptor agonist,137,,AGONIST,1,1,1,,,
1310,1344650,674998,Kappa opioid receptor agonist,137,,AGONIST,1,1,1,,,
1311,1343316,446784,Kappa opioid receptor agonist,137,,AGONIST,1,1,1,,,
1312,1343637,1543312,Kappa opioid receptor agonist,137,,AGONIST,1,1,1,,,
1313,1343658,76963,Kappa opioid receptor partial agonist,137,,PARTIAL AGONIST,1,1,1,,,
1314,1344344,1355867,Kappa opioid receptor partial agonist,137,,PARTIAL AGONIST,1,1,1,,,
1315,1343221,674988,Ornithine decarboxylase inhibitor,272,,INHIBITOR,1,1,1,,,
1316,1344269,674536,Androgen Receptor agonist,56,,AGONIST,1,1,1,,,
1317,1344083,52087,Androgen Receptor antagonist,56,,ANTAGONIST,1,1,1,,,
1318,1343266,249414,Androgen Receptor antagonist,56,,ANTAGONIST,1,1,1,,,
1319,1343457,674999,Androgen Receptor agonist,56,,AGONIST,1,1,1,,,
1320,1344580,717,Androgen Receptor antagonist,56,,ANTAGONIST,1,1,1,,,
1321,1343817,328400,Androgen Receptor agonist,56,,AGONIST,1,1,1,,,
1322,1343319,674574,Androgen Receptor agonist,56,,AGONIST,1,1,1,,,
1323,1343701,1363818,Androgen Receptor agonist,56,,AGONIST,1,1,1,,,
1324,1343322,190629,Androgen Receptor agonist,56,,AGONIST,1,1,1,,,
1325,1343154,674286,Androgen Receptor agonist,56,,AGONIST,1,1,1,,,
1326,1343721,674897,Androgen Receptor agonist,56,,AGONIST,1,1,1,,,
1327,1343248,674387,Androgen Receptor agonist,56,,AGONIST,1,1,1,,,
1328,1344069,675052,Androgen Receptor agonist,56,,AGONIST,1,1,1,,,
1329,1344918,364520,Androgen Receptor agonist,56,,AGONIST,1,1,1,,,
1330,1344050,377718,Androgen Receptor agonist,56,,AGONIST,1,1,1,,,
1331,1679375,630886,Androgen Receptor antagonist,56,,ANTAGONIST,1,1,1,,,
1332,1343978,674363,Androgen Receptor agonist,56,,AGONIST,1,1,1,,,
1333,1344474,405364,Androgen Receptor agonist,56,,AGONIST,1,1,1,,,
1334,1344245,940358,Serotonin 4 (5-HT4) receptor partial agonist,168,,PARTIAL AGONIST,1,1,1,,,
1335,1344637,557741,Serotonin 4 (5-HT4) receptor agonist,168,,AGONIST,1,1,1,,,
1336,1344810,674891,Serotonin 4 (5-HT4) receptor agonist,168,,AGONIST,1,1,1,,,
1337,1702558,631810,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
1338,1343195,34094,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
1339,1343984,674395,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
1340,1344008,674844,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
1341,1344239,675012,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
1342,1343282,1280054,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,Long acting,,
1343,1344117,674356,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
1344,1344101,631502,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
1345,1344248,791489,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
1346,1392857,1153493,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,Long acting,,
1347,1344339,739751,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
1348,1343284,2197564,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
1349,1343139,2197669,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,Long acting,,
1350,1343067,991941,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
1351,1343607,864943,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
1352,1343862,675104,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
1353,1344982,674898,Beta-2 adrenergic receptor antagonist,43,,ANTAGONIST,1,1,1,,,
1354,1343142,27570,Beta-2 adrenergic receptor antagonist,43,,ANTAGONIST,1,1,1,,,
1355,1343513,675682,Beta-2 adrenergic receptor antagonist,43,,ANTAGONIST,1,1,1,,,
1356,1343931,674696,Beta-2 adrenergic receptor antagonist,43,,ANTAGONIST,1,1,1,,,
1357,1344220,1538559,Beta-2 adrenergic receptor antagonist,43,,ANTAGONIST,1,1,1,,,
1358,1343238,675014,Beta-2 adrenergic receptor antagonist,43,,ANTAGONIST,1,1,1,,,
1359,1343430,505776,Beta-2 adrenergic receptor antagonist,43,,ANTAGONIST,1,1,1,,,
1360,1344562,8543,Beta-2 adrenergic receptor partial agonist,43,,PARTIAL AGONIST,1,1,1,,,
1361,1344317,546564,Beta-2 adrenergic receptor antagonist,43,,ANTAGONIST,1,1,1,,,
1362,1343861,674871,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
1363,1344396,675128,Beta-2 adrenergic receptor antagonist,43,,ANTAGONIST,1,1,1,,,
1364,1344583,674821,Beta-2 adrenergic receptor antagonist,43,,ANTAGONIST,1,1,1,,,
1365,1343364,8531,Beta-2 adrenergic receptor antagonist,43,,ANTAGONIST,1,1,1,,,
1366,1343201,674369,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
1367,1344658,675066,Beta-2 adrenergic receptor antagonist,43,,ANTAGONIST,1,1,1,,,
1368,1344874,544765,GABA transporter 1 inhibitor,113,,INHIBITOR,1,1,1,reuptake inhibitor,,
1369,1343254,504310,Cytochrome P450 11B1 inhibitor,76,,INHIBITOR,1,1,1,,,
1370,1344479,675582,CAMPATH-1 antigen inhibitor,203,,INHIBITOR,1,1,1,,,
1371,1344597,399361,Neurokinin 1 receptor antagonist,250,,ANTAGONIST,1,1,1,,,
1372,1344749,675733,Neurokinin 1 receptor antagonist,250,,ANTAGONIST,1,1,1,,,
1373,1706042,397524,Coagulation factor X inhibitor,194,,INHIBITOR,1,1,1,,,
1375,1392858,328601,Coagulation factor X inhibitor,194,,INHIBITOR,1,1,1,,,
1376,1344674,421208,Type I iodothyronine deiodinase (Type-I 5'-deiodinase) (DIOI) (Type 1 DI) (5DI) inhibitor,19914,,INHIBITOR,1,1,1,,,
1377,1344540,175106,Niemann-Pick C1-like protein 1 inhibitor,329,,INHIBITOR,1,1,1,,,
1378,1344976,43740,Alanine racemase inhibitor,328,,INHIBITOR,1,1,1,,,
1379,1344410,1369651,Phosphodiesterase 3A inhibitor,170,,INHIBITOR,1,1,1,,,
1380,1343915,50440,Phosphodiesterase 3A inhibitor,170,,INHIBITOR,1,1,1,,,
1381,1343617,674928,Phosphodiesterase 3A inhibitor,170,,INHIBITOR,1,1,1,,,
1382,1343981,581819,Phosphodiesterase 3A inhibitor,170,,INHIBITOR,1,1,1,,,
1384,1344708,141484,Gamma-amino-N-butyrate transaminase inhibitor,153,,INHIBITOR,1,1,1,Irreversible inhibitor,,
1385,1344429,675548,Interleukin 11 receptor alpha agonist,206,,AGONIST,1,1,1,complex with beta but only associcates on ligand binding so excluded,,
1386,1344108,365189,Bacterial DNA-directed RNA polymerase inhibitor,106172,2638,INHIBITOR,1,1,1,,,Beta subunit is binding site
1387,1343501,397074,Bacterial DNA-directed RNA polymerase inhibitor,106172,2638,INHIBITOR,1,1,1,,,Beta subunit is binding site
1388,1344983,497291,Bacterial DNA-directed RNA polymerase inhibitor,106172,2638,INHIBITOR,1,1,1,,,Beta subunit is binding site
1389,1343675,466768,Bacterial DNA-directed RNA polymerase inhibitor,106172,2638,INHIBITOR,1,1,1,,,Beta subunit is binding site
1390,1343129,84251,"1,3-beta-glucan synthase inhibitor",106173,,INHIBITOR,1,1,1,,,
1391,1344468,2335113,"1,3-beta-glucan synthase inhibitor",106173,,INHIBITOR,1,1,1,,,
1392,1344836,699421,"1,3-beta-glucan synthase inhibitor",106173,,INHIBITOR,1,1,1,,,
1393,1344468,2335113,"1,3-beta-glucan synthase inhibitor",106174,,INHIBITOR,1,1,1,,,
1394,1679373,1369604,Cytochrome P450 3A inhibitor,106175,,INHIBITOR,1,1,1,,,
1395,1344285,2197549,Nematode GABA-A receptor positive modulator,106176,,POSITIVE MODULATOR,1,1,1,,,
1396,1344759,86784,Nematode GABA-A receptor positive modulator,106176,,POSITIVE MODULATOR,1,1,1,,,
1397,1390866,675777,Heparan sulfate hydrolytic enzyme,106177,,HYDROLYTIC ENZYME,1,1,1,,,
1398,1343973,675399,Heparan sulfate hydrolytic enzyme,106177,,HYDROLYTIC ENZYME,1,1,1,Replacement of alpha-L-iduronidase enzyme,,
1399,1343380,8167,Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor,106178,,INHIBITOR,1,1,1,,Broad spectrum,
1400,1343697,64200,Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor,106178,,INHIBITOR,1,1,1,,Broad spectrum,
1401,1343386,674348,Squalene monooxygenase inhibitor,106179,,INHIBITOR,1,1,1,,,
1402,1343834,674783,Squalene monooxygenase inhibitor,106179,,INHIBITOR,1,1,1,,,
1403,1343092,56831,Squalene monooxygenase inhibitor,106179,,INHIBITOR,1,1,1,,,
1404,1344056,674444,Squalene monooxygenase inhibitor,106179,,INHIBITOR,1,1,1,,,
1405,1344231,393942,Thymidylate synthase inhibitor,106180,,INHIBITOR,1,1,1,,,
1406,1702537,1377932,Microsomal triglyceride transfer protein inhibitor,106181,2650,INHIBITOR,1,1,1,,,Large subunit (P55157) is binding site
1407,1343423,798263,Slowly adapting pulmonary stretch receptor inhibitor,106182,,INHIBITOR,1,1,1,,,
1408,1344180,37820,Bacterial urease inhibitor,106183,,INHIBITOR,1,1,1,,,
1409,1344208,674404,Envelope glycoprotein inhibitor,106196,,INHIBITOR,1,1,1,Seems to prevent the fusion between the host membrane and lipid-enveloped virus.,,
1410,1392874,1121861,T-lymphocyte activation antigen CD86 inhibitor,106135,,INHIBITOR,1,1,1,,,
1411,1390869,675774,T-lymphocyte activation antigen CD86 inhibitor,106135,,INHIBITOR,1,1,1,,,
1412,1390869,675774,T-lymphocyte activation antigen CD80 inhibitor,106136,,INHIBITOR,1,1,1,,,
1413,1392874,1121861,T-lymphocyte activation antigen CD80 inhibitor,106136,,INHIBITOR,1,1,1,,,
1414,1394675,1153494,Tumor necrosis factor ligand superfamily member 13B inhibitor,106137,,INHIBITOR,1,1,1,,,
1415,1697116,1380301,Synaptosomal-associated protein 25 inhibitor,106138,,INHIBITOR,1,1,1,"BOTOX blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings.",,
1416,1697433,1380836,Synaptosomal-associated protein 25 inhibitor,106138,,INHIBITOR,1,1,1,"BOTOX blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings.",,
1417,1696456,675360,Synaptosomal-associated protein 25 inhibitor,106138,,INHIBITOR,1,1,1,"BOTOX blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings.",,
1418,1344999,675387,Vesicle-associated membrane protein 2 inhibitor,106139,,INHIBITOR,1,1,1,Cleaves snare complex,,
1419,1392878,1121865,Tumor necrosis factor receptor superfamily member 8 inhibitor,106140,,INHIBITOR,1,1,1,,,
1420,1390842,699374,Tumor necrosis factor ligand superfamily member 11 inhibitor,106141,,INHIBITOR,1,1,1,,,
1421,1390844,675779,Complement C5 inhibitor,106142,,INHIBITOR,1,1,1,,,
1422,1394676,1153495,Cytotoxic T-lymphocyte protein 4 inhibitor,106143,,INHIBITOR,1,1,1,,,
1423,1343267,675484,Fusion glycoprotein F0 inhibitor,106144,,INHIBITOR,1,1,1,Pathogen target,,
1424,1344656,674992,Penicillin-binding protein inhibitor,105732,,INHIBITOR,1,1,1,,,
1425,1344380,674339,Penicillin-binding protein inhibitor,105733,,INHIBITOR,1,1,1,Indicated for staphylococcal infections,,
1426,1344278,1671123,Penicillin-binding protein inhibitor,105733,,INHIBITOR,1,1,1,,,
1427,1679389,1369610,Laminin hydrolytic enzyme,106166,,HYDROLYTIC ENZYME,1,1,1,It's a recombinant truncated form of human plasmin with proteolytic activity against protein components of the vitreous body and the vitreoretinal interface,,
1428,1696461,1380975,Collagen hydrolytic enzyme,106167,,HYDROLYTIC ENZYME,1,1,1,,,
1429,1679389,1369610,Collagen hydrolytic enzyme,106167,,HYDROLYTIC ENZYME,1,1,1,It's a recombinant truncated form of human plasmin with proteolytic activity against protein components of the vitreous body and the vitreoretinal interface,,
1430,1679370,520664,26S proteosome inhibitor,106197,2633,INHIBITOR,1,1,1,,,MB1 (P28074) is binding site
1431,1344581,187372,26S proteosome inhibitor,106197,2633,INHIBITOR,1,1,1,,,MB1 (P28074) is binding site
1432,1343214,675082,Cytochrome P450 inhibitor,106198,,INHIBITOR,1,1,1,,,
1433,1343090,16303,Tubulin inhibitor,106199,2630,INHIBITOR,1,1,1,,,Binds to beta tubulin
1434,1343630,29637,Tubulin inhibitor,106200,2631,INHIBITOR,1,1,1,,,Binds to beta tubulin
1435,1344129,26590,Tubulin inhibitor,106200,2631,INHIBITOR,1,1,1,,,Binds to beta tubulin
1436,1344920,406787,Tubulin inhibitor,106200,2631,INHIBITOR,1,1,1,,,Binds to beta tubulin
1437,1344920,406787,Tubulin inhibitor,106201,2632,INHIBITOR,1,1,1,,,Binds to beta tubulin
1438,1343630,29637,Tubulin inhibitor,106201,2632,INHIBITOR,1,1,1,,,Binds to beta tubulin
1439,1344129,26590,Tubulin inhibitor,106201,2632,INHIBITOR,1,1,1,,,Binds to beta tubulin
1440,1343733,250908,Toll-like receptor 7 agonist,101608,,AGONIST,1,1,1,,,
1441,1344184,529987,Toll-like receptor 7 antagonist,101608,,ANTAGONIST,1,1,1,,,
1442,1343301,13494,Cytochrome P450 51 inhibitor,58,,INHIBITOR,1,1,1,"Has also been implicated as a therapy for sickle cell anemia, by inhibiting the gardos channel, causing dehydration of the cells (PMID: 8636434)",,
1443,1343467,675000,Cytochrome P450 51 inhibitor,58,,INHIBITOR,1,1,1,,,
1444,1344267,27308,Cytochrome P450 51 inhibitor,58,,INHIBITOR,1,1,1,,,
1445,1344111,255904,Cytochrome P450 51 inhibitor,58,,INHIBITOR,1,1,1,,,
1446,1343669,8917,Cytochrome P450 51 inhibitor,58,,INHIBITOR,1,1,1,,,
1447,1343866,97867,Cytochrome P450 51 inhibitor,58,,INHIBITOR,1,1,1,,,
1448,1343188,259959,Cytochrome P450 51 inhibitor,58,,INHIBITOR,1,1,1,,,
1449,1344794,444419,Cytochrome P450 51 inhibitor,58,,INHIBITOR,1,1,1,,,
1450,1343577,13758,Cytochrome P450 51 inhibitor,58,,INHIBITOR,1,1,1,,,
1451,1343472,674299,Cytochrome P450 51 inhibitor,58,,INHIBITOR,1,1,1,,,
1452,1343158,674389,Cytochrome P450 51 inhibitor,58,,INHIBITOR,1,1,1,,,
1453,1343397,334337,Cytochrome P450 51 inhibitor,58,,INHIBITOR,1,1,1,,,
1454,1344196,674676,Cytochrome P450 51 inhibitor,58,,INHIBITOR,1,1,1,,,
1455,1343919,674349,Cytochrome P450 51 inhibitor,58,,INHIBITOR,1,1,1,,,
1456,1344740,674787,Cytochrome P450 51 inhibitor,58,,INHIBITOR,1,1,1,,,
1457,1344436,21697,Cyclooxygenase-2 inhibitor,126,,INHIBITOR,1,1,1,,,
1458,1344340,264453,Cyclooxygenase-2 inhibitor,126,,INHIBITOR,1,1,1,,Selective,
1459,1344561,20496,Cyclooxygenase-2 inhibitor,126,,INHIBITOR,1,1,1,,,
1460,1343512,139210,Cyclooxygenase-2 inhibitor,126,,INHIBITOR,1,1,1,,,
1461,1343486,67010,Cyclooxygenase-2 inhibitor,126,,INHIBITOR,1,1,1,,,
1462,1344122,18694,Cyclooxygenase-2 inhibitor,126,,INHIBITOR,1,1,1,,,
1463,1344314,26431,Cyclooxygenase-2 inhibitor,126,,INHIBITOR,1,1,1,,,
1465,1343529,1449169,Cannabinoid CB1 receptor agonist,87,,AGONIST,1,1,1,,,
1466,1343972,4496,Cannabinoid CB1 receptor agonist,87,,AGONIST,1,1,1,,,
1467,1344019,41644,Human herpesvirus 1 DNA polymerase inhibitor,27,,INHIBITOR,1,1,1,,,
1468,1343977,48701,Human herpesvirus 1 DNA polymerase inhibitor,27,,INHIBITOR,1,1,1,,,
1469,1699131,1364024,Human herpesvirus 1 DNA polymerase inhibitor,27,,INHIBITOR,1,1,1,,,
1470,1344771,674801,Human herpesvirus 1 DNA polymerase inhibitor,27,,INHIBITOR,1,1,1,,,
1471,1344059,365284,Human herpesvirus 1 DNA polymerase inhibitor,27,,INHIBITOR,1,1,1,,,
1472,1344412,365538,Human herpesvirus 1 DNA polymerase inhibitor,27,,INHIBITOR,1,1,1,Prodrug enzyme: Thymidine kinase,,
1473,1344925,674405,Human herpesvirus 1 DNA polymerase inhibitor,27,,INHIBITOR,1,1,1,,,
1474,1343220,149095,Human herpesvirus 1 DNA polymerase inhibitor,27,,INHIBITOR,1,1,1,,,
1475,1344916,674331,Human herpesvirus 1 DNA polymerase inhibitor,27,,INHIBITOR,1,1,1,Prodrug enzyme: Thymidine kinase,,
1476,1344100,74284,Human herpesvirus 1 DNA polymerase inhibitor,27,,INHIBITOR,1,1,1,,,
1477,1343636,675061,Human herpesvirus 1 DNA polymerase inhibitor,27,,INHIBITOR,1,1,1,,,
1478,1343388,503213,Synaptic vesicular amine transporter inhibitor,162,,INHIBITOR,1,1,1,,,
1479,1343560,43952,Synaptic vesicular amine transporter inhibitor,162,,INHIBITOR,1,1,1,,,
1480,1344687,674466,Synaptic vesicular amine transporter inhibitor,162,,INHIBITOR,1,1,1,,,
1481,1344773,193281,Synaptic vesicular amine transporter inhibitor,162,,INHIBITOR,1,1,1,,,
1482,1343558,2197715,Synaptic vesicular amine transporter inhibitor,162,,INHIBITOR,1,1,1,,,
1483,1343296,1926820,Synaptic vesicular amine transporter inhibitor,162,,INHIBITOR,1,1,1,,,
1484,1344333,1926755,Synaptic vesicular amine transporter inhibitor,162,,INHIBITOR,1,1,1,,,
1485,1344859,674733,Synaptic vesicular amine transporter inhibitor,162,,INHIBITOR,1,1,1,,,
1486,1343125,23199,Synaptic vesicular amine transporter inhibitor,162,,INHIBITOR,1,1,1,,,
1487,1344227,675129,Synaptic vesicular amine transporter inhibitor,162,,INHIBITOR,1,1,1,,,
1488,1344755,1449151,Dihydrofolate reductase inhibitor,10460,,INHIBITOR,1,1,1,,,
1489,1344960,11305,Histone deacetylase 2 inhibitor,11206,,INHIBITOR,1,1,1,,,
1490,1344392,24418,Human immunodeficiency virus type 1 protease inhibitor,191,,INHIBITOR,1,1,1,,,
1491,1344978,88100,Human immunodeficiency virus type 1 protease inhibitor,191,,INHIBITOR,1,1,1,,,
1492,1343783,213505,Human immunodeficiency virus type 1 protease inhibitor,191,,INHIBITOR,1,1,1,,,
1493,1343093,17347,Human immunodeficiency virus type 1 protease inhibitor,191,,INHIBITOR,1,1,1,,,
1494,1343781,674685,Human immunodeficiency virus type 1 protease inhibitor,191,,INHIBITOR,1,1,1,,,
1495,1344029,17169,Human immunodeficiency virus type 1 protease inhibitor,191,,INHIBITOR,1,1,1,,,
1496,1344485,37316,Human immunodeficiency virus type 1 protease inhibitor,191,,INHIBITOR,1,1,1,,,
1497,1344042,372438,Human immunodeficiency virus type 1 protease inhibitor,191,,INHIBITOR,1,1,1,,,
1498,1343748,675078,Human immunodeficiency virus type 1 protease inhibitor,191,,INHIBITOR,1,1,1,,,
1499,1343477,563318,Human immunodeficiency virus type 1 protease inhibitor,191,,INHIBITOR,1,1,1,,,
1500,1344157,674629,Human immunodeficiency virus type 1 protease inhibitor,191,,INHIBITOR,1,1,1,,,
1501,1344704,630396,Purinergic receptor P2Y12 antagonist,176,,ANTAGONIST,1,1,1,Irreversible inhibitor,,
1502,1343363,551003,Purinergic receptor P2Y12 antagonist,176,,ANTAGONIST,1,1,1,,,
1503,1392859,416772,Purinergic receptor P2Y12 negative allosteric modulator,176,,NEGATIVE ALLOSTERIC MODULATOR,1,1,1,,,
1504,1344889,675724,Purinergic receptor P2Y12 antagonist,176,,ANTAGONIST,1,1,1,Irreversible inhibitor,,
1505,1343522,674754,Muscarinic acetylcholine receptor M2 antagonist,47,,ANTAGONIST,1,1,1,"Indicated for overactive bladder, M2 likely responsible",,
1506,1343367,230999,Muscarinic acetylcholine receptor M2 antagonist,47,,ANTAGONIST,1,1,1,"Indicated for overactive bladder, M2 likely responsible",,
1507,1343595,594843,Muscarinic acetylcholine receptor M2 agonist,47,,AGONIST,1,1,1,"Indicated for urinary retention, M2 likely responsible",,
1508,1344980,675716,Muscarinic acetylcholine receptor M2 antagonist,47,,ANTAGONIST,1,1,1,"Indicated for overactive bladder, M2 likely responsible",,
1509,1344268,674886,Muscarinic acetylcholine receptor M2 antagonist,47,,ANTAGONIST,1,1,1,"Indicated for overactive bladder, M2 likely responsible",,
1510,1344620,445395,Muscarinic acetylcholine receptor M2 antagonist,47,,ANTAGONIST,1,1,1,"Indicated for bradycardia, M2 likely responsible",,
1511,1343115,1418097,Muscarinic acetylcholine receptor M2 antagonist,47,,ANTAGONIST,1,1,1,"Indicated for bradycardia, M2 likely responsible",,
1512,1344421,1594639,Muscarinic acetylcholine receptor M2 antagonist,47,,ANTAGONIST,1,1,1,"Indicated for overactive bladder, M2 likely responsible",,
1513,1344417,229058,Muscarinic acetylcholine receptor M2 antagonist,47,,ANTAGONIST,1,1,1,"Indicated for overactive bladder, M2 likely responsible",,
1514,1343474,170395,Muscarinic acetylcholine receptor M2 antagonist,47,,ANTAGONIST,1,1,1,"Indicated for overactive bladder, M2 likely responsible",,
1515,1343271,1102940,Muscarinic acetylcholine receptor M2 antagonist,47,,ANTAGONIST,1,1,1,"Indicated for overactive bladder, M2 likely responsible",,
1516,1679381,1277553,Tyrosine-protein kinase receptor RET inhibitor,100079,,INHIBITOR,1,1,1,,,
1517,1344744,674436,Tyrosine-protein kinase receptor RET inhibitor,100079,,INHIBITOR,1,1,1,,,
1518,1343773,450864,Tyrosine-protein kinase receptor RET inhibitor,100079,,INHIBITOR,1,1,1,,,
1519,1343277,33576,Tyrosine-protein kinase receptor RET inhibitor,100079,,INHIBITOR,1,1,1,,,
1520,1697532,1380933,B-lymphocyte antigen CD20 binding agent,181,,BINDING AGENT,1,1,1,targets radiotherapy to cell(via tiuxetan),,
1521,1344885,675578,B-lymphocyte antigen CD20 binding agent,181,,BINDING AGENT,1,1,1,"Acts through engagement of immune effector cells, directly activating intracellular death signaling pathways and/or activation of the complement cascade.",,
1522,1390840,675787,B-lymphocyte antigen CD20 binding agent,181,,BINDING AGENT,1,1,1,,,
1523,1343132,675487,B-lymphocyte antigen CD20 binding agent,181,,BINDING AGENT,1,1,1,,,
1524,1344456,675684,Tyrosine-protein kinase ITK/TSK inhibitor,10918,,INHIBITOR,1,1,1,,,
1525,1344219,675072,Penicillin-binding protein inhibitor,105686,,INHIBITOR,1,1,1,,,
1526,1344830,675067,Penicillin-binding protein inhibitor,105686,,INHIBITOR,1,1,1,,,
1527,1343488,171062,Muscle-type nicotinic acetylcholine receptor partial agonist,105709,,PARTIAL AGONIST,1,1,1,depolarizing,,
1528,1343928,674708,Muscle-type nicotinic acetylcholine receptor antagonist,105709,,ANTAGONIST,1,1,1,non-depolarizing,,
1529,1343164,674592,Muscle-type nicotinic acetylcholine receptor antagonist,105709,,ANTAGONIST,1,1,1,non-depolarizing,,
1530,1344770,674944,Muscle-type nicotinic acetylcholine receptor antagonist,105709,,ANTAGONIST,1,1,1,non-depolarizing,,
1531,1344450,699450,Muscle-type nicotinic acetylcholine receptor antagonist,105709,,ANTAGONIST,1,1,1,non-depolarizing,,
1532,1344732,674500,Muscle-type nicotinic acetylcholine receptor antagonist,105709,,ANTAGONIST,1,1,1,non-depolarizing,,
1533,1343729,674673,Muscle-type nicotinic acetylcholine receptor antagonist,105709,,ANTAGONIST,1,1,1,non-depolarizing,,
1534,1343913,674478,Muscle-type nicotinic acetylcholine receptor antagonist,105709,,ANTAGONIST,1,1,1,,,
1535,1343505,567201,Muscle-type nicotinic acetylcholine receptor antagonist,105709,,ANTAGONIST,1,1,1,,,
1536,1344280,101924,Muscle-type nicotinic acetylcholine receptor antagonist,105709,,ANTAGONIST,1,1,1,,,
1537,1344607,674599,Muscle-type nicotinic acetylcholine receptor antagonist,105709,,ANTAGONIST,1,1,1,,,
1538,1344437,101810,Muscle-type nicotinic acetylcholine receptor agonist,105709,,AGONIST,1,1,1,,,
1539,1343421,2197692,Muscle-type nicotinic acetylcholine receptor antagonist,105709,,ANTAGONIST,1,1,1,,,
1540,1344497,674580,Muscle-type nicotinic acetylcholine receptor antagonist,105709,,ANTAGONIST,1,1,1,,,
1541,1343277,33576,Ephrin receptor inhibitor,105738,,INHIBITOR,1,1,1,,,
1542,1343848,261343,Alcohol dehydrogenase class I inhibitor,105739,,INHIBITOR,1,1,1,Competitive inhibitor,,
1543,1344547,33986,DNA inhibitor,105743,,INHIBITOR,1,1,1,"When monophosporylated is incorporates into the DNA, when triphosporylated inhibits the enzymes",,
1544,1344547,33986,DNA inhibitor,105741,,INHIBITOR,1,1,1,"When monophosporylated is incorporates into the DNA, when triphosporylated inhibits the enzymes",,
1545,1344547,33986,DNA inhibitor,105742,,INHIBITOR,1,1,1,"When monophosporylated is incorporates into the DNA, when triphosporylated inhibits the enzymes",,
1546,1343277,33576,Epidermal growth factor receptor inhibitor,105744,,INHIBITOR,1,1,1,,,
1547,1344730,674584,Glutamate-gated chloride channel modulator,105745,,MODULATOR,1,1,1,,,
1548,1344730,674584,Glutamate-gated chloride channel modulator,105746,,MODULATOR,1,1,1,,,
1549,1390915,284208,Glycine receptor (alpha-1/beta) agonist,105747,2639,AGONIST,1,1,1,,,Alpha subunit is binding site
1550,1344688,674684,Glycine receptor (alpha-1/beta) positive modulator,105747,2639,POSITIVE MODULATOR,1,1,1,alpha1/beta is main adult form,,
1551,1343836,238429,Glycine receptor (alpha-1/beta) positive modulator,105747,2639,POSITIVE MODULATOR,1,1,1,alpha1/beta is main adult form,,
1552,1344237,674645,Glycine receptor (alpha-1/beta) positive modulator,105747,2639,POSITIVE MODULATOR,1,1,1,alpha1/beta is main adult form,,
1553,1343444,85649,Glycine receptor (alpha-1/beta) positive modulator,105747,2639,POSITIVE MODULATOR,1,1,1,alpha1/beta is main adult form,,
1554,1344953,238127,Glycine receptor (alpha-1/beta) positive modulator,105747,2639,POSITIVE MODULATOR,1,1,1,alpha1/beta is main adult form,,
1555,1343792,454382,Heavy metals chelating agent,105748,,CHELATING AGENT,1,1,1,gold/arsenic/mercury,,
1556,1343954,2197651,Glycoproteins cross-linking agent,105749,,CROSS-LINKING AGENT,1,1,1,cytoprotective barrier,,
1557,1344505,674934,Hydroxyapatite sequestering agent,105750,,SEQUESTERING AGENT,1,1,1,enhances crystal formation by binding to hydroxyapatite,,
1558,1344413,8193,Zinc chelating agent,105751,,CHELATING AGENT,1,1,1,"Used as antibiotic against diarrhea in the 70s, but nowadays considered in cancer treatments (off-label), for its chelator and ionophore properties with capacity to inhibit proteosome",,
1559,1343455,369179,Copper chelating agent,105752,,CHELATING AGENT,1,1,1,,,
1560,1344710,2197648,Copper chelating agent,105752,,CHELATING AGENT,1,1,1,,,
1561,1344413,8193,Copper chelating agent,105752,,CHELATING AGENT,1,1,1,"Used as antibiotic against diarrhea in the 70s, but nowadays considered in cancer treatments (off-label), for its chelator and ionophore properties with capacity to inhibit proteosome",,
1562,1343749,564990,Iron chelating agent,105753,,CHELATING AGENT,1,1,1,,Selective,
1563,1344336,230444,Iron chelating agent,105753,,CHELATING AGENT,1,1,1,,,
1564,1344413,8193,Iron chelating agent,105753,,CHELATING AGENT,1,1,1,"Used as antibiotic against diarrhea in the 70s, but nowadays considered in cancer treatments (off-label), for its chelator and ionophore properties with capacity to inhibit proteosome",,
1565,1698797,1376013,Janus Kinase (JAK) inhibitor,105757,,INHIBITOR,1,1,1,,,
1566,1392855,61945,KCNQ (Kv7) potassium channel blocker,105758,,BLOCKER,1,1,1,,,
1567,1344277,674903,Monoamine transporter inhibitor,105759,,INHIBITOR,1,1,1,,,
1568,1344126,46385,Monoamine transporter inhibitor,105759,,INHIBITOR,1,1,1,,,
1569,1343542,2197701,Monoamine transporter inhibitor,105759,,INHIBITOR,1,1,1,,,
1570,1344532,547681,Mitochondrial complex I (NADH dehydrogenase) inhibitor,105760,,INHIBITOR,1,1,1,May not be direct target,,
1571,1344378,27029,"3',5'-cyclic phosphodiesterase inhibitor",105761,,INHIBITOR,1,1,1,,,
1572,1344201,674826,Phosphodiesterase 8 inhibitor,105762,,INHIBITOR,1,1,1,,,
1573,1344260,14125,Prostaglandin E2 receptor agonist,105763,,AGONIST,1,1,1,,,
1574,1344996,495572,Retinoic acid receptor agonist,105764,,AGONIST,1,1,1,,,
1575,1343842,2208,Retinoic acid receptor agonist,105764,,AGONIST,1,1,1,,,
1576,1344853,119498,Retinoid X receptor agonist,105765,,AGONIST,1,1,1,,,
1577,1344684,33216,Retinoid receptor agonist,105766,,AGONIST,1,1,1,,,
1578,1344915,169652,Retinoid receptor agonist,105766,,AGONIST,1,1,1,Precise mechanism uncertain. RARG/RXRA are predominant forms in skin,,
1579,1344296,4193,Retinoid receptor agonist,105766,,AGONIST,1,1,1,Precise mechanism uncertain. RARG/RXRA are predominant forms in skin,,
1580,1344162,485738,RNA inhibitor,105768,,INHIBITOR,1,1,1,,,
1581,1344041,2335036,Nicotinic acetylcholine receptor agonist,106002,,AGONIST,1,1,1,,,
1582,1344184,529987,Toll-like receptor 9 antagonist,101567,,ANTAGONIST,1,1,1,,,
1583,1343750,465356,Sodium/potassium-transporting ATPase inhibitor,104770,2653,INHIBITOR,1,1,1,,,Alpha subunit is binding site
1584,1343152,419508,Sodium/potassium-transporting ATPase inhibitor,104770,2653,INHIBITOR,1,1,1,,,Alpha subunit is binding site
1585,1343375,581814,Sodium/potassium-transporting ATPase inhibitor,104770,2653,INHIBITOR,1,1,1,,,Alpha subunit is binding site
1586,1344182,1926906,Sodium/potassium-transporting ATPase inhibitor,104770,2653,INHIBITOR,1,1,1,,,Alpha subunit is binding site
1587,1390915,284208,GABA-A receptor; anion channel positive modulator,104688,,POSITIVE MODULATOR,1,1,1,,,
1588,1343752,635,GABA-A receptor; anion channel allosteric antagonist,104688,2617,ALLOSTERIC ANTAGONIST,1,1,1,Antagonist at benzodiazepine site to treat overdose,,Benzodiazepine site
1589,1343877,1369640,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1590,1343345,2431,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1591,1344856,674654,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1592,1344578,721,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1593,1343535,421334,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1594,1344820,16506,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1595,1343061,99389,GABA-A receptor; anion channel agonist,104688,2616,AGONIST,1,1,1,,,GABA site
1596,1435098,111390,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1597,1344282,27648,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1598,1343662,27419,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1599,1343094,2524,GABA-A receptor; anion channel positive allosteric modulator,104688,2618,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Barbiturate site
1600,1343117,2465,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1601,1344688,674684,GABA-A receptor; anion channel positive allosteric modulator,104688,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Likely allosteric but unclear whether benzodiazepine or barbiturate site involved
1602,1344814,49847,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1603,1344702,674753,GABA-A receptor; anion channel positive allosteric modulator,104688,2618,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Barbiturate site
1604,1344372,674933,GABA-A receptor; anion channel positive allosteric modulator,104688,2618,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Barbiturate site
1605,1344073,151300,GABA-A receptor; anion channel positive modulator,104688,,POSITIVE MODULATOR,1,1,1,,,Likely allosteric but unclear whether benzodiazepine or barbiturate site involved
1606,1343571,1359038,GABA-A receptor; anion channel positive modulator,104688,,POSITIVE MODULATOR,1,1,1,,,Likely allosteric but unclear whether benzodiazepine or barbiturate site involved
1607,1343113,16959,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1608,1343836,238429,GABA-A receptor; anion channel positive modulator,104688,,POSITIVE MODULATOR,1,1,1,,,Likely allosteric but unclear whether benzodiazepine or barbiturate site involved
1609,1344242,19469,GABA-A receptor; anion channel positive modulator,104688,,POSITIVE MODULATOR,1,1,1,,,Unknown binding site
1610,1344931,2408,GABA-A receptor; anion channel positive allosteric modulator,104688,2618,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Barbiturate site
1611,1343765,38588,GABA-A receptor; anion channel positive allosteric modulator,104688,2618,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Barbiturate site
1612,1344105,674741,GABA-A receptor; anion channel positive allosteric modulator,104688,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,"Likely allosteric, unclear whether benzodiazepine or barbiturate site, but is barbiturate-like"
1613,1344326,674371,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1614,1343884,95969,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1615,1343823,65728,GABA-A receptor; anion channel positive allosteric modulator,104688,2618,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Barbiturate site
1616,1343635,11819,GABA-A receptor; anion channel positive allosteric modulator,104688,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Likely allosteric but unclear whether benzodiazepine or barbiturate site involved
1617,1344840,674423,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1618,1343412,2327,GABA-A receptor; anion channel positive allosteric modulator,104688,2618,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Barbiturate site
1619,1344622,95978,GABA-A receptor; anion channel positive allosteric modulator,104688,2618,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Barbiturate site
1620,1344123,674854,GABA-A receptor; anion channel positive allosteric modulator,104688,2618,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Barbiturate site
1621,1344237,674645,GABA-A receptor; anion channel positive allosteric modulator,104688,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Likely allosteric but unclear whether benzodiazepine or barbiturate site involved
1622,1343368,95909,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1623,1343189,675016,GABA-A receptor; anion channel positive allosteric modulator,104688,2618,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Barbiturate site
1624,1344467,38569,GABA-A receptor; anion channel positive allosteric modulator,104688,2618,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Barbiturate site
1625,1344315,29090,GABA-A receptor; anion channel positive modulator,104688,,POSITIVE MODULATOR,1,1,1,,selectivity for beta-3 containing complexes,Likely allosteric but unclear whether benzodiazepine or barbiturate site involved
1626,1344304,2197595,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1627,1344543,95970,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
1628,1343444,85649,GABA-A receptor; anion channel positive allosteric modulator,104688,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Likely allosteric but unclear whether benzodiazepine or barbiturate site involved
1629,1344953,238127,GABA-A receptor; anion channel positive allosteric modulator,104688,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Likely allosteric but unclear whether benzodiazepine or barbiturate site involved
1630,1344546,366279,GABA-A receptor; anion channel positive modulator,104688,,POSITIVE MODULATOR,1,1,1,,,Likely allosteric but unclear whether benzodiazepine or barbiturate site involved
1631,1344013,674740,GABA-A receptor; anion channel positive modulator,104688,,POSITIVE MODULATOR,1,1,1,,,Unknown binding site
1632,1344914,2197691,GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator,105087,2619,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,"Not clear if allosteric, but looks like benzodiazepine"
1633,1343427,421332,GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator,105087,2619,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,"Selective for the brain omega-1 receptor (i.e. BZ1-type, i.e. alpha1/beta1/gamma2-GABA receptor)",
1634,1344476,361469,SRC inhibitor,105769,,INHIBITOR,1,1,1,,,
1635,1343726,674920,Steroid 5-alpha-reductase inhibitor,105770,,INHIBITOR,1,1,1,,,
1636,1343564,675712,Topoisomerase IV inhibitor,105771,,INHIBITOR,1,1,1,,Broad spectrum,
1637,1343943,674449,Topoisomerase IV inhibitor,105771,,INHIBITOR,1,1,1,,Broad spectrum,
1638,1344908,674686,Topoisomerase IV inhibitor,105771,,INHIBITOR,1,1,1,,Broad spectrum,
1639,1343261,246,Topoisomerase IV inhibitor,105771,,INHIBITOR,1,1,1,,Broad spectrum,
1640,1344624,65351,Topoisomerase IV inhibitor,105771,,INHIBITOR,1,1,1,,Broad spectrum,
1641,1343402,674730,Topoisomerase IV inhibitor,105771,,INHIBITOR,1,1,1,,Broad spectrum,
1642,1343083,57175,Topoisomerase IV inhibitor,105772,,INHIBITOR,1,1,1,,,
1643,1343490,674507,Vasopressin receptor agonist,105773,,AGONIST,1,1,1,,,
1644,1343180,674641,Vasopressin receptor agonist,105773,,AGONIST,1,1,1,,,
1645,1343273,2095,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,,
1646,1343569,806511,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1647,1343692,2265,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1648,1343369,1159,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1649,1641032,949710,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1650,1344984,675112,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1651,1344165,674861,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1652,1344393,1103972,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1653,1344807,2247,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1654,1344173,674272,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1655,1343907,153330,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1656,1343660,674302,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1657,1344904,2130,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1658,1343898,2484,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1659,1343908,32842,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1660,1344394,2131,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1661,1343661,674310,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1662,1343939,2525,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1663,1343165,204115,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,,Broad spectrum,
1664,1344289,1216,Bacterial dihydrofolate reductase inhibitor,106169,,INHIBITOR,1,1,1,,Broad spectrum,
1665,1343395,1382807,Bacterial dihydrofolate reductase inhibitor,106169,,INHIBITOR,1,1,1,,Broad spectrum,
1666,1343311,675031,Bacterial dihydrofolate reductase inhibitor,106169,,INHIBITOR,1,1,1,,Broad spectrum,
1667,1344082,111491,Bacterial beta-lactamase TEM inhibitor,106170,,INHIBITOR,1,1,1,,Broad spectrum,
1668,1344822,373856,Bacterial beta-lactamase TEM inhibitor,106170,,INHIBITOR,1,1,1,,Broad spectrum,
1669,1343625,674895,Bacterial beta-lactamase TEM inhibitor,106170,,INHIBITOR,1,1,1,,Broad spectrum,
1670,1344986,2197586,Isoleucyl-tRNA synthetase inhibitor,106171,,INHIBITOR,1,1,1,,,
1671,1343812,35271,Isoleucyl-tRNA synthetase inhibitor,106171,,INHIBITOR,1,1,1,,,
1672,1344186,674375,Radioactive metals chelating agent,106210,,CHELATING AGENT,1,1,1,Chelates radioactive contaminants to increase elimination rate.,,
1673,1344873,674649,Radioactive metals chelating agent,106210,,CHELATING AGENT,1,1,1,,,
1674,1344364,674896,Radioactive metals chelating agent,106210,,CHELATING AGENT,1,1,1,,,
1675,1344887,675388,Uric acid oxidative enzyme,106162,,OXIDATIVE ENZYME,1,1,1,,,
1676,1702657,1378015,Glutamine sequestering agent,106212,,SEQUESTERING AGENT,1,1,1,"Removes excess nitrogen, caused by enzyme deficiency",,
1677,1343346,674994,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1678,1343348,674942,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1679,1344236,466810,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1680,1344574,674969,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1681,1344115,454576,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1682,1343634,674806,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1683,1343597,1418075,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1684,1344425,24806,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,"Indicated for streptococcal, pneumococcal and staphylococcal infections",,
1685,1343891,674803,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,"Indicated for streptococcal, pneumococcal and staphylococcal infections",,
1686,1344645,61680,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1687,1343872,478059,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1688,1343867,624296,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1689,1344168,674308,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1690,1343149,674922,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1691,1343674,674916,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1692,1343596,675069,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1693,1344974,674997,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1694,1343699,674540,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1695,1344003,674481,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1696,1344625,1674197,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1697,1343392,674970,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1698,1344845,674495,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1699,1344616,674474,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1700,1344089,84624,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1701,1344729,1672484,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1702,1344843,674433,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1703,1344498,674623,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1704,1344782,1926822,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1705,1344880,485902,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1706,1344657,229172,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1707,1344250,674719,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1708,1343124,1673259,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1709,1343391,454578,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1710,1343581,143284,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1711,1343626,305519,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1712,1344492,675049,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1713,1344240,430642,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1714,1344118,604643,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1715,1344618,674307,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1716,1343746,460466,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1717,1343338,674317,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1718,1344335,674956,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1719,1344594,674709,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1720,1344480,674913,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1721,1344452,61682,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1722,1343235,112665,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1723,1343495,674967,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1724,1344516,506444,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1725,1343473,674561,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1726,1343764,26386,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1727,1344397,1078476,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1728,1343209,2197386,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1729,1344534,226400,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1730,1343591,167260,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1731,1344307,674771,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
1732,1343208,610112,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,Lethal effect due to binding PBP 2 and PBP 1B in Enterobacteriaceae and Pseudomonas aeruginosa,,
1733,1344321,12465,Bacterial penicillin-binding protein 2 inhibitor,105684,,INHIBITOR,1,1,1,,,
1734,1343353,674652,Penicillin-binding protein inhibitor,105685,,INHIBITOR,1,1,1,,,
1735,1344283,992160,Penicillin-binding protein inhibitor,105685,,INHIBITOR,1,1,1,,,
1736,1343819,2197438,Penicillin-binding protein inhibitor,105685,,INHIBITOR,1,1,1,,,
1737,1343215,1369646,Voltage-sensitive sodium channel alpha-subunit blocker,105696,,BLOCKER,1,1,1,,,
1738,1343655,421902,Voltage-sensitive sodium channel blocker,105697,,BLOCKER,1,1,1,,,
1739,1343728,22641,ATP-binding cassette sub-family A member 1 inhibitor,105698,,INHIBITOR,1,1,1,,,
1740,1343082,508828,Transmembrane glycoprotein gp41 inhibitor,105699,,INHIBITOR,1,1,1,,,
1741,1344576,674419,Acetylcholinesterase inhibitor,105700,,INHIBITOR,1,1,1,,,
1742,1343205,456266,"DNA topoisomerase I, mitochondrial inhibitor",105701,,INHIBITOR,1,1,1,,,
1743,1344716,675731,"Carbamoyl-phosphate synthase [ammonia], mitochondrial positive allosteric modulator",105702,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,
1744,1343926,431141,Amidophosphoribosyltransferase inhibitor,105704,,INHIBITOR,1,1,1,Prodrug enzyme: hypoxanthine-guanine phosphoribosyl transferase (HGPRT; EC 2.4.2.8),,
1745,1343237,674702,Amidophosphoribosyltransferase inhibitor,105704,,INHIBITOR,1,1,1,Prodrug enzyme: hypoxanthine-guanine phosphoribosyl transferase (HGPRT; ec 2.4.2.8),,
1746,1344643,674351,Amidophosphoribosyltransferase inhibitor,105704,,INHIBITOR,1,1,1,Prodrug enzyme: hypoxanthine-guanine phosphoribosyl transferase (HGPRT; EC 2.4.2.8),,
1747,1344617,126356,Dihydropteroate synthase 1 inhibitor,105705,,INHIBITOR,1,1,1,,,
1748,1343175,674531,Dihydropteroate synthase 1 inhibitor,105705,,INHIBITOR,1,1,1,,,
1749,1343470,99024,Voltage-activated calcium channel beta 1 subunit blocker,105774,,BLOCKER,1,1,1,,,
1750,1343470,99024,Voltage-activated calcium channel beta 2 subunit blocker,105775,,BLOCKER,1,1,1,,,
1751,1344855,27340,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
1752,1343608,2287105,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1753,1343393,421157,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1754,1343533,2197439,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1755,1343406,1418074,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1756,1343138,1673803,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
1757,1343344,674680,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
1758,1343961,674461,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
1759,1343715,1592294,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
1760,1343987,1926909,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
1761,1344414,674888,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
1762,1344325,378124,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1763,1344388,674539,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
1764,1343768,373970,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1765,1344686,674425,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1766,1344703,171587,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
1767,1344166,1674082,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1768,1343857,455284,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1769,1343385,674583,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
1770,1343200,674457,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
1771,1343868,373985,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1772,1344507,2197700,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1773,1344449,1418014,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1774,1343797,675022,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1775,1344731,430250,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1776,1344415,674600,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
1777,1343820,1031364,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1778,1344949,1445828,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1779,1343874,674832,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1780,1344060,1592405,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1781,1343873,1449150,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
1782,1343615,420999,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
1783,1343118,12506,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
1784,1343651,2197442,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1785,1343058,2197640,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
1786,1344894,674639,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
1787,1343640,570147,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,Broad spectrum,23S RRNA
1788,1343176,12428,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
1789,1696165,675456,Interleukin-2 receptor agonist,106146,2647,AGONIST,1,1,1,,,Binding site involves alpha and beta subunits
1790,1343717,675587,Interleukin-2 receptor inhibitor,106146,2648,INHIBITOR,1,1,1,,,Alpha subunit is binding site
1791,1697230,675367,Interleukin-2 receptor binding agent,106146,2647,BINDING AGENT,1,1,1,targets toxin to cell,,Binding site involves alpha and beta subunits
1792,1343975,675419,Interleukin-2 receptor inhibitor,106146,2648,INHIBITOR,1,1,1,,,Alpha subunit is binding site
1793,1344037,675588,T cell surface glycoprotein CD3 inhibitor,106147,2656,INHIBITOR,1,1,1,,,Epsilon is binding site
1794,1344738,675569,Granulocyte-macrophage colony-stimulating factor receptor agonist,106148,2640,AGONIST,1,1,1,,,Alpha subunit is binding site
1795,1696822,1381313,Interferon alpha/beta receptor agonist,106149,,AGONIST,1,1,1,,,Alpha subunit is binding site
1796,1696371,1380774,Interferon alpha/beta receptor agonist,106149,,AGONIST,1,1,1,,,Alpha subunit is binding site
1797,1343711,675368,Interferon alpha/beta receptor agonist,106149,,AGONIST,1,1,1,,,Alpha subunit is binding site
1798,1343710,675521,Interferon alpha/beta receptor agonist,106149,,AGONIST,1,1,1,,,Alpha subunit is binding site
1799,1343942,675549,Interferon alpha/beta receptor agonist,106149,,AGONIST,1,1,1,,,Alpha subunit is binding site
1800,1344442,675616,Interferon alpha/beta receptor agonist,106149,,AGONIST,1,1,1,,,Alpha subunit is binding site
1801,1343435,675558,Interferon alpha/beta receptor agonist,106149,,AGONIST,1,1,1,,,Alpha subunit is binding site
1802,1343709,675613,Interferon alpha/beta receptor agonist,106149,,AGONIST,1,1,1,,,Alpha subunit is binding site
1803,1696745,675394,Interferon gamma receptor agonist,106150,,AGONIST,1,1,1,,,Alpha subunit is binding site
1804,1343126,8873,Ergosterol sequestering agent,106007,,SEQUESTERING AGENT,1,1,1,forms pore in membrane by binding ergosterol,,
1805,1343351,444572,Ergosterol sequestering agent,106007,,SEQUESTERING AGENT,1,1,1,,,
1806,1343172,674607,Ergosterol sequestering agent,106007,,SEQUESTERING AGENT,1,1,1,,,
1807,1343471,675024,Lead chelating agent,106008,,CHELATING AGENT,1,1,1,,,
1808,1344611,2197400,Calcium chelating agent,106009,,CHELATING AGENT,1,1,1,,,
1809,1344706,675516,Cell membrane inhibitor,106010,,INHIBITOR,1,1,1,Disrupts cell membrane,,
1810,1344051,675500,Cell membrane inhibitor,106010,,INHIBITOR,1,1,1,,,
1811,1343230,374037,Cell membrane inhibitor,106010,,INHIBITOR,1,1,1,It binds to bacterial membranes and causes a rapid depolarization of membrane potential,,
1812,1343105,2335059,Cell membrane inhibitor,106010,,INHIBITOR,1,1,1,Disrupts cell membrane,,
1813,1343793,1763651,Cell outer membrane inhibitor,106011,,INHIBITOR,1,1,1,,,
1814,1343216,1449181,Cell outer membrane inhibitor,106011,,INHIBITOR,1,1,1,Disrupts cell membrane,,
1815,1343287,2197585,Cell outer membrane inhibitor,106011,,INHIBITOR,1,1,1,,,
1816,1344701,253862,Cell membrane inhibitor,106012,,INHIBITOR,1,1,1,Disrupts cell membrane,,
1817,1344592,674598,Cell membrane inhibitor,106014,,INHIBITOR,1,1,1,"Disrupts bacterial membrane, promotes potassium outflux",,
1818,1343914,674509,C55-isoprenyl pyrophosphate inhibitor,106015,,INHIBITOR,1,1,1,,,
1819,1343372,1369648,C55-isoprenyl pyrophosphate inhibitor,106015,,INHIBITOR,1,1,1,,,
1822,1344470,1355854,Cystine reducing agent,106018,,REDUCING AGENT,1,1,1,,,
1823,1679384,705121,Cystine reducing agent,106018,,REDUCING AGENT,1,1,1,,,
1824,1344055,27912,DNA inhibitor,106020,,INHIBITOR,1,1,1,Generates free radicals causing DNA damage in trichomonas + bacterial species.  In H. Pylori infections the oxygen-insensitive NADPH nitroreductase enzymes responsible for metabolite generation are normally found mutated in resistant strains (PMID: 10960092),,
1825,1343229,98346,DNA inhibitor,106020,,INHIBITOR,1,1,1,Generates free radicals causing DNA damage.,,
1826,1344349,674820,DNA inhibitor,106020,,INHIBITOR,1,1,1,Generates free radicals causing DNA damage in trichomonas + bacterial species.  In H. Pylori infections the oxygen-insensitive NADPH nitroreductase enzymes responsible for metabolite generation are normally found mutated in resistant strains (PMID: 10960092),,
1827,1344902,675055,DNA inhibitor,106020,,INHIBITOR,1,1,1,Causes cross-linking of proteins and nucleic acids (PMID: 9880479).,,
1828,1343071,70239,DNA inhibitor,106020,,INHIBITOR,1,1,1,"Prodrug; its activated by the type I nitroreductase (NTR), who produces reactive species, leading to an increase in oxidative stress",,
1829,1344752,151310,DNA inhibitor,106020,,INHIBITOR,1,1,1,Promotes inter-strand DNA cross-linking,,
1830,1344503,674547,DNA inhibitor,106020,,INHIBITOR,1,1,1,Generates free radicals causing DNA damage.,,
1831,1343519,674951,DNA inhibitor,106020,,INHIBITOR,1,1,1,Generates free radicals causing DNA damage.,,
1832,1343070,16592,DNA inhibitor,106020,,INHIBITOR,1,1,1,Generates free radicals causing DNA damage.,,
1833,1343240,496769,70S ribosome inhibitor,106075,2626,INHIBITOR,1,1,1,Indicated for staph aur and strep pyogenes.,,Binding site is 50S ribosomal protein L3
1834,1343240,496769,70S ribosome inhibitor,106082,2625,INHIBITOR,1,1,1,Indicated for staph aur and strep pyogenes.,,Binding site is 50S ribosomal protein L3
1837,1390839,675786,Interleukin-12 inhibitor,106132,2646,INHIBITOR,1,1,1,,,Beta subunit is binding site
1838,1390839,675786,Interleukin-23 inhibitor,106133,2649,INHIBITOR,1,1,1,,,Beta (p40) subunit is binding site
1839,1390841,699373,Interleukin-6 receptor alpha subunit inhibitor,106134,,INHIBITOR,1,1,1,"Complex with beta subunit in membrane bound form, but binds to soluble (alpha only) form too",,Alpha subunit is binding site
1840,1702595,1377970,ATP synthase inhibitor,106145,,INHIBITOR,1,1,1,"It has been shown that mutation in the atpE gene, which encodes the c subunit, of the mycobacterial ATP synthase, confers resistant to Bedaquiline, suggesting that Bedaquiline binds crucially to this target, inhibiting the proton pump of M. tuberculosis and therefore interfering with the rotation properties of the transmembrane disk, leading to ATP depletion (PMID: 15591164)",,
1841,1696279,675570,DNA hydrolytic enzyme,105574,,HYDROLYTIC ENZYME,1,1,1,,,
1842,1344585,675539,DNA hydrolytic enzyme,105574,,HYDROLYTIC ENZYME,1,1,1,,,
1843,1344783,675524,DNA inhibitor,105574,,INHIBITOR,1,1,1,intercalates DNA and causes double strand breakage,,
1844,1344673,675685,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1845,1343487,442943,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1846,1343941,674747,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1847,1343763,674952,DNA inhibitor,105574,,INHIBITOR,1,1,1,Alkylating agent,,
1848,1343611,1064511,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1849,1344233,675063,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1850,1344692,674932,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1851,1344141,56644,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1852,1344484,10898,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1853,1344494,243124,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1854,1343730,699405,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1855,1343903,300022,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1856,1344423,418344,DNA inhibitor,105574,,INHIBITOR,1,1,1,Alkylating agent,,
1857,1344302,386327,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1858,1344487,65415,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1859,1343349,11002,DNA inhibitor,105574,,INHIBITOR,1,1,1,Alkylating agent,,
1860,1343072,1595395,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1861,1344865,28310,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1862,1344530,1063,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1863,1344226,453722,DNA inhibitor,105574,,INHIBITOR,1,1,1,Alkylating agent,,
1864,1343549,13590,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1865,1343899,53686,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1866,1344300,674814,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1867,1343967,467361,DNA inhibitor,105574,,INHIBITOR,1,1,1,"Activated by the deoxycytidine kinase to a toxic compound, which then gets incorporated into DNA",,
1868,1343409,5772,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1869,1344852,119640,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1870,1344187,674361,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1871,1344170,402531,DNA inhibitor,105574,,INHIBITOR,1,1,1,Photodynamic therapy,,
1872,1344579,8633,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1873,1343167,418401,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1874,1343926,431141,DNA inhibitor,105574,,INHIBITOR,1,1,1,Prodrug enzyme: hypoxanthine-guanine phosphoribosyl transferase (HGPRT; EC 2.4.2.8),,
1875,1344643,674351,DNA inhibitor,105574,,INHIBITOR,1,1,1,Prodrug enzyme: hypoxanthine-guanine phosphoribosyl transferase (HGPRT; EC 2.4.2.8),,
1876,1343685,674426,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1877,1343998,446279,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1878,1344690,462435,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1879,1344222,581569,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1880,1343231,675080,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1881,1343623,598447,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1882,1343600,10840,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1883,1343645,51182,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1884,1344971,1339278,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1885,1343237,674702,DNA inhibitor,105574,,INHIBITOR,1,1,1,Prodrug enzyme: hypoxanthine-guanine phosphoribosyl transferase (HGPRT; ec 2.4.2.8),,
1886,1343508,840903,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1887,1344163,36864,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1888,1344829,368538,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1889,1344229,674927,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1890,1343788,624185,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
1891,1343623,598447,RNA inhibitor,105575,,INHIBITOR,1,1,1,,,
1892,1343600,10840,RNA inhibitor,105575,,INHIBITOR,1,1,1,,,
1893,1343645,51182,RNA inhibitor,105575,,INHIBITOR,1,1,1,,,
1894,1343167,418401,RNA inhibitor,105575,,INHIBITOR,1,1,1,,,
1895,1344829,368538,RNA inhibitor,105575,,INHIBITOR,1,1,1,,,
1896,1344971,1339278,RNA inhibitor,105575,,INHIBITOR,1,1,1,,,
1897,1343564,675712,Bacterial DNA gyrase inhibitor,105577,,INHIBITOR,1,1,1,,,
1898,1343943,674449,Bacterial DNA gyrase inhibitor,105577,,INHIBITOR,1,1,1,,,
1899,1343134,146,Bacterial DNA gyrase inhibitor,105577,,INHIBITOR,1,1,1,,,
1900,1343720,214701,Bacterial DNA gyrase inhibitor,105577,,INHIBITOR,1,1,1,,,
1901,1343960,241,Bacterial DNA gyrase inhibitor,105577,,INHIBITOR,1,1,1,,,
1902,1344441,210388,Bacterial DNA gyrase inhibitor,105577,,INHIBITOR,1,1,1,,,
1903,1343402,674730,Bacterial DNA gyrase inhibitor,105577,,INHIBITOR,1,1,1,,,
1904,1343261,246,Bacterial DNA gyrase inhibitor,105577,,INHIBITOR,1,1,1,,,
1905,1344405,147,Bacterial DNA gyrase inhibitor,105577,,INHIBITOR,1,1,1,,,
1906,1344908,674686,Bacterial DNA gyrase inhibitor,105577,,INHIBITOR,1,1,1,,,
1907,1344624,65351,Bacterial DNA gyrase inhibitor,105577,,INHIBITOR,1,1,1,,,
1908,1344006,557467,Bacterial DNA gyrase inhibitor,105577,,INHIBITOR,1,1,1,,,
1909,1343340,1795,DNA gyrase inhibitor,105578,,INHIBITOR,1,1,1,,,
1910,1344695,674344,DNA gyrase inhibitor,105578,,INHIBITOR,1,1,1,,,
1911,1343077,1712,DNA gyrase inhibitor,105578,,INHIBITOR,1,1,1,,,
1912,1344142,674572,DNA gyrase inhibitor,105578,,INHIBITOR,1,1,1,,,
1913,1343083,57175,DNA gyrase inhibitor,105597,,INHIBITOR,1,1,1,,,
1914,1345004,543306,Sphingosine 1-phosphate receptor agonist,105736,,AGONIST,1,1,1,,EDG5 less relevant,
1915,1344222,581569,DNA polymerase (alpha/delta/epsilon) inhibitor,105737,,INHIBITOR,1,1,1,,,
1916,1343645,51182,DNA polymerase (alpha/delta/epsilon) inhibitor,105737,,INHIBITOR,1,1,1,,,
1917,1343956,624161,DNA polymerase (alpha/delta/epsilon) inhibitor,105737,,INHIBITOR,1,1,1,,,
1918,1344009,480382,DNA polymerase (alpha/delta/epsilon) inhibitor,105737,,INHIBITOR,1,1,1,,,
1919,1344291,674333,Voltage-gated calcium channel blocker,105734,,BLOCKER,1,1,1,,,
1920,1343561,136161,Voltage-gated calcium channel modulator,105734,2657,MODULATOR,1,1,1,,,"alpha2delta-1 is binding site: 23836974, 23642658"
1921,1344058,88316,Voltage-gated calcium channel modulator,105734,2657,MODULATOR,1,1,1,,,"alpha2delta-1 is binding site: 23836974, 23642658"
1922,1344044,1051353,Voltage-gated calcium channel modulator,105734,2657,MODULATOR,1,1,1,,,"alpha2delta-1 is binding site: 23836974, 23642658"
1923,1343838,33889,DNA polymerase/reverse transcriptase inhibitor,105706,,INHIBITOR,1,1,1,,,
1924,1343689,83515,DNA polymerase/reverse transcriptase inhibitor,105706,,INHIBITOR,1,1,1,,,
1925,1344959,366271,DNA polymerase/reverse transcriptase inhibitor,105706,,INHIBITOR,1,1,1,,,
1926,1344547,33986,DNA polymerase/reverse transcriptase inhibitor,105706,,INHIBITOR,1,1,1,"When monophosporylated is incorporates into the DNA, when triphosporylated inhibits the enzymes",,
1927,1696663,1381154,Globotriosylceramide hydrolytic enzyme,106213,,HYDROLYTIC ENZYME,1,1,1,,,
1928,1343211,255347,DNA inhibitor,106214,,INHIBITOR,1,1,1,Direct DNA binding,,
1929,1343613,47675,DNA inhibitor,106215,,INHIBITOR,1,1,1,Incorporation into DNA,,
1930,1343825,169321,DNA inhibitor,106215,,INHIBITOR,1,1,1,"Virustatic antimetabolites; recent studies indicate its role as an anti-cancer (pmid: 6436227, 18600528)",,
1931,1344027,378218,DNA inhibitor,106216,,INHIBITOR,1,1,1,,,
1932,1343532,63445,DNA inhibitor,106216,,INHIBITOR,1,1,1,,,
1933,1344027,378218,DNA inhibitor,106217,,INHIBITOR,1,1,1,,,
1934,1343917,222633,DNA inhibitor,106218,,INHIBITOR,1,1,1,,,
1935,1344872,314132,DNA inhibitor,106219,,INHIBITOR,1,1,1,,,Binds minor groove of DNA
1936,1344872,314132,Kinetoplast DNA inhibitor,106220,,INHIBITOR,1,1,1,"Binds DNA, concentrated in kinetoplast",,
1937,1343250,674399,ATP inhibitor,106221,,INHIBITOR,1,1,1,"Non N-containing biphosphonates, moa: its incorporated in ATP anologues, which accumulate in osteoclasts leading to its early apoptosis (specific to osteoclast, because it binds to hydropatite, and is then slowly released when the bone is reabsorded)",,
1938,1343856,674993,ATP inhibitor,106221,,INHIBITOR,1,1,1,"1st generation of biphosphonates, moa: its incorporated in ATP anologues, which accumulate in osteoclasts leading to its early apoptosis (specific to osteoclast, because it binds to hydropatite, and is then slowly released when the bone is reabsorded)",,
1939,1343524,1672744,DNA gyrase inhibitor,105636,,INHIBITOR,1,1,1,,,
1940,1344688,674684,Potassium channel subfamily K member 10 opener,105637,,OPENER,1,1,1,,,
1941,1344237,674645,Potassium channel subfamily K member 10 opener,105637,,OPENER,1,1,1,,,
1942,1343444,85649,Potassium channel subfamily K member 10 opener,105637,,OPENER,1,1,1,,,
1943,1344953,238127,Potassium channel subfamily K member 10 opener,105637,,OPENER,1,1,1,,,
1944,1343836,238429,Potassium channel subfamily K member 10 opener,105637,,OPENER,1,1,1,,,
1945,1344688,674684,Potassium channel subfamily K member 18 opener,105638,,OPENER,1,1,1,,,
1946,1344237,674645,Potassium channel subfamily K member 18 opener,105638,,OPENER,1,1,1,,,
1947,1343444,85649,Potassium channel subfamily K member 18 opener,105638,,OPENER,1,1,1,,,
1948,1344953,238127,Potassium channel subfamily K member 18 opener,105638,,OPENER,1,1,1,,,
1949,1343836,238429,Potassium channel subfamily K member 18 opener,105638,,OPENER,1,1,1,,,
1950,1344431,675468,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1951,1679382,1229711,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1952,1344506,83000,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1953,1344192,674605,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1954,1344023,89357,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1955,1344483,674557,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1956,1343934,38898,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1957,1343452,674666,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1958,1343210,674973,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1959,1344430,674388,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1960,1343823,65728,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1961,1343854,150452,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1962,1343204,674971,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1963,1343725,675680,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,Dronedarone reported to have antiarrhythmic properties belonging to all four Vaughan-Williams classes,,
1964,1343727,674429,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1965,1343075,2039153,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1966,1344313,208749,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1967,1344080,458912,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1968,1344546,366279,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1969,1343684,674394,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1970,1344653,674792,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1971,1343233,66016,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1972,1344571,15086,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1973,1343893,674770,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1974,1343441,32027,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1975,1345005,88739,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1976,1343606,674391,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1977,1344022,674285,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1978,1343320,674548,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1979,1344151,674974,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1980,1344881,674346,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1981,1344667,21845,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1982,1343238,675014,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1983,1343136,674415,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1984,1344001,595277,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1985,1344256,675705,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1986,1343673,139014,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1987,1344827,921,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1988,1343315,674537,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1989,1344751,83044,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1990,1344712,674292,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1991,1343308,38727,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1992,1344559,6723,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1993,1344529,674360,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1994,1343269,674724,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1995,1343404,39857,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
1996,1343326,674274,Adrenergic receptor antagonist,105670,,ANTAGONIST,1,1,1,,,
1997,1343714,674784,Adrenergic receptor agonist,105670,,AGONIST,1,1,1,,,
1998,1344098,705952,Adrenergic receptor agonist,105670,,AGONIST,1,1,1,,,
1999,1344068,28976,Adrenergic receptor agonist,105670,,AGONIST,1,1,1,,,
2000,1343106,1674090,Adrenergic receptor agonist,105670,,AGONIST,1,1,1,,,
2001,1344763,858397,Adrenergic receptor agonist,105670,,AGONIST,1,1,1,,,
2002,1344661,674656,Adrenergic receptor agonist,105670,,AGONIST,1,1,1,,,
2003,1703520,59519,D2-like dopamine receptor antagonist,105671,,ANTAGONIST,1,1,1,,,
2004,1343112,674454,D2-like dopamine receptor agonist,105671,,AGONIST,1,1,1,,,
2005,1343313,6216,D2-like dopamine receptor antagonist,105671,,ANTAGONIST,1,1,1,,,
2006,1344072,550303,D2-like dopamine receptor antagonist,105671,,ANTAGONIST,1,1,1,,,
2007,1344626,2261,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
2008,1343359,2197565,D2-like dopamine receptor antagonist,105671,,ANTAGONIST,1,1,1,,,
2009,1343904,1672024,D2-like dopamine receptor agonist,105671,,AGONIST,1,1,1,,,
2010,1343601,1535336,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
2011,1344691,152751,D2-like dopamine receptor antagonist,105671,,ANTAGONIST,1,1,1,,,
2012,1343813,7714,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
2013,1344411,675106,D2-like dopamine receptor antagonist,105671,,ANTAGONIST,1,1,1,,,
2014,1343562,674420,D2-like dopamine receptor antagonist,105671,,ANTAGONIST,1,1,1,,,
2015,1344608,674362,D2-like dopamine receptor agonist,105671,,AGONIST,1,1,1,,,
2016,1344000,583530,D2-like dopamine receptor antagonist,105671,,ANTAGONIST,1,1,1,,,
2017,1343203,674937,D2-like dopamine receptor inverse agonist,105671,,INVERSE AGONIST,1,1,1,,,
2018,1343417,674867,D2-like dopamine receptor antagonist,105671,,ANTAGONIST,1,1,1,,,
2019,1343767,5970,D2-like dopamine receptor antagonist,105671,,ANTAGONIST,1,1,1,,,
2020,1343130,466038,D2-like dopamine receptor agonist,105671,,AGONIST,1,1,1,,,
2021,1343678,675011,D2-like dopamine receptor antagonist,105671,,ANTAGONIST,1,1,1,,,
2022,1344270,1038355,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
2023,1343604,34197,D2-like dopamine receptor antagonist,105671,,ANTAGONIST,1,1,1,,,
2024,1344332,1678284,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
2025,1343541,258371,D2-like dopamine receptor agonist,105671,,AGONIST,1,1,1,,,
2026,1344273,3859,D2-like dopamine receptor inverse agonist,105671,,INVERSE AGONIST,1,1,1,,,
2027,1344316,2335118,D2-like dopamine receptor inverse agonist,105671,,INVERSE AGONIST,1,1,1,,,
2028,1343976,706035,D2-like dopamine receptor antagonist,105671,,ANTAGONIST,1,1,1,,,
2029,1343179,799627,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
2030,1344176,2197704,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
2031,1343642,16654,GABA-A receptor negative allosteric modulator,106003,,NEGATIVE ALLOSTERIC MODULATOR,1,1,1,"mode not clear, but seems negative and likely allosteric, binds at picrotoxin site?",,
2032,1343642,16654,GABA-A receptor negative allosteric modulator,106004,,NEGATIVE ALLOSTERIC MODULATOR,1,1,1,"mode not clear, but seems negative and likely allosteric, binds at picrotoxin site?",,
2033,1344762,338934,Pyruvate:ferredoxin oxidoreductase inhibitor,106005,,INHIBITOR,1,1,1,,,
2034,1344762,338934,Pyruvate:ferredoxin oxidoreductase inhibitor,106006,,INHIBITOR,1,1,1,,,
2035,1696409,1380812,Asparagine hydrolytic enzyme,106202,,HYDROLYTIC ENZYME,1,1,1,,,
2036,1696764,1381255,Asparagine hydrolytic enzyme,106202,,HYDROLYTIC ENZYME,1,1,1,,,
2038,1343114,675522,Fibrinogen inhibitor,106205,,INHIBITOR,1,1,1,,,
2039,1435115,1204086,Methotrexate hydrolytic enzyme,106206,,HYDROLYTIC ENZYME,1,1,1,,,
2040,1344556,675374,Fatty acids hydrolytic enzyme,106207,,HYDROLYTIC ENZYME,1,1,1,,,
2041,1343695,675563,Heparin inhibitor,106208,,INHIBITOR,1,1,1,,,
2042,1344727,675481,Integrin alpha-L/beta-2 (LFA-1) inhibitor,106151,2644,INHIBITOR,1,1,1,,,Alpha subunit is binding site
2043,1344143,2096404,Amylin receptor AMY2; CALCR/RAMP2 agonist,106152,2636,AGONIST,1,1,1,"Is amylin analogue, calcitonin receptor is binding site",,Calcitonin receptor is binding site
2044,1344142,674572,Topoisomerase IV inhibitor,105735,,INHIBITOR,1,1,1,,,
2045,1343077,1712,Topoisomerase IV inhibitor,105735,,INHIBITOR,1,1,1,,,
2046,1344695,674344,Topoisomerase IV inhibitor,105735,,INHIBITOR,1,1,1,,,
2047,1343340,1795,Topoisomerase IV inhibitor,105735,,INHIBITOR,1,1,1,,,
2048,1344688,674684,Potassium channel subfamily K member 3 opener,105602,,OPENER,1,1,1,,,
2049,1343206,2197390,Potassium channel subfamily K member 3 blocker,105602,,BLOCKER,1,1,1,,,
2050,1344237,674645,Potassium channel subfamily K member 3 opener,105602,,OPENER,1,1,1,,,
2051,1343444,85649,Potassium channel subfamily K member 3 opener,105602,,OPENER,1,1,1,,,
2052,1344953,238127,Potassium channel subfamily K member 3 opener,105602,,OPENER,1,1,1,,,
2053,1343836,238429,Potassium channel subfamily K member 3 opener,105602,,OPENER,1,1,1,,,
2054,1344688,674684,Potassium channel subfamily K member 9 opener,105603,,OPENER,1,1,1,,,
2055,1343206,2197390,Potassium channel subfamily K member 9 blocker,105603,,BLOCKER,1,1,1,,,
2056,1344237,674645,Potassium channel subfamily K member 9 opener,105603,,OPENER,1,1,1,,,
2057,1343444,85649,Potassium channel subfamily K member 9 opener,105603,,OPENER,1,1,1,,,
2058,1344953,238127,Potassium channel subfamily K member 9 opener,105603,,OPENER,1,1,1,,,
2059,1343836,238429,Potassium channel subfamily K member 9 opener,105603,,OPENER,1,1,1,,,
2060,1344688,674684,Potassium channel subfamily K member 2 opener,105604,,OPENER,1,1,1,,,
2061,1343836,238429,Potassium channel subfamily K member 2 opener,105604,,OPENER,1,1,1,,,
2062,1344237,674645,Potassium channel subfamily K member 2 opener,105604,,OPENER,1,1,1,,,
2063,1343444,85649,Potassium channel subfamily K member 2 opener,105604,,OPENER,1,1,1,,,
2064,1344953,238127,Potassium channel subfamily K member 2 opener,105604,,OPENER,1,1,1,,,
2065,1343278,704780,DNA-directed RNA polymerase inhibitor,105831,,INHIBITOR,1,1,1,,,
2066,1344167,2197422,70S ribosome inhibitor,105832,2622,INHIBITOR,1,1,1,"Indicated for Staphylococcus aureus, Streptococcus pneumoniae",,23S RRNA
2067,1343852,26280,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,"Indicated for Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Enterococcus faecium",,23S RRNA
2068,1344190,559106,70S ribosome inhibitor,105832,2622,INHIBITOR,1,1,1,"Indicated for Streptococcus pneumoniae, Streptococcus pyogenes, Diplococcus pneumoniae",,23S RRNA (site A)
2069,1343516,2197694,70S ribosome inhibitor,105944,2623,INHIBITOR,1,1,1,,,Binding site 23S and 16S RNA (interface)
2070,1344356,1449186,70S ribosome inhibitor,105944,2623,INHIBITOR,1,1,1,,,Binding site 23S and 16S RNA (interface)
2071,1344577,23522,70S ribosome inhibitor,105944,2659,INHIBITOR,1,1,1,,,30S ribosomal protein S1
2072,1344297,2197435,70S ribosome inhibitor,106001,2624,INHIBITOR,1,1,1,,,23S RRNA (site A)
2073,1344064,577488,70S ribosome inhibitor,106001,2624,INHIBITOR,1,1,1,,,23S RRNA (site A)
2074,1344666,675406,Bilirubin sequestering agent,106153,,SEQUESTERING AGENT,1,1,1,"To expand the circulating blood volume in case of shock or hemorrhage, but also used in liver failure to bind excessive plasma bilirubin",,
2075,1344878,675490,Bile acids sequestering agent,106154,,SEQUESTERING AGENT,1,1,1,Removes bile acids from the enterohepatic circulation by adsorbing and combing with the bile acids in the intestine and forming an insoluble complex which is extrected in the feces,,
2076,1344457,675572,Bile acids sequestering agent,106154,,SEQUESTERING AGENT,1,1,1,,,
2077,1344705,675562,Bile acids sequestering agent,106154,,SEQUESTERING AGENT,1,1,1,,,
2078,1343801,675814,Glucocerebroside hydrolytic enzyme,106155,,HYDROLYTIC ENZYME,1,1,1,Given in cases of gaucher disease to overcome a deficiency of beta-glucocerebrosidase activity. Imiglucerase catalyses the hydrolysis of glucocerebroside to glucose and ceramide,,
2079,1679365,1285397,Glucocerebroside hydrolytic enzyme,106155,,HYDROLYTIC ENZYME,1,1,1,Given in cases of gaucher disease to overcome a deficiency of beta-glucocerebrosidase activity. Imiglucerase catalyses the hydrolysis of glucocerebroside to glucose and ceramide,,
2080,1343588,675396,Glucocerebroside hydrolytic enzyme,106155,,HYDROLYTIC ENZYME,1,1,1,Given in cases of gaucher disease to overcome a deficiency of beta-glucocerebrosidase activity. Imiglucerase catalyses the hydrolysis of glucocerebroside to glucose and ceramide,,
2081,1344683,675389,Glucocerebroside hydrolytic enzyme,106155,,HYDROLYTIC ENZYME,1,1,1,,,
2082,1343454,675398,2'-deoxyadenosine hydrolytic enzyme,106156,,HYDROLYTIC ENZYME,1,1,1,"Replaces the ada enzyme in case of deficiency, and hydrolyses purine substrates",,
2083,1343454,675398,Adenosine hydrolytic enzyme,106157,,HYDROLYTIC ENZYME,1,1,1,"Replaces the ada enzyme in case of deficiency, and hydrolyses purine substrates",,
2084,1390863,675773,Dermatan sulfate hydrolytic enzyme,106158,,HYDROLYTIC ENZYME,1,1,1,To replace endogenous lysosomal enzymes required for the catabollism of GAG in case of mucopolysaccharide storage disorders,,
2085,1343973,675399,Dermatan sulfate hydrolytic enzyme,106158,,HYDROLYTIC ENZYME,1,1,1,Replacement of alpha-L-iduronidase enzyme,,
2086,1344821,675380,Starch hydrolytic enzyme,106159,,HYDROLYTIC ENZYME,1,1,1,Replaces digestive enzymes when pancreas is not fully functional; hydrolyses starches to dextrins and short chain sugars such as maltose and maltriose,,
2087,1390871,675775,Starch hydrolytic enzyme,106159,,HYDROLYTIC ENZYME,1,1,1,"1,4-alpha glucose polysaccharides (substrate)",,
2088,1344945,675593,Polypeptides proteolytic enzyme,106160,,PROTEOLYTIC ENZYME,1,1,1,"It's a proteolytic enzyme derived from papaya, which hydrolysis proteins in the nucleus pulposus, and helps to manage pain in disc herniations",,
2089,1343438,675559,Polypeptides proteolytic enzyme,106160,,PROTEOLYTIC ENZYME,1,1,1,"To replace endogenous digestive enzyme chymotrypsin, which protects against pancreatitis, in cases where loss of function variants have been identified in the CTRC gene; preferential cleavage: leu-|-xaa, tyr-|-xaa, phe-|-xaa, met-|-xaa, trp-|-xaa, gln-|-xaa, asn-|-xaa.",,
2090,1344213,675598,Polypeptides hydrolytic enzyme,106160,,HYDROLYTIC ENZYME,1,1,1,,,
2091,1344569,675600,Sucrose hydrolytic enzyme,106161,,HYDROLYTIC ENZYME,1,1,1,Replaces endogenous human sucrase in case of congenital sucrase-isomaltase deficiency (CSIS),,
2092,1390856,699376,Uric acid oxidative enzyme,106162,,OXIDATIVE ENZYME,1,1,1,"It's a recombinant uricase, which catalysis the oxidation of uric acid to allantoin, approved for the treatment of chronic gout",,
2093,1344153,675495,Phosphate sequestering agent,106163,,SEQUESTERING AGENT,1,1,1,It's a non-absorbed binding crosslinked polymer which binds to phosphate and removes it from circulation in case of hyperphosphatemia,,
2094,1695913,456123,Apo-B 100 mRNA antisense inhibitor,106164,,ANTISENSE INHIBITOR,1,1,1,"It's an antisense oligonucleotide against apo b-100, the principal apoliprotein of LDL and its metabolic precursor VLDL",,
2095,1343780,675519,Major intermediate early region 2 mRNA antisense inhibitor,106165,,ANTISENSE INHIBITOR,1,1,1,Antisense therapy; It's a phosphorothioate oligonucleotide,,
2096,1344252,49869,Voltage-gated T-type calcium channel blocker,105707,,BLOCKER,1,1,1,,,
2097,1343718,150989,Voltage-gated T-type calcium channel blocker,105707,,BLOCKER,1,1,1,,,
2098,1344736,31857,Voltage-gated T-type calcium channel blocker,105707,,BLOCKER,1,1,1,,,
2099,1343583,31811,Voltage-gated T-type calcium channel blocker,105707,,BLOCKER,1,1,1,,,
2100,1344428,31804,Voltage-gated T-type calcium channel blocker,105707,,BLOCKER,1,1,1,,,
2102,1344725,31289,Voltage-gated potassium channel blocker,105708,,BLOCKER,1,1,1,,,
2103,1344210,674679,Voltage-gated potassium channel blocker,105708,,BLOCKER,1,1,1,,,
2105,3130881,1336998,Unknown,,,,1,1,1,,,
2106,1697503,1380904,Protective antigen binding agent,101164,,BINDING AGENT,1,1,1,"It's a monoclonal antibody that binds free PA, preventing the intracellular entry of anthrax",,
2110,1641031,420212,Unknown,,,,1,1,1,,,
2111,1706440,1380086,Radiotherapy agent,,,,1,1,1,"Radiotherapy agent, binds to hydroxyapatite in bone, where alpha radiation results in double strand DNA breaks.",,
2112,1583665,1285396,Surfactant agent,,,,1,1,1,Replaces endogenous surfactant in case of deficiency; endogenous pulmonary surfactant lower surface tension at the air-liquid of the alveolar surfaces,,
2113,1343563,675537,Iodine storage agent,,,,1,1,1,"It is a synthetic thyroglobulin, hence it works as an iodine storage, and when necessary it is degraded in lysossomes into T4 and T3 hormones",,
2114,1343805,675628,Unknown,,,,1,1,1,"Mode of action not fully understood; it seems to inhibit some HPV enzymes, and it has some antioxidant properties",,
2115,1343396,675597,DNA inhibitor,105574,,INHIBITOR,1,1,1,Photodynamic therapy,,
2116,1343078,675546,Surfactant agent,,,,1,1,1,Replaces endogenous surfactant in case of deficiency; endogenous pulmonary surfactant lower surface tension at the air-liquid of the alveolar surfaces,,
2117,1343219,675438,Unknown,,,,1,1,1,Hypotensive effect not fully understood,,
2118,1344204,675567,Unknown,,,,1,1,1,,,
2119,1343464,675586,Unknown,,,,1,1,1,,,
2120,1343649,675428,Unknown,,,,1,1,1,Mode of action not fully understood; it seems to provide a protective coating to the bladder wall,,
2121,1343731,675460,Unknown,,,,1,1,1,,,
2122,1344061,675604,Unknown,,,,1,1,1,Contains components of myelin basic protein and may act as a decoy for the immune response,,
2123,1344734,675816,Unknown,,,,1,1,1,,,
2125,1344500,675611,Surfactant agent,,,,1,1,1,Replaces endogenous surfactant in case of deficiency; endogenous pulmonary surfactant lower surface tension at the air-liquid of the alveolar surfaces,,
2126,1343930,675553,Surfactant agent,,,,1,1,1,Replaces endogenous surfactant in case of deficiency; endogenous pulmonary surfactant lower surface tension at the air-liquid of the alveolar surfaces,,
2127,1344121,675443,Surfactant agent,,,,1,1,1,Replaces endogenous surfactant in case of deficiency; endogenous pulmonary surfactant lower surface tension at the air-liquid of the alveolar surfaces,,
2130,1344002,1017790,Unknown,,,,1,1,1,Antitussive drug; probable action in the CNS cough centre,,
2131,1344781,674662,Unknown,,,,1,1,1,"Mode of action not fully understood; it seems to increase beta-oxidation, inhibit acyl-CoA:1,2-diacylglycerol acyltransferase (EC 2.3.1.20), decreas lipogenesis in the liver, and increase plasma lipoprotein lipase activity",,
2132,1679372,1369605,Unknown,,,,1,1,1,"Mode of action not fully understood; it seems to increase beta-oxidation, inhibit acyl-CoA:1,2-diacylglycerol acyltransferase (EC 2.3.1.20), decreas lipogenesis in the liver, and increase plasma lipoprotein lipase activity",,
2133,1344439,4775,Unknown,,,,1,1,1,"Microtubule inhibitor, but this is likely not the mode of action against HPV",,
2134,1641024,88317,Unknown,,,,1,1,1,,,
2135,1344416,674342,Unknown,,,,1,1,1,,,
2136,1343632,1763649,Unknown,,,,1,1,1,,,
2137,1344309,543263,Unknown,,,,1,1,1,"Mode of action not fully understood; it seems to interfere with calcium release, leading to vasodilation",,
2138,1344138,674533,DNA inhibitor,105574,,INHIBITOR,1,1,1,Photodynamic therapy,,
2139,1344711,2335163,Antifoaming agent,,,,1,1,1,Rupture of thick liquid films by surface tension disruption,,
2140,1344952,674819,Unknown,,,,1,1,1,,,
2141,1343670,82047,Unknown,,,,1,1,1,"Mode of action not fully understood; it seems to inhibit calcium influx into mast cells, stabilizing them",,
2142,1344257,1376010,Unknown,,,,1,1,1,,,
2143,1344125,144744,Unknown,,,,1,1,1,,,
2144,1344678,674698,Unknown,,,,1,1,1,,,
2145,1343585,76538,Colonic bacteria substrate,,,,1,1,1,Increases water content in the colon,,
2146,1343408,674966,Unknown,,,,1,1,1,,,
2147,1343724,193096,Unknown,,,,1,1,1,,,
2148,1344944,674627,Unknown,,,,1,1,1,,,
2149,1344955,1449158,DNA inhibitor,105574,,INHIBITOR,1,1,1,Photodynamic therapy,,
2150,1343593,1248748,Unknown,,,,1,1,1,,,
2151,1344259,575670,Glutamine sequestering agent,106212,,SEQUESTERING AGENT,1,1,1,"Removes excess nitrogen, caused by enzyme deficiency",,
2152,1343461,694073,Unknown,,,,1,1,1,,,
2153,1344200,35486,Unknown,,,,1,1,1,,,
2154,1343821,675001,Unknown,,,,1,1,1,"Mode of action not fully understood; it seems to inhibit calcium influx into mast cells, stabilizing them",,
2155,1344758,675813,Unknown,,,,1,1,1,,,
2156,1344917,233590,Unknown,,,,1,1,1,,,
2157,1344850,2197728,Unknown,,,,1,1,1,,,
2158,1343680,674989,Unknown,,,,1,1,1,,,
2159,1343242,675750,Unknown,,,,1,1,1,,,
2160,1343426,674838,Unknown,,,,1,1,1,,,
2161,1344195,674631,Unknown,,,,1,1,1,,,
2162,1343756,1248732,Unknown,,,,1,1,1,"Provides a DHFR-independent source of folate, counteracting methotrexate toxicity. Can enhance toxic effects of fluoropyrimidines in cancer therapy through conversion to 5,10-methylenetetrahydrofolate, stabilising binding of 5-fluoro-2'-deoxyuridine-5'-monophosphate to thymidylate synthase",,
2163,1343761,2197596,Unknown,,,,1,1,1,"Mode of action not fully understood; it seems to inhibit calcium influx into mast cells, stabilizing them",,
2164,1344927,674665,Unknown,,,,1,1,1,"Mode of action not fully understood; it seems to act as a muscle relaxant by interfering with GABA A receptors, sodium channels and calcium channels",,
2165,1344816,178495,Unknown,,,,1,1,1,,,
2166,1344764,304398,Unknown,,,,1,1,1,,,
2167,1344322,112480,Reactive metabolite scavenging agent,,,,1,1,1,Prodrug. Scavenge of reactive oxygen species and reactive metabolites of cisplatin,,
2168,1343787,604618,Unknown,,,,1,1,1,,,
2169,1343665,674510,pH lowering agent,,,,1,1,1,Antimicrobial activity,,
2170,1343741,10009,Unknown,,,,1,1,1,,,
2171,1343484,2197393,Unknown,,,,1,1,1,,,
2172,1343463,674660,Unknown,,,,1,1,1,,,
2173,1344664,88841,Unknown,,,,1,1,1,,,
2174,1583658,1204084,Unknown,,,,1,1,1,,,
2175,1343383,264400,Reducing agent,,,,1,1,1,Prevents cysteine excretion,,
2177,1641020,575613,Unknown,,,,1,1,1,,,
2178,1344021,58232,Unknown,,,,1,1,1,Mode of action not fully understood; it seems to cause the disruption of the lipid layers in plasmodium parasites,,
2179,1344801,2197568,Unknown,,,,1,1,1,,,
2180,1344551,674657,Unknown,,,,1,1,1,,,
2181,1344247,674305,Unknown,,,,1,1,1,,,
2182,1344861,2197378,Calcium chelating agent,106009,,CHELATING AGENT,1,1,1,Divalent and Trivalent metal chelating agent. Removes Ca2+ in case of hypercalciemia,,
2183,1344954,453721,Unknown,,,,1,1,1,,,
2184,1343986,21741,Unknown,,,,1,1,1,,,
2185,1343191,1369669,Unknown,,,,1,1,1,,,
2186,1344601,674873,Unknown,,,,1,1,1,,,
2187,1343782,1336997,Unknown,,,,1,1,1,,,
2188,1344573,230249,Unknown,,,,1,1,1,,,
2189,1343890,674887,Unknown,,,,1,1,1,,,
2190,1343334,1826000,Unknown,,,,1,1,1,Disruption of membrane transport (direct or indirect effect on the primary proton pump which energizes transport),,
2192,1343297,675105,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
2193,1344765,674309,Glutamine sequestering agent,106212,,SEQUESTERING AGENT,1,1,1,"Removes excess nitrogen, caused by enzyme deficiency",,
2194,1344491,674894,Unknown,,,,1,1,1,,,
2195,1343196,675738,Unknown,,,,1,1,1,,,
2196,1344591,674923,Unknown,,,,1,1,1,Antitussive drug; probable action in the CNS cough centre,,
2198,1435099,112090,Unknown,,,,1,1,1,,,
2199,1344567,674611,Unknown,,,,1,1,1,,,
2200,1343970,353011,Iron chelating agent,105753,,CHELATING AGENT,1,1,1,Trivalent metal cations chelating agent; inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell,,
2201,1344110,96595,Unknown,,,,1,1,1,,,
2202,1641027,316347,Unknown,,,,1,1,1,,,
2203,1343347,1369638,Radioactive metals chelating agent,106210,,CHELATING AGENT,1,1,1,Scavenge of radioactive and non-radioactive cesium and thalium,,
2204,1343190,674612,Unknown,,,,1,1,1,,,
2205,1344046,1336999,Unknown,,,,1,1,1,,,
2206,1344901,6480,Unknown,,,,1,1,1,,,
2207,1344128,1379795,Unknown,,,,1,1,1,,,
2209,1343168,674576,Unknown,,,,1,1,1,,,
2210,1343700,230966,Unknown,,,,1,1,1,,,
2211,1344867,100157,Unknown,,,,1,1,1,,,
2212,1344434,611679,Unknown,,,,1,1,1,,,
2213,1343666,675122,Unknown,,,,1,1,1,,,
2214,1343538,1038354,Unknown,,,,1,1,1,,,
2215,1344017,33254,Unknown,,,,1,1,1,,,
2216,1679387,69277,Protein synthesis inhibitor,,,,1,1,1,Inhibition of protein synthesis independent of direct BCR-ABL binding,,
2217,1344243,453538,Unknown,,,,1,1,1,Mode of action not fully understood; it seems to interact with GABA A receptors as other carbinol hypnotic drugs,,
2218,1344183,178545,Unknown,,,,1,1,1,Iodine seems to lead to protein precipitation,,
2219,1343500,675044,DNA inhibitor,105574,,INHIBITOR,1,1,1,Photodynamic therapy,,
2220,1343924,308917,Unknown,,,,1,1,1,"Mode of action not fully understood; it seems to interact with IKKB, which may play a role in its anti-rheumatic effects",,
2223,1343288,674802,Unknown,,,,1,1,1,Antitussive drug; probable action in the CNS cough centre,,
2224,1343970,353011,Aluminium chelating agent,106544,,CHELATING AGENT,1,1,1,Trivalent metal cations chelating agent; inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell,,
2225,1343098,674672,DNA inhibitor,105574,,INHIBITOR,1,1,1,Nitogen mustard component is DNA alkylating agent,,
2226,1343835,16450,Anandamide amidohydrolase inhibitor,11291,,INHIBITOR,1,1,1,"FAAH converts acetaminophen into the active metabolite AM404, but this conversion also competes with degradation of anandamide increasing its concentration and effects",,
2227,1343835,16450,Vanilloid receptor opener,10260,,OPENER,1,1,1,"Active metabolite, AM404, activates vanilloid receptor (TRPV1)",,
2228,1434795,1204085,Asparagine hydrolytic enzyme,106202,,HYDROLYTIC ENZYME,1,1,1,,,
2229,1696022,1380340,Fatty acids hydrolytic enzyme,106207,,HYDROLYTIC ENZYME,1,1,1,,,
2230,1696022,1380340,Starch hydrolytic enzyme,106159,,HYDROLYTIC ENZYME,1,1,1,,,
2231,1696022,1380340,Polypeptides hydrolytic enzyme,106160,,HYDROLYTIC ENZYME,1,1,1,,,
2232,1696288,1380693,Luteinizing hormone/Choriogonadotropin receptor agonist,95,,AGONIST,1,1,1,,,
2233,1696288,1380693,Follicle stimulating hormone receptor agonist,99,,AGONIST,1,1,1,,,
2234,1702610,1377982,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,"Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling",,
2235,1702636,685006,Human immunodeficiency virus type 1 integrase inhibitor,12456,,INHIBITOR,1,1,1,HIV-1 integrase strand transfer inhibitor,,
2236,1705141,1379657,Serotonin 1a (5-HT1a) receptor agonist,51,,AGONIST,1,1,1,,,
2237,1705141,1379657,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,reuptake inhibitor,,
2238,1705141,1379657,Serotonin 3a (5-HT3a) receptor antagonist,144,,ANTAGONIST,1,1,1,,,
2239,1706467,1380104,Soluble guanylate cyclase positive allosteric modulator,105048,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,"Riociguat has a dual mode of action. It sensitizes sGC to endogenous NO by stabilizing the NO-sGC binding and it also directly stimulates sGC via a different binding site, independently of NO. Recent studies have suggested that sCG stimulators bind to an allosteric nucleotide-binding site in the catalytic domains of sCG. The exact molecular mechanism of sCG stimulation remains a matter of debate.",,
2240,1699882,1376143,"Endothelin receptor, ET-A/ET-B antagonist",104833,,ANTAGONIST,1,1,1,,,
2241,1392932,1121919,B-lymphocyte antigen CD20 binding agent,181,,BINDING AGENT,1,1,1,"Obinutuzumab mediates B-cell lysis through engagement of immune effector cells, directly activating intracellular death signaling pathways and/or activation of the complement cascade.",,
2242,1702685,1214046,Tyrosine-protein kinase BTK inhibitor,100097,248,INHIBITOR,1,1,1,Irreversible inhibitor,,Binds to a cysteine residue in the BTK active site
2243,1977637,1626792,"Hepatitis C virus serine protease, NS3/NS4A inhibitor",104803,,INHIBITOR,1,1,1,,,
2244,1702492,139940,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
2245,1702581,1377959,Cytochrome P450 51 inhibitor,58,,INHIBITOR,1,1,1,,,
2246,1702662,499120,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"Indicated for COPD, M3 responsible",,
2247,1706452,708075,Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor,12097,,INHIBITOR,1,1,1,,,
2248,1704318,1378885,Estrogen receptor modulator,104682,,MODULATOR,1,1,1,"Bazedoxifene profile is antagonistic in breast and endometrial tissue, while an estrogen agonist in bone tissue;  Bazedoxifene in combination with conjugated estrogens is the first approved tissue-selective estrogen receptor complex (TSEC)",,
2249,1938076,2197732,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
2250,1938076,2197732,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
2251,1702655,1418091,Potassium-transporting ATPase inhibitor,104758,2651,INHIBITOR,1,1,1,,,Alpha subunit is likely binding site
2252,1702639,1378002,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
2253,1702639,1378002,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
2254,1937947,29890,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
2255,1938079,1592384,Phosphate sequestering agent,106163,,SEQUESTERING AGENT,1,1,1,It is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis,,
2256,1705350,49931,Dihydrofolate reductase inhibitor,6,,INHIBITOR,1,1,1,,,
2257,1702610,1377982,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,"Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling",,
2258,1702610,1377982,Receptor protein-tyrosine kinase erbB-4 inhibitor,12699,,INHIBITOR,1,1,1,"Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling",,
2260,1343374,86042,"3',5'-cyclic phosphodiesterase inhibitor",105761,,INHIBITOR,1,1,1,,,
2262,1344134,674579,Peptidoglycan inhibitor,107948,,INHIBITOR,1,1,1,,,
2263,1344164,230691,Unknown,,,,1,1,1,"May act through thioredoxin reductase of acne causing bacteria (e.g., Staphylococcus epidermidis and Propionibacterium acnes)",,
2264,1705039,458773,Phosphodiesterase 4 inhibitor,104679,,INHIBITOR,1,1,1,,Selective,
2267,1699803,1376097,Adrenergic receptor agonist,105670,,AGONIST,1,1,1,,,
2268,1705422,25047,Unknown,,,,1,1,1,"The mechanism of action of miltefosine is likely to involve interaction with lipids (phospholipids and sterols), including membrane lipids, inhibition of cytochrome c oxidase (mitochondrial function), and apoptosis-like cell death.",,
2269,1699794,1376092,Melatonin receptor agonist,104733,,AGONIST,1,1,1,,,
2270,1704784,1379337,Androgen Receptor agonist,56,,AGONIST,1,1,1,,,
2272,1695932,1380123,Leptin receptor agonist,102709,,AGONIST,1,1,1,,,
2273,1392946,1121933,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,,,
2274,1392954,1121941,Interleukin-6 inhibitor,104209,,INHIBITOR,1,1,1,,,
2276,1695896,1380107,Glucagon-like peptide 1 receptor agonist,11758,,AGONIST,1,1,1,,,
2277,1697541,1380942,Keratan sulfate hydrolytic enzyme,108157,,HYDROLYTIC ENZYME,1,1,1,,,
2278,1697541,1380942,Chondroitin-6-sulfate hydrolytic enzyme,108158,,HYDROLYTIC ENZYME,1,1,1,,,
2279,1706047,435188,Histone deacetylase inhibitor,104681,,INHIBITOR,1,1,1,,,
2280,1701847,2197637,Peptidoglycan inhibitor,107948,,INHIBITOR,1,1,1,,,
2281,1702654,1378013,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,Long-acting,,
2282,1702556,1377939,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,,,23S RRNA
2284,1699887,1376147,Lanosterol 14-alpha demethylase inhibitor,108435,,INHIBITOR,1,1,1,,,
2285,1702626,630322,Orexin receptor antagonist,108439,,ANTAGONIST,1,1,1,,,
2288,2139051,1763612,Peptidoglycan inhibitor,107948,,INHIBITOR,1,1,1,,,
2289,1705140,1379656,Proteinase-activated receptor 1 antagonist,10653,,ANTAGONIST,1,1,1,,,
2291,1706461,1380100,Sodium/glucose cotransporter 2 inhibitor,20092,,INHIBITOR,1,1,1,,,
2292,2139054,353270,Leucine-tRNA ligase inhibitor,108436,,INHIBITOR,1,1,1,,,
2293,1976758,1570706,ALK tyrosine kinase receptor inhibitor,100417,,INHIBITOR,1,1,1,,,
2294,1706439,1380085,Prostanoid IP receptor agonist,143,,AGONIST,1,1,1,,,
2295,1706078,366860,Vasopressin receptor agonist,105773,,AGONIST,1,1,1,,,
2297,1879133,1448219,PI3-kinase p110-delta subunit inhibitor,11177,,INHIBITOR,1,1,1,,,
2298,1699846,2335037,Ceramide glucosyltransferase inhibitor,286,,INHIBITOR,1,1,1,,,
2300,1976818,1626777,Programmed cell death protein 1 inhibitor,108437,,INHIBITOR,1,1,1,,,
2301,1937945,1592322,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,,,
2303,1937945,1592322,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
2305,1937945,1592322,Fibroblast growth factor receptor inhibitor,104793,,INHIBITOR,1,1,1,,"FGFR 1, 2 + 3",
2306,1763604,1449220,Mu opioid receptor antagonist,129,,ANTAGONIST,1,1,1,,,
2307,1879135,1548671,Nonstructural protein 5A inhibitor,108438,,INHIBITOR,1,1,1,,,
2308,1697108,1380293,Glucagon-like peptide 1 receptor agonist,11758,,AGONIST,1,1,1,,,
2309,1697542,1380943,Interferon alpha/beta receptor agonist,106149,,AGONIST,1,1,1,,,
2310,1392971,1121958,Integrin alpha-4/beta-7 inhibitor,104768,,INHIBITOR,1,1,1,,,
2311,1703571,705377,Unknown,,,,1,1,1,,,
2312,1705097,341603,Neurokinin 1 receptor antagonist,250,,ANTAGONIST,1,1,1,,,
2313,2139038,1417028,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker,103531,,BLOCKER,1,1,1,,,
2314,1702600,1377974,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
2315,1879127,1425665,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
2316,1879144,319858,CDK6/cyclin D1 inhibitor,104977,1744,INHIBITOR,1,1,1,,,
2317,1879144,319858,Cyclin-dependent kinase 4/cyclin D1 inhibitor,104295,2150,INHIBITOR,1,1,1,,,
2318,1702572,1377952,Coagulation factor X inhibitor,194,,INHIBITOR,1,1,1,,,
2319,1696026,1380344,Parathyroid hormone receptor agonist,160,,AGONIST,1,1,1,,,
2320,1976739,469866,"PARP 1, 2 and 3 inhibitor",109545,,INHIBITOR,1,1,1,,,
2322,1392876,1121863,T cell surface glycoprotein CD3 cross-linking agent,106147,,CROSS-LINKING AGENT,1,1,1,,,
2323,1392876,1121863,B-lymphocyte antigen CD19 cross-linking agent,109546,,CROSS-LINKING AGENT,1,1,1,,,
2324,1706441,1380087,Bacterial beta-lactamase TEM inhibitor,106170,,INHIBITOR,1,1,1,,,
2325,1976749,1623950,Nonstructural protein 5A inhibitor,108438,,INHIBITOR,1,1,1,,,
2326,1696513,1381004,Programmed cell death protein 1 inhibitor,108437,,INHIBITOR,1,1,1,,,
2327,1392952,1121939,Interleukin 17A inhibitor,109547,,INHIBITOR,1,1,1,,,
2328,1976817,1626776,Disialoganglioside GD2 binding agent,109548,,BINDING AGENT,1,1,1,,,
2330,1976772,1626764,Lanosterol 14-alpha demethylase inhibitor,109549,,INHIBITOR,1,1,1,,,
2331,1976772,1626764,Lanosterol 14-alpha demethylase inhibitor,109550,,INHIBITOR,1,1,1,,,
2332,2139005,1763559,Phosphate sequestering agent,106163,,SEQUESTERING AGENT,1,1,1,,,
2333,1699285,2197273,Neuraminidase inhibitor,10738,,INHIBITOR,1,1,1,,,
2334,1699285,2197273,Neuraminidase inhibitor,21,,INHIBITOR,1,1,1,,,
2335,2138999,343964,Unknown,,,,1,1,1,,,
2336,1706217,1248741,Topoisomerase IV inhibitor,107934,,INHIBITOR,1,1,1,,,
2337,1706217,1248741,Topoisomerase IV inhibitor,109552,,INHIBITOR,1,1,1,,,
2338,1706217,1248741,DNA gyrase inhibitor,107908,,INHIBITOR,1,1,1,,,
2339,1706217,1248741,DNA gyrase inhibitor,109553,,INHIBITOR,1,1,1,,,
2340,2473671,1927217,Histone deacetylase inhibitor,104681,,INHIBITOR,1,1,1,,,
2341,2472828,1926834,Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor,12097,,INHIBITOR,1,1,1,,,
2342,1705052,626138,Purinergic receptor P2Y12 antagonist,176,,ANTAGONIST,1,1,1,,,
2346,1699876,1376140,Cystic fibrosis transmembrane conductance regulator stabiliser,11540,,STABILISER,1,1,1,Modulates the folding and trafficking of CFTR protein in patients with one or two copies of the F508del mutation. Acts on the membrane-spanning domain 1 of the CFTR protein.,,
2347,1976715,1626732,Neprilysin inhibitor,236,,INHIBITOR,1,1,1,,,
2348,1702682,1378030,Dopamine D2 receptor partial agonist,72,,PARTIAL AGONIST,1,1,1,,,
2349,1702682,1378030,Serotonin 1a (5-HT1a) receptor partial agonist,51,,PARTIAL AGONIST,1,1,1,,,
2350,1702682,1378030,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
2353,1976731,442077,Cell membrane disrupting agent,109551,,DISRUPTING AGENT,1,1,1,,,
2355,1702645,685091,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,,,
2357,1344348,674751,Phosphate sequestering agent,106163,,SEQUESTERING AGENT,1,1,1,,,
2358,1698586,675081,Betaine-homocysteine S-methyltransferase substrate,109554,,SUBSTRATE,1,1,1,,,
2359,1706330,65605,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
2363,1705898,958409,Voltage-gated T-type calcium channel blocker,105707,,BLOCKER,1,1,1,,,
2364,2473404,1825632,"Hepatitis C virus serine protease, NS3/NS4A inhibitor",104803,,INHIBITOR,1,1,1,,,
2365,1344095,13928,Retinoic acid receptor agonist,105764,,AGONIST,1,1,1,Prodrug. RARG/RXRA are predominant forms in skin,,
2366,1343725,675680,Inward rectifier potassium channel 2 blocker,104372,,BLOCKER,1,1,1,,,
2367,1343725,675680,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker,103531,,BLOCKER,1,1,1,,HCN4 is predominant form in sinoatrial node and atrioventricular node,
2368,1344828,674281,Muscarinic acetylcholine receptor M1 agonist,61,,AGONIST,1,1,1,"Indicated for dry mouth, M1 likely involved",,
2369,1343853,14406,Muscarinic acetylcholine receptor M1 agonist,61,,AGONIST,1,1,1,"Indicated for dry mouth, M1 likely involved",,
2370,1344532,547681,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,109555,,INHIBITOR,1,1,1,,,
2386,1696132,1380450,Anoctamin-1 blocker,104568,,BLOCKER,1,1,1,,,
2387,1344310,674418,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,Activity against other receptors such as 5HT2A and D2 may underlie efficacy of anxiolytic and antipsychotic effects ,,
2388,1343411,674385,Phosphodiesterase 4 inhibitor,104679,,INHIBITOR,1,1,1,,,
2389,1343411,674385,Phosphodiesterase 3 inhibitor,104707,,INHIBITOR,1,1,1,,,
2390,1343411,674385,Adenosine receptor antagonist,105024,,ANTAGONIST,1,1,1,,,
2391,1344969,1369656,Phosphate sequestering agent,106163,,SEQUESTERING AGENT,1,1,1,,,
2393,1702635,1503092,Nonstructural protein 5A inhibitor,108438,,INHIBITOR,1,1,1,,,
2394,1699758,1376072,Sodium/glucose cotransporter 2 inhibitor,20092,,INHIBITOR,1,1,1,,,
2395,2473250,1927037,Somatostatin receptor 3 agonist,11261,,AGONIST,1,1,1,,,
2396,2473250,1927037,Somatostatin receptor 5 agonist,11265,,AGONIST,1,1,1,,,
2397,2473250,1927037,Somatostatin receptor 2 agonist,117,,AGONIST,1,1,1,,,
2398,2473250,1927037,Somatostatin receptor 1 agonist,12786,,AGONIST,1,1,1,,,
2399,2472829,1926835,Angiotensin-converting enzyme inhibitor,69,,INHIBITOR,1,1,1,,,
2400,1976742,1626748,Smoothened homolog inhibitor,101400,,INHIBITOR,1,1,1,,,
2401,1707063,1381980,Subtilisin/kexin type 9 inhibitor,12353,,INHIBITOR,1,1,1,,,
2402,1702644,1339907,Dopamine D3 receptor modulator,130,,MODULATOR,1,1,1,Mixed antagonist/partial agonist,,
2403,1702644,1339907,Dopamine D2 receptor modulator,72,,MODULATOR,1,1,1,Mixed antagonist/partial agonist,,
2404,1707060,1540527,Subtilisin/kexin type 9 inhibitor,12353,,INHIBITOR,1,1,1,,,
2405,1699969,388819,Unknown,,,,1,1,1,,,
2406,1705111,2039301,Neurokinin 1 receptor antagonist,250,,ANTAGONIST,1,1,1,,,
2407,1705133,1379651,Unknown,,,,1,1,1,,,
2408,1976744,102584,Thymidine phosphorylase inhibitor,11723,,INHIBITOR,1,1,1,,,
2409,1695958,1380135,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
2410,1763614,1449229,Dopamine D2 receptor partial agonist,72,,PARTIAL AGONIST,1,1,1,Prodrug of aripiprazole,,
2411,1763614,1449229,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,Prodrug of aripiprazole,,
2412,1763614,1449229,Serotonin 1a (5-HT1a) receptor partial agonist,51,,PARTIAL AGONIST,1,1,1,Prodrug of aripiprazole,,
2413,2472846,1926845,Dabigatran sequestering agent,109706,,SEQUESTERING AGENT,1,1,1,,,
2414,1695895,1380106,Potassium chelating agent,109707,,CHELATING AGENT,1,1,1,,,
2415,1706211,493099,DNA inhibitor,105574,,INHIBITOR,1,1,1,Alkylating agent,,
2416,1697337,1380577,Pyrophosphate hydrolytic enzyme,109708,,HYDROLYTIC ENZYME,1,1,1,First-in-class enzyme replacement therapy of TNSALP in case of hypophosphatasia (HPP),,
2420,1696290,1380695,Interleukin-5 inhibitor,103470,,INHIBITOR,1,1,1,,,
2421,1879163,1540509,Human immunodeficiency virus type 1 reverse transcriptase inhibitor,228,,INHIBITOR,1,1,1,Prodrug of tenofovir; active metabolite tenofovir diphosphate,,
2422,1879125,1540479,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,Reversible inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase 1 (MEK1) and MEK2,,
2423,1879125,1540479,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor,11046,,INHIBITOR,1,1,1,Reversible inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase 1 (MEK1) and MEK2,,
2424,2472960,1926912,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,"Binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion)",,
2425,1392891,1121878,Lymphocyte differentiation antigen CD38 inhibitor,100622,,INHIBITOR,1,1,1,,,
2426,2473783,1927281,26S proteosome inhibitor,106197,2633,INHIBITOR,1,1,1,Prodrug of ixazomib,,Beta-5 subunit
2427,1392931,1121918,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
2428,1392894,1121881,SLAM family member 7 inhibitor,109709,,INHIBITOR,1,1,1,,,
2429,1938046,1592355,Cholesterol ester hydrolytic enzyme,109711,,HYDROLYTIC ENZYME,1,1,1,,,
2430,1938046,1592355,Triglyceride hydrolytic enzyme,109712,,HYDROLYTIC ENZYME,1,1,1,,,
2431,2583412,2039291,ALK tyrosine kinase receptor inhibitor,100417,,INHIBITOR,1,1,1,,,
2432,2583412,2039291,Tyrosine-protein kinase receptor RET inhibitor,100079,,INHIBITOR,1,1,1,,,
2433,1705119,1379644,Rocuronium sequestering agent,109713,,SEQUESTERING AGENT,1,1,1,,,
2434,1705119,1379644,Vecuronium sequestering agent,109714,,SEQUESTERING AGENT,1,1,1,,,
2435,1699893,406189,Prostanoid IP receptor agonist,143,,AGONIST,1,1,1,,,
2436,1702621,1377990,Solute carrier family 22 member 12 inhibitor,102767,,INHIBITOR,1,1,1,,,
3876,2472735,81913,Serine/threonine-protein kinase Aurora-A inhibitor,20014,,INHIBITOR,1,1,1,,,
3877,2472735,81913,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
3878,2472735,81913,SRC inhibitor,105769,,INHIBITOR,1,1,1,,,
3879,2472735,81913,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,,,
3880,2472735,81913,Fibroblast growth factor receptor inhibitor,104793,,INHIBITOR,1,1,1,,,
3881,2472735,81913,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,,,
3882,2473042,1926958,G protein-coupled receptor 44 antagonist,20174,,ANTAGONIST,1,1,1,,,
3883,2473329,1927086,Androgen Receptor modulator,56,,MODULATOR,1,1,1,,,
3888,2472749,1102616,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
3889,2472749,1102616,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,,,
3890,2472749,1102616,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
3891,2472749,1102616,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
3892,2473359,364875,Interleukin-8 receptor B antagonist,10773,,ANTAGONIST,1,1,1,,High selectivity for CXCR2 over CXCR1,
3893,2473019,1926946,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,,,
3895,2473006,1926938,Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor,10752,,INHIBITOR,1,1,1,,,
3896,2473692,1927232,Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor,104912,,INHIBITOR,1,1,1,,,
3898,2473055,1926968,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
3899,2473055,1926968,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,,,
3900,1703517,244636,Retinoid receptor modulator,105766,,MODULATOR,1,1,1,,,
3901,1976764,1626758,Unknown,,,,1,1,1,,,
4052,2473614,1927204,Estrogen receptor modulator,104682,,MODULATOR,1,1,1,SERM,,
4053,2473182,1927022,Retinoic acid receptor antagonist,105764,,ANTAGONIST,1,1,1,,,
4054,2473183,1927023,Androgen Receptor modulator,56,,MODULATOR,1,1,1,SARM,,
4055,2472916,1926895,Androgen Receptor modulator,56,,MODULATOR,1,1,1,"Selective androgen receptor modulator (SARM). Ph1 study completed, compound not in pipeline published in February 2014.",,
4056,2473615,1927205,Androgen Receptor modulator,56,,MODULATOR,1,1,1,SARM,,
4057,2473482,52642,Androgen Receptor antagonist,56,,ANTAGONIST,1,1,1,Vitamin E derivate,,
4058,2473752,1927266,Androgen Receptor modulator,56,,MODULATOR,1,1,1,selective androgen modulator (SARM),,
4059,2473616,1528799,Androgen Receptor modulator,56,,MODULATOR,1,1,1,"Selective androgen receptor inhibitor and down-regulator (SARD). AZD3514 binds to AR, inhibits its nuclear translocation, ligand-dependent and independent transcriptional activity and is able to induce AR down-regulation in vitro and in vivo. .Discontinued, safety/efficacy reasons.",,
4060,2472765,479591,Androgen Receptor modulator,56,,MODULATOR,1,1,1,Selective androgen modulator (SARM). No information about further clinical development (http://www.drugs.com/clinical_trials/ligand-research-published-journal-medicinal-chemistry-lgd-2941-shows-promise-treating-muscle-bone-2222.html),,
4061,2473753,1927267,LXR-beta agonist,20113,,AGONIST,1,1,1,,,
4062,2472917,1926896,LXR-beta modulator,20113,,MODULATOR,1,1,1,"Ph1 study terminated in 2013, undisclosed reasons",,
4063,2472917,1926896,LXR-alpha modulator,11269,,MODULATOR,1,1,1,"Ph1 study terminated in 2013, undisclosed reasons",,
4064,2473330,515833,LXR-beta agonist,20113,,AGONIST,1,1,1,"project terminated in 2007, reason quoted as ""unfavorable profile for further development"" (http://www.karobio.com/investormedia/pressreleaser/pressrelease?pid=3005162)",,
4065,2473330,515833,LXR-alpha agonist,11269,,AGONIST,1,1,1,"project terminated in 2007, reason quoted as ""unfavorable profile for further development"" (http://www.karobio.com/investormedia/pressreleaser/pressrelease?pid=3005162)",,
4066,2473331,1927087,LXR-beta agonist,20113,,AGONIST,1,1,1,"discontinued in 2008, did not meet criteria in clinical trials (http://www.daiichisankyo.com/media_investors/investor_relations/ir_calendar/files/005144/imm2009_01_30_26_01.pdf)",,
4067,2473331,1927087,LXR-alpha agonist,11269,,AGONIST,1,1,1,"discontinued in 2008, did not meet criteria in clinical trials (http://www.daiichisankyo.com/media_investors/investor_relations/ir_calendar/files/005144/imm2009_01_30_26_01.pdf)",,
4068,2473617,441984,LXR-beta agonist,20113,,AGONIST,1,1,1,,,
4069,2473617,441984,LXR-alpha agonist,11269,,AGONIST,1,1,1,,,
4070,2473047,1926962,Bile acid receptor FXR agonist,11180,,AGONIST,1,1,1,,,
4071,1702527,455243,Bile acid receptor FXR agonist,11180,,AGONIST,1,1,1,"A Ph1 trial was terminated in May due to pharmacokinetics issues, development stopped.",,
4072,2473754,436607,Glucocorticoid receptor antagonist,25,,ANTAGONIST,1,1,1,Company reports initiation of No Ph1 trial in 2010 but no ID found and no further trials planned. Discontinuedcompound?,,
4073,2472766,1926806,Glucocorticoid receptor antagonist,25,,ANTAGONIST,1,1,1,"Ph1 trial initiated in Septemebr 2014, no trial ID found.",,
4074,2473184,1927024,Mineralocorticoid receptor antagonist,48,,ANTAGONIST,1,1,1,"Ph1 study terminated, development discontinued in 2012 (http://www.pfizer.com/sites/default/files/product-pipeline/pipeline_2012_1108.pdf)",,
4075,2473332,1927088,Progesterone receptor antagonist,36,,ANTAGONIST,1,1,1,,,
4076,2473483,1927144,Peroxisome proliferator-activated receptor delta agonist,12227,,AGONIST,1,1,1,Development discontinued (http://fr.reuters.com/article/idUKL0461650920080404),,
4077,2473483,1927144,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,Development discontinued (http://fr.reuters.com/article/idUKL0461650920080404),,
4078,2472767,1926807,Peroxisome proliferator-activated receptor delta agonist,12227,,AGONIST,1,1,1,A Ph1 trial was completed in 2008 but can't find trial ID or any further planned trials (http://www.drugs.com/clinical_trials/cerenis-therapeutics-announces-successful-completion-phase-clinical-trial-cer-002-cardiovascular-4272.html). Compound still in the company pipeline.,,
4079,2473048,1926963,Peroxisome proliferator-activated receptor delta agonist,12227,,AGONIST,1,1,1,"Ph1 trial completed in 2006, no new trials reported. Development discontinued?",,
4080,2473185,1927025,Peroxisome proliferator-activated receptor delta agonist,12227,,AGONIST,1,1,1,Ph1b study completed in 2011 (no trial ID). Compound outlicensed to T3D Therapeutics Inc in 2013.,,
4081,2473185,1927025,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,Ph1b study completed in 2011 (no trial ID). Compound outlicensed to T3D Therapeutics Inc in 2013.,,
4082,2473618,1927206,Nuclear receptor ROR-gamma antagonist,103982,,ANTAGONIST,1,1,1,,,
4083,2473333,1927089,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,"According to reports, Ph1 trial was completed but can't find trial ID or any further planned trials. Discontinued",,
4084,2473334,1746288,Thyroid hormone receptor beta-1 agonist,271,,AGONIST,1,1,1,,,
4085,2473186,49481,Vitamin D receptor agonist,64,,AGONIST,1,1,1,,,
4086,2473049,1925392,Androgen Receptor modulator,56,,MODULATOR,1,1,1,,,
4087,2473465,1927133,Tyrosine-protein kinase SYK inhibitor,10906,,INHIBITOR,1,1,1,Dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor ,,
4088,2473465,1927133,Tyrosine-protein kinase JAK1 inhibitor,10919,,INHIBITOR,1,1,1,Dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor ,,
4089,2473465,1927133,Tyrosine-protein kinase JAK3 inhibitor,10849,,INHIBITOR,1,1,1,Dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor ,,
4090,2473465,1927133,Tyrosine-protein kinase TYK2 inhibitor,12694,,INHIBITOR,1,1,1,Dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor ,,
4091,2473619,1927207,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
4092,2473619,1927207,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
4093,2473050,2286380,Tyrosine-protein kinase ABL inhibitor,8,,INHIBITOR,1,1,1,"ABL001 binds to a pocket on the BCR-ABL kinase domain that is normally occupied by the myristoylated N-terminus of ABL1 (""ABL001, a potent allosteric inhibitor of BCR-ABL, prevents emergence of resistant disease when administered in combination with nilotinib in an in vivo murine model of chronic myeloid leukemia"". Blood. 2014;124(21) [abstract 398])",,
4094,1706450,1301588,Serine/threonine-protein kinase Aurora inhibitor,109668,,INHIBITOR,1,1,1,Multitargeted kinase inhibitor ,,
4095,1706450,1301588,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,Multitargeted kinase inhibitor ,,
4096,1706450,1301588,SRC inhibitor,105769,,INHIBITOR,1,1,1,Multitargeted kinase inhibitor ,,
4097,1706450,1301588,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,Multitargeted kinase inhibitor ,,
4098,2473755,1927268,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4099,2473335,1927090,Tyrosine-protein kinase JAK2 inhibitor,10938,,INHIBITOR,1,1,1,,,
4100,2473187,1060577,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
4101,2473187,1060577,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,,,
4102,2473187,1060577,Receptor protein-tyrosine kinase erbB-4 inhibitor,12699,,INHIBITOR,1,1,1,,,
4103,2473188,562391,Insulin-like growth factor I receptor inhibitor,234,,INHIBITOR,1,1,1,,,
4104,2473756,1927269,Cyclin-dependent kinase 1 inhibitor,12071,,INHIBITOR,1,1,1,,,
4105,2473756,1927269,Cyclin-dependent kinase 2 inhibitor,11678,,INHIBITOR,1,1,1,,,
4106,2473756,1927269,Cyclin-dependent kinase 4 inhibitor,12946,,INHIBITOR,1,1,1,,,
4107,2473336,486594,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4108,2472918,1926897,PI3-kinase p110-delta subunit inhibitor,11177,,INHIBITOR,1,1,1,,,
4109,2472768,579815,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,"AMG548 has been shown to inhibit Wnt/ß-catenin signaling which is thought to be due to cross-reactivity with/inhibition of casein kinase Id/¿ (CSNK1D and CSNK1E, PMID:21513885)",,
4110,2473337,1412359,Serine/threonine-protein kinase Aurora inhibitor,109668,,INHIBITOR,1,1,1,Pan-Aurora kinase inhibitor,,
4111,2472919,1062422,3-phosphoinositide dependent protein kinase-1 inhibitor,10612,,INHIBITOR,1,1,1,,,
4112,2473757,2335158,Fibroblast growth factor receptor inhibitor,104793,,INHIBITOR,1,1,1,,,
4113,2473758,2335159,Serine/threonine-protein kinase AKT inhibitor,105106,,INHIBITOR,1,1,1,Allosteric inhibitor,,
4114,2473484,1927145,Serine/threonine-protein kinase B-raf inhibitor,100126,,INHIBITOR,1,1,1,,,
4115,2473484,1927145,Serine/threonine-protein kinase RAF inhibitor,10904,,INHIBITOR,1,1,1,,,
4116,2473620,1927208,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4117,2472769,1926808,Macrophage colony stimulating factor receptor inhibitor,12840,,INHIBITOR,1,1,1,,,
4118,2473485,1927146,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4119,2473485,1927146,Tyrosine-protein kinase TIE-2 inhibitor,12913,,INHIBITOR,1,1,1,,,
4120,2473338,218011,Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor,10752,,INHIBITOR,1,1,1,,,
4121,2473338,218011,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
4122,2472920,1289169,Serine/threonine-protein kinase Aurora inhibitor,109668,,INHIBITOR,1,1,1,Pan-Aurora kinase inhibitor,,
4123,2473339,1927092,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,Non-competitive MEK1/2 inhibitor.,,
4124,2473339,1927092,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor,11046,,INHIBITOR,1,1,1,Non-competitive MEK1/2 inhibitor.,,
4125,2473621,1927209,ALK tyrosine kinase receptor inhibitor,100417,,INHIBITOR,1,1,1,,,
4126,2473340,1927093,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,"Irreversible inhibitor, also potent at ERBB4.",,
4127,2473340,1927093,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,"Irreversible inhibitor, also potent at ERBB4.",,
4128,2472921,568339,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,"Also potent against KDR, FLT4, KIT, and ABL1. Selective inhibitor of mutant FLT3.",,
4129,2472921,568339,Tyrosine-protein kinase receptor RET inhibitor,100079,,INHIBITOR,1,1,1,"Also potent against KDR, FLT4, KIT, and ABL1. Selective inhibitor of mutant FLT3.",,
4130,2472770,1926809,Rho-associated protein kinase inhibitor,104981,,INHIBITOR,1,1,1,,,
4131,2472770,1926809,MAP kinase-activated protein kinase 2 inhibitor,11082,,INHIBITOR,1,1,1,,,
4132,2473052,1926966,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,No assay data or further target information found,,
4133,2473189,1927026,Tyrosine-protein kinase ABL inhibitor,8,,INHIBITOR,1,1,1,,,
4134,2473189,1927026,Tyrosine-protein kinase SRC inhibitor,10434,,INHIBITOR,1,1,1,,,
4135,2473341,1290955,Glycogen synthase kinase-3 inhibitor,104772,,INHIBITOR,1,1,1,,,
4136,2473759,1927272,Serine/threonine-protein kinase PIM inhibitor,109737,,INHIBITOR,1,1,1,,,
4137,2473760,263849,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,No further data/studies for the compound found.,,
4138,2473486,452952,Cyclin-dependent kinase inhibitor,109746,,INHIBITOR,1,1,1,"Potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9  (CDK1 CDK2 and CDK9)",,
4139,2472771,1428626,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,,,
4140,2473053,1343530,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4141,2473190,2335160,Serine-protein kinase ATR inhibitor,20139,,INHIBITOR,1,1,1,,,
4143,2473487,1927147,Neurotrophic tyrosine kinase receptor inhibitor,109739,,INHIBITOR,1,1,1,,,
4144,2473191,1927028,Nerve growth factor receptor Trk-A inhibitor,11902,,INHIBITOR,1,1,1,,,
4145,2473191,1927028,Neurotrophic tyrosine kinase receptor type 2 inhibitor,100413,,INHIBITOR,1,1,1,,,
4146,2473191,1927028,NT-3 growth factor receptor inhibitor,101034,,INHIBITOR,1,1,1,,,
4147,2472922,6836,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4148,2473761,1348359,Serine/threonine-protein kinase Chk1 inhibitor,12967,,INHIBITOR,1,1,1,"Development discontinued, part of Astra Zeneca's Open Innovation program",,
4149,2472772,1162276,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,ATP-competitive mTORC1/mTORC2 inhibitor,,
4150,2473762,1927273,PI3-kinase p110-beta subunit inhibitor,12576,,INHIBITOR,1,1,1,,,
4151,2473762,1927273,PI3-kinase p110-delta subunit inhibitor,11177,,INHIBITOR,1,1,1,,,
4152,2473763,1671912,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,,,
4153,2473763,1671912,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor,11046,,INHIBITOR,1,1,1,,,
4154,2473342,1927094,PI3-kinase p110-beta subunit inhibitor,12576,,INHIBITOR,1,1,1,,,
4155,2473342,1927094,PI3-kinase p110-alpha subunit inhibitor,11362,,INHIBITOR,1,1,1,,,
4156,2472923,1926898,Serine/threonine-protein kinase AKT inhibitor,12666,,INHIBITOR,1,1,1,Allosteric inhibitor.,,
4157,2472923,1926898,Serine/threonine-protein kinase AKT2 inhibitor,10695,,INHIBITOR,1,1,1,Allosteric inhibitor.,,
4158,2473764,1927274,Dual specificity protein kinase TTK inhibitor,30011,,INHIBITOR,1,1,1,,,
4159,2473622,2172856,Fibroblast growth factor receptor inhibitor,104793,,INHIBITOR,1,1,1,,,
4160,2473343,2287308,Serine/threonine-protein kinase B-raf inhibitor,100126,,INHIBITOR,1,1,1,,,
4161,2472773,1926810,Focal adhesion kinase 1 inhibitor,11242,,INHIBITOR,1,1,1,,,
4162,1699687,430493,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
4163,1700607,167995,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,"Allosteric MAPK14 inhibitor. In addition to MAPK11,  BIRB-796 has been shown to inhibit MAPK11, MAPK12 and MAPK13 (PMID:15755732).",,
4164,2473344,71663,Cyclin-dependent kinase 2 inhibitor,11678,,INHIBITOR,1,1,1,,,
4165,2473344,71663,Cyclin-dependent kinase 7 inhibitor,12829,,INHIBITOR,1,1,1,,,
4166,2473344,71663,Cyclin-dependent kinase 9 inhibitor,11626,,INHIBITOR,1,1,1,,,
4167,2473488,1927148,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4168,2472924,1926899,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4169,2472924,1926899,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,,,
4170,2473345,1927096,PI3-kinase p110-delta subunit inhibitor,11177,,INHIBITOR,1,1,1,,,
4171,2473345,1927096,PI3-kinase p110-gamma subunit inhibitor,11939,,INHIBITOR,1,1,1,,,
4172,2473765,1927275,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,ATP-competitive mTORC1/mTORC2 inhibitor,,
4173,2473765,1927275,DNA-dependent protein kinase inhibitor,10056,,INHIBITOR,1,1,1,ATP-competitive mTORC1/mTORC2 inhibitor,,
4174,2139009,1763562,Tyrosine-protein kinase BTK inhibitor,100097,,INHIBITOR,1,1,1,Irreversible inhibitor,,
4175,2473056,1926969,Tyrosine-protein kinase TIE-2 inhibitor,12913,,INHIBITOR,1,1,1,Also potent inhibitor of NTRK1 and NTRK2,,
4176,2473623,1331916,Tyrosine-protein kinase TIE-2 inhibitor,12913,,INHIBITOR,1,1,1,,,
4177,2473623,1331916,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
4178,2473489,1342038,Serine/threonine-protein kinase B-raf inhibitor,100126,,INHIBITOR,1,1,1,,,
4179,2473489,1342038,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
4180,2473489,1342038,Tyrosine-protein kinase receptor RET inhibitor,100079,,INHIBITOR,1,1,1,,,
4181,2472925,1926900,ALK tyrosine kinase receptor inhibitor,100417,,INHIBITOR,1,1,1,,,
4182,2472925,1926900,Focal adhesion kinase 1 inhibitor,11242,,INHIBITOR,1,1,1,,,
4183,2473057,250604,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,Its Prodrug Clinical Candidate is CEP-7055,,
4184,2472926,250483,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,Prodrug-active metabolite is CEP-5214,,
4185,2473766,1927276,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
4186,2473766,1927276,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
4187,2473766,1927276,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,,,
4188,2473766,1927276,Platelet-derived growth factor receptor beta inhibitor,197,,INHIBITOR,1,1,1,,,
4189,2473490,1927149,Fibroblast growth factor receptor inhibitor,104793,,INHIBITOR,1,1,1,No references found,,
4190,2473490,1927149,Tyrosine-protein kinase receptor Tie-1 inhibitor,100906,,INHIBITOR,1,1,1,No references found,,
4191,2473490,1927149,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,No references found,,
4192,2473192,508707,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,,,
4193,2473767,1927277,Serine/threonine-protein kinase Aurora-B inhibitor,10781,,INHIBITOR,1,1,1,,,
4194,2473767,1927277,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
4195,2472774,1926811,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
4196,2472774,1926811,Macrophage colony stimulating factor receptor inhibitor,12840,,INHIBITOR,1,1,1,,,
4197,2472774,1926811,Tyrosine-protein kinase JAK2 inhibitor,10938,,INHIBITOR,1,1,1,,,
4198,2473346,603809,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,Inhibits class I (HDAC1 HDAC2 HDAC3 HDAC8) and II (HDAC4 HDAC5 HDAC6 HDAC7 HDAC9 HDAC10) HDACs,,
4199,2473346,603809,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,Inhibits class I (HDAC1 HDAC2 HDAC3 HDAC8) and II (HDAC4 HDAC5 HDAC6 HDAC7 HDAC9 HDAC10) HDACs,,
4200,2473346,603809,Histone deacetylase inhibitor,104681,,INHIBITOR,1,1,1,Inhibits class I (HDAC1 HDAC2 HDAC3 HDAC8) and II (HDAC4 HDAC5 HDAC6 HDAC7 HDAC9 HDAC10) HDACs,,
4201,2472927,1966216,PI3-kinase p110-delta subunit inhibitor,11177,,INHIBITOR,1,1,1,Inhibits mainly class I and IIb HDACS (PMID:22693356),,
4202,2472927,1966216,PI3-kinase p110-beta subunit inhibitor,12576,,INHIBITOR,1,1,1,Inhibits mainly class I and IIb HDACS (PMID:22693356),,
4203,2472927,1966216,PI3-kinase p110-alpha subunit inhibitor,11362,,INHIBITOR,1,1,1,Inhibits mainly class I and IIb HDACS (PMID:22693356),,
4204,2472927,1966216,Histone deacetylase inhibitor,104681,,INHIBITOR,1,1,1,Inhibits mainly class I and IIb HDACS (PMID:22693356),,
4205,2473347,520120,Serine/threonine-protein kinase Aurora inhibitor,109668,,INHIBITOR,1,1,1,Pan-Aurora kinase inhibitor,,
4206,2473347,520120,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,Pan-Aurora kinase inhibitor,,
4207,2473663,1927214,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4208,2473663,1927214,Tyrosine-protein kinase TIE-2 inhibitor,12913,,INHIBITOR,1,1,1,,,
4209,2473663,1927214,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,,,
4210,2473663,1927214,Neurotrophic tyrosine kinase receptor inhibitor,109739,,INHIBITOR,1,1,1,,,
4211,2472775,1926812,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,ATP-competitive mTORC1/mTORC2 inhibitor,,
4212,2473348,1927097,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,"Dual MTOR/PI3K inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4213,2473348,1927097,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,"Dual MTOR/PI3K inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4214,2472928,1926902,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4215,2472776,1926813,MAP kinase ERK1 inhibitor,11639,,INHIBITOR,1,1,1,,,
4216,2472776,1926813,MAP kinase ERK2 inhibitor,11638,,INHIBITOR,1,1,1,,,
4217,2473349,1927098,Tyrosine-protein kinase JAK1 inhibitor,10919,,INHIBITOR,1,1,1,Backup to GSK-2586184 (GLPG-0778),,
4218,2473768,2126088,Mitogen-activated protein kinase kinase kinase 5 inhibitor,30034,,INHIBITOR,1,1,1,,,
4219,2472778,1926815,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,,,
4220,2473350,622556,Serine/threonine-protein kinase Aurora-B inhibitor,10781,,INHIBITOR,1,1,1,,,
4221,2473350,622556,Serine/threonine-protein kinase Aurora-C inhibitor,20171,,INHIBITOR,1,1,1,,,
4222,1976765,699312,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,"Dual MTOR/PIK3 inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4223,1976765,699312,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,"Dual MTOR/PIK3 inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4224,2472779,1926816,Focal adhesion kinase 1 inhibitor,11242,,INHIBITOR,1,1,1,,,
4225,2473491,1677842,PI3-kinase p110-beta subunit inhibitor,12576,,INHIBITOR,1,1,1,,,
4226,2473352,1248755,Serine/threonine-protein kinase PLK1 inhibitor,10907,,INHIBITOR,1,1,1,,,
4227,2472780,1926817,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4228,2473624,469313,Serine/threonine-protein kinase AKT inhibitor,105106,,INHIBITOR,1,1,1,,,
4229,2473624,469313,cAMP-dependent protein kinase (PKA) inhibitor,104720,,INHIBITOR,1,1,1,,,
4230,2473624,469313,Protein kinase C (PKC) inhibitor,104683,,INHIBITOR,1,1,1,,,
4231,2795535,2077913,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,EGFR mutant selective including both activating mutations and T790M (PMID: 26508839),,
4232,2472781,1926818,Tyrosine-protein kinase BTK inhibitor,100097,,INHIBITOR,1,1,1,,,
4233,2473770,1927280,Serine/threonine-protein kinase PLK1 inhibitor,10907,,INHIBITOR,1,1,1,,,
4234,2473353,2335161,Fibroblast growth factor receptor 1 inhibitor,10266,,INHIBITOR,1,1,1,,,
4235,2473353,2335161,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
4236,2473193,1927029,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
4237,2473492,1927150,Tyrosine-protein kinase SYK inhibitor,10906,,INHIBITOR,1,1,1,,,
4238,2473058,1926970,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
4239,2472930,1926904,PI3-kinase p110-alpha subunit inhibitor,11362,,INHIBITOR,1,1,1,,,
4240,2473117,1926982,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,Multi-targeted tyrosine kinase inhibitor,,
4241,2473117,1926982,Tyrosine-protein kinase FYN inhibitor,11755,,INHIBITOR,1,1,1,Multi-targeted tyrosine kinase inhibitor,,
4242,2473117,1926982,Tyrosine-protein kinase LCK inhibitor,10140,,INHIBITOR,1,1,1,Multi-targeted tyrosine kinase inhibitor,,
4243,2473117,1926982,Tyrosine-protein kinase Lyn inhibitor,11842,,INHIBITOR,1,1,1,Multi-targeted tyrosine kinase inhibitor,,
4244,2473117,1926982,Tyrosine-protein kinase SRC inhibitor,10434,,INHIBITOR,1,1,1,Multi-targeted tyrosine kinase inhibitor,,
4245,2473117,1926982,Vascular endothelial growth factor receptor 3 inhibitor,11752,,INHIBITOR,1,1,1,Multi-targeted tyrosine kinase inhibitor,,
4246,2473117,1926982,Tyrosine-protein kinase YES inhibitor,18033,,INHIBITOR,1,1,1,Multi-targeted tyrosine kinase inhibitor,,
4247,2473117,1926982,Receptor protein-tyrosine kinase erbB-4 inhibitor,12699,,INHIBITOR,1,1,1,Multi-targeted tyrosine kinase inhibitor,,
4248,2473117,1926982,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,Multi-targeted tyrosine kinase inhibitor,,
4249,2472702,1405757,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4250,2473561,2007613,Macrophage colony stimulating factor receptor inhibitor,12840,,INHIBITOR,1,1,1,,,
4251,2472703,430311,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
4252,2473118,1248758,Serine/threonine-protein kinase Aurora-A inhibitor,20014,,INHIBITOR,1,1,1,,,
4253,2473118,1248758,Serine/threonine-protein kinase Aurora-B inhibitor,10781,,INHIBITOR,1,1,1,,,
4254,2473118,1248758,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
4255,2473118,1248758,Tyrosine-protein kinase ABL inhibitor,8,,INHIBITOR,1,1,1,,,
4256,2472704,1926776,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,No further data/studies for the compound found.,,
4257,2472984,1926923,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,Thought to also inhibit MAPK11 and MAP2K6 but no further details available/found.,,
4258,2473262,1927043,Serine/threonine-protein kinase PIM inhibitor,109737,,INHIBITOR,1,1,1,,,
4259,2473431,1927112,Serine/threonine-protein kinase B-raf inhibitor,100126,,INHIBITOR,1,1,1,No references found,,
4260,2473431,1927112,Serine/threonine-protein kinase RAF inhibitor,10904,,INHIBITOR,1,1,1,No references found,,
4261,2472985,2099025,Neurotrophic tyrosine kinase receptor inhibitor,109739,,INHIBITOR,1,1,1,,,
4262,2472847,1926846,Tyrosine-protein kinase JAK2 inhibitor,10938,,INHIBITOR,1,1,1,,,
4263,2472986,1926925,Ribosomal protein S6 kinase 1 inhibitor,12944,,INHIBITOR,1,1,1,,,
4264,2473683,1927226,Serine/threonine-protein kinase Chk1 inhibitor,12967,,INHIBITOR,1,1,1,,,
4265,2473119,1926983,Serine/threonine-protein kinase AKT inhibitor,105106,,INHIBITOR,1,1,1,,,
4266,2473119,1926983,Ribosomal protein S6 kinase (P70S6K) inhibitor,105025,,INHIBITOR,1,1,1,,,
4267,2473536,1927156,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4268,2473432,1927113,Fibroblast growth factor receptor inhibitor,104793,,INHIBITOR,1,1,1,,,
4269,2472848,1926847,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4270,2473263,1927044,Serine/threonine-protein kinase B-raf inhibitor,100126,,INHIBITOR,1,1,1,,,
4271,2473263,1927044,Serine/threonine-protein kinase RAF inhibitor,10904,,INHIBITOR,1,1,1,,,
4272,2473263,1927044,Serine/threonine-protein kinase A-Raf inhibitor,103465,,INHIBITOR,1,1,1,,,
4273,2473562,1927169,Mitochondrial complex I (NADH dehydrogenase) inhibitor,105760,,INHIBITOR,1,1,1,,,
4274,2472987,1926926,Serine/threonine-protein kinase PLK1 inhibitor,10907,,INHIBITOR,1,1,1,,,
4275,2472850,1926849,Serine/threonine-protein kinase AKT inhibitor,105106,,INHIBITOR,1,1,1,No references found,,
4276,2472851,1671735,Serine/threonine-protein kinase Aurora-A inhibitor,20014,,INHIBITOR,1,1,1,,,
4277,2473684,1927227,Serine/threonine-protein kinase Aurora inhibitor,109668,,INHIBITOR,1,1,1,,,
4278,2473120,1517937,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4279,2473120,1517937,Macrophage-stimulating protein receptor inhibitor,11379,,INHIBITOR,1,1,1,,,
4280,2472852,1926850,MAP kinase ERK1 inhibitor,11639,,INHIBITOR,1,1,1,,,
4281,2472852,1926850,MAP kinase ERK2 inhibitor,11638,,INHIBITOR,1,1,1,,,
4282,1701389,1377224,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,No references found,,
4283,1701389,1377224,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor,11046,,INHIBITOR,1,1,1,No references found,,
4284,2473433,1927114,Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor,10752,,INHIBITOR,1,1,1,,,
4285,2473685,2145228,PI3-kinase p110-alpha subunit inhibitor,11362,,INHIBITOR,1,1,1,,,
4286,2473563,1797534,RAF serine/threonine protein kinase inhibitor,109740,,INHIBITOR,1,1,1,,,
4287,2473686,428508,Serine/threonine-protein kinase Aurora-A inhibitor,20014,,INHIBITOR,1,1,1,,,
4288,2472853,1926851,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
4289,2472853,1926851,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,,,
4290,2472854,1926852,Serine/threonine-protein kinase AKT inhibitor,12666,,INHIBITOR,1,1,1,,,
4291,2472854,1926852,Serine/threonine-protein kinase AKT3 inhibitor,10696,,INHIBITOR,1,1,1,,,
4292,2472854,1926852,Ribosomal protein S6 kinase (P70S6K) inhibitor,105025,,INHIBITOR,1,1,1,,,
4293,2473564,1927170,Cell division cycle 7-related protein kinase inhibitor,100077,,INHIBITOR,1,1,1,,,
4294,2473565,1117805,Serine/threonine-protein kinase PLK1 inhibitor,10907,,INHIBITOR,1,1,1,,,
4295,2473121,1926984,Mitochondrial complex I (NADH dehydrogenase) inhibitor,105760,,INHIBITOR,1,1,1,"Prodrug - active metabolite is ME-344. Mitochondrial inhibitor, specific molecular target for ME-344 has not been completely defined but has been shown to inhibit mitochondrial oxidative phosphorylation (OXPHOS) complex I (PMID:25973307), may also inhibit the mTORC1-and mTORC2-dependent pathways (PMID:25411085, http://mct.aacrjournals.org/content/12/11_Supplement/A17.short).",,
4296,1763609,1449225,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,,,
4297,2472705,2211072,Tyrosine-protein kinase BTK inhibitor,100097,,INHIBITOR,1,1,1,,,
4298,2473687,2197739,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,,,
4299,2473688,1037721,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
4300,2473688,1037721,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
4301,2473566,1927171,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,ATP-competitive mTORC1/mTORC2 inhibitor,,
4302,2473566,1927171,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,ATP-competitive mTORC1/mTORC2 inhibitor,,
4303,2473566,1927171,Serine/threonine-protein kinase receptor R3 inhibitor,100909,,INHIBITOR,1,1,1,ATP-competitive mTORC1/mTORC2 inhibitor,,
4304,2472988,1075318,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,,,
4305,2473434,1413663,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,ATP-competitive mTORC1/mTORC2 inhibitor,,
4306,2473264,1927045,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,Multi-targeted kinase irreversible inhibitor,,
4307,2473264,1927045,Fibroblast growth factor receptor 1 inhibitor,10266,,INHIBITOR,1,1,1,Multi-targeted kinase irreversible inhibitor,,
4308,2473264,1927045,Platelet-derived growth factor receptor beta inhibitor,197,,INHIBITOR,1,1,1,Multi-targeted kinase irreversible inhibitor,,
4309,2473264,1927045,Tyrosine-protein kinase SRC inhibitor,10434,,INHIBITOR,1,1,1,Multi-targeted kinase irreversible inhibitor,,
4310,2473122,1926985,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,,,
4311,2473123,1926986,Serine/threonine-protein kinase Chk1 inhibitor,12967,,INHIBITOR,1,1,1,,,
4312,2473124,630975,Focal adhesion kinase 1 inhibitor,11242,,INHIBITOR,1,1,1,,,
4313,2473567,1273600,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4314,2472706,1624674,Serine/threonine-protein kinase PAK 4 inhibitor,100080,,INHIBITOR,1,1,1,,,
4315,2472989,1926927,Serine/threonine-protein kinase Aurora-A inhibitor,20014,,INHIBITOR,1,1,1,,,
4316,2472989,1926927,Serine/threonine-protein kinase Aurora-B inhibitor,10781,,INHIBITOR,1,1,1,,,
4317,2473689,1322310,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4318,2472707,1987927,Tyrosine-protein kinase JAK1 inhibitor,10919,,INHIBITOR,1,1,1,,,
4319,2473435,692957,Cyclin-dependent kinase inhibitor,109746,,INHIBITOR,1,1,1,,,
4320,2473125,1285213,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,Also potent against ABL1,,
4321,2473265,707528,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,ATP-competitive PI3K/mTOR inhibitor,,
4322,2473265,707528,PI3-kinase p110-alpha subunit inhibitor,11362,,INHIBITOR,1,1,1,ATP-competitive PI3K/mTOR inhibitor,,
4323,2472855,1926853,Insulin-like growth factor I receptor inhibitor,234,,INHIBITOR,1,1,1,,,
4324,2472990,1926928,Macrophage colony stimulating factor receptor inhibitor,12840,,INHIBITOR,1,1,1,,,
4325,2473690,1927230,Macrophage colony stimulating factor receptor inhibitor,12840,,INHIBITOR,1,1,1,,,
4326,2473690,1927230,Nerve growth factor receptor Trk-A inhibitor,11902,,INHIBITOR,1,1,1,,,
4327,2473690,1927230,Neurotrophic tyrosine kinase receptor type 2 inhibitor,100413,,INHIBITOR,1,1,1,,,
4328,2473690,1927230,NT-3 growth factor receptor inhibitor,101034,,INHIBITOR,1,1,1,,,
4329,2472856,1926854,Serine/threonine-protein kinase B-raf inhibitor,100126,,INHIBITOR,1,1,1,,,
4330,2473126,1926987,Tyrosine-protein kinase SYK inhibitor,10906,,INHIBITOR,1,1,1,,,
4331,2473127,1926988,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,No references found,,
4332,2473568,1927172,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,No references found,,
4333,2473568,1927172,PI3-kinase p110-alpha subunit inhibitor,11362,,INHIBITOR,1,1,1,No references found,,
4334,2472857,1926855,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,"Also studied in veterinary cancers. Dual MTOR/PI3K inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4335,2472857,1926855,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,"Also studied in veterinary cancers. Dual MTOR/PI3K inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4336,2473128,1926989,Unknown,,,,1,1,1,,,
4337,2473266,1141617,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4338,2473691,1927231,Tyrosine-protein kinase JAK3 inhibitor,10849,,INHIBITOR,1,1,1,Prodrug of R333,,
4339,2473691,1927231,Tyrosine-protein kinase SYK inhibitor,10906,,INHIBITOR,1,1,1,Prodrug of R333,,
4340,2472751,361203,Cyclin-dependent kinase 1 inhibitor,12071,,INHIBITOR,1,1,1,,,
4341,2472751,361203,Cyclin-dependent kinase 2 inhibitor,11678,,INHIBITOR,1,1,1,,,
4342,2472751,361203,Cyclin-dependent kinase 4 inhibitor,12946,,INHIBITOR,1,1,1,,,
4343,1704167,1378738,Tyrosine-protein kinase JAK1 inhibitor,10919,,INHIBITOR,1,1,1,Prodrug of R-507,,
4344,1704167,1378738,Tyrosine-protein kinase JAK3 inhibitor,10849,,INHIBITOR,1,1,1,Prodrug of R-507,,
4345,2472991,1926929,Serine/threonine-protein kinase B-raf inhibitor,100126,,INHIBITOR,1,1,1,Mutant BRAF (V600E) kinase inhibitor,,
4346,2472992,1926930,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,"Bind allosterically to MEK and prevents its phosphorylation by, and release from, RAF. This results in the formation of a stable Raf-MEK-RO5126766 complex and the inhibition of RAF kinase (PMID:23667175).",,
4347,2472992,1926930,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor,11046,,INHIBITOR,1,1,1,"Bind allosterically to MEK and prevents its phosphorylation by, and release from, RAF. This results in the formation of a stable Raf-MEK-RO5126766 complex and the inhibition of RAF kinase (PMID:23667175).",,
4348,2472993,1926931,Serine/threonine-protein kinase RAF inhibitor,10904,,INHIBITOR,1,1,1,,,
4349,2472858,1926856,Serine/threonine-protein kinase Chk1 inhibitor,12967,,INHIBITOR,1,1,1,,,
4350,2473693,1521302,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,ATP-competitive mTORC1/mTORC2 inhibitor,,
4351,2473569,1927173,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,Thought to be a dual PI3K/mTOR inhibitor but no binding/selectivity/assay data found for any of the targets.,,
4352,2473269,1927048,Serine/threonine-protein kinase Chk1 inhibitor,12967,,INHIBITOR,1,1,1,,,
4353,2472994,1926932,Cyclin-dependent kinase 1 inhibitor,12071,,INHIBITOR,1,1,1,,,
4354,2472994,1926932,Cyclin-dependent kinase 2 inhibitor,11678,,INHIBITOR,1,1,1,,,
4355,2472994,1926932,Cyclin-dependent kinase 4 inhibitor,12946,,INHIBITOR,1,1,1,,,
4356,2472994,1926932,Cyclin-dependent kinase 5 inhibitor,12947,,INHIBITOR,1,1,1,,,
4357,2472994,1926932,Cyclin-dependent kinase 7 inhibitor,12829,,INHIBITOR,1,1,1,,,
4358,2472994,1926932,Cyclin-dependent kinase 9 inhibitor,11626,,INHIBITOR,1,1,1,,,
4359,2473270,340673,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,Binds to both p38a (MAPK14) and p38ß (MAPK11) isoforms,,
4360,2473129,1037777,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,,,
4361,2473129,1037777,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor,11046,,INHIBITOR,1,1,1,,,
4362,2473130,1926990,PI3-kinase p110-delta subunit inhibitor,11177,,INHIBITOR,1,1,1,,,
4363,2473130,1926990,PI3-kinase p110-gamma subunit inhibitor,11939,,INHIBITOR,1,1,1,,,
4364,2472708,320136,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4365,2472708,320136,MAP kinase p38 beta inhibitor,10120,,INHIBITOR,1,1,1,,,
4366,2473271,1927049,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,Also potent ERBB4 inhibitor,,
4367,2473271,1927049,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,Also potent ERBB4 inhibitor,,
4368,2473570,1927174,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4369,2472859,1926857,PI3-kinase p110-beta subunit inhibitor,12576,,INHIBITOR,1,1,1,,,
4370,2473131,1926991,FK506-binding protein 1A inhibitor,80,,INHIBITOR,1,1,1,"A rapamycin (sirolimus) derivative. Inhibits proliferation signalling probably, like rapamycin, via interaction with FK Binding Protein-12 and the mammalian target of rapamycin (mTOR) (http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc).",,
4371,2473694,1927233,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,No references found,,
4372,2472709,1926779,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4373,2472710,1563660,Serine/threonine-protein kinase Chk1 inhibitor,12967,,INHIBITOR,1,1,1,,,
4374,2472860,1037713,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4375,2472711,621164,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4376,2473437,1521160,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,"Prodrug - active metabolite is LY-294002. Dual MTOR/PI3K inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor.",,
4377,2473437,1521160,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,"Prodrug - active metabolite is LY-294002. Dual MTOR/PI3K inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor.",,
4378,2472712,1281325,Serine/threonine-protein kinase PIM inhibitor,109737,,INHIBITOR,1,1,1,,,
4379,2472995,698457,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4380,2472713,520055,Serine/threonine-protein kinase Aurora inhibitor,109668,,INHIBITOR,1,1,1,Pan-Aurora kinase inhibitor,,
4381,2473132,1926992,Serine/threonine-protein kinase AKT inhibitor,12666,,INHIBITOR,1,1,1,Compound is thought to be an Akt pathway inhibitor and inhibits Akt phosphorylation but does not bind to ATP-binding site (or any site?) on Akt kinases (PMID:17602463),,
4382,2473272,430410,Cyclin-dependent kinase 2 inhibitor,11678,,INHIBITOR,1,1,1,Also potent against CDK1 and CDK4,,
4383,2473273,1927050,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4384,1700675,1037718,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,,,
4385,2472714,1037736,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,,,
4386,2472714,1037736,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
4387,2473438,1441421,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,,,
4388,2473438,1441421,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
4389,2472715,1926780,Tyrosine-protein kinase SYK inhibitor,10906,,INHIBITOR,1,1,1,,,
4390,2472996,1038036,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,,,
4391,2472996,1038036,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor,11046,,INHIBITOR,1,1,1,,,
4392,2472716,1926781,Serine/threonine-protein kinase Aurora-B inhibitor,10781,,INHIBITOR,1,1,1,Potently inhibits multiple kinases.,,
4393,2472717,1566128,Serine/threonine-protein kinase PLK1 inhibitor,10907,,INHIBITOR,1,1,1,,,
4394,2473133,1926993,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4395,2473133,1926993,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,,,
4396,2473571,1927175,Serine/threonine-protein kinase Aurora-A inhibitor,20014,,INHIBITOR,1,1,1,,,
4397,2472997,1926933,Choline kinase alpha inhibitor,11628,,INHIBITOR,1,1,1,,,
4398,2473439,1276066,Cyclin-dependent kinase 1 inhibitor,12071,,INHIBITOR,1,1,1,,,
4399,2473439,1276066,Cyclin-dependent kinase 2 inhibitor,11678,,INHIBITOR,1,1,1,,,
4400,2473439,1276066,Cyclin-dependent kinase 7 inhibitor,12829,,INHIBITOR,1,1,1,,,
4401,2473439,1276066,Cyclin-dependent kinase 9 inhibitor,11626,,INHIBITOR,1,1,1,,,
4402,2473439,1276066,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
4403,2473439,1276066,Tyrosine-protein kinase JAK2 inhibitor,10938,,INHIBITOR,1,1,1,,,
4404,2473440,2197740,PI3-kinase p110-delta subunit inhibitor,11177,,INHIBITOR,1,1,1,,,
4405,2473572,1927176,Serine/threonine-protein kinase Aurora inhibitor,109668,,INHIBITOR,1,1,1,,,
4406,2473441,744551,Unknown,,,,1,1,1,"Anti-inflammatory drug, mechanism of action may involve the inhibition of NF-kB and the early transient inhibition of P38 MAP kinase signaling pathways.",,
4407,2472718,1926782,Focal adhesion kinase 1 inhibitor,11242,,INHIBITOR,1,1,1,,,
4408,2473134,611731,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,"Inhibitor of class I phosphoinositide 3-kinase (PI3K) isoforms, ATP-competitive mTORC1/mTORC2 inhibitor",,
4409,2473134,611731,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,"Inhibitor of class I phosphoinositide 3-kinase (PI3K) isoforms, ATP-competitive mTORC1/mTORC2 inhibitor",,
4410,2473274,2197741,Serine-protein kinase ATR inhibitor,20139,,INHIBITOR,1,1,1,,,
4411,2473573,431685,Tyrosine-protein kinase JAK3 inhibitor,10849,,INHIBITOR,1,1,1,,,
4412,2473695,1927234,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,,,
4413,2473135,1926994,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,,,
4414,2473135,1926994,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor,11046,,INHIBITOR,1,1,1,,,
4415,2472719,2252482,ALK tyrosine kinase receptor inhibitor,100417,,INHIBITOR,1,1,1,,,
4416,2473574,1927177,Tyrosine-protein kinase JAK2 inhibitor,10938,,INHIBITOR,1,1,1,,,
4417,2472998,1926934,Tyrosine-protein kinase ABL inhibitor,8,,INHIBITOR,1,1,1,"Also potent inhibitor of AURKA, AURKB, FGFR1-3, and ALK.",,
4418,2472998,1926934,Insulin-like growth factor I receptor inhibitor,234,,INHIBITOR,1,1,1,"Also potent inhibitor of AURKA, AURKB, FGFR1-3, and ALK.",,
4419,2472998,1926934,SRC inhibitor,105769,,INHIBITOR,1,1,1,"Also potent inhibitor of AURKA, AURKB, FGFR1-3, and ALK.",,
4420,2472720,1926784,Serine/threonine-protein kinase AKT inhibitor,105106,,INHIBITOR,1,1,1,,,
4421,2472720,1926784,Ribosomal protein S6 kinase (P70S6K) inhibitor,105025,,INHIBITOR,1,1,1,,,
4422,2472721,1926785,Serine/threonine-protein kinase Chk1 inhibitor,12967,,INHIBITOR,1,1,1,,,
4423,2472721,1926785,Serine/threonine-protein kinase Chk2 inhibitor,10531,,INHIBITOR,1,1,1,,,
4424,2472999,574917,Rho-associated protein kinase inhibitor,104981,,INHIBITOR,1,1,1,,,
4425,2472722,1926786,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,"Also shown to inhibit EGFR, FLT4 and RET (PMID:15928657)",,
4426,2473327,1927085,Tyrosine-protein kinase receptor UFO inhibitor,100410,,INHIBITOR,1,1,1,,,
4427,2473327,1927085,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4428,2473044,1926960,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,,,
4429,1976752,680196,G1/S-specific cyclin D1 inhibitor,10522,,INHIBITOR,1,1,1,Prodrug of ON-013100,,
4430,1699850,631950,Serotonin 2a (5-HT2a) receptor inverse agonist,107,,INVERSE AGONIST,1,1,1,,,
4431,1702638,1176030,Histamine H3 receptor antagonist,10280,,ANTAGONIST,1,1,1,,,
4432,1703247,1378273,Histamine H3 receptor agonist,10280,,AGONIST,1,1,1,GT-2331 exhibits differential pharmacology at the H3 receptor depending on which receptor mediated G-protein signalling pathway is examined (functional selectivity). May indicate presence of alternative ligand bound active state receptor conformations.,,
4433,2473000,1444852,Smoothened homolog antagonist,101400,,ANTAGONIST,1,1,1,,,
4434,2472861,1625127,Smoothened homolog antagonist,101400,,ANTAGONIST,1,1,1,,,
4435,2473275,366096,Metabotropic glutamate receptor 2 agonist,12895,,AGONIST,1,1,1,Active metabolite of LY2140023,,
4436,2473275,366096,Metabotropic glutamate receptor 3 agonist,10167,,AGONIST,1,1,1,Active metabolite of LY2140023,,
4437,2473276,1927052,Metabotropic glutamate receptor 5 modulator,11280,,MODULATOR,1,1,1,Positive allosteric modulator (PAM),,
4438,2473442,1927117,C-C chemokine receptor type 9 antagonist,101345,,ANTAGONIST,1,1,1,,,
4439,2473443,1927118,Glucagon receptor agonist,146,,AGONIST,1,1,1,dual glucagon-like peptide-1/glucagon receptor agonist,,
4440,2472723,1823083,Sphingosine 1-phosphate receptor Edg-1 agonist,11631,,AGONIST,1,1,1,,,
4441,2473575,2279012,Cannabinoid CB2 receptor agonist,259,,AGONIST,1,1,1,,,
4442,2473696,1927235,Bradykinin B1 receptor antagonist,11156,,ANTAGONIST,1,1,1,,,
4443,2473697,1927236,Cannabinoid CB1 receptor agonist,87,,AGONIST,1,1,1,,,
4444,2473697,1927236,Cannabinoid CB2 receptor agonist,259,,AGONIST,1,1,1,,,
4445,2473001,1926935,Free fatty acid receptor 1 agonist,100431,,AGONIST,1,1,1,Discontinueddue to toxicity,,
4446,2473444,1927119,Metabotropic glutamate receptor 2 agonist,12895,,AGONIST,1,1,1,"From poster: orally bioavailable prodrug for a potent, selective mGlu2/3 receptor agonist, have no more information.",,
4447,2473444,1927119,Metabotropic glutamate receptor 3 agonist,10167,,AGONIST,1,1,1,"From poster: orally bioavailable prodrug for a potent, selective mGlu2/3 receptor agonist, have no more information.",,
4448,2472724,1926788,Metabotropic glutamate receptor 2 agonist,12895,,AGONIST,1,1,1,,,
4449,2473002,1926936,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
4450,2472862,1926858,Adenosine A2a receptor antagonist,252,,ANTAGONIST,1,1,1,,,
4451,2473445,1927120,Adenosine A2a receptor antagonist,252,,ANTAGONIST,1,1,1,,,
4452,2473445,1927120,Phosphodiesterase 10A inhibitor,100010,,INHIBITOR,1,1,1,,,
4453,2473277,329541,Adenosine A2a receptor antagonist,252,,ANTAGONIST,1,1,1,,,
4454,2473136,1926995,Vasopressin V1a receptor antagonist,134,,ANTAGONIST,1,1,1,,,
4455,2473003,1355745,Cholecystokinin B receptor antagonist,11522,,ANTAGONIST,1,1,1,,,
4456,2473004,1262987,Histamine H4 receptor antagonist,11290,,ANTAGONIST,1,1,1,,,
4457,2473698,1927237,Dopamine D2 receptor modulator,72,,MODULATOR,1,1,1,"Dopidine (dopaminergic stabilizer), have not found any reference about pharmcology for the compound.",,
4458,2472863,1926859,Dopamine D2 receptor modulator,72,,MODULATOR,1,1,1,Dopidine (dopaminergic stabilizer),,
4459,2473137,1733196,Cannabinoid CB2 receptor agonist,259,,AGONIST,1,1,1,,,
4460,2473576,1927179,C-X-C chemokine receptor type 4 antagonist,10473,,ANTAGONIST,1,1,1,,,
4461,2472864,1926860,Adenosine A1 receptor partial agonist,114,,PARTIAL AGONIST,1,1,1,Compound not in current pipeline,,
4462,2473577,1927180,Adenosine A1 receptor agonist,114,,AGONIST,1,1,1,,,
4463,2472725,77702,Adenosine A1 receptor antagonist,114,,ANTAGONIST,1,1,1,,,
4464,2473446,430009,Adenosine A2b receptor antagonist,278,,ANTAGONIST,1,1,1,,,
4465,2473578,1070029,Adenosine A2b receptor antagonist,278,,ANTAGONIST,1,1,1,,,
4466,2473278,1927053,Adenosine A2b receptor antagonist,278,,ANTAGONIST,1,1,1,,,
4467,2473278,1927053,Adenosine A3 receptor antagonist,280,,ANTAGONIST,1,1,1,,,
4468,2473447,1927121,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,Dual acting MABA (beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists),,
4469,2473447,1927121,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,Dual acting MABA (beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists),,
4470,2473448,1927122,Cysteinyl leukotriene receptor 1 antagonist,179,,ANTAGONIST,1,1,1,Inhibits PDE3 and PDE4 IC50 2.01uM and 4.7uM respectively (PMID:15541426),,
4471,1701360,1377197,Neurokinin 1 receptor antagonist,250,,ANTAGONIST,1,1,1,,,
4472,2138982,1763539,Frizzled-8 antagonist,109744,,ANTAGONIST,1,1,1,mAB,,
4473,1879186,1540524,Frizzled-1 antagonist,105681,,ANTAGONIST,1,1,1,mAB,,
4474,1879186,1540524,Frizzled-2 antagonist,109741,,ANTAGONIST,1,1,1,mAB,,
4475,1879186,1540524,Frizzled-5 antagonist,109742,,ANTAGONIST,1,1,1,mAB,,
4476,1879186,1540524,Frizzled-7 antagonist,109743,,ANTAGONIST,1,1,1,mAB,,
4477,1879186,1540524,Frizzled-8 antagonist,109744,,ANTAGONIST,1,1,1,mAB,,
4478,1701388,1544440,Motilin receptor agonist,11061,,AGONIST,1,1,1,,,
4479,2473699,1301682,Fibroblast growth factor receptor 1 inhibitor,10266,,INHIBITOR,1,1,1,Multi-targeted kinase inhibitor,,
4480,2473699,1301682,Fibroblast growth factor receptor 2 inhibitor,10264,,INHIBITOR,1,1,1,Multi-targeted kinase inhibitor,,
4481,2473699,1301682,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,Multi-targeted kinase inhibitor,,
4482,2473699,1301682,Platelet-derived growth factor receptor beta inhibitor,197,,INHIBITOR,1,1,1,Multi-targeted kinase inhibitor,,
4483,2473699,1301682,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,Multi-targeted kinase inhibitor,,
4484,2473699,1301682,Serine/threonine-protein kinase Aurora-A inhibitor,20014,,INHIBITOR,1,1,1,Multi-targeted kinase inhibitor,,
4485,2473699,1301682,Serine/threonine-protein kinase PLK4 inhibitor,30003,,INHIBITOR,1,1,1,Multi-targeted kinase inhibitor,,
4487,2473005,1926937,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,"Compound is most potent against PIK3CD, low potency against EGFR, KDR and PDGFRB",,
4488,2473005,1926937,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,"Compound is most potent against PIK3CD, low potency against EGFR, KDR and PDGFRB",,
4489,2473005,1926937,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,"Compound is most potent against PIK3CD, low potency against EGFR, KDR and PDGFRB",,
4490,2473005,1926937,Platelet-derived growth factor receptor beta inhibitor,197,,INHIBITOR,1,1,1,"Compound is most potent against PIK3CD, low potency against EGFR, KDR and PDGFRB",,
4491,2473579,1927181,Neurotrophic tyrosine kinase receptor inhibitor,109739,,INHIBITOR,1,1,1,,,
4492,2473579,1927181,Protein kinase C (PKC) inhibitor,104683,,INHIBITOR,1,1,1,,,
4493,2473579,1927181,Tyrosine-protein kinase receptor RET inhibitor,100079,,INHIBITOR,1,1,1,,,
4494,2473579,1927181,Platelet-derived growth factor receptor beta inhibitor,197,,INHIBITOR,1,1,1,,,
4495,2473579,1927181,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
4496,2473138,1926996,Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor,10752,,INHIBITOR,1,1,1,Prodrug - active metabolite is IMD-0560,,
4497,2473007,1926939,Cell division cycle 7-related protein kinase inhibitor,100077,,INHIBITOR,1,1,1,,,
4498,2472726,1926789,Cyclin-dependent kinase 4 inhibitor,12946,,INHIBITOR,1,1,1,,,
4499,2472726,1926789,Cyclin-dependent kinase 6 inhibitor,10480,,INHIBITOR,1,1,1,,,
4500,2472865,382857,Vanilloid receptor antagonist,10260,,ANTAGONIST,1,1,1,"Discontinued, causes increased core body temperature.",,
4501,2473139,418623,Vanilloid receptor antagonist,10260,,ANTAGONIST,1,1,1,,,
4502,2473140,1926997,Vanilloid receptor antagonist,10260,,ANTAGONIST,1,1,1,,,
4503,2473700,478192,Neuronal acetylcholine receptor; alpha4/beta2 antagonist,104283,,ANTAGONIST,1,1,1,Racemic compound.,,
4504,2473580,1149921,GABA receptor alpha-2 subunit positive allosteric modulator,12770,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,
4505,2473580,1149921,GABA receptor alpha-3 subunit positive allosteric modulator,12757,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,
4506,2473280,1927055,P2X purinoceptor 7 negative allosteric modulator,10417,,NEGATIVE ALLOSTERIC MODULATOR,1,1,1,,,
4507,2473281,2011154,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
4508,2473282,1927057,Sodium channel protein type IX alpha subunit blocker,18061,,BLOCKER,1,1,1,,,
4509,2473008,1926940,Sodium channel protein type IX alpha subunit blocker,18061,,BLOCKER,1,1,1,Backup to XEN402.,,
4510,2472866,1926861,Sodium channel protein type IX alpha subunit blocker,18061,,BLOCKER,1,1,1,,,
4511,2472866,1926861,Sodium channel protein type X alpha subunit blocker,18080,,BLOCKER,1,1,1,,,
4512,2473283,1927058,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,Shows no specificity among human SCN channel family members (SCN1A-11A).,,
4513,2473701,427222,Neuronal acetylcholine receptor protein alpha-7 subunit positive allosteric modulator,10635,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,Type I positive allosteric modulator.,,
4514,2473581,352807,Neuronal acetylcholine receptor protein alpha-7 subunit agonist,10635,,AGONIST,1,1,1,,,
4515,2473449,1422239,Neuronal acetylcholine receptor protein alpha-7 subunit agonist,10635,,AGONIST,1,1,1,,,
4516,2472867,1926862,Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist,10635,,PARTIAL AGONIST,1,1,1,,,
4517,2473009,1442581,G protein-coupled receptor 44 antagonist,20174,,ANTAGONIST,1,1,1,Indication: Allergic diseases,,
4518,2472868,1926863,G protein-coupled receptor 44 antagonist,20174,,ANTAGONIST,1,1,1,Indication: Allergic diseases,,
4519,2473284,557248,G protein-coupled receptor 44 antagonist,20174,,ANTAGONIST,1,1,1,,,
4520,2472727,1926790,G protein-coupled receptor 44 antagonist,20174,,ANTAGONIST,1,1,1,,,
4521,2473260,1927042,Tyrosine-protein kinase BTK inhibitor,100097,,INHIBITOR,1,1,1,"Ph1b trial planned, not yet recruiting (NCT02537028)",,
4522,2473045,1926961,PI3-kinase p110-delta subunit inhibitor,11177,,INHIBITOR,1,1,1,,,
4523,2472760,1926804,Dual specificity protein kinase TTK inhibitor,30011,,INHIBITOR,1,1,1,,,
4524,2473750,1927265,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,,,
4525,2472761,1926805,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
4526,2472761,1926805,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,,,
4527,2473751,1789648,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,,,
4528,2473612,1927203,Serine/threonine-protein kinase PLK1 inhibitor,10907,,INHIBITOR,1,1,1,No assay data or further target information found,,
4529,2583003,2039196,Transient receptor potential cation channel subfamily V member 4 antagonist,11847,,ANTAGONIST,1,1,1,,,
4530,2583502,2039324,Sodium channel protein type IX alpha subunit blocker,18061,,BLOCKER,1,1,1,"Reversible sodium channel blocker that is selective for Nav1.7, which is expressed primarily on peripheral nociceptor C-fiber neurons and is required for pain sensing in humans.",,
4531,2583701,2039367,P2X purinoceptor 7 antagonist,10417,,ANTAGONIST,1,1,1,,,
4532,2583503,2039325,Neuronal acetylcholine receptor; alpha4/beta2 modulator,104283,,MODULATOR,1,1,1,,,
4533,1705237,38729,Sodium channel protein type II alpha subunit blocker,18072,,BLOCKER,1,1,1,,,
4534,1705237,38729,Sodium channel protein type III alpha subunit blocker,18075,,BLOCKER,1,1,1,,,
4535,1705237,38729,Voltage-gated L-type calcium channel blocker,104801,,BLOCKER,1,1,1,,,
4536,1705237,38729,Voltage-gated N-type calcium channel alpha-1B subunit blocker,10511,,BLOCKER,1,1,1,,,
4537,1705237,38729,Voltage-gated P/Q-type calcium channel alpha-1A subunit blocker,18016,,BLOCKER,1,1,1,,,
4538,1705292,38677,Glutamate receptor ionotropic AMPA antagonist,104825,,ANTAGONIST,1,1,1,Non-competitive AMPA receptor antagonist.,,
4539,1705292,38677,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
4540,1700874,1376719,Sulfonylurea receptors; K-ATP channels opener,104737,,OPENER,1,1,1,,,
4541,2583573,1383254,Glutamate [NMDA] receptor antagonist,104706,,ANTAGONIST,1,1,1,Non-competitive antagonist.,,
4542,1879141,1540490,Vanilloid receptor antagonist,10260,,ANTAGONIST,1,1,1,,,
4543,2583702,2039368,Vanilloid receptor antagonist,10260,,ANTAGONIST,1,1,1,,,
4544,2583703,2039369,Vanilloid receptor antagonist,10260,,ANTAGONIST,1,1,1,,,
4545,2583607,2039349,Transient receptor potential cation channel subfamily A member 1 antagonist,101412,,ANTAGONIST,1,1,1,,,
4546,2583406,2039286,Transient receptor potential cation channel subfamily M member 8 agonist,103167,,AGONIST,1,1,1,,,
4547,2583704,2039370,Glutamate receptor ionotropic AMPA positive allosteric modulator,104825,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,Ampakine molecule.,,
4548,2583608,2039350,Glutamate receptor ionotropic AMPA positive allosteric modulator,104825,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Binds to LBD (ligand binding domain) of GRIA2.
4549,2583504,2039326,Glutamate [NMDA] receptor antagonist,104706,,ANTAGONIST,1,1,1,,,
4550,2583609,2039351,Sodium channel protein type IX alpha subunit blocker,18061,,BLOCKER,1,1,1,,,
4551,2473285,1927059,Estrogen receptor alpha antagonist,19,,ANTAGONIST,1,1,1,,,
4552,2472869,1926864,Estrogen receptor alpha degrader,19,,DEGRADER,1,1,1,FDA accepted IND-application in December 2014. Is a SERM (selective estrogen receptor modulator) and SERD (selective estrogen receptor down-regulator/degrader),,
4553,1705077,1379611,Estrogen receptor modulator,104682,,MODULATOR,1,1,1,selective estrogen modulator (SERM),,
4554,2473702,1927238,Estrogen receptor modulator,104682,,MODULATOR,1,1,1,SERM,,
4555,1699931,491,Estrogen receptor modulator,104682,,MODULATOR,1,1,1,"SERM, development stopped as ineffective compared to tamoxifen.",,
4556,2473450,1927123,Estrogen receptor agonist,104682,,AGONIST,1,1,1,"A Phase Iia was ended prematurerly, development of compound for hot flushes discontinued in 2010 (http://karobio.com/investormedia/pressreleaser/pressrelease?pid=545341)",,
4557,1699809,694933,Peroxisome proliferator-activated receptor agonist,109738,,AGONIST,1,1,1,Ph2 study terminated due to safety concerns,,
4558,1701429,1377254,Peroxisome proliferator-activated receptor agonist,109738,,AGONIST,1,1,1,Ph2 study terminated due to safety concerns,,
4559,2473286,119754,Retinoid X receptor agonist,105765,,AGONIST,1,1,1,,,
4560,2473582,1927182,Androgen Receptor modulator,56,,MODULATOR,1,1,1,SARM,,
4561,2472870,1951344,Androgen Receptor antagonist,56,,ANTAGONIST,1,1,1,,,
4562,1702648,1378008,Androgen Receptor antagonist,56,,ANTAGONIST,1,1,1,,,
4563,1702648,1378008,Cytochrome P450 17A1 inhibitor,12949,,INHIBITOR,1,1,1,,,
4564,2473703,1947752,Estrogen receptor alpha antagonist,19,,ANTAGONIST,1,1,1,Selective estrogen receptor degrader (SERD),,
4565,2472871,1926866,Estrogen receptor alpha agonist,19,,AGONIST,1,1,1,Capesaris is proposed INN,,
4566,1706432,1408997,Estrogen receptor modulator,104682,,MODULATOR,1,1,1,Active metabolite of tamoxifen,,
4567,1706432,1408997,Estrogen-related receptor gamma antagonist,11255,,ANTAGONIST,1,1,1,Active metabolite of tamoxifen,,
4568,1705787,313824,Estrogen receptor beta agonist,174,,AGONIST,1,1,1,Development discontinued after Ph2 trial,,
4569,1699855,360298,Estrogen receptor beta agonist,174,,AGONIST,1,1,1,"Ph2 study for indication Benign Prostatic Hyperplasia was terminated, drug in Ph2 trial for Schizophrenia.",,
4570,2473451,328126,Estrogen receptor beta agonist,174,,AGONIST,1,1,1,,,
4571,2473010,1926941,Estrogen receptor beta agonist,174,,AGONIST,1,1,1,Main metabolite is ESR2 agonist (:http://www.curadis.eu/index.php?page=cr-1447),,
4572,2473010,1926941,Androgen Receptor agonist,56,,AGONIST,1,1,1,Main metabolite is ESR2 agonist (:http://www.curadis.eu/index.php?page=cr-1447),,
4573,1976719,1626735,Glucocorticoid receptor modulator,25,,MODULATOR,1,1,1,Active metbolite of PF-04171327,,
4574,2473704,1927240,Glucocorticoid receptor antagonist,25,,ANTAGONIST,1,1,1,,,
4575,2473705,1927241,Mineralocorticoid receptor antagonist,48,,ANTAGONIST,1,1,1,,,
4576,2473452,1927124,Mineralocorticoid receptor antagonist,48,,ANTAGONIST,1,1,1,,,
4577,2473706,1927242,Mineralocorticoid receptor antagonist,48,,ANTAGONIST,1,1,1,,,
4578,1976746,1442757,Mineralocorticoid receptor antagonist,48,,ANTAGONIST,1,1,1,,,
4579,1702502,244434,Progesterone receptor antagonist,36,,ANTAGONIST,1,1,1,,,
4580,1702587,1377964,Progesterone receptor modulator,36,,MODULATOR,1,1,1,"Mixed-profile progestagen, selective progesterone receptor modulator",,
4581,1706223,1248744,Progesterone receptor antagonist,36,,ANTAGONIST,1,1,1,,,
4582,2473011,1926942,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,,,
4583,2473453,1927125,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,"Status last updated May 2009, discontinued?",,
4584,2472728,247418,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,Compound failed to show an advantage over marketed fenofibrate in Ph2 trial. Also potential adverse effects on kidney function (http://www.firstwordpharma.com/node/110221#axzz3Oj1URprS). Developement on hold or discontinued?,,
4585,2473707,1927243,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,"Report about Ph2 trial in Canada 2007, no trial ID or references found. Compound may have been discontinued.",,
4586,2473141,366667,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,"Not in pipeline, development discontinued?",,
4587,2473583,1927183,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,Development discontinued (http://fr.reuters.com/article/idUKL04616509200804042),,
4588,1705873,149594,Peroxisome proliferator-activated receptor gamma modulator,133,,MODULATOR,1,1,1,Drug in Ph1 or 2? Development status unknown.,,
4589,1702920,173090,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,"1000-fold less potent at PPARA. Last updated November 2009, discontinued?",,
4590,1701418,305459,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,"Development stopped (PMID:20932114). There are reports of adverse events associated with PPARalfa/gamma dual agonist, for example weight gain, increased risk of bladder cancer and hyperplasia.",,
4591,1701418,305459,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,"Development stopped (PMID:20932114). There are reports of adverse events associated with PPARalfa/gamma dual agonist, for example weight gain, increased risk of bladder cancer and hyperplasia.",,
4592,2472873,384165,Peroxisome proliferator-activated receptor delta agonist,12227,,AGONIST,1,1,1,,,
4593,2473454,1927126,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,,,
4594,2473584,499717,Peroxisome proliferator-activated receptor gamma modulator,133,,MODULATOR,1,1,1,"Ph2 study terminated, compound development discontinued. Selective PPAR gamma modulator (SPPAR?M)",,
4595,2472874,1926869,Peroxisome proliferator-activated receptor gamma modulator,133,,MODULATOR,1,1,1,Selective PPAR gamma modulator (SPPAR?M),,
4596,2473142,699274,Peroxisome proliferator-activated receptor gamma modulator,133,,MODULATOR,1,1,1,Selective PPAR gamma modulator (SPPAR?M),,
4597,2473455,1927127,Peroxisome proliferator-activated receptor gamma modulator,133,,MODULATOR,1,1,1,Selective PPAR gamma modulator (SPPAR?M) properties. Discontinued no advantage was demonstrated in clinical trials compared existing peroxisome proliferator activated receptor (PPAR) agonists,,
4598,2473456,1927128,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,"Daichii Sankyo has suspended inhouse development in jan 2013, supports external development of the compound.",,
4599,1699797,1376094,Peroxisome proliferator-activated receptor gamma modulator,133,,MODULATOR,1,1,1,"Selective PPAR gamma modulator (SPPAR?M), SLC22A12 inhibitor",,
4600,1699797,1376094,Solute carrier family 22 member 12 inhibitor,102767,,INHIBITOR,1,1,1,"Selective PPAR gamma modulator (SPPAR?M), SLC22A12 inhibitor",,
4601,2472729,175008,Retinoic acid receptor alpha agonist,57,,AGONIST,1,1,1,"Not updated trial information since May 2008, discontinued?",,
4602,1702509,1377918,Retinoic acid receptor gamma agonist,240,,AGONIST,1,1,1,,,
4603,2473012,1096822,Retinoid X receptor alpha modulator,275,,MODULATOR,1,1,1,"R-enantiomer of etodolac, does not have COX inhibitory activity. Ph2 trials terminated. Received orphan product designation by FDA in 2002",,
4604,2473457,515180,Thyroid hormone receptor beta-1 agonist,271,,AGONIST,1,1,1,Ph2 study withdrawn. Prodrug of MB07344.,,
4605,1701591,1377377,Vitamin D receptor agonist,64,,AGONIST,1,1,1,orphan designation by EU January 2014,,
4606,2472875,592303,Vitamin D receptor agonist,64,,AGONIST,1,1,1,,,
4607,1701390,1377225,Vitamin D receptor agonist,64,,AGONIST,1,1,1,,,
4608,1702602,1377975,Vitamin D receptor agonist,64,,AGONIST,1,1,1,,,
4609,2473013,1926943,Vitamin D receptor agonist,64,,AGONIST,1,1,1,Development terminated due to unmet primary end points for treatment of OAB in Ph2b trial,,
4610,1702521,582954,Protein kinase C (PKC) inhibitor,104683,,INHIBITOR,1,1,1,,,
4611,2473287,586744,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,"Also potent inhibitor of SRC, ABL1 and CSF1R",,
4612,2473287,586744,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,"Also potent inhibitor of SRC, ABL1 and CSF1R",,
4613,2473287,586744,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,"Also potent inhibitor of SRC, ABL1 and CSF1R",,
4614,2473287,586744,Vascular endothelial growth factor receptor 1 inhibitor,10979,,INHIBITOR,1,1,1,"Also potent inhibitor of SRC, ABL1 and CSF1R",,
4615,2473585,1927184,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
4616,2473458,1927130,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
4617,2472876,1926870,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,Multi-targeted receptor tyrosine kinase inhibitor,,
4618,2472876,1926870,Vascular endothelial growth factor receptor 3 inhibitor,11752,,INHIBITOR,1,1,1,Multi-targeted receptor tyrosine kinase inhibitor,,
4619,2472876,1926870,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,Multi-targeted receptor tyrosine kinase inhibitor,,
4620,2472876,1926870,Platelet-derived growth factor receptor beta inhibitor,197,,INHIBITOR,1,1,1,Multi-targeted receptor tyrosine kinase inhibitor,,
4621,2473288,1927061,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4622,2473542,1927160,ALK tyrosine kinase receptor inhibitor,100417,,INHIBITOR,1,1,1,Inhibits ALK and EGFR gatekeeper mutants. Does not inhibit wild type (native) EGFR.,,
4623,2473542,1927160,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,Inhibits ALK and EGFR gatekeeper mutants. Does not inhibit wild type (native) EGFR.,,
4624,2472966,1926914,Rho-associated protein kinase inhibitor,104981,,INHIBITOR,1,1,1,,,
4625,1699831,1376112,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,Also ERBB4 inhibitor,,
4626,1699831,1376112,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,Also ERBB4 inhibitor,,
4627,2472877,619398,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4628,2473289,1927062,"c-Jun N-terminal kinase, JNK inhibitor",104822,,INHIBITOR,1,1,1,,,
4629,1706465,1380102,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,,,
4630,1706465,1380102,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor,11046,,INHIBITOR,1,1,1,,,
4631,1976724,1626739,Janus Kinase (JAK) inhibitor,105757,,INHIBITOR,1,1,1,,,
4632,2473459,511261,Cyclin-dependent kinase inhibitor,109746,,INHIBITOR,1,1,1,,,
4633,2473708,494066,Tyrosine-protein kinase ABL inhibitor,8,,INHIBITOR,1,1,1,,,
4634,2473708,494066,Serine/threonine-protein kinase Aurora-A inhibitor,20014,,INHIBITOR,1,1,1,,,
4635,2473708,494066,Serine/threonine-protein kinase Aurora-B inhibitor,10781,,INHIBITOR,1,1,1,,,
4636,2473708,494066,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
4637,2473708,494066,Tyrosine-protein kinase JAK2 inhibitor,10938,,INHIBITOR,1,1,1,,,
4638,2473708,494066,Tyrosine-protein kinase JAK3 inhibitor,10849,,INHIBITOR,1,1,1,,,
4639,2473144,30847,Insulin-like growth factor I receptor inhibitor,234,,INHIBITOR,1,1,1,"Allosteric inhibitor, thought to inhibit IGFR1 by interfering with phosphorylation of the kinase domain A-loop at a site distinct form ATP-binidng site.",,
4640,2473290,1927063,Unknown,,,,1,1,1,,,
4641,2473709,693474,Tyrosine-protein kinase JAK2 inhibitor,10938,,INHIBITOR,1,1,1,Also potent inhibitor of JAK1,,
4642,2472878,1297331,Serine/threonine-protein kinase WEE1 inhibitor,100098,,INHIBITOR,1,1,1,,,
4644,2473145,1673970,Fibroblast growth factor receptor inhibitor,104793,,INHIBITOR,1,1,1,Compound can be found in AstraZeneca's clinical compound bank for OpenInnovation opportunities.,,
4646,2473586,1790692,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4647,1705242,1037712,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,Non-adenosine-5'-triphosphate (ATP) competitive inhibitor,,
4648,1705242,1037712,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor,11046,,INHIBITOR,1,1,1,Non-adenosine-5'-triphosphate (ATP) competitive inhibitor,,
4649,2473015,1572454,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,,,
4650,2473015,1572454,Receptor tyrosine-protein kinase erbB-3 inhibitor,102678,,INHIBITOR,1,1,1,,,
4651,2473015,1572454,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
4652,2473147,1926999,Tyrosine-protein kinase ABL inhibitor,8,,INHIBITOR,1,1,1,,,
4653,2473147,1926999,Tyrosine-protein kinase SRC inhibitor,10434,,INHIBITOR,1,1,1,,,
4654,2472730,1926791,Cyclin-dependent kinase inhibitor,109746,,INHIBITOR,1,1,1,,,
4655,2473710,1363819,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
4656,2473710,1363819,Platelet-derived growth factor receptor beta inhibitor,197,,INHIBITOR,1,1,1,,,
4657,2473710,1363819,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,,,
4658,2473710,1363819,Vascular endothelial growth factor receptor 3 inhibitor,11752,,INHIBITOR,1,1,1,,,
4660,2472731,699032,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,Allosteric inhibitor,,
4661,2472731,699032,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor,11046,,INHIBITOR,1,1,1,Allosteric inhibitor,,
4662,1937964,1220034,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,"Dual MTOR/PIK3 inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4663,1937964,1220034,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,"Dual MTOR/PIK3 inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4664,2473016,1926945,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,"Dual MTOR/PIK3 inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4665,2473016,1926945,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,"Dual MTOR/PIK3 inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4666,2472880,490644,Serine/threonine-protein kinase PLK1 inhibitor,10907,,INHIBITOR,1,1,1,Also potent inhibitor of PLK2 and PLK3.,,
4667,2473711,1927244,Serine/threonine-protein kinase Aurora-B inhibitor,10781,,INHIBITOR,1,1,1,,,
4668,1879120,1335704,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,,,
4669,2472732,692415,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,Active metabolite of prodrug BMS-751324,,
4670,2473712,1927245,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,,,
4671,2473712,1927245,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
4672,2473712,1927245,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
4673,2473712,1927245,Receptor protein-tyrosine kinase erbB-4 inhibitor,12699,,INHIBITOR,1,1,1,,,
4674,2473713,570962,Insulin-like growth factor I receptor inhibitor,234,,INHIBITOR,1,1,1,,,
4675,2473713,570962,Insulin receptor inhibitor,35,,INHIBITOR,1,1,1,,,
4676,2472733,455596,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,"Also potent inhibitor of MST1R, AXL and TYRO3.",,
4677,2472734,1926792,Cell division cycle 7-related protein kinase inhibitor,100077,,INHIBITOR,1,1,1,,,
4678,2473291,1927064,Tyrosine-protein kinase JAK2 inhibitor,10938,,INHIBITOR,1,1,1,,,
4679,2472881,1926871,MAP kinase ERK1 inhibitor,11639,,INHIBITOR,1,1,1,,,
4680,2472881,1926871,MAP kinase ERK2 inhibitor,11638,,INHIBITOR,1,1,1,,,
4681,2473714,1567700,PI3-kinase p110-alpha subunit inhibitor,11362,,INHIBITOR,1,1,1,,,
4682,2473587,1927186,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,"Intercalates to DNA and following metabolic activation, covalently crosslinks DNA strands (PMID: 12007568, PMID:25896848)",,
4683,2473587,1927186,DNA topoisomerase II inhibitor,104727,,INHIBITOR,1,1,1,"Intercalates to DNA and following metabolic activation, covalently crosslinks DNA strands (PMID: 12007568, PMID:25896848)",,
4684,2473148,1927000,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,ATP-competitive mTORC1/mTORC2 inhibitor,,
4685,2473292,1037724,c-Jun N-terminal kinase 1 inhibitor,12261,,INHIBITOR,1,1,1,,,
4686,2473292,1037724,c-Jun N-terminal kinase 2 inhibitor,11407,,INHIBITOR,1,1,1,,,
4687,2473292,1037724,c-Jun N-terminal kinase 3 inhibitor,11408,,INHIBITOR,1,1,1,,,
4688,1699894,1279264,c-Jun N-terminal kinase 1 inhibitor,12261,,INHIBITOR,1,1,1,,,
4689,1699894,1279264,c-Jun N-terminal kinase 2 inhibitor,11407,,INHIBITOR,1,1,1,,,
4690,1699894,1279264,c-Jun N-terminal kinase 3 inhibitor,11408,,INHIBITOR,1,1,1,,,
4691,2473017,169054,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,Allosteric inhibitor,,
4692,2473017,169054,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor,11046,,INHIBITOR,1,1,1,Allosteric inhibitor,,
4693,1705986,1380049,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4694,2473538,1927157,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,"Irreversible inhibitor, EGFR T790M mutant selective",,
4695,1702633,1377998,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,,,
4696,1702633,1377998,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
4697,2473149,2335153,Nerve growth factor receptor Trk-A inhibitor,11902,,INHIBITOR,1,1,1,,,
4698,2473293,692515,Casein kinase II alpha inhibitor,10044,,INHIBITOR,1,1,1,,,
4699,1706014,14221,Cyclin-dependent kinase 2 inhibitor,11678,,INHIBITOR,1,1,1,,,
4700,1706014,14221,Cyclin-dependent kinase 7 inhibitor,12829,,INHIBITOR,1,1,1,,,
4701,1706014,14221,Cyclin-dependent kinase 9 inhibitor,11626,,INHIBITOR,1,1,1,,,
4702,1706014,14221,Cyclin-dependent kinase 1 inhibitor,12071,,INHIBITOR,1,1,1,,,
4703,1706014,14221,Cyclin-dependent kinase 5 inhibitor,12947,,INHIBITOR,1,1,1,,,
4704,1706451,1117804,Tyrosine-protein kinase ABL inhibitor,8,,INHIBITOR,1,1,1,"Also potent against other kinases (Src, LYN, FGR, and HCK, KDR, FLT3 and TIE2)",,
4705,2473150,1927002,Rho-associated protein kinase inhibitor,104981,,INHIBITOR,1,1,1,,,
4706,2473407,1450297,Fibroblast growth factor receptor 1 inhibitor,10266,,INHIBITOR,1,1,1,"E-3810 is an ambiguous research code for this compouynd, also research code for rabeprazole, a proton pump inhibitor.",,
4707,2473407,1450297,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,"E-3810 is an ambiguous research code for this compouynd, also research code for rabeprazole, a proton pump inhibitor.",,
4708,2473407,1450297,Fibroblast growth factor receptor 2 inhibitor,10264,,INHIBITOR,1,1,1,"E-3810 is an ambiguous research code for this compouynd, also research code for rabeprazole, a proton pump inhibitor.",,
4709,2473460,626299,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,,,
4710,2473460,626299,Mitogen-activated protein kinase kinase kinase 1 inhibitor,12276,,INHIBITOR,1,1,1,,,
4711,1937975,1592343,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4712,1937975,1592343,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,,,
4713,1705102,604615,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,Irreversible inhibitor,,
4714,2473461,520121,Serine/threonine-protein kinase Aurora-A inhibitor,20014,,INHIBITOR,1,1,1,Tartrate salt of ENMD-981693,,
4715,2473461,520121,Serine/threonine-protein kinase Aurora-B inhibitor,10781,,INHIBITOR,1,1,1,Tartrate salt of ENMD-981693,,
4716,2473461,520121,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,Tartrate salt of ENMD-981693,,
4717,2473461,520121,Fibroblast growth factor receptor 3 inhibitor,11926,,INHIBITOR,1,1,1,Tartrate salt of ENMD-981693,,
4718,2473461,520121,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,Tartrate salt of ENMD-981693,,
4719,2473461,520121,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,Tartrate salt of ENMD-981693,,
4720,2473461,520121,Macrophage colony stimulating factor receptor inhibitor,12840,,INHIBITOR,1,1,1,Tartrate salt of ENMD-981693,,
4721,2473294,1927065,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4722,2473588,1927187,MAP kinase-activated protein kinase 5 inhibitor,11105,,INHIBITOR,1,1,1,,,
4723,2139018,1763569,Tyrosine-protein kinase JAK1 inhibitor,10919,,INHIBITOR,1,1,1,,,
4724,2473715,1927246,PI3-kinase p110-delta subunit inhibitor,11177,,INHIBITOR,1,1,1,,,
4725,2472961,1750027,Tyrosine-protein kinase SYK inhibitor,10906,,INHIBITOR,1,1,1,,,
4726,1702545,692959,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
4727,1702545,692959,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
4728,1702545,692959,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4729,1702545,692959,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,,,
4730,1702545,692959,Tyrosine-protein kinase TIE-2 inhibitor,12913,,INHIBITOR,1,1,1,,,
4731,1702545,692959,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
4732,1763611,1449226,Serine/threonine-protein kinase AKT inhibitor,105106,,INHIBITOR,1,1,1,,,
4733,1976776,1626767,Serine/threonine-protein kinase AKT inhibitor,105106,,INHIBITOR,1,1,1,,,
4734,2139016,1763568,Tyrosine-protein kinase JAK1 inhibitor,10919,,INHIBITOR,1,1,1,,,
4735,1699825,1376108,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4736,2473151,1927003,Epidermal growth factor receptor inhibitor,105744,,INHIBITOR,1,1,1,Irreversible inhibitor,,
4737,2473589,1927188,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
4738,1702474,341327,Tyrosine-protein kinase ABL inhibitor,8,,INHIBITOR,1,1,1,,,
4739,1702474,341327,Tyrosine-protein kinase Lyn inhibitor,11842,,INHIBITOR,1,1,1,,,
4740,2472884,1926874,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,,,
4741,2472884,1926874,Insulin-like growth factor I receptor inhibitor,234,,INHIBITOR,1,1,1,,,
4742,1937943,1592320,PI3-kinase p110-gamma subunit inhibitor,11939,,INHIBITOR,1,1,1,,,
4743,1937943,1592320,PI3-kinase p110-delta subunit inhibitor,11177,,INHIBITOR,1,1,1,,,
4744,2473152,1927004,Ephrin type-B receptor 4 inhibitor,100129,,INHIBITOR,1,1,1,,,
4745,2473152,1927004,Platelet-derived growth factor receptor beta inhibitor,197,,INHIBITOR,1,1,1,,,
4746,2473152,1927004,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,,,
4747,1695962,1380138,Protein kinase C delta inhibitor,12247,,INHIBITOR,1,1,1,,,
4748,2473462,1927131,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4749,2473153,1927005,Insulin-like growth factor I receptor inhibitor,234,,INHIBITOR,1,1,1,,,
4750,2473153,1927005,Insulin receptor inhibitor,35,,INHIBITOR,1,1,1,,,
4751,2472885,579824,Tyrosine-protein kinase SRC inhibitor,10434,,INHIBITOR,1,1,1,Targets the peptide substrate-binding site and is a non-ATP competitive inhibitor.,,
4752,2472886,311715,Glycogen synthase kinase-3 beta inhibitor,10197,,INHIBITOR,1,1,1,,,
4753,2472886,311715,Glycogen synthase kinase-3 alpha inhibitor,11017,,INHIBITOR,1,1,1,,,
4754,1879132,1540483,TGF-beta receptor type I inhibitor,13004,,INHIBITOR,1,1,1,,,
4755,1879151,1540498,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,Also potent inhibitor or MAPK11,,
4756,1937960,1592335,Serine/threonine-protein kinase Chk1 inhibitor,12967,,INHIBITOR,1,1,1,,,
4757,1706449,1380093,Tyrosine-protein kinase JAK2 inhibitor,10938,,INHIBITOR,1,1,1,,,
4758,2139022,1763572,Cyclin-dependent kinase 4 inhibitor,12946,,INHIBITOR,1,1,1,,,
4759,2139022,1763572,Cyclin-dependent kinase 6 inhibitor,10480,,INHIBITOR,1,1,1,,,
4764,1702525,436277,Serine/threonine-protein kinase Aurora inhibitor,109668,,INHIBITOR,1,1,1,Pan-Aurora kinase inhibitor,,
4765,2473018,616367,Serine/threonine-protein kinase AKT inhibitor,105106,,INHIBITOR,1,1,1,Allosteric AKT inhibitor.,,
4766,2472736,1172876,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4767,1701431,205165,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
4768,1701431,205165,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
4769,1701431,205165,Platelet-derived growth factor receptor beta inhibitor,197,,INHIBITOR,1,1,1,,,
4770,1699844,1376121,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,"Inhibits mutant forms of KIT, FLT3 and PDGFRA (http://www.google.com/patents/US20080226747).",,
4771,1699844,1376121,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,"Inhibits mutant forms of KIT, FLT3 and PDGFRA (http://www.google.com/patents/US20080226747).",,
4772,1699844,1376121,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,"Inhibits mutant forms of KIT, FLT3 and PDGFRA (http://www.google.com/patents/US20080226747).",,
4773,1699844,1376121,Platelet-derived growth factor receptor alpha inhibitor,12627,,INHIBITOR,1,1,1,"Inhibits mutant forms of KIT, FLT3 and PDGFRA (http://www.google.com/patents/US20080226747).",,
4774,2473154,1927006,Glycogen synthase kinase-3 beta inhibitor,10197,,INHIBITOR,1,1,1,,,
4775,2473295,1927066,Tyrosine-protein kinase JAK2 inhibitor,10938,,INHIBITOR,1,1,1,,,
4776,2473463,1619524,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,ATP-competitive mTORC1/mTORC2 inhibitor,,
4777,2473716,424611,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,,,
4778,2473296,1927067,Cyclin-dependent kinase 4 inhibitor,12946,,INHIBITOR,1,1,1,"Also thought to inhibit CDK1, CDK6 and CDK9 (http://www.bloodjournal.org/content/122/21/1636?sso-checked=true)",,
4779,2473464,1927132,Cyclin-dependent kinase 1 inhibitor,12071,,INHIBITOR,1,1,1,,,
4780,2473464,1927132,Cyclin-dependent kinase 4 inhibitor,12946,,INHIBITOR,1,1,1,,,
4781,2473464,1927132,Cyclin-dependent kinase 9 inhibitor,11626,,INHIBITOR,1,1,1,,,
4782,2472888,453228,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,,,
4783,2472888,453228,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor,11046,,INHIBITOR,1,1,1,,,
4784,1706733,1381735,Serine/threonine-protein kinase receptor R3 inhibitor,100909,,INHIBITOR,1,1,1,,,
4785,2473020,696704,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,"Dual MTOR/PIK3 inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4786,2473020,696704,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,"Dual MTOR/PIK3 inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4787,1976763,596528,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,"Dual MTOR/PIK3 inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4788,1976763,596528,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,"Dual MTOR/PIK3 inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4789,2473717,1927247,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,No assay data or further target information found,,
4790,2473021,619399,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4791,2473022,436278,Serine/threonine-protein kinase Aurora inhibitor,109668,,INHIBITOR,1,1,1,Pan-Aurora kinase inhibitor,,
4792,2473718,559790,Cyclin-dependent kinase 1 inhibitor,12071,,INHIBITOR,1,1,1,,,
4793,2473718,559790,Cyclin-dependent kinase 2 inhibitor,11678,,INHIBITOR,1,1,1,,,
4794,2473718,559790,Cyclin-dependent kinase 4 inhibitor,12946,,INHIBITOR,1,1,1,,,
4795,2473718,559790,Nerve growth factor receptor Trk-A inhibitor,11902,,INHIBITOR,1,1,1,,,
4796,2473155,2089491,Macrophage colony stimulating factor receptor inhibitor,12840,,INHIBITOR,1,1,1,Overexpression of the CSF1R ligand promotes tumor cell proliferation which is inhibited by pexidartinib in CSF1R-dependent tumors. Pexidartinib inhibited a CSF1R dependent cell line in vivo.,,
4797,2473155,2089491,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
4798,2473155,2089491,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
4799,2473719,441100,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,,,
4800,2473720,1927248,Tyrosine-protein kinase SYK inhibitor,10906,,INHIBITOR,1,1,1,,,
4801,1699783,619384,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4802,2473156,1927008,Tyrosine-protein kinase JAK3 inhibitor,10849,,INHIBITOR,1,1,1,Active metabolite of R-348,,
4803,2473156,1927008,Tyrosine-protein kinase SYK inhibitor,10906,,INHIBITOR,1,1,1,Active metabolite of R-348,,
4804,2473590,1927189,Tyrosine-protein kinase SYK inhibitor,10906,,INHIBITOR,1,1,1,,,
4805,2473721,460144,Tyrosine-protein kinase SYK inhibitor,10906,,INHIBITOR,1,1,1,Active metabolite of prodrug R-788 (Fostamatinib),,
4806,2473591,568340,Serine/threonine-protein kinase B-raf inhibitor,100126,,INHIBITOR,1,1,1,,,
4807,2473591,568340,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,,,
4808,1699898,470511,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,,,
4809,1937984,1265685,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,"Dual MTOR/PIK3 inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4810,1937984,1265685,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,"Dual MTOR/PIK3 inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4811,1937937,1438174,Serine/threonine-protein kinase AKT inhibitor,105106,,INHIBITOR,1,1,1,,,
4812,2139042,1563853,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,Developed as an isoform-specific PI3K inhibitor with compound exhibiting high affinity for mutated PI3Ka )doi:10.1158/1538-7445.AM2013-DDT02-01).,,
4813,2473722,1927249,Unknown,,,,1,1,1,Multi-targeted kinase inhibitor,,
4814,2472737,1926794,Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor,10752,,INHIBITOR,1,1,1,,,
4815,2472679,1824379,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,,,
4816,2473665,1927215,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,,,
4817,2473665,1927215,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,,,
4818,2473592,1927190,Rho-associated protein kinase inhibitor,104981,,INHIBITOR,1,1,1,,,
4819,1706059,497877,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,Also potent inhibitor of MAPK11,,
4820,2472889,1926875,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,Multi-targeted receptor tyrosine kinase inhibitor,,
4821,2472889,1926875,Vascular endothelial growth factor receptor 1 inhibitor,10979,,INHIBITOR,1,1,1,Multi-targeted receptor tyrosine kinase inhibitor,,
4822,2472889,1926875,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,Multi-targeted receptor tyrosine kinase inhibitor,,
4823,2472889,1926875,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,Multi-targeted receptor tyrosine kinase inhibitor,,
4824,2472889,1926875,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,Multi-targeted receptor tyrosine kinase inhibitor,,
4825,2472889,1926875,Vascular endothelial growth factor receptor 3 inhibitor,11752,,INHIBITOR,1,1,1,Multi-targeted receptor tyrosine kinase inhibitor,,
4826,2472890,328880,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4827,2473297,387990,PI3-kinase p110-gamma subunit inhibitor,11939,,INHIBITOR,1,1,1,,,
4828,2473297,387990,PI3-kinase p110-delta subunit inhibitor,11177,,INHIBITOR,1,1,1,,,
4829,2473298,442167,SRC inhibitor,105769,,INHIBITOR,1,1,1,Prodrug - active metabolite is TG-100-572 (HY-10184),,
4830,2473298,442167,Ephrin type-B receptor 4 inhibitor,100129,,INHIBITOR,1,1,1,Prodrug - active metabolite is TG-100-572 (HY-10184),,
4831,2473298,442167,Fibroblast growth factor receptor 1 inhibitor,10266,,INHIBITOR,1,1,1,Prodrug - active metabolite is TG-100-572 (HY-10184),,
4832,2473298,442167,Fibroblast growth factor receptor 2 inhibitor,10264,,INHIBITOR,1,1,1,Prodrug - active metabolite is TG-100-572 (HY-10184),,
4833,2473298,442167,Platelet-derived growth factor receptor beta inhibitor,197,,INHIBITOR,1,1,1,Prodrug - active metabolite is TG-100-572 (HY-10184),,
4834,2473298,442167,Vascular endothelial growth factor receptor 1 inhibitor,10979,,INHIBITOR,1,1,1,Prodrug - active metabolite is TG-100-572 (HY-10184),,
4835,2473298,442167,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,Prodrug - active metabolite is TG-100-572 (HY-10184),,
4836,2473593,568337,Cyclin-dependent kinase 2 inhibitor,11678,,INHIBITOR,1,1,1,,,
4837,2473593,568337,Cyclin-dependent kinase 4 inhibitor,12946,,INHIBITOR,1,1,1,,,
4838,2473593,568337,Cyclin-dependent kinase 6 inhibitor,10480,,INHIBITOR,1,1,1,,,
4839,2473593,568337,Serine/threonine-protein kinase Chk1 inhibitor,12967,,INHIBITOR,1,1,1,,,
4840,2473593,568337,3-phosphoinositide dependent protein kinase-1 inhibitor,10612,,INHIBITOR,1,1,1,,,
4841,2473593,568337,Protein kinase C (PKC) inhibitor,104683,,INHIBITOR,1,1,1,,,
4842,1702244,452471,Serine/threonine-protein kinase AKT inhibitor,105106,,INHIBITOR,1,1,1,,,
4843,1976769,1626762,Focal adhesion kinase 1 inhibitor,11242,,INHIBITOR,1,1,1,,,
4844,1976769,1626762,Protein tyrosine kinase 2 beta inhibitor,100995,,INHIBITOR,1,1,1,,,
4845,1937956,1592331,Tyrosine-protein kinase JAK3 inhibitor,10849,,INHIBITOR,1,1,1,,,
4846,2472891,619385,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,Also potent inhibitor of MAPK11,,
4847,2473723,193962,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
4848,2473724,1927250,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,,,
4849,2473724,1927250,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
4850,2472892,1926876,Serine/threonine-protein kinase B-raf inhibitor,100126,,INHIBITOR,1,1,1,"Selectively targets RAF kinases including BRAF, RAF1 and the BRAF mutant (V600E) (http://www.exelixis.com/sites/default/files/pdf/XL281-001_ASCO-2009.pdf)",,
4851,2472892,1926876,Serine/threonine-protein kinase RAF inhibitor,10904,,INHIBITOR,1,1,1,"Selectively targets RAF kinases including BRAF, RAF1 and the BRAF mutant (V600E) (http://www.exelixis.com/sites/default/files/pdf/XL281-001_ASCO-2009.pdf)",,
4852,2473100,1926832,Ephrin type-B receptor 4 inhibitor,100129,,INHIBITOR,1,1,1,,,
4853,2473100,1926832,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
4854,2473100,1926832,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,,,
4855,2473725,1927251,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
4856,2473725,1927251,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,,,
4857,2473725,1927251,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
4858,2473466,1927134,Fibroblast growth factor receptor inhibitor,104793,,INHIBITOR,1,1,1,Spectrum Selective Kinase Inhibitor (SSKI),,
4859,2473466,1927134,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,Spectrum Selective Kinase Inhibitor (SSKI),,
4860,2473466,1927134,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,Spectrum Selective Kinase Inhibitor (SSKI),,
4861,2473466,1927134,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,Spectrum Selective Kinase Inhibitor (SSKI),,
4862,2473466,1927134,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,Spectrum Selective Kinase Inhibitor (SSKI),,
4863,2473726,586852,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,,,
4864,2473594,1193367,Fibroblast growth factor receptor inhibitor,104793,,INHIBITOR,1,1,1,,,
4865,2473261,1832976,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4866,2473351,1927099,PI3-kinase p110-delta subunit inhibitor,11177,,INHIBITOR,1,1,1,,,
4867,2473024,1677558,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
4868,2472929,1926903,PI3-kinase p110-delta subunit inhibitor,11177,,INHIBITOR,1,1,1,,,
4869,2472849,2335152,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,"Dual MTOR/PIK3 inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4870,2472849,2335152,PI3-kinase class I inhibitor,109750,,INHIBITOR,1,1,1,"Dual MTOR/PIK3 inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor",,
4871,1699754,1376069,Chloride channel protein 2 activator,103797,,ACTIVATOR,1,1,1,,,
4872,2473299,171245,Neurokinin 1 receptor antagonist,250,,ANTAGONIST,1,1,1,,,
4873,1706411,687528,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
4874,1699834,714326,Corticotropin releasing factor receptor 1 antagonist,124,,ANTAGONIST,1,1,1,,,
4875,2472738,1054194,Serotonin 1a (5-HT1a) receptor antagonist,51,,ANTAGONIST,1,1,1,,,
4876,2472738,1054194,Serotonin 1b (5-HT1b) receptor antagonist,106,,ANTAGONIST,1,1,1,,,
4877,2472738,1054194,Serotonin 1d (5-HT1d) receptor antagonist,105,,ANTAGONIST,1,1,1,,,
4878,2472738,1054194,Serotonin transporter antagonist,121,,ANTAGONIST,1,1,1,,,
4879,1702990,1173774,Dopamine D3 receptor agonist,130,,AGONIST,1,1,1,Ethyl ester prodrug of of levodopa (PMID:16476809).,,
4880,2473025,1270807,Glucagon receptor antagonist,146,,ANTAGONIST,1,1,1,,,
4881,2472795,1275690,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
4882,1706447,1279630,Adenosine A2a receptor agonist,252,,AGONIST,1,1,1,,,
4883,2473026,1333580,Beta-3 adrenergic receptor agonist,226,,AGONIST,1,1,1,Phase 2 study in 2011 terminated.,,
4884,2473026,1333580,Beta-2 adrenergic receptor antagonist,43,,ANTAGONIST,1,1,1,Phase 2 study in 2011 terminated.,,
4885,2473026,1333580,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,Phase 2 study in 2011 terminated.,,
4886,1699880,1347056,Oxytocin receptor antagonist,116,,ANTAGONIST,1,1,1,,,
4887,1976721,1349878,Smoothened homolog antagonist,101400,,ANTAGONIST,1,1,1,Inhibits smoothened which is involved in hedgehog pathway signalling and inhibited tumor growth in a mouse model.,,
4888,2472939,345770,Beta-3 adrenergic receptor agonist,226,,AGONIST,1,1,1,,,
4889,1702531,1364998,Serotonin 4 (5-HT4) receptor agonist,168,,AGONIST,1,1,1,,,
4890,1699759,1508212,Muscarinic acetylcholine receptor antagonist,104691,,ANTAGONIST,1,1,1,,,
4891,1699804,1376098,Purinergic receptor P2Y12 antagonist,176,,ANTAGONIST,1,1,1,,,
4892,1699857,1376128,Serotonin 4 (5-HT4) receptor agonist,168,,AGONIST,1,1,1,"two Ph2 studies terminated, no reason given.",,
4893,1699862,1376132,Histamine H3 receptor antagonist,10280,,ANTAGONIST,1,1,1,,,
4894,1699895,1376150,Serotonin 6 (5-HT6) receptor antagonist,10627,,ANTAGONIST,1,1,1,,,
4895,1701432,1377256,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
4896,1701432,1377256,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
4897,1701432,1377256,Dopamine transporter inhibitor,155,,INHIBITOR,1,1,1,,,
4898,1701432,1377256,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
4899,1701432,1377256,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,,,
4900,1701432,1377256,Alpha-1a adrenergic receptor antagonist,125,,ANTAGONIST,1,1,1,,,
4901,1701432,1377256,Serotonin 3 (5-HT3) receptor antagonist,104714,,ANTAGONIST,1,1,1,,,
4902,1701438,1377261,Serotonin 2c (5-HT2c) receptor agonist,108,,AGONIST,1,1,1,,,
4903,1701438,1377261,Serotonin 2b (5-HT2b) receptor antagonist,227,,ANTAGONIST,1,1,1,,,
4904,1701438,1377261,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
4905,1701440,1377262,Neurokinin 1 receptor antagonist,250,,ANTAGONIST,1,1,1,,,
4906,1702554,1377937,Neurokinin 1 receptor antagonist,250,,ANTAGONIST,1,1,1,"Phase 2 study terminated, isolated seizure events to be assessed (PMC3071576)",,
4907,1704403,2197676,Serotonin 1b (5-HT1b) receptor antagonist,106,,ANTAGONIST,1,1,1,,,
4908,1704403,2197676,Serotonin 1d (5-HT1d) receptor antagonist,105,,ANTAGONIST,1,1,1,,,
4909,1705115,1379641,Adenosine A1 receptor agonist,114,,AGONIST,1,1,1,,,
4910,1706396,2197690,Adenosine A1 receptor antagonist,114,,ANTAGONIST,1,1,1,Discontinueddue to lack of oral formulation/poor solubility?,,
4911,1706456,1380096,Beta-3 adrenergic receptor agonist,226,,AGONIST,1,1,1,,,
4912,1701295,1377134,Dopamine D2 receptor partial agonist,72,,PARTIAL AGONIST,1,1,1,,,
4913,1701397,1383167,C-C chemokine receptor type 5 antagonist,10580,,ANTAGONIST,1,1,1,,,
4914,1701397,1383167,C-C chemokine receptor type 2 antagonist,11575,,ANTAGONIST,1,1,1,,,
4915,1937988,1414543,Smoothened homolog antagonist,101400,,ANTAGONIST,1,1,1,,,
4916,2472739,1421862,Histamine H3 receptor antagonist,10280,,ANTAGONIST,1,1,1,,,
4917,1699868,1376134,Interleukin-8 receptor A antagonist,11574,,ANTAGONIST,1,1,1,,High selectivity for CXCR2 over CXCR1,
4918,1699868,1376134,Interleukin-8 receptor B antagonist,10773,,ANTAGONIST,1,1,1,,High selectivity for CXCR2 over CXCR1,
4919,1879154,1439217,Calcitonin gene-related peptide type 1 receptor antagonist,19904,,ANTAGONIST,1,1,1,,,
4920,1937989,1439375,Interleukin-8 receptor B antagonist,10773,,ANTAGONIST,1,1,1,,,
4921,2473158,1445925,Histamine H3 receptor antagonist,10280,,ANTAGONIST,1,1,1,,,
4922,1879142,1540491,Mu opioid receptor antagonist,129,,ANTAGONIST,1,1,1,"Peripherally-restricted opioid receptor antagonist, affinity for OPRM1, OPRK1, OPRD1. Efficasy target OPRM1, no selectivity infomration found.",,
4923,1879164,1540510,Calcitonin gene-related peptide type 1 receptor antagonist,19904,,ANTAGONIST,1,1,1,,,
4924,2473727,102752,Corticotropin releasing factor receptor 1 antagonist,124,,ANTAGONIST,1,1,1,,,
4925,1937962,1592336,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
4926,1937962,1592336,Muscarinic acetylcholine receptor M2 antagonist,47,,ANTAGONIST,1,1,1,,,
4927,1937962,1592336,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,,,
4928,1937966,1592338,Serotonin 1f (5-HT1f) receptor agonist,279,,AGONIST,1,1,1,,,
4929,1937981,1592348,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
4930,1937983,1592349,Interleukin-8 receptor B antagonist,10773,,ANTAGONIST,1,1,1,,,
4931,1976748,1604993,Metabotropic glutamate receptor 5 antagonist,11280,,ANTAGONIST,1,1,1,,,
4932,2472894,1607023,Histamine H3 receptor antagonist,10280,,ANTAGONIST,1,1,1,,,
4933,1976733,1626744,Mu opioid receptor antagonist,129,,ANTAGONIST,1,1,1,"Peripherally-restricted opioid receptor antagonist, affinity for OPRM1, OPRK1, OPRD1. Efficasy target OPRM1.",,
4934,2139000,1763555,Metabotropic glutamate receptor 2 modulator,12895,,MODULATOR,1,1,1,Negative allosteric modulator (NAM). Removed from development pipeline January 2015 (http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm),,
4935,2139000,1763555,Metabotropic glutamate receptor 3 modulator,10167,,MODULATOR,1,1,1,Negative allosteric modulator (NAM). Removed from development pipeline January 2015 (http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm),,
4936,2139014,1763566,Prostanoid IP receptor agonist,143,,AGONIST,1,1,1,,,
4937,2139043,1763588,Metabotropic glutamate receptor 5 modulator,11280,,MODULATOR,1,1,1,Negative allosteric modulator (NAM),,
4938,1705474,402091,Adenosine A1 receptor agonist,114,,AGONIST,1,1,1,,,
4939,1699771,430253,Cannabinoid CB1 receptor antagonist,87,,ANTAGONIST,1,1,1,"Ph 2 study terminated and Ph2/3 study withdrawn, development Discontinuedbecause of potential serious side effects linked to targetting of CNR1 (http://en.wikipedia.org/wiki/Ibipinabant).",,
4940,1702669,324544,Mu opioid receptor antagonist,129,,ANTAGONIST,1,1,1,"Compound is art of the combination product ALKS-5461, where samidorphan is combined with buprenorphine ALKS-5461 is being developed as an as antidepressant drug.",,
4941,1705226,438452,Oxytocin receptor antagonist,116,,ANTAGONIST,1,1,1,,,
4942,1705789,471459,Adenosine A2a receptor antagonist,252,,ANTAGONIST,1,1,1,"Decvelopment of compound against Parkinson's discontinued but Vernalis has outlicensed the compound to Redox Therapies for use in immuno-oncology.  Also high potency at ADORA2B, ADORA1A and ADORA3",,
4943,1699814,519979,Neurokinin 1 receptor antagonist,250,,ANTAGONIST,1,1,1,,,
4944,2472740,490011,Histamine H3 receptor inverse agonist,10280,,INVERSE AGONIST,1,1,1,,,
4945,1937982,454842,Motilin receptor agonist,11061,,AGONIST,1,1,1,,,
4946,1699829,515198,Corticotropin releasing factor receptor 1 antagonist,124,,ANTAGONIST,1,1,1,,,
4947,2473300,454366,Histamine H3 receptor antagonist,10280,,ANTAGONIST,1,1,1,Ph 2 trial terminated,,
4948,2139039,554350,Smoothened homolog antagonist,101400,,ANTAGONIST,1,1,1,,,
4949,2472895,1926878,Histamine H3 receptor antagonist,10280,,ANTAGONIST,1,1,1,,,
4950,2473728,1927252,Smoothened homolog antagonist,101400,,ANTAGONIST,1,1,1,,,
4951,2473027,2197742,C5a anaphylatoxin chemotactic receptor antagonist,12679,,ANTAGONIST,1,1,1,,,
4952,2473467,1927135,C-C chemokine receptor type 2 antagonist,11575,,ANTAGONIST,1,1,1,,,
4953,2473729,1927253,C-C chemokine receptor type 1 antagonist,10547,,ANTAGONIST,1,1,1,,,
4954,2472896,1926879,Histamine H3 receptor antagonist,10280,,ANTAGONIST,1,1,1,,,
4955,2473595,2335154,Vasopressin V1a receptor antagonist,134,,ANTAGONIST,1,1,1,,,
4956,2472897,1926880,G protein-coupled receptor 44 antagonist,20174,,ANTAGONIST,1,1,1,,,
4957,2473596,1927192,G protein-coupled receptor 44 antagonist,20174,,ANTAGONIST,1,1,1,,,
4958,2472898,1926881,C-C chemokine receptor type 2 antagonist,11575,,ANTAGONIST,1,1,1,,,
4959,2472898,1926881,C-C chemokine receptor type 5 antagonist,10580,,ANTAGONIST,1,1,1,,,
4960,2472741,1926795,Glucagon receptor antagonist,146,,ANTAGONIST,1,1,1,,,
4961,2473597,1927193,Serotonin 6 (5-HT6) receptor antagonist,10627,,ANTAGONIST,1,1,1,,,
4962,2473730,1927254,Adenosine A1 receptor agonist,114,,AGONIST,1,1,1,Partial agonist,,
4963,2473731,1927255,Nociceptin receptor antagonist,138,,ANTAGONIST,1,1,1,,,
4964,2473028,1926949,Calcium sensing receptor positive allosteric modulator,282,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,Positive allosteric modulator,,
4965,2473029,1926950,Sphingosine 1-phosphate receptor Edg-1 agonist,11631,,AGONIST,1,1,1,,,
4966,2473302,1927069,Serotonin 7 (5-HT7) receptor antagonist,10209,,ANTAGONIST,1,1,1,Phase 2 study in 2010 Discontinued no further studies recorded.,,
4967,2473468,1927136,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
4968,2472899,1926882,Cannabinoid CB2 receptor agonist,259,,AGONIST,1,1,1,"Phase 2 study in 2012 completed, no further studies recorded.",,
4969,2472821,1926833,Neurokinin 1 receptor antagonist,250,,ANTAGONIST,1,1,1,,,
4970,2473159,1927010,Metabotropic glutamate receptor 5 antagonist,11280,,ANTAGONIST,1,1,1,,,
4971,2472900,1926883,Corticotropin releasing factor receptor 1 antagonist,124,,ANTAGONIST,1,1,1,,,
4972,2473469,2335155,Adenosine A2a receptor antagonist,252,,ANTAGONIST,1,1,1,,,
4973,2473470,1927138,Cannabinoid CB1 receptor antagonist,87,,ANTAGONIST,1,1,1,,,
4974,2473525,672805,Calcium sensing receptor antagonist,282,,ANTAGONIST,1,1,1,,,
4975,2473732,711568,Orexin receptor 1 antagonist,10009,,ANTAGONIST,1,1,1,,,
4976,2473732,711568,Orexin receptor 2 antagonist,12968,,ANTAGONIST,1,1,1,,,
4977,2473030,1926951,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
4978,2473030,1926951,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,,,
4979,2472742,378616,Cannabinoid CB2 receptor agonist,259,,AGONIST,1,1,1,,,
4980,2473303,1280906,C-C chemokine receptor type 5 antagonist,10580,,ANTAGONIST,1,1,1,,,
4981,2473598,1264900,G protein-coupled receptor 44 antagonist,20174,,ANTAGONIST,1,1,1,,,
4982,2473599,1439366,C-C chemokine receptor type 1 antagonist,10547,,ANTAGONIST,1,1,1,,,
4983,2473304,1927070,C-C chemokine receptor type 2 antagonist,11575,,ANTAGONIST,1,1,1,,,
4984,2473031,1926952,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
4985,2473305,1927071,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,,,
4986,2473160,1927011,Adenosine A1 receptor antagonist,114,,ANTAGONIST,1,1,1,,,
4987,2473306,1927072,Adenosine A1 receptor agonist,114,,AGONIST,1,1,1,,,
4988,2473733,1927256,Adenosine A1 receptor agonist,114,,AGONIST,1,1,1,,,
4989,2473032,76361,Adenosine A3 receptor agonist,280,,AGONIST,1,1,1,,,
4990,2473161,391061,Vasopressin V1a receptor antagonist,134,,ANTAGONIST,1,1,1,,,
4991,2472743,1250535,Calcitonin gene-related peptide type 1 receptor antagonist,19904,,ANTAGONIST,1,1,1,,,
4992,1699516,346036,Calcitonin gene-related peptide type 1 receptor antagonist,19904,,ANTAGONIST,1,1,1,,,
4993,1976770,1626763,G protein-coupled receptor 44 antagonist,20174,,ANTAGONIST,1,1,1,,,
4994,2473600,1589277,G protein-coupled receptor 44 antagonist,20174,,ANTAGONIST,1,1,1,,,
4995,2473601,558931,G protein-coupled receptor 44 antagonist,20174,,ANTAGONIST,1,1,1,,,
4996,2473667,1927216,Orexin receptor 1 antagonist,10009,,ANTAGONIST,1,1,1,,,
4997,2473667,1927216,Orexin receptor 2 antagonist,12968,,ANTAGONIST,1,1,1,,,
4998,1699805,1376099,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
4999,1699805,1376099,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
5000,1699805,1376099,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,,
5001,1705914,2197551,Mu opioid receptor agonist,129,,AGONIST,1,1,1,Haven't found any references that  mentioned activity at targets,,
5002,1705914,2197551,Delta opioid receptor agonist,136,,AGONIST,1,1,1,Haven't found any references that  mentioned activity at targets,,
5003,1705914,2197551,Kappa opioid receptor agonist,137,,AGONIST,1,1,1,Haven't found any references that  mentioned activity at targets,,
5004,2472964,298316,Endothelin receptor ET-A antagonist,249,,ANTAGONIST,1,1,1,,,
5005,2472964,298316,Type-1 angiotensin II receptor antagonist,115,,ANTAGONIST,1,1,1,,,
5006,2139021,1763571,Histamine H4 receptor antagonist,11290,,ANTAGONIST,1,1,1,,,
5007,2473602,1927194,Histamine H4 receptor antagonist,11290,,ANTAGONIST,1,1,1,,,
5008,2582999,628156,Sphingosine 1-phosphate receptor Edg-1 agonist,11631,,AGONIST,1,1,1,,,
5009,2472902,1926884,Serotonin 4 (5-HT4) receptor agonist,168,,AGONIST,1,1,1,,,
5010,2473734,1161221,Gonadotropin-releasing hormone receptor antagonist,118,,ANTAGONIST,1,1,1,,,
5011,2473735,704238,Bradykinin B1 receptor antagonist,11156,,ANTAGONIST,1,1,1,,,
5012,2472903,396930,Bradykinin B1 receptor antagonist,11156,,ANTAGONIST,1,1,1,,,
5013,1699888,1376148,Opioid receptors; mu/kappa/delta antagonist,104765,,ANTAGONIST,1,1,1,,,
5014,2472744,189057,Cholecystokinin B receptor antagonist,11522,,ANTAGONIST,1,1,1,,,
5015,2473736,1927257,Mu opioid receptor partial agonist,129,,PARTIAL AGONIST,1,1,1,"Centrally acting, selective for OPRM1 but also potent agonist at OPRD1 and OPRK1",,
5016,2473737,320007,Interleukin-8 receptor A modulator,11574,,MODULATOR,1,1,1,"Ph 2 study terminated, being developed for new indication (http://www.dompe.com/Diabetology/).",,
5017,2473737,320007,Interleukin-8 receptor B modulator,10773,,MODULATOR,1,1,1,"Ph 2 study terminated, being developed for new indication (http://www.dompe.com/Diabetology/).",,
5018,2473471,1927139,Cannabinoid CB2 receptor agonist,259,,AGONIST,1,1,1,,,
5019,2473033,564955,Bradykinin B2 receptor antagonist,10034,,ANTAGONIST,1,1,1,,,
5020,2473307,1927073,C-X-C chemokine receptor type 4 antagonist,10473,,ANTAGONIST,1,1,1,,,
5021,2472745,1279531,Adenosine A2a receptor agonist,252,,AGONIST,1,1,1,,,
5022,2473738,1927258,Adenosine A2a receptor agonist,252,,AGONIST,1,1,1,,,
5023,2473162,1927012,Adenosine A1 receptor agonist,114,,AGONIST,1,1,1,,,
5024,2473162,1927012,Adenosine A2a receptor agonist,252,,AGONIST,1,1,1,,,
5025,2473603,624199,Adenosine A2a receptor agonist,252,,AGONIST,1,1,1,"Phase 2 trial terminated, poor efficacy results",,
5026,2473739,597839,Adenosine A1 receptor antagonist,114,,ANTAGONIST,1,1,1,"Phase 2 study terminated early, no reason given (PMID:21641345). Company aquired by Abbott, compound not on current pipeline.",,
5027,2472904,1926885,Metabotropic glutamate receptor 5 modulator,11280,,MODULATOR,1,1,1,,,
5028,2472905,1926886,Metabotropic glutamate receptor 5 negative allosteric modulator,11280,,NEGATIVE ALLOSTERIC MODULATOR,1,1,1,,,
5029,2473163,1927013,Metabotropic glutamate receptor 5 modulator,11280,,MODULATOR,1,1,1,Discontinuedfor safety reasons.,,
5030,2473604,1927195,Metabotropic glutamate receptor 5 negative allosteric modulator,11280,,NEGATIVE ALLOSTERIC MODULATOR,1,1,1,,,
5031,1702534,603815,Serotonin 2a (5-HT2a) receptor inverse agonist,107,,INVERSE AGONIST,1,1,1,Discontinued did not meet trial endpoints.,,
5032,2473472,1528559,Metabotropic glutamate receptor 5 modulator,11280,,MODULATOR,1,1,1,,,
5033,2472746,1926796,Neurokinin 1 receptor antagonist,250,,ANTAGONIST,1,1,1,,,
5034,2473164,1927014,Muscarinic acetylcholine receptor antagonist,104691,,ANTAGONIST,1,1,1,Non-selective muscarinic receptor antagonist and sodium channel blocker.,,
5035,2473164,1927014,Sodium channel protein type X alpha subunit blocker,18080,,BLOCKER,1,1,1,Non-selective muscarinic receptor antagonist and sodium channel blocker.,,
5036,2473164,1927014,Sodium channel protein type XI alpha subunit blocker,18078,,BLOCKER,1,1,1,Non-selective muscarinic receptor antagonist and sodium channel blocker.,,
5037,1702530,1334397,Neuropeptide Y receptor type 5 antagonist,11336,,ANTAGONIST,1,1,1,Not in current pipeline,,
5038,2472906,1926887,Neuropeptide Y receptor type 5 antagonist,11336,,ANTAGONIST,1,1,1,,,
5039,2473308,1147515,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,,,
5040,2473165,1927015,Cannabinoid CB1 receptor antagonist,87,,ANTAGONIST,1,1,1,Discontinued possibly due to psychiatric side effects as seen with withdrawn CNR1 antagonist rimonabant.,,
5041,2473309,66547,Serotonin 1a (5-HT1a) receptor agonist,51,,AGONIST,1,1,1,,,
5042,2473166,1673031,Serotonin 1b (5-HT1b) receptor antagonist,106,,ANTAGONIST,1,1,1,,,
5043,2473166,1673031,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
5044,2472907,572209,Vasopressin V1b receptor antagonist,148,,ANTAGONIST,1,1,1,,,
5045,1705136,552841,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,Binds to ADRA1B with affinity of 456nM (http://media.corporate-ir.net/media_files/irol/14/142048/scientific_pubs/113004.pdf),,
5046,2473605,1733801,Adenosine A1 receptor partial agonist,114,,PARTIAL AGONIST,1,1,1,,,
5047,1705990,318060,Cannabinoid CB1 receptor antagonist,87,,ANTAGONIST,1,1,1,,,
5048,1699853,1376126,Proteinase-activated receptor 1 antagonist,10653,,ANTAGONIST,1,1,1,,,
5049,1705108,433495,Purinergic receptor P2Y12 antagonist,176,,ANTAGONIST,1,1,1,"Phase 2 study terminated, possibly due to adverse effects.",,
5050,1705979,97869,Prostanoid EP4 receptor agonist,262,,AGONIST,1,1,1,,,
5051,2473034,1340183,Serotonin 4 (5-HT4) receptor partial agonist,168,,PARTIAL AGONIST,1,1,1,"Binds to other 5-HT receptors with micromolar affinity. Can't find any clinical trial IDs, only mentions that the compound has been through phase 2 trials (OTHER:http://en.wikipedia.org/wiki/SL65.0155).",,
5052,1705043,1449166,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,,,
5053,1705972,258847,Serotonin 1a (5-HT1a) receptor agonist,51,,AGONIST,1,1,1,Not in current pipelines.,,
5054,2472747,2000990,Gonadotropin-releasing hormone receptor antagonist,118,,ANTAGONIST,1,1,1,,,
5055,1706430,582578,Urotensin II receptor antagonist,10927,,ANTAGONIST,1,1,1,Discontinueddue to lack of efficacy.,,
5056,1706063,625730,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,Discontinued does not have competitive profile (http://www.chiesi.es/Assets/docs/Annual_report_2010.pdf),,
5057,1706016,26648,Gonadotropin-releasing hormone receptor antagonist,118,,ANTAGONIST,1,1,1,,,
5058,1703415,1051419,Serotonin 1a (5-HT1a) receptor antagonist,51,,ANTAGONIST,1,1,1,,,
5059,1705959,1380030,Endothelin receptor ET-A antagonist,249,,ANTAGONIST,1,1,1,,,
5060,2472940,427183,Alpha-1a adrenergic receptor partial agonist,125,,PARTIAL AGONIST,1,1,1,,,
5061,1705630,1379842,Calcium sensing receptor modulator,282,,MODULATOR,1,1,1,Can't find trial IDs (http://adisinsight.springer.com/drugs/800007039),,
5062,1705974,32821,Beta-3 adrenergic receptor agonist,226,,AGONIST,1,1,1,Discontinueddue to lack of efficacy (http://business.highbeam.com/436989/article-1G1-108457473/rafabegron-dainippon-takeda-Discontinuedeurope-usa),,
5063,1705918,1449171,Oxytocin receptor antagonist,116,,ANTAGONIST,1,1,1,,,
5064,1705907,1379995,Bradykinin B2 receptor antagonist,10034,,ANTAGONIST,1,1,1,Possible safety concerns?,,
5065,1701461,32222,Ghrelin receptor agonist,11536,,AGONIST,1,1,1,Ghrelin mimetic. Discontinued lack of efficacy and possible side effects due to CYP3A4 inhibition.,,
5066,1701461,32222,Cytochrome P450 3A4 inhibitor,17045,,INHIBITOR,1,1,1,Ghrelin mimetic. Discontinued lack of efficacy and possible side effects due to CYP3A4 inhibition.,,
5067,1703371,59348,Type-1 angiotensin II receptor antagonist,115,,ANTAGONIST,1,1,1,,,
5068,1703371,59348,Solute carrier family 22 member 12 inhibitor,102767,,INHIBITOR,1,1,1,,,
5069,1703371,59348,Solute carrier family 22 member 6 inhibitor,103829,,INHIBITOR,1,1,1,,,
5070,1703371,59348,Solute carrier family 22 member 8 inhibitor,103830,,INHIBITOR,1,1,1,,,
5071,2473360,1383058,Platelet activating factor receptor antagonist,251,,ANTAGONIST,1,1,1,,,
5072,1704416,1378980,Adrenergic receptor alpha-2 agonist,104743,,AGONIST,1,1,1,,,
5073,1702466,179627,Endothelin receptor ET-A antagonist,249,,ANTAGONIST,1,1,1,,,
5074,1702466,179627,Endothelin receptor ET-B antagonist,247,,ANTAGONIST,1,1,1,,,
5075,1702798,1121291,Leukotriene B4 receptor 1 antagonist,10542,,ANTAGONIST,1,1,1,Active metabolites are BIIL 260 and BIIL 315,,
5076,1701406,143957,Leukotriene B4 receptor 1 antagonist,10542,,ANTAGONIST,1,1,1,,,
5077,1701406,143957,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,,,
5078,1699367,460266,Neurokinin 1 receptor antagonist,250,,ANTAGONIST,1,1,1,Discontinueddue to lack of efficacy.,,
5079,1706102,6760,Neurokinin 3 receptor antagonist,10982,,ANTAGONIST,1,1,1,,,
5080,1700727,141205,Vasopressin V1a receptor antagonist,134,,ANTAGONIST,1,1,1,,,
5081,1700727,141205,Oxytocin receptor antagonist,116,,ANTAGONIST,1,1,1,,,
5082,1704551,1379111,Cannabinoid CB1 receptor agonist,87,,AGONIST,1,1,1,,,
5083,1704551,1379111,Cannabinoid CB2 receptor agonist,259,,AGONIST,1,1,1,,,
5084,1703664,705709,Cholecystokinin B receptor antagonist,11522,,ANTAGONIST,1,1,1,,,
5085,1701565,2197352,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
5086,1702910,489439,Neurokinin 1 receptor antagonist,250,,ANTAGONIST,1,1,1,,,
5087,1702994,1121299,Serotonin 1b (5-HT1b) receptor agonist,106,,AGONIST,1,1,1,,,
5088,1702994,1121299,Serotonin 1d (5-HT1d) receptor agonist,105,,AGONIST,1,1,1,,,
5089,1702994,1121299,G protein-coupled receptor 44 antagonist,20174,,ANTAGONIST,1,1,1,,,
5090,2473473,622622,Melanocortin receptor 4 agonist,10142,,AGONIST,1,1,1,,,
5091,2139040,1763586,Melanocortin receptor 4 agonist,10142,,AGONIST,1,1,1,Peptide,,
5092,1702482,1377905,Calcitonin gene-related peptide type 1 receptor agonist,19904,,AGONIST,1,1,1,"Peptide, active fragment of ADNP",,
5093,1702482,1377905,"Amylin receptor AMY1, CALCR/RAMP1 agonist",104908,,AGONIST,1,1,1,"Peptide, active fragment of ADNP",,
5094,1697365,1169899,Vasopressin V1a receptor agonist,134,,AGONIST,1,1,1,Peptide,,
5095,2473606,1927196,Proto-oncogene Mas agonist,109748,,AGONIST,1,1,1,A pharmaceutical grade formulation of endogenous ligand,,
5096,2473035,1926953,Melanocortin receptor 3 agonist,11003,,AGONIST,1,1,1,,,
5097,2473035,1926953,Melanocortin receptor 1 agonist,11869,,AGONIST,1,1,1,,,
5098,1703103,1378134,Bradykinin B2 receptor agonist,10034,,AGONIST,1,1,1,,,
5099,1697345,1380584,Glucagon-like peptide 2 receptor agonist,102687,,AGONIST,1,1,1,,,
5100,2473607,1927197,C-X-C chemokine receptor type 4 antagonist,10473,,ANTAGONIST,1,1,1,,,
5101,2473036,1926954,C-X-C chemokine receptor type 4 antagonist,10473,,ANTAGONIST,1,1,1,,,
5102,2472748,1926798,C-X-C chemokine receptor type 4 antagonist,10473,,ANTAGONIST,1,1,1,,,
5103,2473037,1926955,Neuropeptide Y receptor type 4 agonist,10143,,AGONIST,1,1,1,Pancreatic polypeptide analogue. Phase 2 study terminated.,,
5104,2473167,1927016,Oxytocin receptor agonist,116,,AGONIST,1,1,1,,,
5105,2473168,467723,GABA-B receptor 1 agonist,10227,,AGONIST,1,1,1,,,
5106,2473168,467723,GABA-B receptor 2 agonist,100031,,AGONIST,1,1,1,,,
5107,2472750,1966506,Tyrosine-protein kinase JAK1 inhibitor,10919,,INHIBITOR,1,1,1,The compound is thought to be JAK1 selective but no selectivity data available.,,
5108,2473310,1927074,Tyrosine-protein kinase JAK1 inhibitor,10919,,INHIBITOR,1,1,1,The compound is thought to be JAK1 selective but no selectivity data available.,,
5109,2473169,1927017,Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor,10752,,INHIBITOR,1,1,1,Prodrug - active metabolite is IMD-0354,,
5110,2139037,1763584,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,Inhibits FLT3 signalling and proliferation and induces apoptosis in leukemia cells expressing FLT3-ITD.,Inhibits multiple receptor tyrosine kinases. Active against FLT3 and certain FLT3 variants.,ATP-binding site
5111,2139037,1763584,Tyrosine-protein kinase receptor UFO inhibitor,100410,,INHIBITOR,1,1,1,,,
5112,2473311,1927075,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
5113,2473740,349135,Vanilloid receptor antagonist,10260,,ANTAGONIST,1,1,1,,,
5114,2472908,1926888,Vanilloid receptor antagonist,10260,,ANTAGONIST,1,1,1,,,
5115,2473312,1927076,Vanilloid receptor antagonist,10260,,ANTAGONIST,1,1,1,,,
5116,2473038,1926956,Vanilloid receptor antagonist,10260,,ANTAGONIST,1,1,1,,,
5117,2473313,1927077,Vanilloid receptor antagonist,10260,,ANTAGONIST,1,1,1,,,
5118,2473314,1927078,Vanilloid receptor antagonist,10260,,ANTAGONIST,1,1,1,,,
5119,2473315,1149947,GABA receptor alpha-2 subunit positive allosteric modulator,12770,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,Discontinued by AstraZeneca but in trials by other sponsors. Compound is listed in AstaZeneca's clinical and/or preclinical compound bank and available for research projects.,"Binding affinity is high at GABAAa1, a2 and a3 (Ki of 0.5, 0.3 and 1.3 nM, respectively), but not GA",
5120,2473315,1149947,GABA receptor alpha-3 subunit positive allosteric modulator,12757,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,Discontinued by AstraZeneca but in trials by other sponsors. Compound is listed in AstaZeneca's clinical and/or preclinical compound bank and available for research projects.,"Binding affinity is high at GABAAa1, a2 and a3 (Ki of 0.5, 0.3 and 1.3 nM, respectively), but not GA",
5121,2472909,1926889,HERG blocker,165,,BLOCKER,1,1,1,,,
5122,2472909,1926889,Sodium channel protein type V alpha subunit blocker,11480,,BLOCKER,1,1,1,,,
5123,2473170,1927018,HERG blocker,165,,BLOCKER,1,1,1,"L-type calcium channel (CACNA1C, CACNA1D, CACNA1S, CACNA1F)",,
5124,2473170,1927018,Sodium channel protein type V alpha subunit blocker,11480,,BLOCKER,1,1,1,"L-type calcium channel (CACNA1C, CACNA1D, CACNA1S, CACNA1F)",,
5125,2473170,1927018,Voltage-gated L-type calcium channel blocker,104801,,BLOCKER,1,1,1,"L-type calcium channel (CACNA1C, CACNA1D, CACNA1S, CACNA1F)",,
5126,1701413,316483,Neuronal acetylcholine receptor; alpha4/beta2 partial agonist,104283,,PARTIAL AGONIST,1,1,1,,,
5127,1705705,480532,Glutamate [NMDA] receptor blocker,104706,,BLOCKER,1,1,1,"Non-selective, open-channel blocker.",,
5128,2473741,1422105,Neuronal acetylcholine receptor protein alpha-7 subunit agonist,10635,,AGONIST,1,1,1,Compound is listed in AstaZeneca's clinical and/or preclinical compound bank and available for research projects (http://openinnovation.astrazeneca.com/what-we-offer/compound/azd0328-2/).,,
5129,2473039,681317,Glutamate [NMDA] receptor antagonist,104706,,ANTAGONIST,1,1,1,Selective NMDA glycine site antagonist,,
5130,2473040,1359153,Glutamate NMDA receptor; GRIN1/GRIN2B antagonist,104297,,ANTAGONIST,1,1,1,"Non-competitive antagonist, negative modulator.",GRIN2B selective.,Binds to ifenprodil site on N-terminal domain.
5131,2473608,1927198,Glutamate NMDA receptor; GRIN1/GRIN2B antagonist,104297,,ANTAGONIST,1,1,1,"Non-competitive antagonist, negative modulator.",GRIN2B selective.,Binds to ifenprodil site on N-terminal domain.
5132,2473316,2197743,Glutamate [NMDA] receptor partial agonist,104706,,PARTIAL AGONIST,1,1,1,"Partial agonist of the glycin-site on GRIN1-subunits, preferentially modulates NR2B-containing NMDAR receptor complexes.",,
5133,2472686,1926766,Glutamate [NMDA] receptor partial agonist,104706,,PARTIAL AGONIST,1,1,1,"NMDA glycin site partial-agonist, preferentially modulates NR2B-containing NMDAR receptor complexes","Partial agonist of the glycin-site on GRIN1-subunits, preferentially modulates NR2B-containing NMDAR",Partial agonist of the glycin-site on GRIN1-subunits.
5134,1705337,704821,Glutamate [NMDA] receptor positive allosteric modulator,104706,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,"PAM of the glycin-site on GRIN1-subunits, binds to other allosteric site?",,
5135,2473609,1927200,Glutamate [NMDA] receptor antagonist,104706,,ANTAGONIST,1,1,1,Antagonist of the glycin-site on GRIN1-subunits.,,
5136,2473041,1926957,P2X purinoceptor 7 antagonist,10417,,ANTAGONIST,1,1,1, Compound is listed in AstaZeneca's clinical and/or preclinical compound bank and available for research projects (http://openinnovation.astrazeneca.com/what-we-offer/compound/azd9056/).,,
5137,2472910,2041038,P2X purinoceptor 3 antagonist,11904,,ANTAGONIST,1,1,1,P2RX3 and P2RX2/3 trimers allosteric antagonist,,
5138,2473171,1173912,P2X purinoceptor 7 antagonist,10417,,ANTAGONIST,1,1,1,,,
5139,1976728,707012,Neuronal acetylcholine receptor protein alpha-7 subunit agonist,10635,,AGONIST,1,1,1,,,
5140,2473082,19774,Glutamate NMDA receptor; GRIN1/GRIN2B antagonist,104297,,ANTAGONIST,1,1,1,Development discontinued due to QT prolongation.,Selective for the NR2B subunit.,
5141,2473317,1927080,Neuronal acetylcholine receptor protein alpha-7 subunit agonist,10635,,AGONIST,1,1,1,Alpha-7 nicotinic receptor: consists entirely of a7 subunits (pentamere) CNS-type.,,
5142,2473173,1927020,Sodium channel protein type IX alpha subunit blocker,18061,,BLOCKER,1,1,1,,,
5143,2473242,1926762,Sodium channel protein type IX alpha subunit blocker,18061,,BLOCKER,1,1,1,,,
5144,2472752,1926800,Sodium channel protein type X alpha subunit blocker,18080,,BLOCKER,1,1,1,,,
5145,2473610,1927201,"Amiloride-sensitive sodium channel, ENaC blocker",104888,,BLOCKER,1,1,1,,,
5146,2473174,1927021,Voltage-gated N-type calcium channel alpha-1B subunit blocker,10511,,BLOCKER,1,1,1,,,
5147,2473318,1927081,Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist,10635,,PARTIAL AGONIST,1,1,1,Alpha-7 nicotinic receptor: consists entirely of a7 subunits (pentamere) CNS-type.,,
5148,2473474,1927140,Neuronal acetylcholine receptor protein alpha-7 subunit positive allosteric modulator,10635,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,
5149,2473742,555345,Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist,10635,,PARTIAL AGONIST,1,1,1,,,
5150,2472753,1926801,Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist,10635,,PARTIAL AGONIST,1,1,1,,,
5151,2472753,1926801,Serotonin 3 (5-HT3) receptor antagonist,104714,,ANTAGONIST,1,1,1,,,
5152,2473743,1927259,Neuronal acetylcholine receptor protein alpha-7 subunit agonist,10635,,AGONIST,1,1,1,Open channel stabilizer.,,
5153,1702511,209696,Nicotinic acetylcholine receptor alpha4/beta2/alpha5 partial agonist,107887,,PARTIAL AGONIST,1,1,1,,,
5154,1702511,209696,Neuronal acetylcholine receptor; alpha6/beta2 partial agonist,104898,,PARTIAL AGONIST,1,1,1,,,
5155,1701449,1377234,Neuronal acetylcholine receptor; alpha4/beta2 agonist,104283,,AGONIST,1,1,1,selectivity for the cytisine binding site on CHRNA4,Selectivity for the cytisine binding site on CHRNA4.,
5156,1705235,404474,Neuronal acetylcholine receptor; alpha4/beta2 agonist,104283,,AGONIST,1,1,1,selectivity for the cytisine binding site on CHRNA4,Selectivity for the cytisine binding site on CHRNA4.,
5157,2473611,1927202,Neuronal acetylcholine receptor; alpha4/beta2 agonist,104283,,AGONIST,1,1,1,,,
5158,2473611,1927202,Neuronal acetylcholine receptor; alpha3/beta4 agonist,104288,,AGONIST,1,1,1,,,
5159,2473319,1440335,Neuronal acetylcholine receptor; alpha4/beta2 agonist,104283,,AGONIST,1,1,1,,,
5160,2472911,1926891,Glutamate receptor ionotropic AMPA antagonist,104825,,ANTAGONIST,1,1,1,Competitive antagonist of the AMPA receptor.,,
5161,2472911,1926891,Glutamate receptor ionotropic kainate antagonist,104902,,ANTAGONIST,1,1,1,,,
5163,1699609,199699,Calcium-activated potassium channel subunit alpha-1 activator,11839,,ACTIVATOR,1,1,1,"Indication:Bronchial asthma, COPD, Allergic rhinitis",,
5164,2473320,306619,Glutamate NMDA receptor; GRIN1/GRIN2B antagonist,104297,,ANTAGONIST,1,1,1,"Non-competitive antagonist, negative modulator.",GRIN2B selective.,Binds to ifenprodil site on N-terminal domain.
5165,2473475,1927141,Cystic fibrosis transmembrane conductance regulator activator,11540,,ACTIVATOR,1,1,1,"Indication: Cystic Fibrosis, COPD",,
5166,2472754,1926802,Vanilloid receptor inhibitor,10260,,INHIBITOR,1,1,1,"Indication: Postoperative Pain, Neurogenic Bladder Disorder.
Ph2 study terminated, development halted?",,
5167,2472677,1926763,Cystic fibrosis transmembrane conductance regulator positive modulator,11540,,POSITIVE MODULATOR,1,1,1,"CF-drug in development for people with one or two copies of the F508del mutation. A CFTR corrector that modulates the folding and trafficking of CFTR protein. In Ph3 in combination with CFTR potentiator Ivacaftor.
Indication: Cystic Fibrosis, COPD",,
5168,2473321,369710,Calcium-activated potassium channel subunit alpha-1 activator,11839,,ACTIVATOR,1,1,1,Indication: Erectile dysfunction,,
5169,1706434,2197574,Glutamate receptor ionotropic AMPA antagonist,104825,,ANTAGONIST,1,1,1,"Active metabolite of oral prodrug NGX424. 
AMPA/Kainate receptor antagonist, selective for GRIK1 subunit containing receptors.
Indication: Migraine, Postoperative pain",,
5170,1706434,2197574,Glutamate receptor ionotropic kainate antagonist,104902,,ANTAGONIST,1,1,1,"Active metabolite of oral prodrug NGX424. 
AMPA/Kainate receptor antagonist, selective for GRIK1 subunit containing receptors.
Indication: Migraine, Postoperative pain",,
5171,2473322,603466,Voltage-gated N-type calcium channel alpha-1B subunit blocker,10511,,BLOCKER,1,1,1,"Indication: Lumbosacral Radiculopathy, Postherpetic Neuralgia",,
5172,1706429,367314,Prostanoid DP receptor antagonist,12659,,ANTAGONIST,1,1,1,"Laropiprant was in Ph4 in combination with niacin to reduce blood cholesterol but drug was withdrawn due to adverse effects out weighing benefits. Laropiprant itself has no cholesterol lowering effect, but it reduces facial flushes induced by niacin (https://en.wikipedia.org/wiki/Laropiprant). Indication: Rosacea, Seasonal Allergies",,
5173,1702627,1280563,Prostanoid DP receptor antagonist,12659,,ANTAGONIST,1,1,1,Indication: Asthma,,
5174,1702627,1280563,G protein-coupled receptor 44 antagonist,20174,,ANTAGONIST,1,1,1,Indication: Asthma,,
5175,2473476,1075798,C-C chemokine receptor type 5 antagonist,10580,,ANTAGONIST,1,1,1,"HIV-1 entry inhibitor, noncompetitive CCR5 allosteric antagonist. Indication: HIV infections",,
5176,2473323,1927082,Neurokinin 3 receptor antagonist,10982,,ANTAGONIST,1,1,1,,,
5177,1976737,1626747,Glucocorticoid receptor modulator,25,,MODULATOR,1,1,1,pro-drug of PF-00251802. Indication: Rheumatoid Arthritis,,
5178,2473477,1927142,Fibroblast growth factor receptor 4 inhibitor,11925,,INHIBITOR,1,1,1,,,
5179,2473324,2077912,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,EGF816 is an irreversible TKI that demonstrates selectivity for mutant EGFRs compared with WT EGFR and targets activating and resistance mutations with equal potency (doi: 10.1158/1538-7445.AM2014-1734).,,
5180,2472983,1926922,Rho-associated protein kinase inhibitor,104981,,INHIBITOR,1,1,1,,,
5181,2473177,2087700,Tyrosine-protein kinase receptor UFO inhibitor,100410,,INHIBITOR,1,1,1,,,
5182,1696542,1381033,CD40 ligand inhibitor,109787,,INHIBITOR,1,1,1,Discontinued early due to thromboses in some recipients.,,
5183,1706674,1381696,Tumor necrosis factor receptor superfamily member 8 agonist,106140,,AGONIST,1,1,1,"After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations.",,
5184,2583407,60106,Glutamate [NMDA] receptor blocker,104706,,BLOCKER,1,1,1,Being developed as PET scan ligand.,,
5185,2583705,2039371,Glutamate [NMDA] receptor antagonist,104706,,ANTAGONIST,1,1,1,,,
5186,2583705,2039371,Monoamine oxidase A inhibitor,86,,INHIBITOR,1,1,1,,,
5187,1699874,1376139,Glutamate receptor ionotropic AMPA antagonist,104825,,ANTAGONIST,1,1,1,"AMPA/Kainate receptor antagonist, selective for GRIK1 subunit containing receptors. Active metabolite is NGX424.",,
5188,1699874,1376139,Glutamate receptor ionotropic kainate 1 antagonist,12376,,ANTAGONIST,1,1,1,"AMPA/Kainate receptor antagonist, selective for GRIK1 subunit containing receptors. Active metabolite is NGX424.",,
5189,2583408,2039287,Neuronal acetylcholine receptor protein alpha-7 subunit agonist,10635,,AGONIST,1,1,1,,,
5190,2583092,2039220,Neuronal acetylcholine receptor protein alpha-7 subunit modulator,10635,,MODULATOR,1,1,1,"ASM-024 displays both antagonistic and agonistic activity on CHRNA7, is thought to be a so called ""a7 silent agonist"": produce little or no CHRNA7 channel activation on its own but effectively activate the ion channel when combined with the type II positive allosteric modulator (PAM) PNU-120596.",,
5191,2583092,2039220,Neuronal acetylcholine receptor; alpha3/beta4 antagonist,104288,,ANTAGONIST,1,1,1,"ASM-024 displays both antagonistic and agonistic activity on CHRNA7, is thought to be a so called ""a7 silent agonist"": produce little or no CHRNA7 channel activation on its own but effectively activate the ion channel when combined with the type II positive allosteric modulator (PAM) PNU-120596. (A minimal pharmacophore for a nicotinic alpha7 silent agonist, relevance for the therapeutic development of treatments for asthma Poster#: 224.06/C24. Neuroscience Meeting Planner. New Orleans, LA: Soci",,
5192,2583092,2039220,Muscarinic acetylcholine receptor M1 antagonist,61,,ANTAGONIST,1,1,1,"ASM-024 displays both antagonistic and agonistic activity on CHRNA7, is thought to be a so called ""a7 silent agonist"": produce little or no CHRNA7 channel activation on its own but effectively activate the ion channel when combined with the type II positive allosteric modulator (PAM) PNU-120596. (A minimal pharmacophore for a nicotinic alpha7 silent agonist, relevance for the therapeutic development of treatments for asthma Poster#: 224.06/C24. Neuroscience Meeting Planner. New Orleans, LA: Soci",,
5193,2583092,2039220,Muscarinic acetylcholine receptor M2 antagonist,47,,ANTAGONIST,1,1,1,"ASM-024 displays both antagonistic and agonistic activity on CHRNA7, is thought to be a so called ""a7 silent agonist"": produce little or no CHRNA7 channel activation on its own but effectively activate the ion channel when combined with the type II positive allosteric modulator (PAM) PNU-120596. (A minimal pharmacophore for a nicotinic alpha7 silent agonist, relevance for the therapeutic development of treatments for asthma Poster#: 224.06/C24. Neuroscience Meeting Planner. New Orleans, LA: Soci",,
5194,2583092,2039220,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,"ASM-024 displays both antagonistic and agonistic activity on CHRNA7, is thought to be a so called ""a7 silent agonist"": produce little or no CHRNA7 channel activation on its own but effectively activate the ion channel when combined with the type II positive allosteric modulator (PAM) PNU-120596. (A minimal pharmacophore for a nicotinic alpha7 silent agonist, relevance for the therapeutic development of treatments for asthma Poster#: 224.06/C24. Neuroscience Meeting Planner. New Orleans, LA: Soci",,
5195,2583093,2039221,Neuronal acetylcholine receptor; alpha4/beta2 partial agonist,104283,,PARTIAL AGONIST,1,1,1,,,
5196,1705961,1380032,Voltage-gated potassium channel blocker,105708,,BLOCKER,1,1,1,,,
5197,1705961,1380032,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
5198,1705919,2197553,Glutamate receptor ionotropic AMPA antagonist,104825,,ANTAGONIST,1,1,1,Competitive antagonist.,,
5199,1705075,712102,Glutamate receptor ionotropic AMPA positive allosteric modulator,104825,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,Ampakine molecule.,,
5200,1705786,712973,Glutamate receptor ionotropic AMPA positive allosteric modulator,104825,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,
5201,1702476,1377901,Unknown,,,,1,1,1,,,
5202,1701649,1377430,Sulfonylurea receptors; K-ATP channels opener,104737,,OPENER,1,1,1,,,
5203,1702552,591640,Voltage-gated calcium channel modulator,105734,,MODULATOR,1,1,1,Ligand for the voltage-gated calcium channel alpha-2-delta subunit.,,
5204,1704059,181427,Neuronal acetylcholine receptor; alpha4/beta2 agonist,104283,,AGONIST,1,1,1,"SIB-1765F is a racemate with two isomers, SIB-1508Y and SIB-1680WD. SIB-1508Y is thought to be the active isomer.",,
5205,1699740,1376061,GABA-A receptor; anion channel partial agonist,104688,2617,PARTIAL AGONIST,1,1,1,,,Benzodiazepine site
5206,2583409,2039288,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
5207,1706093,1380071,GABA-A receptor; anion channel inverse agonist,104688,2617,INVERSE AGONIST,1,1,1,Partial inverese agonist.,,Benzodiazepine site
5208,2583410,2039289,Transient receptor potential cation channel subfamily A member 1 antagonist,101412,,ANTAGONIST,1,1,1,,,
5209,2583411,2039290,Transient receptor potential cation channel subfamily V member 3 antagonist,101224,,ANTAGONIST,1,1,1,,,
5210,2583289,2039264,Vanilloid receptor antagonist,10260,,ANTAGONIST,1,1,1,,,
5211,2583706,2039372,Glutamate receptor ionotropic AMPA positive allosteric modulator,104825,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,Ampakine molecule.,,
5212,2583505,2039327,Vanilloid receptor antagonist,10260,,ANTAGONIST,1,1,1,Small interfering RNA (siRNA).,,
5213,2583707,2039373,GABA-A receptor; anion channel agonist,104688,,AGONIST,1,1,1,,,
5214,2583465,252174,GABA receptor beta-3 subunit positive allosteric modulator,11881,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,
5215,1699717,6288,Estrogen receptor modulator,104682,,MODULATOR,1,1,1,"SERM, development stopped as ineffective compared to tamoxifen.",,
5216,1705903,103971,Estrogen receptor modulator,104682,,MODULATOR,1,1,1,SERM,,
5217,2473478,2335156,Androgen Receptor antagonist,56,,ANTAGONIST,1,1,1,,,
5218,1705256,1117936,Androgen Receptor modulator,56,,MODULATOR,1,1,1,SARM,,
5219,2472755,1672700,Androgen Receptor antagonist,56,,ANTAGONIST,1,1,1,,,
5220,2473744,1927260,Estrogen receptor beta agonist,174,,AGONIST,1,1,1,"Herbal preparation, most active estrogenic compound in MF101 is the flavanone liquiritigenin which is a Erbeta selective agonist ( http://en.wikipedia.org/wiki/Liquiritigenin, PMC2277338)",,
5221,1702508,574221,Bile acid receptor FXR agonist,11180,,AGONIST,1,1,1,,,
5222,1699886,1376146,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,,,
5223,1702213,431456,Progesterone receptor modulator,36,,MODULATOR,1,1,1,"Development discontinued due to ""endometrial changes"" experienced by some patients. Is a selective progesterone receptor modulator.",,
5224,2473745,1927261,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,Selective PPAR alpha modulator (SPPAR?M) properties. Ph3 in Japan,,
5225,1706424,598833,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,Development discontinued after Ph3 in 2005 due to abnormalities in liver enzyme tests (http://www.firstwordpharma.com/node/218757#axzz3OLRFCbFS3).,,
5226,1706424,598833,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,Development discontinued after Ph3 in 2005 due to abnormalities in liver enzyme tests (http://www.firstwordpharma.com/node/218757#axzz3OLRFCbFS3).,,
5227,1699743,520672,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,Development stopped due to safety concerns and lack of efficacy (http://www.roche.com/media/media_releases/med-cor-2013-07-10.htm),,
5228,1699743,520672,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,Development stopped due to safety concerns and lack of efficacy (http://www.roche.com/media/media_releases/med-cor-2013-07-10.htm),,
5229,1705437,311988,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,Discontinueddue to safety concerns,,
5230,1705437,311988,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,Discontinueddue to safety concerns,,
5231,1706224,33827,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,"All Ph3 trials terminated, discontinued due to safety concerns (http://en.wikipedia.org/wiki/Tesaglitazar)",,
5232,1706224,33827,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,"All Ph3 trials terminated, discontinued due to safety concerns (http://en.wikipedia.org/wiki/Tesaglitazar)",,
5233,1700194,1376261,Peroxisome proliferator-activated receptor gamma partial agonist,133,,PARTIAL AGONIST,1,1,1,Discontinueddue to safety concerns,,
5234,1701182,1377023,Peroxisome proliferator-activated receptor gamma agonist,133,,AGONIST,1,1,1,"Development discontinued in 2009, not sufficiently differentiate from existing product",,
5235,1702475,1139916,Peroxisome proliferator-activated receptor gamma antagonist,133,,ANTAGONIST,1,1,1,"Ph3 study terminated, safety and efficacy to be re-evaluated in new Ph2 study in 2014/2015. Activates KEAP1-Nrf2 pathway (http://en.wikipedia.org/wiki/Bardoxolone_methyl, http://www.kyowa-kirin.com/news_releases/2014/e20140702_01.html)",,
5236,1702475,1139916,Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor,10752,,INHIBITOR,1,1,1,"Ph3 study terminated, safety and efficacy to be re-evaluated in new Ph2 study in 2014/2015. Activates KEAP1-Nrf2 pathway (http://en.wikipedia.org/wiki/Bardoxolone_methyl, http://www.kyowa-kirin.com/news_releases/2014/e20140702_01.html)",,
5237,1702475,1139916,Keap1/Nrf2 inhibitor,107924,,INHIBITOR,1,1,1,"Ph3 study terminated, safety and efficacy to be re-evaluated in new Ph2 study in 2014/2015. Activates KEAP1-Nrf2 pathway (http://en.wikipedia.org/wiki/Bardoxolone_methyl, http://www.kyowa-kirin.com/news_releases/2014/e20140702_01.html)",,
5238,2472756,1345403,Thyroid hormone receptor beta-1 agonist,271,,AGONIST,1,1,1,Development discontinued in 2012 due to cartilage damage seen in animal study (http://www.karobio.com/investormedia/pressreleaser/pressrelease?pid=6395352),,
5239,1706230,1248747,Vitamin D receptor agonist,64,,AGONIST,1,1,1,"Ph3 trials terminated, unknown reason",,
5240,1976723,2197733,Vitamin D receptor agonist,64,,AGONIST,1,1,1,vitamin D3 analogue,,
5241,2472757,1248752,Fibroblast growth factor receptor 3 inhibitor,11926,,INHIBITOR,1,1,1,"Approved veterinary - 2012. Not recommended for approval (Negative opinion) in EU, phase 3 trials in US.",,
5242,2472757,1248752,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,"Approved veterinary - 2012. Not recommended for approval (Negative opinion) in EU, phase 3 trials in US.",,
5243,2472757,1248752,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,"Approved veterinary - 2012. Not recommended for approval (Negative opinion) in EU, phase 3 trials in US.",,
5244,1705239,371147,Macrophage colony stimulating factor receptor inhibitor,12840,,INHIBITOR,1,1,1,,,
5245,1705239,371147,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
5246,1705239,371147,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,,,
5247,1705239,371147,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
5248,1705248,573133,Macrophage colony stimulating factor receptor inhibitor,12840,,INHIBITOR,1,1,1,,,
5249,1705248,573133,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
5250,1705248,573133,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
5251,1705248,573133,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,,,
5252,1705248,573133,Tyrosine-protein kinase receptor RET inhibitor,100079,,INHIBITOR,1,1,1,,,
5253,1699897,1376152,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,"Mechanism of action is still unclear, it is thought that Tivantinib displays cytotoxic activity via mechanisms other than only cMET inhibition (PMID:23712183)",,
5254,1702551,361444,Tyrosine-protein kinase ABL inhibitor,8,,INHIBITOR,1,1,1,,,
5255,1702551,361444,Tyrosine-protein kinase SRC inhibitor,10434,,INHIBITOR,1,1,1,,,
5256,2472758,363089,Serine/threonine-protein kinase Aurora-B inhibitor,10781,,INHIBITOR,1,1,1,,,
5257,1705219,456867,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
5258,1705219,456867,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,,,
5259,1705219,456867,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
5260,2473534,1817518,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,"Binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion)",,
5261,1699885,695878,Serine/threonine-protein kinase PLK1 inhibitor,10907,,INHIBITOR,1,1,1,,,
5262,1705230,343041,Fibroblast growth factor receptor inhibitor,104793,,INHIBITOR,1,1,1,Active metabolite of Brivanib alaninate,,
5263,1705230,343041,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,Active metabolite of Brivanib alaninate,,
5264,1705049,441029,Fibroblast growth factor receptor inhibitor,104793,,INHIBITOR,1,1,1,Prodrug - active metabolite is BMS-540215,,
5265,1705049,441029,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,Prodrug - active metabolite is BMS-540215,,
5266,2473479,52141,Mitogen-activated protein kinase kinase kinase 11 inhibitor,11870,,INHIBITOR,1,1,1,"CEP-1347 inhibits c-Jun N-terminal kinase signaling pathway by inhibition of mixed lineage kinases (MLKs), upstreams and known activators of JNK signaling.",,
5267,2473479,52141,Mitogen-activated protein kinase kinase kinase 10 inhibitor,11873,,INHIBITOR,1,1,1,"CEP-1347 inhibits c-Jun N-terminal kinase signaling pathway by inhibition of mixed lineage kinases (MLKs), upstreams and known activators of JNK signaling.",,
5268,2473479,52141,Mitogen-activated protein kinase kinase kinase 9 inhibitor,12038,,INHIBITOR,1,1,1,"CEP-1347 inhibits c-Jun N-terminal kinase signaling pathway by inhibition of mixed lineage kinases (MLKs), upstreams and known activators of JNK signaling.",,
5269,2473479,52141,Mitogen-activated protein kinase kinase kinase 13 inhibitor,103453,,INHIBITOR,1,1,1,"CEP-1347 inhibits c-Jun N-terminal kinase signaling pathway by inhibition of mixed lineage kinases (MLKs), upstreams and known activators of JNK signaling.",,
5270,2473479,52141,Mitogen-activated protein kinase kinase kinase 12 inhibitor,104320,,INHIBITOR,1,1,1,"CEP-1347 inhibits c-Jun N-terminal kinase signaling pathway by inhibition of mixed lineage kinases (MLKs), upstreams and known activators of JNK signaling.",,
5271,1706061,597145,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
5272,1706061,597145,Tyrosine-protein kinase JAK2 inhibitor,10938,,INHIBITOR,1,1,1,,,
5273,1706061,597145,Nerve growth factor receptor Trk-A inhibitor,11902,,INHIBITOR,1,1,1,,,
5274,1706061,597145,Neurotrophic tyrosine kinase receptor type 2 inhibitor,100413,,INHIBITOR,1,1,1,,,
5275,1706061,597145,NT-3 growth factor receptor inhibitor,101034,,INHIBITOR,1,1,1,,,
5276,1706061,597145,Tyrosine-protein kinase receptor RET inhibitor,100079,,INHIBITOR,1,1,1,,,
5277,1702340,547496,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,Canertinib is an irreversible pan-ErbB tyrosine kinase inhibitor.,,
5278,1702340,547496,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,Canertinib is an irreversible pan-ErbB tyrosine kinase inhibitor.,,
5279,1702340,547496,Receptor protein-tyrosine kinase erbB-4 inhibitor,12699,,INHIBITOR,1,1,1,Canertinib is an irreversible pan-ErbB tyrosine kinase inhibitor.,,
5280,1699900,617563,Tyrosine-protein kinase JAK1 inhibitor,10919,,INHIBITOR,1,1,1,,,
5281,1699900,617563,Tyrosine-protein kinase JAK2 inhibitor,10938,,INHIBITOR,1,1,1,,,
5282,1699810,619400,MAP kinase p38 alpha inhibitor,10188,,INHIBITOR,1,1,1,,,
5283,1699810,619400,MAP kinase p38 beta inhibitor,10120,,INHIBITOR,1,1,1,,,
5284,2473746,1927262,Tyrosine-protein kinase ABL inhibitor,8,,INHIBITOR,1,1,1,,,
5285,1706035,299120,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,Neratinib is an irreversible pan-HER tyrosine kinase inhibitor.,,
5286,1706035,299120,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,Neratinib is an irreversible pan-HER tyrosine kinase inhibitor.,,
5287,1699852,14366,Cyclin-dependent kinase 2 inhibitor,11678,,INHIBITOR,1,1,1,,,
5288,1699852,14366,Cyclin-dependent kinase 4 inhibitor,12946,,INHIBITOR,1,1,1,,,
5289,1699852,14366,Cyclin-dependent kinase 6 inhibitor,10480,,INHIBITOR,1,1,1,,,
5290,1699852,14366,Cyclin-dependent kinase 9 inhibitor,11626,,INHIBITOR,1,1,1,,,
5291,1699852,14366,Cyclin-dependent kinase 1 inhibitor,12071,,INHIBITOR,1,1,1,,,
5292,1699852,14366,Cyclin-dependent kinase 7 inhibitor,12829,,INHIBITOR,1,1,1,,,
5293,1702681,1378029,Tyrosine-protein kinase JAK1 inhibitor,10919,,INHIBITOR,1,1,1,,,
5294,1702681,1378029,Tyrosine-protein kinase JAK2 inhibitor,10938,,INHIBITOR,1,1,1,,,
5295,1702549,715901,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
5296,2473043,1926959,Cyclin-dependent kinase 4 inhibitor,12946,,INHIBITOR,1,1,1,,,
5297,2473043,1926959,Cyclin-dependent kinase 6 inhibitor,10480,,INHIBITOR,1,1,1,,,
5298,2139024,1763574,Serine/threonine-protein kinase B-raf inhibitor,100126,,INHIBITOR,1,1,1,Selective for mutation containing BRAF (V600E mutation) with little or no activity against wild-type BRAF.,,
5299,2473221,83217,Protein kinase C beta inhibitor,11636,,INHIBITOR,1,1,1,,,
5300,1699449,144959,Protein kinase C beta inhibitor,11636,,INHIBITOR,1,1,1,,,
5301,2139011,1677014,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,Non-ATP-competitive allosteric inhibitor,,
5302,2139011,1677014,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor,11046,,INHIBITOR,1,1,1,Non-ATP-competitive allosteric inhibitor,,
5303,1699827,1376110,Cyclin-dependent kinase 1 inhibitor,12071,,INHIBITOR,1,1,1,,,
5304,1699827,1376110,Cyclin-dependent kinase 2 inhibitor,11678,,INHIBITOR,1,1,1,,,
5305,1699827,1376110,Cyclin-dependent kinase 5 inhibitor,12947,,INHIBITOR,1,1,1,,,
5306,1699827,1376110,Cyclin-dependent kinase 9 inhibitor,11626,,INHIBITOR,1,1,1,,,
5307,1702642,520053,Serine/threonine-protein kinase Aurora-A inhibitor,20014,,INHIBITOR,1,1,1,,,
5308,1702667,1334185,Proteinase-activated receptor 1 inhibitor,10653,,INHIBITOR,1,1,1,"Allosteric inhibitor, does not interact with ATP binidng site. May act by binding to c-Raf and indirectly suppress PI3K and Plk1 pathways. PMID: 24493827 and http://www.onconova.com/product-pipeline/rigosertib.php.",,
5309,1702601,623658,Insulin-like growth factor I receptor inhibitor,234,,INHIBITOR,1,1,1,,,
5310,1702601,623658,Insulin receptor inhibitor,35,,INHIBITOR,1,1,1,,,
5311,1702618,1377989,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,Dacomitinib is an irreversible pan-ERBB inhibitor.,,
5312,1702618,1377989,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,Dacomitinib is an irreversible pan-ERBB inhibitor.,,
5313,1702618,1377989,Receptor protein-tyrosine kinase erbB-4 inhibitor,12699,,INHIBITOR,1,1,1,Dacomitinib is an irreversible pan-ERBB inhibitor.,,
5314,1702752,608601,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,Multi-kinase inhibitor,,
5315,1702752,608601,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,Multi-kinase inhibitor,,
5316,1702752,608601,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,Multi-kinase inhibitor,,
5317,1702752,608601,Protein kinase C (PKC) inhibitor,104683,,INHIBITOR,1,1,1,Multi-kinase inhibitor,,
5318,1702752,608601,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,Multi-kinase inhibitor,,
5319,1706190,165012,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
5320,1706190,165012,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,,,
5321,1706190,165012,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
5322,1706190,165012,Macrophage colony stimulating factor receptor inhibitor,12840,,INHIBITOR,1,1,1,,,
5323,1699806,1376100,Tyrosine-protein kinase SYK inhibitor,10906,,INHIBITOR,1,1,1,Prodrug - active metabolite is R-406,,
5324,1879123,1420377,Dual specificity mitogen-activated protein kinase kinase 1 inhibitor,11409,,INHIBITOR,1,1,1,Approved in Switzerland 2015 for use in combination with vemurafenib as a treatment for patients with advanced melanoma.,,
5325,1879123,1420377,Dual specificity mitogen-activated protein kinase kinase 2 inhibitor,11046,,INHIBITOR,1,1,1,Approved in Switzerland 2015 for use in combination with vemurafenib as a treatment for patients with advanced melanoma.,,
5326,1937986,714243,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,Potent inhibitor of BRD4 (PMID: 24584101).,,
5327,1937986,714243,Tyrosine-protein kinase JAK2 inhibitor,10938,,INHIBITOR,1,1,1,Potent inhibitor of BRD4 (PMID: 24584101).,,
5328,1976740,1344709,Tyrosine-protein kinase JAK2 inhibitor,10938,,INHIBITOR,1,1,1,,,
5329,1976740,1344709,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
5330,2473325,1927084,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
5331,1703657,12911,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
5332,1703657,12911,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
5333,2473480,12922,Fibroblast growth factor receptor inhibitor,104793,,INHIBITOR,1,1,1,"Ph 3 trial discontinued, compound on hold?",,
5334,2473480,12922,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,"Ph 3 trial discontinued, compound on hold?",,
5335,2473480,12922,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,"Ph 3 trial discontinued, compound on hold?",,
5336,2473498,494834,Fibroblast growth factor receptor 3 inhibitor,11926,,INHIBITOR,1,1,1,,,
5337,2473498,494834,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
5338,2473498,494834,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
5339,2473498,494834,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,,,
5340,2473498,494834,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
5341,2473747,1927263,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,,,
5342,1705788,442178,Intermediate conductance calcium-activated potassium channel protein 4 blocker,10992,,BLOCKER,1,1,1,,,
5343,1705232,682106,Gonadotropin-releasing hormone receptor antagonist,118,,ANTAGONIST,1,1,1,,,
5344,1699819,1051539,Endothelin receptor ET-A antagonist,249,,ANTAGONIST,1,1,1,,,
5345,1705038,1066574,C-C chemokine receptor type 5 antagonist,10580,,ANTAGONIST,1,1,1,Discontinueddue to liver toxicity concerns.,,
5346,2472656,1069144,Neurokinin 1 receptor antagonist,250,,ANTAGONIST,1,1,1,"Filing withdrawn, development halted.",,
5347,1701424,316774,Interleukin-8 receptor A modulator,11574,,MODULATOR,1,1,1,,,
5348,1701424,316774,Interleukin-8 receptor B modulator,10773,,MODULATOR,1,1,1,,,
5349,1699851,1267108,Ghrelin receptor agonist,11536,,AGONIST,1,1,1,,,
5350,1703273,1279532,Adenosine A2a receptor agonist,252,,AGONIST,1,1,1,,,
5351,1701386,1279628,Adenosine A2a receptor agonist,252,,AGONIST,1,1,1,All registered studies Discontinued Developed as pharmacologic stress agent for myocardial perfusion imaging.,,
5352,1702505,347877,Serotonin 1a (5-HT1a) receptor agonist,51,,AGONIST,1,1,1,"Development stopped, not superior enough to placebo.",,
5353,1699746,1376064,Ghrelin receptor agonist,11536,,AGONIST,1,1,1,,,
5354,1699781,556582,Cannabinoid CB1 receptor antagonist,87,,ANTAGONIST,1,1,1,Development Discontinuedbecause of potential serious side effects linked to targetting of CNR1 (http://en.wikipedia.org/wiki/Otenabant).,,
5355,1702661,1378017,Adenosine A2a receptor antagonist,252,,ANTAGONIST,1,1,1,,,
5356,1702677,1378025,Mu opioid receptor antagonist,129,,ANTAGONIST,1,1,1,,,
5357,1705074,1379609,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,Discontinued(strategic reasons),,
5358,1705074,1379609,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,Discontinued(strategic reasons),,
5359,1705074,1379609,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,Discontinued(strategic reasons),,
5360,1705074,1379609,Adrenergic receptor alpha-2 antagonist,104743,,ANTAGONIST,1,1,1,Discontinued(strategic reasons),,
5361,1705088,1379619,Serotonin 1a (5-HT1a) receptor antagonist,51,,ANTAGONIST,1,1,1,Not in current pipeline,,
5362,1705138,1379654,C-C chemokine receptor type 5 antagonist,10580,,ANTAGONIST,1,1,1,Discontinueddue to disappointing results in Ph2 and Ph3 studies.,,
5363,2473613,1383170,Metabotropic glutamate receptor 2 agonist,12895,,AGONIST,1,1,1,"Inactive prodrug of LY404039. Eli Lilly Discontinueddevelopment, a Ph1 study sponsored by New York University School of Medicine is recruiting patients.",,
5364,2473613,1383170,Metabotropic glutamate receptor 3 agonist,10167,,AGONIST,1,1,1,"Inactive prodrug of LY404039. Eli Lilly Discontinueddevelopment, a Ph1 study sponsored by New York University School of Medicine is recruiting patients.",,
5365,1705114,1418061,Serotonin 1a (5-HT1a) receptor agonist,51,,AGONIST,1,1,1,"Development discontunued, failed to meet primary efficacy endpoints, no difference between drug and placebo. Newron developing drug for Rett syndrome and received EMA and FDA orphan designation in July 2015. Agonist/partial agonistic/antagonsitic effect depending on dopamine receptor isoform.",,
5366,1705114,1418061,Dopamine D2 receptor partial agonist,72,,PARTIAL AGONIST,1,1,1,"Development discontunued, failed to meet primary efficacy endpoints, no difference between drug and placebo. Newron developing drug for Rett syndrome and received EMA and FDA orphan designation in July 2015. Agonist/partial agonistic/antagonsitic effect depending on dopamine receptor isoform.",,
5367,1705114,1418061,Dopamine D3 receptor agonist,130,,AGONIST,1,1,1,"Development discontunued, failed to meet primary efficacy endpoints, no difference between drug and placebo. Newron developing drug for Rett syndrome and received EMA and FDA orphan designation in July 2015. Agonist/partial agonistic/antagonsitic effect depending on dopamine receptor isoform.",,
5368,1705114,1418061,Dopamine D4 receptor agonist,90,,AGONIST,1,1,1,"Development discontunued, failed to meet primary efficacy endpoints, no difference between drug and placebo. Newron developing drug for Rett syndrome and received EMA and FDA orphan designation in July 2015. Agonist/partial agonistic/antagonsitic effect depending on dopamine receptor isoform.",,
5369,1937941,1439374,C-C chemokine receptor type 9 antagonist,101345,,ANTAGONIST,1,1,1,"Phase 3 trials terminated, compound development discontinued due to lack of efficacy and adverse events. Still in ChemoCentryx pipeline, compound on hold. Indication: Crohn’s disease",,
5370,1706428,364983,Cannabinoid CB1 receptor inverse agonist,87,,INVERSE AGONIST,1,1,1,"Merck has Discontinueddevelopment of the drug, potential serious side effects linked to targetting of CNR1 (http://en.wikipedia.org/wiki/Taranabant)",,
5371,2473748,1525737,Sphingosine 1-phosphate receptor Edg-1 agonist,11631,,AGONIST,1,1,1,Siponimod reduces lymphocyte numbers in peripheral blood by blocking their release from the lymph nodes. The mechanism of theraputic effects in MS are unknown.,High binding affinity for S1P receptors 1 and 5. ,
5373,1879134,1540484,Prostanoid FP receptor agonist,140,,AGONIST,1,1,1,Prodrug of latanoprost acid and butanediol mononitrate. Nitric oxide (NO)-donating prostaglandin F2-alpha analog,,
5374,1702523,402280,Calcitonin gene-related peptide type 1 receptor antagonist,19904,,ANTAGONIST,1,1,1,,,
5375,1705225,410123,Adenosine A2a receptor antagonist,252,,ANTAGONIST,1,1,1,Discontinued no more effective than placebo.,,
5376,1879139,22393,Ghrelin receptor agonist,11536,,AGONIST,1,1,1,,,
5377,1937954,1592329,Mu opioid receptor antagonist,129,,ANTAGONIST,1,1,1,All phase 3 studies have been terminated.,,
5378,1976735,1626745,Prostanoid IP receptor agonist,143,,AGONIST,1,1,1,,,
5379,2139029,1757098,Serotonin 6 (5-HT6) receptor antagonist,10627,,ANTAGONIST,1,1,1,,,
5380,1702543,361763,Adenosine A1 receptor antagonist,114,,ANTAGONIST,1,1,1,,,
5381,2473175,454365,Histamine H3 receptor inverse agonist,10280,,INVERSE AGONIST,1,1,1,,,
5382,1705224,520543,Corticotropin releasing factor receptor 1 antagonist,124,,ANTAGONIST,1,1,1,,,
5383,1699787,76666,Adenosine A1 receptor antagonist,114,,ANTAGONIST,1,1,1,Discontinued no more effective than placebo.,,
5384,1705218,545114,Beta-3 adrenergic receptor agonist,226,,AGONIST,1,1,1,,,
5385,1703726,1378338,Endothelin receptor ET-A antagonist,249,,ANTAGONIST,1,1,1,,,
5386,2472912,2197744,Adenosine A3 receptor agonist,280,,AGONIST,1,1,1,,,
5387,1879122,1540477,Nociceptin receptor agonist,138,,AGONIST,1,1,1,,,
5388,1879122,1540477,Opioid receptors; mu/kappa/delta agonist,104765,,AGONIST,1,1,1,,,
5389,1705104,1590761,Serotonin 2a (5-HT2a) receptor inverse agonist,107,,INVERSE AGONIST,1,1,1,,,
5390,2473326,388891,Neurokinin 2 receptor antagonist,10184,,ANTAGONIST,1,1,1,,,
5391,2472913,120674,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
5392,1699537,94071,Endothelin receptor ET-A antagonist,249,,ANTAGONIST,1,1,1,Discontinueddue to lack of clinical benefit.,,
5393,1699537,94071,Endothelin receptor ET-B antagonist,247,,ANTAGONIST,1,1,1,Discontinueddue to lack of clinical benefit.,,
5394,1705997,1380056,Thromboxane A2 receptor antagonist,246,,ANTAGONIST,1,1,1,Discontinueddue to lack of clinical benefit?,,
5395,1705984,1380047,Vasopressin V2 receptor antagonist,112,,ANTAGONIST,1,1,1,"Application for marketing approval in the EU withdrawn, compound Discontinueddue to safety concerns.",,
5396,1706096,2197705,Endothelin receptor ET-A antagonist,249,,ANTAGONIST,1,1,1,Ph 3 trial Discontinueddue to adverse effects.,,
5397,1705978,1380043,Beta-3 adrenergic receptor agonist,226,,AGONIST,1,1,1,Not in current pipeline,,
5398,1705950,2197557,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,"Phase 3 study terminated, primary endpoint was not met on the double blind data (NCT01355874)",,
5399,1706026,182389,Endothelin receptor ET-A antagonist,249,,ANTAGONIST,1,1,1,Phase 3 study terminated due to lack of efficacy,,
5400,1699525,457258,Neurotensin receptor 1 antagonist,12910,,ANTAGONIST,1,1,1,,,
5401,1703486,1121279,Serotonin 1a (5-HT1a) receptor agonist,51,,AGONIST,1,1,1,,,
5402,1700683,73070,Vasopressin V2 receptor antagonist,112,,ANTAGONIST,1,1,1,FDA has denied approval.,,
5403,1700631,30255,Endothelin receptor ET-A antagonist,249,,ANTAGONIST,1,1,1,Discontinued failed to meet primary endpoints in phase 3 study,,
5404,1700631,30255,Endothelin receptor ET-B antagonist,247,,ANTAGONIST,1,1,1,Discontinued failed to meet primary endpoints in phase 3 study,,
5407,1701393,1360388,Melanocortin receptor 4 agonist,10142,,AGONIST,1,1,1,"Alpha-MSH analogue. Binds MC1R, MC3R, MC4R and MC5R but most potent against MC1R and MC4R. MC4R is expressed on neurons in the central nervous system and likely to be involved in efficacy. MC3R may also be involved, but role poorly understood.",,
5408,2473749,1927264,Calcitonin receptor agonist,119,,AGONIST,1,1,1,"peptide drug, oral salmon calcitonin",,
5409,1879168,1927033,Calcium sensing receptor agonist,282,,AGONIST,1,1,1,Peptide,,
5410,1695937,1380126,Glucagon-like peptide 1 receptor agonist,11758,,AGONIST,1,1,1,"Peptide, GLP-1 analogue. Development stopped due to adverse events.",,
5411,1697398,1380624,Relaxin receptor 1 activator,103749,,ACTIVATOR,1,1,1,"Peptide, recombinant human relaxin-2. EMA and FDA regulators have rejected marketing authorisation.",,
5412,1697398,1380624,Relaxin receptor 2 activator,103801,,ACTIVATOR,1,1,1,"Peptide, recombinant human relaxin-2. EMA and FDA regulators have rejected marketing authorisation.",,
5413,1696496,1380990,Glucagon-like peptide 1 receptor agonist,11758,,AGONIST,1,1,1,"Peptide, GLP-1 analogue.",,
5414,1700178,1376245,Somatostatin receptor 2 agonist,117,,AGONIST,1,1,1,"Somatostatin analogue. Not apporved by FDA, rejected by advisory panel. Not in current company pipeline and no further development reported.",,
5415,1700178,1376245,Somatostatin receptor 3 agonist,11261,,AGONIST,1,1,1,"Somatostatin analogue. Not apporved by FDA, rejected by advisory panel. Not in current company pipeline and no further development reported.",,
5416,1700178,1376245,Somatostatin receptor 5 agonist,11265,,AGONIST,1,1,1,"Somatostatin analogue. Not apporved by FDA, rejected by advisory panel. Not in current company pipeline and no further development reported.",,
5417,2472759,1926803,Gonadotropin-releasing hormone receptor agonist,118,,AGONIST,1,1,1,,,
5418,1697338,1380578,Gonadotropin-releasing hormone receptor antagonist,118,,ANTAGONIST,1,1,1,,,
5419,1702583,596524,Dopamine D2 receptor modulator,72,,MODULATOR,1,1,1,Dopaminergic stabilizer,,
5420,1976761,1422241,Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist,10635,,PARTIAL AGONIST,1,1,1,Alpha-7 nicotinic receptor: consists entirely of a7 subunits (pentamere) CNS-type.,,
5421,1705975,1380041,Voltage-gated N-type calcium channel alpha-1B subunit blocker,10511,,BLOCKER,1,1,1,,,
5422,1705975,1380041,Monoamine oxidase B inhibitor,104,,INHIBITOR,1,1,1,,,
5423,1705975,1380041,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
5424,1705975,1380041,Glutamate [NMDA] receptor antagonist,104706,,ANTAGONIST,1,1,1,,,
5425,1699896,1376151,Neuronal acetylcholine receptor; alpha4/beta2 antagonist,104283,,ANTAGONIST,1,1,1,TC-5214 [S-(+)-mecamylamine] was more effective than TC-5213 [R-(-)-mecamylamine] in inhibiting the LS a4ß2 NNRs. TC-5214 potentiated and TC-5213 inhibited agonist-induced activation of HS a4ß2 NNRs.,,
5426,1700750,3103,Calcium-activated potassium channel subunit alpha-1 opener,11839,,OPENER,1,1,1,Indication: Stroke,,
5427,1700750,3103,Voltage-gated potassium channel subunit Kv7.5 activator,12005,,ACTIVATOR,1,1,1,Indication: Stroke,,
5428,1700750,3103,Voltage-gated potassium channel subunit Kv7.4 activator,11125,,ACTIVATOR,1,1,1,Indication: Stroke,,
5429,1700750,3103,Voltage-gated potassium channel subunit Kv7.2 activator,10397,,ACTIVATOR,1,1,1,Indication: Stroke,,
5430,1700750,3103,"Voltage-gated potassium channel, KQT; KCNQ2(Kv7.2)/KCNQ3(Kv7.3) activator",105510,,ACTIVATOR,1,1,1,Indication: Stroke,,
5431,1700750,3103,Voltage-gated potassium channel KCNQ3/KCNQ4 activator,109991,,ACTIVATOR,1,1,1,Indication: Stroke,,
5432,1937967,1562844,G protein-coupled receptor 44 antagonist,20174,,ANTAGONIST,1,1,1,"Indication: Seasonal allergic rhinitis, asthma",,
5433,2472914,1926892,Prostanoid DP receptor antagonist,12659,,ANTAGONIST,1,1,1,,,
5434,1699778,568338,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,Multi-kinase inhibitor,,
5435,1699778,568338,Tyrosine-protein kinase receptor RET inhibitor,100079,,INHIBITOR,1,1,1,Multi-kinase inhibitor,,
5436,1699778,568338,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,Multi-kinase inhibitor,,
5437,1699778,568338,Platelet-derived growth factor receptor inhibitor,104773,,INHIBITOR,1,1,1,Multi-kinase inhibitor,,
5438,2472915,1768774,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,"Atypical antipsychotic, shows partial agonism at the presynaptic D2 receptors and acts as an antagonist at postsynaptic D2 receptors (PMID: 25120104).",,
5439,2472915,1768774,Dopamine D2 receptor partial agonist,72,,PARTIAL AGONIST,1,1,1,"Atypical antipsychotic, shows partial agonism at the presynaptic D2 receptors and acts as an antagonist at postsynaptic D2 receptors (PMID: 25120104).",,
5440,2472915,1768774,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,"Atypical antipsychotic, shows partial agonism at the presynaptic D2 receptors and acts as an antagonist at postsynaptic D2 receptors (PMID: 25120104).",,
5441,2473409,1927106,Voltage-gated calcium channel alpha2/delta subunit 1 modulator,150,,MODULATOR,1,1,1,,,
5442,2473409,1927106,Voltage-gated calcium channel alpha2/delta subunit 2 modulator,11959,,MODULATOR,1,1,1,,,
5443,1392865,1121852,Mucin-16 other,109778,,OTHER,1,1,1,"It does not bind directly to CA-125, but it works as a ""surrogate"" antigen, enabling the immune system to identify and attack tumour cells displaying the CA-125 protein.",,
5444,1392875,1121862,Interleukin-5 receptor subunit alpha inhibitor,109779,,INHIBITOR,1,1,1,"Binds to an epitope on IL5RA which is in close proximity to the IL-5 binding site and thus inhibits IL-5 receptor signaling, independent of ligand.",,
5445,1392879,1121866,Interleukin-23 inhibitor,106133,2649,INHIBITOR,1,1,1,IgG1 monoclonal antibody with genetically engineered complementarity-determining regions that have high affinity for the IL-12/23 p40 subunit protein.,,Beta (p40) subunit is binding site
5446,1392879,1121866,Interleukin-12 inhibitor,106132,2646,INHIBITOR,1,1,1,IgG1 monoclonal antibody with genetically engineered complementarity-determining regions that have high affinity for the IL-12/23 p40 subunit protein.,,Beta (p40) subunit is binding site
5448,1392880,1121867,Interleukin-17 receptor A antagonist,109781,,ANTAGONIST,1,1,1,,,
5449,1392893,1121880,Heat shock protein 90 homolog inhibitor,109799,,INHIBITOR,1,1,1,"Binds to the yeast antigen heat shock protein hsp90 (rhMAB-hsp90) (present in the fungal cell wall and in extracellular material, particularly around foci of infection) preventing a conformational change needed for fungal viability.",,
5450,1392899,1121886,Integrin beta-7 antagonist,10917,,ANTAGONIST,1,1,1,"Binds the ß7 subunit of the integrins a4ß7 and aEß7, blocking interaction with their ligands.",,
5451,1392900,1121887,Folate receptor alpha inhibitor,10103,,INHIBITOR,1,1,1,,,
5452,1392903,1121890,Insulin-like growth factor I receptor antagonist,234,,ANTAGONIST,1,1,1,Blocks binding of IGF-1 to its receptor (IGF1R) and specifically inhibits the IGF-1-induced receptor autophosphorylation.,,
5453,1392907,1121894,Beta-nerve growth factor inhibitor,103854,,INHIBITOR,1,1,1,"Potent anti-IL-1ß neutralizing antibody, binds to a unique IL-1ß epitope that is proximal to, but does not overlap with the receptor/ligand interface.",,
5454,1392908,1121895,Insulin-like growth factor I receptor antagonist,234,,ANTAGONIST,1,1,1,Inhibits the high-affinity binding of IGF-I and IGF-II to IGF-IR preventing the subsequent triggering of the PI3K/Akt signaling pathway.,,
5455,1392909,1121896,Beta amyloid A4 protein binding agent,10656,,BINDING AGENT,1,1,1,Binds with sub-nanomolar affinity to a conformational epitope expressed on amyloid-ß fibrils. Neutralises disease-relevant aggregated forms of amyloid-beta.,,
5456,1392910,1121897,Interleukin-1 beta negative allosteric modulator,104335,,NEGATIVE ALLOSTERIC MODULATOR,1,1,1,"Potent anti-IL-1ß neutralizing antibody. Binds to a unique IL-1ß epitope that is proximal to, but does not overlap with the receptor/ligand interface.",,
5457,1392911,1121898,Carbonic anhydrase IX other,12952,,OTHER,1,1,1,"Binds to the CA9 (G250) antigen expressed on the tumour cells, thereby triggering an immune reaction called Antibody-Dependent Cellular Cytotoxicity (ADCC). Through this mechanism, effector cells, e.g. NK (natural killer) cells, of the immune system are activated to kill the tumour cells.",,
5458,1392919,1121906,Interleukin-13 inhibitor,109782,,INHIBITOR,1,1,1,,,
5459,1392926,1121913,Fusion glycoprotein F0 inhibitor,106144,,INHIBITOR,1,1,1,"Targets a highly conserved epitope in the A antigenic site of the RSV fusion (F) protein, which is important in the invasion of RSV from cell to cell.",,
5460,1392927,1121914,CD22 binding agent,11695,,BINDING AGENT,1,1,1,"The Fv at the amino terminus binds to CD22 present on the B-cell malignancy being targeted, and the carboxyl terminal lysine residue at position 613 is rapidly removed by plasma carboxypeptidase, generating a protein ending in REDL. Very soon after binding, the recombinant immunotoxin-CD22 complex is internalized through clathrin-coated pits into the endocytic compartment, where 2 steps occur: (i) reduction of the disulfide bond in domain II, and (ii) a furin-catalyzed cleavage in the middle of ",,
5461,1392935,1121922,Hepatocyte growth factor receptor antagonist,11451,,ANTAGONIST,1,1,1,"Binds to the extracellular domain of MET, preventing the binding of its ligand, hepatocyte growth factor (HGF).",,
5462,1392937,1121924,T-cell surface glycoprotein CD3 epsilon chain binding agent,233,,BINDING AGENT,1,1,1,"Modulates the T-cell receptor (TCR)–CD3 complex resulting in the cells becoming 'blind' to antigen (a process that is also known as antigenic modulation). In addition, the monoclonal antibody preferentially induces anergy or apoptosis of activated T cells through alterations in TCR-mediated signal transduction.",,
5463,1392947,1121934,Hepatocyte growth factor inhibitor,101207,,INHIBITOR,1,1,1,"In November 2014, Amgen halted all clinical studies of its compound rilotumumab (formerly AMG 102) in advanced gastric cancer. ",,
5464,1392955,1121942,Interleukin-6 inhibitor,104209,,INHIBITOR,1,1,1,It binds to soluble IL-6 and inhibits IL-6-mediated signal transducers and activation of transcription-3 phosphorylation (STAT-3).,,
5465,1392956,1121943,Beta amyloid A4 protein binding agent,10656,,BINDING AGENT,1,1,1,Targets the mid-region of the neurotoxic Amyloid ß peptide after it is produced. Neutralises disease-relevant aggregated forms of amyloid-beta.  Amyloid ß is an early biomarker of Alzheimer's disease pathology and the major component of plaques found in AD-affected brain.,,
5466,1392959,1121946,Tumor necrosis factor ligand superfamily member 13B inhibitor,106137,,INHIBITOR,1,1,1,High-affinity human antibody with neutralizing activity against membrane-bound and soluble BAFF.,,
5467,1392962,1121949,T-cell surface glycoprotein CD3 epsilon chain other,233,,OTHER,1,1,1,It binds to an epitope of the CD3-epsilon chain expressed on mature T cells. Modulates the T-cell receptor (TCR)–CD3 complex resulting in the cells becoming 'blind' to antigen (antigenic immunomodulation of the TCR complex).,,
5468,1392964,1121951,Tumor necrosis factor receptor superfamily member 10B agonist,103092,,AGONIST,1,1,1,"Mimics the natural receptor ligand TRAIL and binds to TRAIL-R2 (without crosslinking), activating signal transduction pathways that may result in tumor cell apoptosis and a reduction in tumor growth.",,
5469,1392965,1121952,Interleukin-13 inhibitor,109782,,INHIBITOR,1,1,1,IL-13-neutralizing IgG4 monoclonal antibody.,,
5470,1695941,1380127,Epidermal growth factor receptor erbB1 antagonist,9,,ANTAGONIST,1,1,1,"Effectively blocks EGF-R signaling, and can potently induce Ab-dependent cell-mediated cytotoxicity (ADCC).",,
5471,1695964,1380140,Sclerostin inhibitor,109783,,INHIBITOR,1,1,1,"Inhibits the protein sclerostin, and has a dual effect on bone, both increasing bone formation and decreasing bone breakdown.",,
5472,1696007,1380183,Mucin-16 other,109778,,OTHER,1,1,1,"Oregovomab targets the circulating tumour-associated antigen CA125. The complex formation of MAb-B43.13 with CA125 appears to facilitate activation of immune specific B and T Cell responses to CA125, otherwise not recognised by the immune system.",,
5473,1697060,1380245,Complement C5 inhibitor,106142,,INHIBITOR,1,1,1,,,
5474,1697122,1380307,B-lymphocyte antigen CD20 binding agent,181,,BINDING AGENT,1,1,1,"Humanized monoclonal antibody designed to target CD20-positive B cells, which are implicated in the inflammatory and neurodegenerative processes of multiple sclerosis.  By targeting CD20-positive B cells, this molecule depletes  (antibody-dependent cell-mediated cytotoxicity) pre-B cells and mature B cells without affecting plasma cells or progenitor cells in the bone marrow.",,
5475,1697142,1380327,Integrin alpha-5/beta-1 antagonist,104798,,ANTAGONIST,1,1,1,,,
5476,1697144,1380329,T-cell surface antigen CD4 other,10476,,OTHER,1,1,1,Induces a strong depletion of CD4-positive T cells (antibody-dependent cell-mediated cytotoxicity (ADCC)).,,
5477,1696156,1380474,TNF-alpha inhibitor,185,,INHIBITOR,1,1,1,Gene fusion of the extracellular portion of human type 1 TNFR with the constant domains of human IgG heavy chain (TNFR-IgG).,,
5478,1696176,1380494,CD22 other,11695,,OTHER,1,1,1,Binds to CD22-expressing lymphocytes. It is used to determined through nuclear imaging the extent of CD22-expressing lymphomas.,,
5479,1696239,1380644,Lipopolysaccharide (LPS) other,109804,,OTHER,1,1,1,Inhibits priming effect of lipopolysaccharide (LPS) on the release of reactive oxygen species. Enhances classical-pathway complement fixation.,"Although endotoxins vary across gram-negative species, it has been demonstrated in vitro to react wi",
5480,1696304,1380708,Ganglioside GD3 other,109803,,OTHER,1,1,1,"Mitumomab is an anti-idiotypic antibody that mimics GD3, a ganglioside that is expressed on the surface of tumor cells and is of neuroectodermal origin.  Induce antibodies against GD3 ganglioside.",,
5481,1697406,1380832,TNF-alpha inhibitor,185,,INHIBITOR,1,1,1,,,
5482,1697407,1380833,Beta-nerve growth factor inhibitor,103854,,INHIBITOR,1,1,1,,,
5483,1697439,1380842,Beta amyloid A4 protein binding agent,10656,,BINDING AGENT,1,1,1,Targets N-terminus of amyloid beta. Induces Fc receptor mediated fagocytosis of amyloid-beta peptide.,,
5484,1697475,1380877,CD22 binding agent,11695,,BINDING AGENT,1,1,1,"Whenit binds to the CD22 antigen on malignant B-cells, it is internalized into the cell, where the cytotoxic agent calicheamicin is released to destroy the cell.",,
5485,1697523,1380924,Cytotoxic T-lymphocyte protein 4 inhibitor,106143,,INHIBITOR,1,1,1,"Blocks the binding of the antigen-presenting cell ligands B7.1 and B7.2 to CTLA-4, resulting in inhibition of B7-CTLA-4-mediated downregulation of T-cell activation.",,
5486,1697540,1380941,Interleukin-4 receptor subunit alpha antagonist,109786,,ANTAGONIST,1,1,1,,,
5487,1696503,1380996,Interleukin-6 receptor alpha subunit antagonist,106134,,ANTAGONIST,1,1,1,,,
5488,1696586,1381077,T-cell surface glycoprotein CD3 epsilon chain inhibitor,233,,INHIBITOR,1,1,1, Non–FcR-binding anti-CD3 monoclonal antibody (mAb) directed against the invariant CD3e chain of the TCR.,,
5489,1696662,1381153,TNF-alpha inhibitor,185,,INHIBITOR,1,1,1,Reduces the concentration of interleukin-6 in serum.,,
5490,1696742,1381233,Transforming growth factor beta-2 inhibitor,108251,,INHIBITOR,1,1,1,,,
5491,1696925,1381416,Myeloid cell surface antigen CD33 other,81,,OTHER,1,1,1,Antibody-dependent cell mediated cytotoxixity. Complement mediated cytotoxicity.,,
5492,1696952,1381443,Leukocyte adhesion glycoprotein LFA-1 alpha inhibitor,190,,INHIBITOR,1,1,1,,,
5493,1696966,1381457,T-lymphocyte activation antigen CD80 inhibitor,106136,,INHIBITOR,1,1,1,Antibody-dependent cell-mediated cytotoxicity (ADCC).,,
5494,1696968,1381459,Basigin other,109788,,OTHER,1,1,1,"Depletes activated T cells (CD4+ and CD8+) and B cells via a complement-dependent cytotoxic mechanism, while resting lymphocytes are unaffected.",,
5495,1706824,1381801,Mucin-1 binding agent,109790,,BINDING AGENT,1,1,1,"The antibody is attached to the radioisotope Yttrium-90, which irradiates and destroys the cells bound by the antibody and those in close proximity.  Targets MUC1 that expressed by several types of secretory epithelial-derived cancers.",,Directed against the specific antigenic epitope PDTR sequence in the MUC1 tandem repeat.
5496,2583005,1381846,Receptor tyrosine-protein kinase erbB-3 inhibitor,102678,,INHIBITOR,1,1,1,,,
5497,1706942,1381887,"HLA class II histocompatibility antigen, DRB1-10 beta chain other",109791,,OTHER,1,1,1,Antibody-dependent cell-mediated cytotoxicity (ADCC).,,
5498,1707138,1382032,T-cell receptor antagonist,109802,,ANTAGONIST,1,1,1,"Targets aß heterodimer of the T cell receptor, resulting in modulation of the receptor of the surface of the targeted T cells and apoptosis, not mitogenic and has a reduced capacity to stimulate the production of inflammatory cytokines.",,
5499,2583121,2039224,Vascular endothelial growth factor A binding agent,187,,BINDING AGENT,1,1,1,"Binds to VEGFA, allowing the detection of VEGFA distribution using gamma scintigraphy.",,
5500,1707189,1382066,Urushiol inhibitor,109805,,INHIBITOR,1,1,1,,,"Reacts with the catechol moiety of urushiol, the region of the allergen being critically important i"
5501,1707216,1382093,Interleukin-1 alpha inhibitor,109792,,INHIBITOR,1,1,1,Prevents binding of IL1A to interleukin-1 receptor type 1.,,
5502,2583246,2039251,Carbonic anhydrase IX binding agent,12952,,BINDING AGENT,1,1,1,cG250 can be internalized by G250 antigen-expressing renal cell carcinoma (RCC) cells.,,
5503,1696468,1380979,Carbonic anhydrase IX binding agent,12952,,BINDING AGENT,1,1,1,"The antibody binds to G250 antigen, found on over 90 % of clear cell renal cell carcinomas, and can be visualised by means of positron emission tomography (PET).",,
5504,2583330,2039268,Carbonic anhydrase IX binding agent,12952,,BINDING AGENT,1,1,1,Radioimmunotherapy. The antibody can be internalized by G250 antigen-expressing renal cell carcinoma (RCC) cells.,,
5505,1707061,1626783,Subtilisin/kexin type 9 inhibitor,12353,,INHIBITOR,1,1,1,"PCSK9 causes the degradation of LDLR, then inhibiting PCSK9 would mean prolonging the lifespan of LDLR, which would lead to drastic reductions in plasma LDL-C levels.",,
5506,2583708,2039374,Unknown,,,,1,1,1,,,
5507,1699821,1376106,Voltage-gated calcium channel modulator,105734,,MODULATOR,1,1,1,Ligand for the voltage-gated calcium channel alpha-2-delta subunit.,,
5508,1700733,433297,GABA receptor alpha-1 subunit positive allosteric modulator,74,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,
5509,1699978,132234,GABA-A receptor; agonist GABA site agonist,104905,,AGONIST,1,1,1,Potent agonist at alpha4beta3delta-containing receptors.,,
5510,1937957,1592332,Nonstructural protein 5A inhibitor,108438,,INHIBITOR,1,1,1,,,
5511,2583260,1356484,"Hepatitis C virus serine protease, NS3/NS4A inhibitor",104803,,INHIBITOR,1,1,1,,,
5512,1705050,609761,Synaptic vesicle glycoprotein 2A modulator,31000,,MODULATOR,1,1,1,,,
5513,1706747,1926775,Protective antigen binding agent,101164,,BINDING AGENT,1,1,1,,,
5514,1392918,1121905,Interleukin 17A inhibitor,109547,,INHIBITOR,1,1,1,,,
5515,1695974,1380150,Interleukin-5 inhibitor,103470,,INHIBITOR,1,1,1,,,
5516,1976726,1626740,Apoptosis regulator Bcl-2 inhibitor,100304,,INHIBITOR,1,1,1,,,
5518,2583007,2039198,Programmed cell death 1 ligand 1 inhibitor,109807,,INHIBITOR,1,1,1,,,
5520,1701466,704633,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
5521,2583006,2039197,Plasminogen activator,12,,ACTIVATOR,1,1,1,,,
5522,2792167,675292,Acetylcholinesterase inhibitor,93,,INHIBITOR,1,1,1,Irreversible,,
5528,1392870,1121857,Tumor necrosis factor ligand superfamily member 13B inhibitor,106137,,INHIBITOR,1,1,1,Soluble receptor. Acts as a decoy receptor for TNFSF13 (APRIL) and TNFSF13B (BAFF).,,
5533,1696504,1382102,Growth/differentiation factor 2 inhibitor,116831,,INHIBITOR,1,1,1,Ligand trap for BMP9 and BMP10,,
5534,2472901,630553,Serotonin 6 (5-HT6) receptor antagonist,10627,,ANTAGONIST,1,1,1,,,
5535,1699500,1383550,Voltage-gated potassium channel blocker,105708,,BLOCKER,1,1,1,Potassium channel blocker that inhibits both transient outward (Ito) and delayed rectifier (IK) potassium currents.,,
5537,1705100,1379629,Kinetoplast DNA inhibitor,106220,,INHIBITOR,1,1,1,,,Binds to the DNA minor groove in AT sequences of at least four consecutive AT base pairs
5538,1695897,1380108,Interferon alpha/beta receptor agonist,106149,,AGONIST,1,1,1,,,
5540,1695906,1380112,TRAIL receptor-1 agonist,12693,,AGONIST,1,1,1,"Binds to and activates TRAIL receptors 1 and 2 (TRAIL-R1/R2), which may activate caspases and induce p53-independent apoptosis.",,
5541,1695930,1380122,Telomerase reverse transcriptase inhibitor,12622,,INHIBITOR,1,1,1,Competes with telomere binding leading to dose-dependent nihibition of telomerase (IC50 0.45µM) and progressively telomere shortening.,,Binds the template region of the RNA component of telomerase (hTR or hTERC)
5542,1695936,1380125,Blood group Rh(D) polypeptide inhibitor,114957,,INHIBITOR,1,1,1,,,
5543,1695942,1380128,Toll-like receptor 3 agonist,103039,,AGONIST,1,1,1,,,
5545,1695951,1380132,Erythropoietin receptor agonist,201,,AGONIST,1,1,1,,,
5547,1695959,1380136,Coagulation factor IX inhibitor,193,,INHIBITOR,1,1,1,"Blocks the factor VIIIa/IXa–catalyzed conversion of factor X to factor Xa. Itas antidote. B007, is an oligonucleotide complementary to a portion of RB006 that binds effectively to RB006, thereby neutralizing its anti–factor IXa activity.",,
5548,1695965,1380141,Potassium chelating agent,109707,,CHELATING AGENT,1,1,1,,,
5550,1696420,1380823,Vascular endothelial growth factor receptor 1 and 2 (Flt-1 and KDR) agonist,105010,,AGONIST,1,1,1,,,
5553,1696447,1380968,Telomerase reverse transcriptase inhibitor,12622,,INHIBITOR,1,1,1,"Competitive telomerase inhibitor, which binds directly to the active site of the enzyme, thus inhibiting its activity.",,Targets the template region of the human functional telomerase RNA (hTR) subunit.
5554,1696448,1380969,Triglyceride hydrolytic enzyme,109712,,HYDROLYTIC ENZYME,1,1,1,Lipases catalyse the hydrolysis of lipids.,,
5555,1696465,1380978,"HLA class II histocompatibility antigen, DRB1-15 beta chain modulator",116871,,MODULATOR,1,1,1,"Immunomodulator. Binds to antigenic peptide-presenting MHC Class II molecules,  HLA-DR2 (DRB1*1501) haplotype. ",,
5556,1696485,1380984,Antithrombin-III inhibitor,16,,INHIBITOR,1,1,1,Indireclyt inhibits factor Xa (FXa) via binding to Antithrombin III.,,
5558,1696495,1380989,Interferon lambda receptor agonist,116864,,AGONIST,1,1,1,,,
5559,1696499,1380993,Melanoma cells disrupting agent,81258,,DISRUPTING AGENT,1,1,1,Causes lysis of tumour cells.,,
5560,1696508,1381001,Dystrophin pre-mRNA positive modulator,116818,,POSITIVE MODULATOR,1,1,1,Induces specific exon skipping during messenger RNA (mRNA) splicing correcting the open reading frame of the DMD gene and thus to restore dystrophin expression. ,,
5562,1696859,1381350,Plasminogen activator,12,,ACTIVATOR,1,1,1,,Fibrin-selective.,
5565,1697291,1380544,Dystrophin pre-mRNA positive modulator,116818,,POSITIVE MODULATOR,1,1,1,"Phosphorodiamidate morpholino oligomer (PMO) that selectively binds to exon 51 of dystrophin pre-mRNA, restoring the open reading frame and ena-
bling production of functional truncated in-frame dystrophin protein. ",,Binds to exon 51 of dystrophin pre-mRNA.
5566,1697417,1380835,Insulin receptor agonist,35,,AGONIST,1,1,1,,,
5567,1697435,1380838,Granulocyte colony stimulating factor receptor agonist,207,,AGONIST,1,1,1,Long-acting granulocyte colony-stimulating factor (G-CSF) composed of a genetic fusion between recombinant human serum albumin and G-CSF.,,
5569,1697446,1380849,Interleukin 13 receptor binding agent,116865,,BINDING AGENT,1,1,1,Cytotoxic. Targets and kills tumor cells that express the IL13 receptor (IL13R).,,
5571,1697493,1380894,Tubulin stabiliser,104766,,STABILISER,1,1,1,,,
5574,1697548,1380949,Toll-like receptor 5 agonist,105414,,AGONIST,1,1,1,Binds to and activates TLR5 thereby stimulating tumor necrosis factor production and activating nuclear factor kappa B (NF-kB).,,
5575,1699209,421145,Type-1 angiotensin II receptor antagonist,115,,ANTAGONIST,1,1,1,,,
5577,1699354,56713,Protein farnesyltransferase inhibitor,104690,,INHIBITOR,1,1,1,"Inhibits isolated human FPT with IC50s of 0.86 nm and 7.9 nm observed for a lamin B peptide and for the K-RasB peptide, respectively. Competitive inhibitor for both the K-ras and lamin B1 peptide substrates (Ki = 0.5 nm) and noncompetitive for the farnesylpyrophosphate substrate.",,
5579,1699462,1376048,Serotonin 3 (5-HT3) receptor antagonist,105029,,ANTAGONIST,1,1,1,,,
5580,1699526,259664,P-glycoprotein 1 inhibitor,11398,,INHIBITOR,1,1,1,,Specifically inhibitS ABCB1 among ABC transporters (KD = 5.1 nM).,
5581,1699723,390556,Glutamate [NMDA] receptor negative allosteric modulator,104706,,NEGATIVE ALLOSTERIC MODULATOR,1,1,1,Noncompetitive binding to NMDA glutamate receptors,NMDA subtype non-selective ,
5582,1699742,1376063,Toll-like receptor 9 agonist,101567,,AGONIST,1,1,1,"Targets TLR9, thereby activating dendritic and B cells and stimulating cytotoxic T cell and antibody responses against tumor cells bearing tumor antigens",,
5583,1699745,1161875,Cholesteryl ester transfer protein inhibitor,10517,,INHIBITOR,1,1,1,,,
5584,1699747,87493,Type-1 angiotensin II receptor antagonist,115,,ANTAGONIST,1,1,1,,,
5585,1699749,1376066,DNA topoisomerase II inhibitor,104727,,INHIBITOR,1,1,1,"Intercalates into DNA and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis",,
5586,1699750,459679,Coagulation factor X inhibitor,194,,INHIBITOR,1,1,1,,,
5587,1699755,1376070,Phosphate sequestering agent,106163,,SEQUESTERING AGENT,1,1,1,"Acts in the GI tract as a non-calcium, non-metallic phosphate binder",,
5588,1699757,140637,Cholesteryl ester transfer protein inhibitor,10517,,INHIBITOR,1,1,1,,,
5589,1699768,1376080,Glutathione S-transferase Pi inhibitor,11416,,INHIBITOR,1,1,1,Ezatiostat is metabolized to TLK117. TLK117 selectively binds to and disrupts the interaction of GST P1-1 with JNK.,,
5591,1699772,71256,Tubulin inhibitor,104766,,INHIBITOR,1,1,1,Destabilizes microtubules and blocks cell cycle transition specifically at G2-M phase.,,Binding site of D-24851 does not overlap with tubulin binding sites of vincristine or colchicine.
5592,1699775,1376085,Neuronal acetylcholine receptor; alpha3/beta4 partial agonist,104288,,PARTIAL AGONIST,1,1,1,,,
5593,1699780,474601,Cathepsin K inhibitor,10495,,INHIBITOR,1,1,1,,,
5595,1699793,470953,Cytochrome P450 26A1 inhibitor,100146,,INHIBITOR,1,1,1,,,
5597,1699801,75302,Thrombin inhibitor,11,,INHIBITOR,1,1,1,"Reversible direct, selective thrombin inhibitor",,
5598,1699802,1376096,Tubulin stabiliser,104766,,STABILISER,1,1,1,,"Interacts with the Tubulin heterodimer, but shows preference to Tubulin beta III in neurons.",
5599,1699807,460014,Dipeptidyl peptidase IV inhibitor,11140,,INHIBITOR,1,1,1,,,
5601,1699811,1376101,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
5602,1699812,76250,DNA cross-linking agent,105574,,CROSS-LINKING AGENT,1,1,1,,,
5603,1699813,1376102,Dopamine receptors; D2 & D3 partial agonist,104754,,PARTIAL AGONIST,1,1,1,,,
5604,1699818,248537,Phospholipase A2 group IIA inhibitor,10584,,INHIBITOR,1,1,1,,Inhibits sPLA2 activity with an IC50=9 +/- 1 nM ,
5605,1699823,1376107,Transthyretin stabiliser,12704,,STABILISER,1,1,1,"Binds TTR with negative cooperativity and kinetically stabilizes WT-TTR and amyloidogenic mutant homotetramers under denaturing and physiologic conditions, inhibiting amyloidogenesis.",,Binds with high affinity to TTR at its Thyroxine (T4)-binding sites
5607,1699826,1376109,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,,,
5608,1699836,1376114,DNA cross-linking agent,105574,,CROSS-LINKING AGENT,1,1,1,Forms formaldehyde-mediated adducts with DNA (favours the CpG motif) and stimulates topoisomerase II-mediated DNA cleavage,,"Binds d(TCATATGA)2, d(CCGAGAATTCCGG)2 {double bulge}, d(TACGATGAGTA) : d(TACCATCGTA) {single bulge}"
5609,1699838,1376116,Progesterone receptor modulator,36,,MODULATOR,1,1,1,,,
5610,1699839,1376117,Aminopeptidase inhibitor,116855,,INHIBITOR,1,1,1,"Inhibition of the aminopeptidases disrupts normal protein turnover leading to peptide accumulation and decrease in free amino acids which leads to a stress response, amino acid depravation response, including activation of stress-related pathways such NF-¿B and pro-apoptotic regulators.",,
5611,1699842,1376119,Phosphodiesterase 5A inhibitor,3,,INHIBITOR,1,1,1,,,
5612,1699845,1376122,Tubulin inhibitor,104766,,INHIBITOR,1,1,1,"Chromene analog that binds to endothelial microtubules promoting mitotic spindle destabilization, inhibition of tubulin polymerization and eventual induction of endothelial cell apoptosis.",,Binds to the colchicine-binding site on beta-tubulin.
5613,1699847,37095,Steryl-sulfatase inhibitor,11267,,INHIBITOR,1,1,1,,,
5615,1699849,1376125,Tryptophan 5-hydroxylase inhibitor,116867,,INHIBITOR,1,1,1,,,
5616,1699854,1376127,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
5617,1699863,365195,Mycobacterium tuberculosis H37Rv inhibitor,104907,,INHIBITOR,1,1,1,"Inhibits the synthesis of mycobacterial cell wall components, methoxy mycolic acid and ketomycolic acid. Pro-drug activated by the enzyme deazaflavin dependent nitroreductase",,
5618,1699866,1266257,5-lipoxygenase activating protein inhibitor,10102,,INHIBITOR,1,1,1,,,
5619,1699867,560750,Tubulin inhibitor,104766,,INHIBITOR,1,1,1,Microtubule polymerization inhibitor,,"Lexibulin forms H-bonds with the main chain of betaV236 on H7, betaD249 on T7 and aT179 on T5 "
5620,1699872,1376137,Heat-stable enterotoxin receptor agonist,104277,,AGONIST,1,1,1,,,
5621,1699875,1266270,5-lipoxygenase activating protein inhibitor,10102,,INHIBITOR,1,1,1,,,
5622,1699881,1334901,Cholesteryl ester transfer protein inhibitor,10517,,INHIBITOR,1,1,1,Benzazepine-based CETP inhibitor,,
5623,1699891,1376149,Heat shock protein HSP90 inhibitor,104750,,INHIBITOR,1,1,1,"Resorcinolic triazolone inhibitor of Hsp90. Disrupts the association of HSP90 with its cochaperone, p23.",,Binds to the ATP-binding domain at the N-terminus of Hsp90
5624,1699892,191172,Serotonin 4 (5-HT4) receptor agonist,168,,AGONIST,1,1,1,,,
5625,1699899,1376153,Thrombopoietin receptor agonist,265,,AGONIST,1,1,1,,,
5626,1699901,1376154,26S proteosome inhibitor,106197,,INHIBITOR,1,1,1,Irreversible binding,,
5629,1700680,84655,Protein farnesyltransferase inhibitor,104690,,INHIBITOR,1,1,1,,,
5632,1701405,1763643,Toll-like receptor 4/MD-2 antagonist,107938,,ANTAGONIST,1,1,1,"Competes with LPS for binding to the TLR4 receptor complex blocking the activation of NF-kB and production of inflammatory mediators, such as TNF-a and IL6, in response to LPS",,Binds to the hydrophobic pocket of the MD2 portion of the TLR4 receptor complex
5633,1701407,1377237,Integrin alpha-4/beta-1 antagonist,104293,,ANTAGONIST,1,1,1,,,
5634,1701425,1377251,LDL-associated phospholipase A2 inhibitor,10138,,INHIBITOR,1,1,1,,,
5635,1701434,143870,DNA inhibitor,105574,,INHIBITOR,1,1,1,Competes with the transcription factor Sp1 for specific Sp1 DNA binding domains within gene promoter regions during DNA synthesis.,,Binds to the DNA major groove of specific Sp1 DNA binding domains within gene promoter regions.
5636,1701965,2197367,Ribonucleoside-diphosphate reductase RR1 inhibitor,104791,,INHIBITOR,1,1,1,"Irreversible ribonucleotide reductase inhibitor and DNA chain terminator. Phosphorylated by cellular kinases, tezacitabine is converted into its active diphosphate and triphosphate metabolites.",,
5637,1702263,399340,Histone deacetylase inhibitor,104681,,INHIBITOR,1,1,1,,,
5638,1702356,1248742,Coagulation factor X inhibitor,194,,INHIBITOR,1,1,1,,,
5639,1702370,1383165,Tubulin inhibitor,104766,,INHIBITOR,1,1,1,VFL bound to tubulin induces structural changes favoring an inhibition of GTP hydrolysis and inhibition of microtubule assembly,,Interacts with the so-called vinca-alkaloid-binding-domain of tubulin
5640,1702374,433425,Integrin alpha-V/beta-3 antagonist,104292,,ANTAGONIST,1,1,1,,,
5642,1702471,192574,Plasminogen activator inhibitor-1 inhibitor,10588,,INHIBITOR,1,1,1,,,
5643,1702478,599093,Dipeptidyl peptidase IV inhibitor,11140,,INHIBITOR,1,1,1,,,
5646,1702490,36237,Histone deacetylase inhibitor,104681,,INHIBITOR,1,1,1,,,
5647,1702491,139782,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,,,
5649,1702495,52812,Tubulin inhibitor,104766,,INHIBITOR,1,1,1,,,
5650,1702496,1377913,Tubulin disrupting agent,104766,,DISRUPTING AGENT,1,1,1,Reversible tubulin depolymerizing agent. ,,
5651,1702503,434834,Histone deacetylase 1 inhibitor,12697,,INHIBITOR,1,1,1,,"Isotype-selective Class I (HDAC1, -2, -3, and -8) and IV (HDAC11) HDAC inhibitor.",
5652,1702514,1340896,Sodium/glucose cotransporter 2 inhibitor,20092,,INHIBITOR,1,1,1,,,
5653,1702516,353628,Heat shock protein HSP90 inhibitor,104750,,INHIBITOR,1,1,1,,,
5654,1702517,1503492,Tubulin stabiliser,104766,,STABILISER,1,1,1,,,
5655,1702529,1377929,Phospholipase A2 group IIA inhibitor,10584,,INHIBITOR,1,1,1,,Pan-inhibitor of sPLA2 enzymes (groups: IIA IC50: 9–14 nM;  V IC50: 77 nM; and X IC50: 15 nM).,
5656,1702533,1377931,Kinesin-like protein 1 inhibitor,100166,,INHIBITOR,1,1,1,"Allosteric inhibitor of Eg5. ALso inhibits Eg5 localization to the mitotic spindle,",,
5657,1702540,1377935,DNA inhibitor,105574,,INHIBITOR,1,1,1,Enters cells by a nucleoside transporter-independent mechanism and exhibits longer intracellular retention with accompanying longer inhibition of DNA synthesis. It also causes transient inhibition of RNA synthesis,,
5658,1702541,319777,Nicotinamide phosphoribosyltransferase inhibitor,104106,,INHIBITOR,1,1,1,,,
5659,1702546,322351,20S proteosome inhibitor,116833,,INHIBITOR,1,1,1,"Irreversible proteasome inhibitor. Inhibits all three proteolytic chymotrypsin-like (CT-L, b5), trypsin-like (T-L, b2) and caspase-like (C-L, b1) activities. ",,
5660,1702547,1162025,Cardiac myosin activator,116866,,ACTIVATOR,1,1,1,Selectively activates the S1 domain of cardiac myosin.,,
5661,1702548,625898,Tubulin inhibitor,104766,,INHIBITOR,1,1,1,Tubulin-depolymerizing agent.,,NPI-2358 binds to the colchicine-binding site of tubulin.
5662,1702550,494280,"PARP 1, 2 and 3 inhibitor",109545,,INHIBITOR,1,1,1,,,
5663,1702559,1377941,Beta-glucocerebrosidase stabiliser,10733,,STABILISER,1,1,1,Specifically and reversibly binds GBA (GCase) in the ER with high affinity; this stabilizes the active form of the enzyme in the ER and increases trafficking of GBA to lysosomes,,
5664,1702564,1377945,Transthyretin stabiliser,12704,,STABILISER,1,1,1,,,Binds with high affinity to TTR at its Thyroxine (T4)-binding sites
5665,1702566,471176,Lysosomal alpha-glucosidase stabiliser,10977,,STABILISER,1,1,1,"Selectively and reversibly binds and stabilises the endogenous enzyme, facilitating proper protein folding and trafficking to lysosomes",,
5666,1702571,1377951,DNA inhibitor,105574,,INHIBITOR,1,1,1,Cytotoxic. Interferes with DNA synthesis by introducing single-strand DNA breaks leading to arrest of the cell division cycle at G2 phase and development of double-strand DNA breaks.,,
5667,1702574,1377953,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
5669,1702580,628723,Coagulation factor X inhibitor,194,,INHIBITOR,1,1,1,,,
5670,1702592,81559,GABA-B receptor agonist,104988,,AGONIST,1,1,1,,,
5672,1702608,1377981,Sodium/glucose cotransporter 2 inhibitor,20092,,INHIBITOR,1,1,1,,"SGLT2 selective. IC50 rSGLT2= 14.5nM; mSGLT2= 5.0 nM vs IC50 rSGLT1=8200 nM; IC50 mSGLT1, 1800 nM.",
5673,1702623,1377991,Caspase-8 inhibitor,10244,,INHIBITOR,1,1,1,Irreversible inhibitor,,
5674,1702625,651088,"PARP 1, 2 and 3 inhibitor",109545,,INHIBITOR,1,1,1,,,
5675,1702631,2197672,Heat shock cognate 71 kDa protein inhibitor,103588,,INHIBITOR,1,1,1,Immunomodulator. Inhibits the ability of HSC70 to refold denatured protein,,
5679,1702659,1265566,Cytochrome P450 17A1 inhibitor,12949,,INHIBITOR,1,1,1,,,
5681,1702665,624225,Poly [ADP-ribose] polymerase 2 inhibitor,100933,,INHIBITOR,1,1,1,,IC(50) inhibition PARP2 (2.1 nM),
5682,1702676,1378024,Dipeptidyl peptidase IV inhibitor,11140,,INHIBITOR,1,1,1,,,
5683,1702683,1142547,Sodium/glucose cotransporter 2 inhibitor,20092,,INHIBITOR,1,1,1,,It shows >2000-fold selectivity for SGLT2 inhibition (relative to SGLT1) in vitro,
5684,1702686,1378032,Dipeptidyl peptidase IV inhibitor,11140,,INHIBITOR,1,1,1,,,
5685,1702689,1378035,Granulocyte colony stimulating factor receptor agonist,207,,AGONIST,1,1,1,,,
5688,1703285,122252,Adenosine A2a receptor antagonist,252,,ANTAGONIST,1,1,1,,,
5689,1703548,6706,Cyclooxygenase-2 inhibitor,126,,INHIBITOR,1,1,1,,Selectively inhibits COX-2 (IC(50) = 1.1 +/- 0.1microM) compared with COX-1 IC(50)=116 +/- 8 microM.,
5691,1704067,367160,Serotonin 1a (5-HT1a) receptor partial agonist,51,,PARTIAL AGONIST,1,1,1,,"High affinity: D3 and D4 receptors. Low affinity: a1, 5HT2A, 5HT2C, H1 and muscarinic receptors ",
5692,1704507,1379068,Neuronal acetylcholine receptor; alpha9/alpha10 antagonist,104899,,ANTAGONIST,1,1,1,,,
5694,1705040,1379582,GABA-B receptor agonist,104988,,AGONIST,1,1,1,,,
5695,1705042,1379583,DNA topoisomerase I inhibitor,62,,INHIBITOR,1,1,1,,,
5698,1705064,1142450,Purinergic receptor P2Y2 agonist,11907,,AGONIST,1,1,1,Deoxycytidine-uridine dinucleotide with agonist activity at the P2Y2 receptor,,
5700,1705078,565417,Purine nucleoside phosphorylase inhibitor,12690,,INHIBITOR,1,1,1,Highly specific and potent transition state analog inhibitor of PNP that inhibits T-cell proliferation.,,
5702,1705093,1379624,Nucleotide-binding oligomerization domain-containing protein 2 other,103699,,OTHER,1,1,1,Immunostimulant,,
5703,1705098,1379628,Apoptosis regulator Bcl-2 inhibitor,100304,,INHIBITOR,1,1,1,,,BH3 binding groove 
5705,1705122,317540,Gamma-secretase modulator,104717,,MODULATOR,1,1,1,,,
5710,1705221,329498,Caspase inhibitor,116869,,INHIBITOR,1,1,1,,,
5711,1705222,302799,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,,,
5712,1705227,447948,Gamma-secretase inhibitor,104717,,INHIBITOR,1,1,1,Decreases dose-dependently Aß production in the human central nervous system,,
5713,1705229,1179259,Cyclooxygenase-2 inhibitor,126,,INHIBITOR,1,1,1,,,
5717,1705236,103395,DNA topoisomerase II inhibitor,104727,,INHIBITOR,1,1,1,"First-in-class topoisomerase II poison and inhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, and apoptosis",,
5719,1705240,434796,Serotonin 2a (5-HT2a) receptor antagonist,107,,ANTAGONIST,1,1,1,,,
5722,1705245,477344,Tubulin disrupting agent,104766,,DISRUPTING AGENT,1,1,1,,,Binds to the same (or nearby) sites on ß-tubulin as colchicine 
5723,1705246,619010,Gamma-secretase inhibitor,104717,,INHIBITOR,1,1,1,,,
5725,1705254,388574,Monoamine oxidase B inhibitor,104,,INHIBITOR,1,1,1,Highly selective and reversible MAO-B inhibitor ,,
5726,1705255,649450,Glycine transporter 1 inhibitor,11682,,INHIBITOR,1,1,1,Noncompetitive glycine reuptake inhibitor,Selective for GlyT1. No effect on GlyT2-mediated glycine uptake,
5727,1705293,21393,Hemoglobin HbA negative modulator,104753,,NEGATIVE MODULATOR,1,1,1,"Reduces hemoglobin-oxygen binding affinity facilitating oxygen release from hemoglobin, resulting in increases in tissue partial pressure of oxygen",,
5728,1705782,515421,Gamma-secretase inhibitor,104717,,INHIBITOR,1,1,1,Thiophene sulfonamide gamma-secretase inhibitor (GSI) that selectively inhibits cleavage of APP over Notch.,,
5729,1705783,154,LDL-associated phospholipase A2 inhibitor,10138,,INHIBITOR,1,1,1,Reversible oral inhibitor ,,
5730,1705880,280181,DNA cross-linking agent,105574,,CROSS-LINKING AGENT,1,1,1,Forms formaldehyde-mediated adducts with DNA (favours the CpG motif) and stimulates topoisomerase II-mediated DNA cleavage,,"Binds d(TCATATGA)2, d(CCGAGAATTCCGG)2 {double bulge}, d(TACGATGAGTA) : d(TACCATCGTA) {single bulge}"
5732,1705989,2197560,Sodium/hydrogen exchanger 3 inhibitor,12588,,INHIBITOR,1,1,1,Anti-angiogenic amino sterol,,
5733,1706027,183934,Heat shock protein HSP90 inhibitor,104750,,INHIBITOR,1,1,1,Disrupts the Hsp90 chaperone complex. ,,"Binds to a highly conserved 25 kDa N-terminal domain of Hsp90, a binding site for ATP  "
5734,1706031,234541,Dipeptidyl peptidase IV inhibitor,11140,,INHIBITOR,1,1,1,,,
5737,1706054,467796,DNA topoisomerase II alpha inhibitor,63,,INHIBITOR,1,1,1,"Intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication.",,
5740,1706071,508147,Apoptosis regulator Bcl-2 inhibitor,100304,,INHIBITOR,1,1,1,,"High affinity for Bcl-xL, Bcl-2, and Bcl-w (Ki =1 nmol/L).","Occupies the BH3 binding groove of Bcl-xL, Bcl-2, and Bcl-w."
5743,1706252,687792,Selectin inhibitor,116868,,INHIBITOR,1,1,1,,,
5744,1706298,121457,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
5746,1706409,235143,Squalene synthetase inhibitor,11120,,INHIBITOR,1,1,1,,,
5748,1706413,514258,Kappa opioid receptor agonist,137,,AGONIST,1,1,1,,,
5752,1706443,1380088,DNA topoisomerase II alpha inhibitor,63,,INHIBITOR,1,1,1,,,
5753,1706446,1380091,Retinoid isomerohydrolase inhibitor,116832,,INHIBITOR,1,1,1,"Nonretinoid compound with a unique mode of action in the retinal pigment epithelium, where it modulates the biosynthesis of visual chromophore through its effect on retinal pigment epithelium-specific 65 kDa protein isomerase. ",,
5754,1706460,1380099,Retinoid isomerohydrolase inhibitor,116832,,INHIBITOR,1,1,1,,,
5758,1879128,1540481,Glutamate [NMDA] receptor negative allosteric modulator,104706,,NEGATIVE ALLOSTERIC MODULATOR,1,1,1,Noncompetitive binding to NMDA glutamate receptors,NMDA subtype non-selective ,
5759,1879129,1175867,Free fatty acid receptor 1 positive allosteric modulator,100431,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,Potentiates insulin secretion in a glucose-dependent manner by activating FFAR1 expressed in pancreatic ß cells,,Binds to a non-canonical site created between TM helices 3–5 and the extracellular loop 2 regions
5760,1879136,1540486,Monoamine transporter inhibitor,105759,,INHIBITOR,1,1,1,"Selectively inhibits the reuptake of serotonin, norepinephrine, and dopamine",,
5761,1879146,693510,NEDD8 activating enzyme inhibitor,116863,,INHIBITOR,1,1,1,Potent inhibitor of NEDD8 activating enzyme (NAE) (IC50 = 0.004uM).,,
5762,1879149,1540496,Diacylglycerol O-acyltransferase 1 inhibitor,101414,,INHIBITOR,1,1,1,,,
5763,1879156,2039417,P-selectin antagonist,12723,,ANTAGONIST,1,1,1,,"E-selectin IC50 = 4.3uM, P-selectin IC50 = 423uM and L-selectin IC50 = 337uM",
5766,1879165,1540511,Synaptic vesicular amine transporter inhibitor,162,,INHIBITOR,1,1,1,,,
5767,1879166,1167181,Quinone reductase 1) modulator,13055,,MODULATOR,1,1,1,,,
5769,1937940,1351456,Integrin alpha-L/beta-2 (LFA-1) antagonist,106151,,ANTAGONIST,1,1,1,,,Binds with high-affinity to the site I domain of the aL subunit on LFA-1
5770,1937949,1592325,Sodium/glucose cotransporter 1 inhibitor,18036,,INHIBITOR,1,1,1,,"Human SGLT1 IC50=36 nmol/l, human SGLT2 IC50=1.8 nmol/l ",
5771,1937958,1592333,Ileal bile acid transporter inhibitor,12909,,INHIBITOR,1,1,1,Inhibits ileal bile acid reuptake via the inhibition of Ileal sodium/bile acid cotransporter,,
5773,1937968,1592339,Folate receptor alpha binding agent,10103,,BINDING AGENT,1,1,1,"The folate moiety of vintafolide binds to folic acid receptors on the tumor cell surface and the agent is internalized via folate receptor-mediated endocytosis, delivering the tubulin-binding DAVLBH moiety directly into the tumor cell; DAVLBH binding to tubulin results in the disruption of microtubule assembly-disassembly dynamics, cell cycle arrest, and tumor cell apoptosis",,
5774,1937969,1592340,cIAP1/cIAP2 inhibitor,107891,,INHIBITOR,1,1,1,"Specifically target cIAP1 and cIAP2 for degradation, resulting in a switch in TNFR signaling that leads to activation of caspase-8 and induction of apoptosis ",Specifically targets cIAP1 and cIAP2,
5777,1937980,1592347,Fast skeletal troponin complex activator,116862,,ACTIVATOR,1,1,1,,,
5778,1938025,1592376,DNA topoisomerase I inhibitor,62,,INHIBITOR,1,1,1,"Its active metabolite, 7-ethyl-10-hydroxycamptothecin, binds to and stabilizes the topoisomerase I-DNA complex, leading to single- and double-stranded DNA breaks and inhibiting DNA repair.",,
5780,1938029,2335134,Heparanase inhibitor,11653,,INHIBITOR,1,1,1,,,
5783,1938047,1592382,DNA topoisomerase I inhibitor,62,,INHIBITOR,1,1,1,,,
5784,1976725,277493,Cyclooxygenase-2 inhibitor,126,,INHIBITOR,1,1,1,,,
5785,1976732,1528018,Hypoxia-inducible factor prolyl hydroxylase inhibitor,116860,,INHIBITOR,1,1,1,,,
5789,1976743,1626749,Poly [ADP-ribose] polymerase 2 inhibitor,100933,,INHIBITOR,1,1,1,,,
5790,1976750,1626751,Poly [ADP-ribose] polymerase-1 inhibitor,11663,,INHIBITOR,1,1,1,,Potent PARP1/2 inhibitor (PARP1 IC50 = 0.57 nmol/L). PARP1 Ki=1.2 nmol/L. PARP2 Ki= 0.85 nmol/L.,
5791,1976753,1626753,DNA cross-linking agent,105574,,CROSS-LINKING AGENT,1,1,1,,,
5798,1980355,660844,DNA topoisomerase II alpha inhibitor,63,,INHIBITOR,1,1,1,"Intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication.",,
5799,2138981,1763538,Platelet-derived growth factor subunit B inhibitor,107993,,INHIBITOR,1,1,1,"Specifically supresses PDGF-B, thereby limiting the recruitment and maturation of pericytes, which in turn induces neovascular regression.",,
5802,2139003,1763557,Monoamine transporter inhibitor,105759,,INHIBITOR,1,1,1,"Dopamine and norepinephrine reuptake inhibitor 
Dasotraline acts as a potent inhibitor of human DA transporters (DAT; dopamine uptake IC50 3¿nM) and NE transporters (NET; norepinephrine uptake IC50 4¿nM), and a weaker inhibitor of human serotonin transporters (SERT; serotonin uptake IC50 15¿nM)",,
5804,2139044,1763589,Sodium/hydrogen exchanger 3 inhibitor,12588,,INHIBITOR,1,1,1,"Acts locally in the gut, where it reduces absorption of sodium and phosphate.",,
5805,2472655,1926756,DNA cross-linking agent,105574,,CROSS-LINKING AGENT,1,1,1,,,
5806,2472675,1926760,Serine/threonine-protein kinase Chk1 inhibitor,12967,,INHIBITOR,1,1,1,Selective ATP competitor inhibitor of Chk1 and Chk2 proteins,,
5807,2472681,429507,DNA inhibitor,105574,,INHIBITOR,1,1,1,"Activated by a process that involves a 1-electron reduction mediated by ubiquitous cellular reductases to generate a radical anion prodrug (RP). When exposed to severe hypoxic conditions (<0.5% O2), the RP can either fragment directly or undergo further reduction at the nitroimidazole site of the prodrug, leading to fragmentation and the release of Bromo isophosphoramide mustard (Br-IPM), a potent DNA alkylating agent",,
5811,2472832,1926837,Hypoxia-inducible factor prolyl hydroxylase inhibitor,116860,,INHIBITOR,1,1,1,,,
5813,2472979,1926919,Elastin proteolytic enzyme,115673,,PROTEOLYTIC ENZYME,1,1,1,Recombinant human chymotrypsin-like elastase family member 1 (CELA1) shown to cleave the elastin component of elastic fibers.,,
5814,2473098,1589794,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
5815,2473238,1927034,Exportin-1 inhibitor,101280,,INHIBITOR,1,1,1,,,
5818,2473406,700566,"Hepatitis C virus serine protease, NS3/NS4A inhibitor",104803,,INHIBITOR,1,1,1,,,
5819,2473550,1166082,Sodium/glucose cotransporter 2 inhibitor,20092,,INHIBITOR,1,1,1,INHIBITOR,,
5820,2473672,1927218,"Indoleamine 2,3-dioxygenase inhibitor",100643,,INHIBITOR,1,1,1,,,
5821,2583091,520269,Phosphodiesterase 4 inhibitor,104679,,INHIBITOR,1,1,1,,,
5822,2583179,318390,Cannabinoid CB1 receptor negative allosteric modulator,87,,NEGATIVE ALLOSTERIC MODULATOR,1,1,1,,,
5826,2473550,1166082,Sodium/glucose cotransporter 2 inhibitor,20092,,INHIBITOR,1,1,1,,,
5827,1702540,1377935,RNA inhibitor,105575,,INHIBITOR,1,1,1,Enters cells by a nucleoside transporter-independent mechanism and exhibits longer intracellular retention with accompanying longer inhibition of DNA synthesis. It also causes transient inhibition of RNA synthesis,,
5829,1704507,1379068,Glutamate [NMDA] receptor antagonist,104706,,ANTAGONIST,1,1,1,,,
5830,1705098,1379628,Apoptosis regulator Bcl-X inhibitor,100217,,INHIBITOR,1,1,1,,,
5831,1705098,1379628,Apoptosis regulator Bcl-W inhibitor,100476,,INHIBITOR,1,1,1,,,
5832,1705098,1379628,Induced myeloid leukemia cell differentiation protein Mcl-1 inhibitor,100468,,INHIBITOR,1,1,1,,,
5833,1705098,1379628,Bcl-2-related protein A1 inhibitor,102423,,INHIBITOR,1,1,1,,,
5834,1705098,1379628,Bcl-2-like protein 10 inhibitor,102637,,INHIBITOR,1,1,1,,,
5835,1976725,277493,Carbonic anhydrase II inhibitor,15,,INHIBITOR,1,1,1,,,One polmacoxib molecule binds the active site of CA II
5836,1976725,277493,Carbonic anhydrase I inhibitor,10193,,INHIBITOR,1,1,1,,,Three polmacoxib molecule binds the active site of CA II
5837,1699813,1376102,Serotonin 1a (5-HT1a) receptor agonist,51,,AGONIST,1,1,1,,,
5838,1879156,2039417,Selectin E antagonist,11517,,ANTAGONIST,1,1,1,,"E-selectin IC50 = 4.3uM, P-selectin IC50 = 423uM and L-selectin IC50 = 337uM",
5839,1879156,2039417,Leukocyte adhesion molecule-1 antagonist,12721,,ANTAGONIST,1,1,1,,"E-selectin IC50 = 4.3uM, P-selectin IC50 = 423uM and L-selectin IC50 = 337uM",
5841,1937949,1592325,Sodium/glucose cotransporter 2 inhibitor,20092,,INHIBITOR,1,1,1,,"Human SGLT1 IC50=36 nmol/l, human SGLT2 IC50=1.8 nmol/l ",
5842,1976750,1626751,Poly [ADP-ribose] polymerase 2 inhibitor,100933,,INHIBITOR,1,1,1,,Potent PARP1/2 inhibitor (PARP1 IC50 = 0.57 nmol/L). PARP1 Ki=1.2 nmol/L. PARP2 Ki= 0.85 nmol/L.,
5843,1705236,103395,DNA inhibitor,105574,,INHIBITOR,1,1,1,"First-in-class topoisomerase II poison and inhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, and apoptosis",,
5844,1976743,1626749,Poly [ADP-ribose] polymerase-1 inhibitor,11663,,INHIBITOR,1,1,1,,,
5845,1701407,1377237,Integrin alpha-4/beta-7 antagonist,104768,,ANTAGONIST,1,1,1,,,
5846,1702503,434834,Histone deacetylase 2 inhibitor,11206,,INHIBITOR,1,1,1,,"Isotype-selective Class I (HDAC1, -2, -3, and -8) and IV (HDAC11) HDAC inhibitor.",
5847,1702503,434834,Histone deacetylase 3 inhibitor,11208,,INHIBITOR,1,1,1,,"Isotype-selective Class I (HDAC1, -2, -3, and -8) and IV (HDAC11) HDAC inhibitor.",
5848,1702503,434834,Histone deacetylase 11 inhibitor,12021,,INHIBITOR,1,1,1,,"Isotype-selective Class I (HDAC1, -2, -3, and -8) and IV (HDAC11) HDAC inhibitor.",
5849,1702503,434834,Histone deacetylase 8 inhibitor,10869,,INHIBITOR,1,1,1,,"Isotype-selective Class I (HDAC1, -2, -3, and -8) and IV (HDAC11) HDAC inhibitor.",
5850,1706071,508147,Apoptosis regulator Bcl-X inhibitor,100217,,INHIBITOR,1,1,1,,"High affinity for Bcl-xL, Bcl-2, and Bcl-w (Ki =1 nmol/L).","Occupies the BH3 binding groove of Bcl-xL, Bcl-2, and Bcl-w."
5851,1706071,508147,Apoptosis regulator Bcl-W inhibitor,100476,,INHIBITOR,1,1,1,,"High affinity for Bcl-xL, Bcl-2, and Bcl-w (Ki =1 nmol/L).","Occupies the BH3 binding groove of Bcl-xL, Bcl-2, and Bcl-w."
5853,1702623,1377991,Caspase-1 inhibitor,11624,,INHIBITOR,1,1,1,Irreversible inhibitor,,
5854,1702623,1377991,Caspase-9 inhibitor,12014,,INHIBITOR,1,1,1,Irreversible inhibitor,,
5855,2472675,1926760,Serine/threonine-protein kinase Chk2 inhibitor,10531,,INHIBITOR,1,1,1,Selective ATP competitor inhibitor of Chk1 and Chk2 proteins,,
5856,1938029,2335134,Basic fibroblast growth factor inhibitor,11729,,INHIBITOR,1,1,1,PI-88 acts as a competitive inhibitor of FGF-2 binding to cell surface and matrix HSPG. ,,
5865,1938029,2335134,Acidic fibroblast growth factor inhibitor,10101,,INHIBITOR,1,1,1,,,
5866,1938029,2335134,Vascular endothelial growth factor A inhibitor,187,,INHIBITOR,1,1,1,,,
5867,1392870,1121857,Tumor necrosis factor ligand superfamily member 13 inhibitor,115397,,INHIBITOR,1,1,1,Soluble receptor. Acts as a decoy receptor for TNFSF13 (APRIL) and TNFSF13B (BAFF).,,
5868,1695906,1380112,Tumor necrosis factor receptor superfamily member 10B agonist,103092,,AGONIST,1,1,1,"Binds to and activates TRAIL receptors 1 and 2 (TRAIL-R1/R2), which may activate caspases and induce p53-independent apoptosis.",,
5869,1696448,1380969,Polypeptides proteolytic enzyme,106160,,PROTEOLYTIC ENZYME,1,1,1,Proteases catalyse the hydrolysis of proteins into smaller polypeptides or amino acids.,,
5870,1696448,1380969,Starch hydrolytic enzyme,106159,,HYDROLYTIC ENZYME,1,1,1,Amylases catalyse the hydrolysis of polyssacharides into sugars.,,
5871,1702374,433425,Integrin alpha-V/beta-5 antagonist,104830,,ANTAGONIST,1,1,1,,,
5872,1702529,1377929,Group X secretory phospholipase A2 inhibitor,11500,,INHIBITOR,1,1,1,,,
5873,1702529,1377929,Phospholipase A2 group V inhibitor,12851,,INHIBITOR,1,1,1,,,
5874,1343902,190484,Dihydrofolate reductase inhibitor,102873,,INHIBITOR,1,1,1,"PAS is incorporated into the folate pathway by dihydropteroate synthase (DHPS) and dihydrofolate synthase (DHFS) to generate a hydroxyl dihydrofolate antimetabolite, which in turn inhibits DHFR enzymatic activity. Mechanism in Crohn's disease/ulcerative colitis may be through PPAR-gamma/NF-kappa-B inhibition",,
5875,1343268,5028,CRL4(CRBN) E3 ubiquitin ligase inhibitor,116917,,INHIBITOR,1,1,1,,,Cereblon
5876,1343323,63649,CRL4(CRBN) E3 ubiquitin ligase inhibitor,116917,,INHIBITOR,1,1,1,,,Cereblon
5877,1706020,63100,CRL4(CRBN) E3 ubiquitin ligase inhibitor,116917,,INHIBITOR,1,1,1,,,Cereblon
5878,1696003,1380179,Lipopolysaccharide (LPS) sequestering agent,109804,,SEQUESTERING AGENT,1,1,1,"Binding of opebacan to LPS precludes LPS binding to both lipopolysaccharide-binding protein (LBP) and LPS receptors such as TLR4, thus inhibiting LPS-induced inflammation, including TNFα production.",,
5879,1696029,1380347,Fibroblast growth factor receptor 2 agonist,10264,,AGONIST,1,1,1,"It binds to the FGF2 receptor and stimulates the proliferation of fibroblasts, epithelial cells, vascular smooth muscle cells, vascular endothelial cells, peridontal and bone tissues. ",,
5880,1696241,1380646,GDNF family receptor alpha-1 agonist,116922,,AGONIST,1,1,1,"Neuroprotective and neuroregenerative effects. Through interactions with its GFRalpha1 coreceptor, Glial cell line-derived NTF (GDNF) signals mainly via the transmembrane Ret receptor tyrosine kinase, thereby activating MEK/MAPK, PI3 kinase (PI3K)/Akt, Src, and PLC gamma pathways, mediating neuronal migration, differentiation, growth, and survival.",,
5882,1696341,1380745,tRNA hydrolytic enzyme,116928,,HYDROLYTIC ENZYME,1,1,1,"Ranpirnase binds to the cell surface and uses the energy-dependent endocytic process to penetrate into the cell, routed through the Golgi apparatus to the cytosol, where it preferentially degrades tRNA (but not ribosmal and mRNA) by catalyzing the cleavage of the P-O5′ bond of RNA on the 3′ side of pyrimidine nucleosides. This RNA degradation leads to inhibition of protein synthesis and, ultimately, to the cytostatic and cytotoxic activity of ranpirnase.",,
5884,1699203,67050,Cyclooxygenase-2 inhibitor,126,,INHIBITOR,1,1,1,"Upon intravenous or intramuscular administration, parecoxib is hydrolyzed by hepatic carboxyesterases to its active form, valdecoxib. Valdecoxib selectively binds to and inhibits COX-2.  This prevents the conversion of arachidonic acid into prostaglandins, which are involved in the regulation of pain, inflammation, and fever.",,
5886,1699467,1352913,Phosphodiesterase 3 inhibitor,104707,,INHIBITOR,1,1,1,"It is a Ca2+ sensitizer. It acts through direct binding with troponin-C thereby increasing the affinity of troponin-C for Ca2+ in a Ca2+ dependent manner. It has phosphodiesterase-III inhibitory properties. It also has a vasodilatory effect, by opening adenosine triphosphate (ATP)-sensitive potassium channels in vascular smooth muscle to cause smooth muscle relaxation.",,
5887,1699492,992582,GABA-A receptor; anion channel positive allosteric modulator,104688,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,"It binds to both, synaptic and extrasynaptic GABA A receptors and acts most potently and effectively at GABA A receptors containing the delta-subunits, potentiating both tonic and phasic inhibition.",,
5889,1699548,348717,Photosensitizer,,,,1,1,1,"Temoporfin is taken up by tumor cells. Its activity is initiated by photoactivation with non-thermal light at a wavelength of 652 nm. The cytotoxic effect is mediated through the generation of highly reactive oxygen species, such as singlet oxygen, resulting from intracellular interaction of temoporﬁn with light and oxygen.  These reactive oxygen species cause the  loss of cell viability.",,
5890,1699551,59311,Acidic fibroblast growth factor inhibitor,10101,,INHIBITOR,1,1,1,"Potent inhibitor of fibroblast growth factor-induced angiogenesis through binding to FGF1. Also blocks binding several other growth factors to their receptors. Competitive inhibitor of GAGs and heparin, has been shown to have antiviral activity (HIV,  HSV-1, HBV, HCV, dengue virus, EV71, Rift Valley Fever Virus, CHIKV and EBOV). Non-specific potent inhibitor of reverse transcriptases of several retroviruses (HTLV-III/LAV) and also inhibits DNA polymerases (DNA primase, DNA polymerase alpha).",,"Binds to fibroblast growth factor 1 in a hydrophobic manner at L14, C16, L133, and L135 residues"
5891,1699583,93440,Arachidonate 5-lipoxygenase inhibitor,55,,INHIBITOR,1,1,1,A reversible 5-lipoxygenase inhibitor resulting in potent and selective inhibition of leukotriene formation.,,
5892,1699664,496771,Protein P inhibitor,116923,,INHIBITOR,1,1,1,"Clevudine is phosphorylated inside the cell to its active form, clevudine triphosphate (clevudine-TP). Clevudine-TP binds to the viral polymerase active site (or a site very close to it) inhibiting the protein priming and viral DNA synthesis. It is suggested that its binding to the viral polymerase active site alters its structure such that the viral polymerase is unable to bind or incorporate any of the natural dNMP substrates.",,
5893,1699971,197166,DNA inhibitor,105574,,INHIBITOR,1,1,1,"Alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle.",,
5894,1700003,21698,Nischarin agonist,11684,,AGONIST,1,1,1,"Activates I1 imidazoline receptors in the rostal ventrolateral medulla (RVLM). The result is the inhibition of peripheral alpha-adrenergic tone, and the decrease of blood pressure, due to a fall in systemic vascular resistant.",,
5895,1700027,23430,Matrix metalloproteinase 9 inhibitor,12592,,INHIBITOR,1,1,1,Inhibits matrix metalloproteinase (MMP) activity by specifically interacting with the Zn2+ in their catalytic site. This compound inhibits MMPs potently and specifically with 50% inhibitory concentrations (IC50S) against most members of the MMP family in the nanomolar range.,,
5896,1700052,519284,Serine/threonine-protein kinase BGLF4 inhibitor,116924,,INHIBITOR,1,1,1,"Inhibits the Epstein-Barr virus (EBV) protein kinase (BGLF4), resulting in inhibition of phosphorylation of the EBV DNA processivity factor BMRF1.",,
5897,1700182,1376249,Unknown,,,,1,1,1,"Interaction mechanism poorly understood. N-terminus of thymalfasin interacts with negative regions of membranes due to the exposure of phosphatidylserine. Once N-terminus inserted into the membrane, the rest may interact with nearby proteins acting as effectors and causing a biological signaling cascade. It induces maturation in T-cells and in dendritic cells. Induces gene expression of Toll-like receptors, interleukin (IL-12) and cytokines. Binds to plasma protein albumin (HSA).",,
5898,1700589,490151,Alpha glucosidase inhibitor,116927,,INHIBITOR,1,1,1,"Voglibose inhibits, in a competitive way, maltase and sucrase enzymes (alpha-glucosidases) in the small intestine (IC50=0.015uM for maltase enzymes and 0.0046uM for sucrase enzymes).  This prevents the breakdown of larger carbohydrates into glucose and decreases the rise in postprandial blood glucose levels.",,
5899,1700645,88246,Dopamine D1 receptor antagonist,88,,ANTAGONIST,1,1,1,It reduces self-injurious behavior in a dose related manner. ,,
5900,1700651,317909,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,"Dexibuprofen works by blocking the cyclo-oxygenase (COX-1, COX2) enzymes. These enzymes are involved in the production of prostaglandins. Some prostaglandins are produced at sites of injury or damage, and cause pain and inflammation. By blocking the effect of COX enzymes, fewer prostaglandins are produced, which means pain and inflammation are eased.",,
5901,1700714,14263,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,"It acts by binding to the norepinephrine transporter and blocking reuptake of extracellular norepinephrine (noradrenaline) back into the terminals. A meta-analysis showed that reboxetine (marketed by Pfizer in Europe, but not in the U.S. ) lacks efficacy.",High selectivity for NET over SERT/DAT. Low affinity for monoamine/histamine/ACh receptors,
5902,1700728,115967,Type-1 angiotensin II receptor antagonist,115,,ANTAGONIST,1,1,1,"This drug is sequentially metabolized by the P450 enzyme system, first to form a hydroxy-intermediate that is then biotransformed to enoltasosartan, another active compound that presents in vitro a higher affinity for the AngII subtype-1 receptors than the parent compound.",,
5903,1700752,936464,Serotonin 1a (5-HT1a) receptor agonist,51,,AGONIST,1,1,1,"It has neurotrophic and neuroprotective activities. Although its mechanism of action is not fully understood, xaliproden appears to either mimic the effects of neurotrophins or stimulate their synthesis, thereby stimulating neuronal cell differentiation and proliferation and inhibiting neuronal cell death.",,"It binds competitively, and with high affinity (Ki = 2.0 nM) to 5-HT1a receptors"
5904,1700754,115554,Pyruvate dehydrogenase kinase inhibitor,104820,,INHIBITOR,1,1,1,"Stimulates oxidative phosphorylation through inhibition of pyruvate dehydrogenase kinase (PDK). By inhibiting PDK, piruvate dehydrogenase (PDH) is then maintained in a catalytically active state, mitochondrial pyruvate consumption is increased, the substrate pool available for glycolysis is lowered and lactic acid production is inhibited.  This agent may stimulate apoptosis in cancer cells by restoring normal mitochondrial-induced apoptotic signaling.",,
5905,1701174,1377015,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,"It binds to the benzodiazepine receptor site of the GABA-A receptor acting as a partial agonist. The activation of the receptor  increases chloride channel opening, thus increasing inhibitory neurotransmission.",It binds to the alpha2/alpha3 subtypes of the GABAA receptor,Benzodiazepine site
5907,1702148,26851,Thromboxane A2 receptor antagonist,246,,ANTAGONIST,1,1,1,"Terbogrel mode of action combines the inhibition of the thromboxane A2 (TxA2) receptor with the inhibition of thromboxane A synthase. This combination not only blocks the formation and action  of TxA2, but it also leads to an enhanced local production of antithrombotic prostaglandins. This mechanism provides potent antithrombotic action without affecting systemic haemostasis.",,
5908,1702327,374007,Thymidylate synthase inhibitor,28,,INHIBITOR,1,1,1,Also leads to an enhanced local production of antithrombotic prostaglandins. This mechanism provides potent antithrombotic action without affecting systemic haemostasis.,,
5909,1702939,283293,Dihydropyrimidine dehydrogenase inhibitor,11159,,INHIBITOR,1,1,1,"5-Fluorouracil (5-FU) has a short half-life (8–22 min) resulting from rapid metabolism in the liver and other tissues by the enzyme dihydropyrimidine dehydrogenase  (DPD).  Eniluracil is an experimental drug that is specifically designed to inactivate DPD and prolong the half-life of 5-FU. In clinical trials, eniluracil has been shown to increase the half-life of 5-FU by 8–30-fold.",,
5910,1703111,1378142,Ghrelin receptor agonist,11536,,AGONIST,1,1,1,It mimics the endogenous growth hormone ghrelin  increasing  the plasma levels of several hormones including growth hormone and insulin-like growth factor 1 ,,
5911,1703469,39781,VP1 capsid protein disrupting agent,116925,,DISRUPTING AGENT,1,1,1,"It binds to a hydrophobic pocket in the VP1 protein in the viral capsid inducing conformational changes, which lead to altered receptor binding, viral uncoating preventing the virus from replicating.","Pleconaril inhibits the replication in cell culture of all 75 human rhinovirus (HRV) species A serotypes and 18 of the 25 species B viruses. The seven resistant serotypes are HRV-4, -5, -42, -84, -93, -97 and -99.",It binds to a hydrophobic pocket in the VP1 protein in the viral capsid.
5912,1703479,680641,Cyclooxygenase-2 inhibitor,126,,INHIBITOR,1,1,1,"Parecoxib is hydrolyzed by hepatic carboxyesterases to its active form, valdecoxib. Valdecoxib selectively binds to and inhibits COX-2. This prevents the conversion of arachidonic acid into prostaglandins, which are involved in the regulation of pain, inflammation, and fever.  It does not inhibit COX-1 at therapeutic concentrations and, therefore, does not interfere with blood coagulation.",,
5913,1703654,249301,DNA polymerase (alpha/delta/epsilon) inhibitor,105737,,INHIBITOR,1,1,1,"The mode of action involves the formation of the triphosphate and incorporation into DNA causing chain termination. Because it lacks a hydroxyl group at the 3'-position, once incorporated into DNA, it causes premature termination of DNA replication and eventually leads to cell death. It is not a permeant for nucleoside transporters (cellular uptake by passive diffusion), it is resistant to deamination, it does not inhibit ribonucleotide reductase, it is activated by deoxycytidine kinase and it is phosphorylated to its triphosphate by 3-phosphoglycerate kinase instead of nucleoside diphosphate kinase.",,
5914,1704070,116848,Type-1 angiotensin II receptor antagonist,115,,ANTAGONIST,1,1,1,"To overcome the poor absorption, the prodrug candesartan cilexetil was developed. During absorption in the gastrointestinal tract candesartan cilexetil is rapidly and completely hydrolyzed to candesartan. It inhibits selectively and noncompetitively,  angiotensin II receptor type1, thus preventing the actions of angiotensin II, such as constricting or squeezing arteries and veins, causing reduction in blood pressure without altering the heart rate.",,
5915,1704316,1378883,Unknown,,,,1,1,1,"Molecular mechanism not well known. Deacetylated in ocular tissue to the active metabolite anecortave desacetate. Functions as an antiangiogenic agent, inhibiting blood vessel growth by decreasing extracellular protease expression and inhibiting endothelial cell migration. Angiostatic activity does not seem to be mediated through any of the commonly known pharmacological receptors. Blocks signals from multiple growth factors, acting downstream and independent of initiating angiogenic stimuli.",,
5916,1705503,111798,Thromboxane A2 receptor antagonist,246,,ANTAGONIST,1,1,1,It inhibits bronchoconstriction by the competitive inhibition of specific binding of thromboxane A2  with its receptor.,,
5917,1706297,378692,Estrogen receptor modulator,104682,,MODULATOR,1,1,1,It is a selective estrogen receptor modulator that binds to and interacts with estrogen receptors as a mixed estrogen agonist/antagonist.  It acts as a potent estrogen antagonist in mammary and uterine tissue while acting as an estrogen agonist to maintain bone density and lower serum cholesterol. ,,
5919,2472667,1926759,Ribonucleoside-diphosphate reductase RR1 inhibitor,104791,,INHIBITOR,1,1,1,Inhibition of ribonucleotide reductase will block DNA synthesis and repair and cellular growth.,,
5920,1700052,519284,Phosphotransferase pUL97 inhibitor,103610,,INHIBITOR,1,1,1,"Inhibits viral DNA synthesis by inhibiting UL97 protein kinase activity. More specifically, it inhibits UL97’s mediated phosphorylation of nuclear Lamin A/C.",,
5921,1704067,367160,Dopamine D2 receptor partial agonist,72,,PARTIAL AGONIST,1,1,1,,"High affinity: D3 and D4 receptors. Low affinity: a1, 5HT2A, 5HT2C, H1 and muscarinic receptors ",
5922,1702665,624225,Poly [ADP-ribose] polymerase-1 inhibitor,11663,,INHIBITOR,1,1,1,,IC(50) inhibition PARP1 (3.8 nM) ,
5923,1705042,1379583,DNA topoisomerase II inhibitor,104727,,INHIBITOR,1,1,1,,,
5924,1696504,1382102,Bone morphogenetic protein 10 inhibitor,115414,,INHIBITOR,1,1,1,Ligand trap for BMP9 and BMP10,,
5925,1697446,1380849,Interleukin-13 receptor subunit alpha-2 binding agent,115902,,BINDING AGENT,1,1,1,Cytotoxic. Targets and kills tumor cells that express the IL13 receptor (IL13R).,,
5927,1707183,1382061,Integrin alpha-V/beta-1 inhibitor,105103,9804,INHIBITOR,1,1,1,"Inhibits ligand binding to all alphav heterodimers (alphavbeta1, alphavbeta3, alphavbeta5, alphavbeta6, alphavbeta8).",Specifically directed against the alphaV subunit of human integrins.,
5928,1707183,1382061,Integrin alpha-V/beta-3 inhibitor,104292,9801,INHIBITOR,1,1,1,"Inhibits ligand binding to all alphav heterodimers (alphavbeta1, alphavbeta3, alphavbeta5, alphavbeta6, alphavbeta8).",Specifically directed against the alphaV subunit of human integrins.,
5929,1707183,1382061,Integrin alpha-V/beta-5 inhibitor,104830,9802,INHIBITOR,1,1,1,"Inhibits ligand binding to all alphav heterodimers (alphavbeta1, alphavbeta3, alphavbeta5, alphavbeta6, alphavbeta8).",Specifically directed against the alphav subunit of human integrins.,
5930,1707183,1382061,Integrin alpha-V/beta-6 inhibitor,104924,9803,INHIBITOR,1,1,1,"Inhibits ligand binding to all alphav heterodimers (alphavbeta1, alphavbeta3, alphavbeta5, alphavbeta6, alphavbeta8).",Specifically directed against the alphav subunit of human integrins.,
5931,1707183,1382061,Integrin alpha-V/beta-8 inhibitor,109649,9805,INHIBITOR,1,1,1,"Inhibits ligand binding to all alphav heterodimers (alphavbeta1, alphavbeta3, alphavbeta5, alphavbeta6, alphavbeta8).",Specifically directed against the alphav subunit of human integrins.,
5932,1707186,1382063,Integrin alpha-V/beta-6 inhibitor,104924,,INHIBITOR,1,1,1,,,
5933,1707187,1382064,von Willebrand factor inhibitor,104515,,INHIBITOR,1,1,1,Inhibits the interaction between ultralarge von Willebrand factor (ULvWF) multimers and platelets by targeting the A1 domain of vWF and thus has the potential to immediately block the ULvWF mediated platelet interactions and the formation of the string-like clots in the blood of patients with acquired  thrombotic thrombocytopenic purpura (TTP).,,A1 domain of vWF.
5934,1707197,1382074,Neural cell adhesion molecule 1 binding agent,114899,,BINDING AGENT,1,1,1,Immunotoxin.,,
5935,1707200,1382077,Mucin-1 other,109790,,OTHER,1,1,1,Antibody-dependent cell-mediated cytotoxicity (ADCC).,,
5937,1707230,1382107,Lysyl oxidase homolog 2 inhibitor,115990,,INHIBITOR,1,1,1,,,
5938,1695967,1380143,Tumor necrosis factor ligand superfamily member 13B inhibitor,106137,,INHIBITOR,1,1,1,Binds to both membrane-bound and soluble BAFF.,,
5939,1696001,1380177,TNF-alpha inhibitor,185,,INHIBITOR,1,1,1,,,
5940,1697339,1380579,Vascular endothelial growth factor A inhibitor,187,,INHIBITOR,1,1,1,Soluble receptor decoy which has a high binding affinity to VEGF and a long half-life in vitreous.,"All isoforms of VEGF-A, VEGF-B, VEGF-C, and PlGF.",
5941,1697339,1380579,Vascular endothelial growth factor B inhibitor,109784,,INHIBITOR,1,1,1,Soluble receptor decoy which has a high binding affinity to VEGF and a long half-life in vitreous.,"All isoforms of VEGF-A, VEGF-B, VEGF-C, and PlGF.",
5942,1697339,1380579,Placenta growth factor inhibitor,103950,,INHIBITOR,1,1,1,Soluble receptor decoy which has a high binding affinity to VEGF and a long half-life in vitreous.,"All isoforms of VEGF-A, VEGF-B, VEGF-C, and PlGF.",
5943,1697339,1380579,Vascular endothelial growth factor C inhibitor,116118,,INHIBITOR,1,1,1,Soluble receptor decoy which has a high binding affinity to VEGF and a long half-life in vitreous.,"All isoforms of VEGF-A, VEGF-B, VEGF-C, and PlGF.",
5944,1706884,1540521,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,Antibody-dependent cell-mediated cytotoxicity (ADCC).,,
5945,1697394,1380620,B-lymphocyte antigen CD20 binding agent,181,,BINDING AGENT,1,1,1,High affinity for Fc gamma RIIIa (CD16) receptors and therefore greater antibody-dependent cellular cytotoxicity (ADCC) activity.,,
5946,2138992,1763549,Programmed cell death 1 ligand 1 inhibitor,109807,,INHIBITOR,1,1,1,Blocks PD-L1 binding to PD-1 (IC50 0.1 nM) and CD80 (IC50 0.04 nM).,,
5947,1938043,1592358,Beta amyloid A4 protein binding agent,10656,,BINDING AGENT,1,1,1,Reduces brain disease-relevant aggregated forms of amyloid-beta (Abeta) in a dose- and time-dependent manner.,"Shows >10,000-fold selectivity for aggregated Abeta over monomer",
5948,1976828,1626787,Activin receptor type-2B antagonist,100992,,ANTAGONIST,1,1,1,"BYM338 prevents myostatin- or activin A-induced atrophy through inhibition of Smad2/3 phosphorylation, thus sparing the myosin heavy chain from degradation.",,
5949,2583506,2039328,Vascular endothelial growth factor A inhibitor,187,,INHIBITOR,1,1,1,,Binds to all isoforms of VEGF-A including VEGF165.,
5950,1879182,1540520,Interleukin-23 inhibitor,106133,9800,INHIBITOR,1,1,1,,,Alpha (p19) subunit is binding site
5951,2583418,2039297,Fibroblast growth factor 23 inhibitor,115874,,INHIBITOR,1,1,1,,,
5952,1697546,1380947,Interleukin-23 inhibitor,106133,9800,INHIBITOR,1,1,1,,,Alpha (p19) subunit is binding site
5953,1697408,1380834,Angiopoietin-1 inhibitor,108253,,INHIBITOR,1,1,1,Inhibits the interaction between the ligands angiopoietin-1 and angiopoietin-2 with the Tie-2 receptor.,,
5954,1697408,1380834,Angiopoietin-2 inhibitor,109785,,INHIBITOR,1,1,1,Inhibits the interaction between the ligands angiopoietin-1 and angiopoietin-2 with the Tie-2 receptor.,,
5955,1392877,1121864,Sclerostin inhibitor,109783,,INHIBITOR,1,1,1,,,
5956,1392884,1121871,Epithelial cell adhesion molecule binding agent,109789,,BINDING AGENT,1,1,1,Immunotoxin,,
5957,1392895,1121882,Tumor necrosis factor receptor superfamily member 12A agonist,114811,,AGONIST,1,1,1,"Activates the NFκB pathway, and that its growth inhibitory activity is dependent on NFκB.",,
5958,1392897,1121884,Mucin-5AC other,114981,,OTHER,1,1,1,Antibody-dependent cell-mediated cytotoxicity.,,
5959,2792995,2096395,Receptor protein-tyrosine kinase erbB-2 binding agent,188,,BINDING AGENT,1,1,1,"Upon binding of the antibody to receptor protein-tyrosine kinase ERBB2, the immunoliposome allows for specific delivery of doxorubicin to tumors overexpressing the ERBB2 receptor.",,
5960,2792995,2096395,DNA inhibitor,105574,,INHIBITOR,1,1,1,"Upon binding of the antibody to the receptor protein-tyrosine kinase ERBB2, the immunoliposome allows for specific delivery of doxorubicin to tumors overexpressing the ERBB2 receptor. Once inside the HER2-expressing tumor cells, doxorubicin intercalates into DNA and interferes with DNA topoisomerase II activity, thereby inhibiting DNA replication and RNA synthesis.",,
5961,2792995,2096395,DNA topoisomerase II alpha inhibitor,63,,INHIBITOR,1,1,1,"Upon binding of the antibody to the receptor protein-tyrosine kinase ERBB2, the immunoliposome allows for specific delivery of doxorubicin to tumors overexpressing the ERBB2 receptor. Once inside the HER2-expressing tumor cells, doxorubicin intercalates into DNA and interferes with DNA topoisomerase II activity, thereby inhibiting DNA replication and RNA synthesis.",,
5962,1695980,1380156,B-lymphocyte antigen CD19 binding agent,109546,,BINDING AGENT,1,1,1,"CD19 is constitutively associated with P-glycoprotein (P-gp). Disruption of this association impairs the drug efflux function of P-gp. Taplitumomab (B43) is linked to the protein PAP, an antiviral from Phytolacca americana which is a ribosome inhibitory hemitoxin. Binding of B43 to CD19, disrupts the association between P-gp and CD19 and the P-gp efflux function is blocked. The PAP toxin moiety is then internalised, irreversibly inhibiting protein synthesis, leading to cellular apoptosis.",High affinity,
5963,1697126,1380311,Vimentin other,114815,,OTHER,1,1,1,"Antibody dependent cell-mediated cytotoxicity, Complement Dependent Cytotoxicity, Natural Killer Cell-induction.",Affinity of pritumumab for its antigen (expressed on U-251MG cell-line) is 4.5×10−7 M,Reactive epitope is located in the c2 (coil 2 of the central rod) domain of vimentin.
5964,1696214,1380532,T-cell surface antigen CD4 inhibitor,10476,,INHIBITOR,1,1,1,It causes consistent blockade of cell-surface CD4 molecules on T lymphocytes blocking the activation of T lymphocytes (no depletion of T cells). Regulation of  the immune response.,,
5965,1697379,1380607,Mucin-1 other,109790,,OTHER,1,1,1,"MUC1 is a glycoprotein overexpressed in breast and other carcinomas. When monoclonal antibody HuHMFG1 (sontuzumab) binds MUC1, it stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing MUC1, resulting in a decrease in tumor burden.",Antibody binding affinity: Kd~1 nmol/L,Binds Pro-Asp-Thr-Arg sequences of tandem repeats in Mucin 1 N-terminal extracellular subunit
5966,2793635,2096408,Dipeptidyl peptidase IV inhibitor,11140,,INHIBITOR,1,1,1,Inhibits the activation of T-cells reducing the immune response occurring during steroid resistant aGvHD.,,
5967,2794248,2096424,Programmed cell death 1 ligand 1 other,109807,,OTHER,1,1,1,"Avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signalling pathways. This results in the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells.",,
5968,2794249,2096425,Matrix metalloproteinase 9 inhibitor,12592,,INHIBITOR,1,1,1,"GS-5745 inhibits MMP9 by two mechanisms: 1) inhibiting the catalytic activity of MMP9 by sterically interfering with proteolysis of substrates 2) inhibiting the processing of MMP9 to an active form by sterically preventing accessibility of activating proteases. This results in an inhibition of extracellular matrix protein degradation and, potentially, the inhibition of angiogenesis, tumor growth, invasion, and metastasis. ",GS-5745 binds to active-MMP9 with ~150–400 lower affinity compared to pro-MMP9 (PMID:28235803),See structure of the complex in PDBe under accession codes: 5TH6 (apo) 5TH9 (GS-5745 complex)
5969,2791713,2096371,Calcitonin gene-related peptide inhibitor,116903,,INHIBITOR,1,1,1,"Inhibits the calcitonin gene-related peptide, or CGRP, a small protein involved in the transmission of, and heightened sensitivity to, pain experienced in migraine.",Kd <20 pM towards CGRP,
5970,2792317,2096380,Calcitonin gene-related peptide type 1 receptor antagonist,19904,,ANTAGONIST,1,1,1,Binds to the CGRP receptor and inhibits the function of CGRP.,,
5971,2795537,2096444,Coagulation factor IX and X other,104934,,OTHER,1,1,1,"Binds to and bridges activated factor IX (factor IXa) and factor X, thereby acting as a factor VIII–mimetic agent ",Very weak antigen-binding affinity,
5972,1706790,1381774,B-lymphocyte antigen CD19 binding agent,109546,,BINDING AGENT,1,1,1,Enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Depletes mature B cells including plasmablasts and plasma cells with the added benefit of reducing serum Ab levels.,,
5973,2791065,2096358,IL6Ralpha/GP130 antagonist,108122,,ANTAGONIST,1,1,1,It blocks IL-6-mediated signal transduction by inhibiting IL-6 binding to transmembrane and soluble IL-6R.,,It binds to IL-6 receptor multiple times. 
5974,1696507,1381000,"5,6-dihydroxyindole-2-carboxylic acid oxidase other",114847,,OTHER,1,1,1,Tumor-specific T-cell response via antibody-dependent cell-mediated phagocytosis  (ADCP),,
5975,1697543,1380944,Angiopoietin-2 inhibitor,109785,,INHIBITOR,1,1,1,"It blocks the binding of Ang2 (an important regulator of tumor angiogenesis and growth) to Tie 2 (with an IC50 of approximately 60 pmol/L)  decreasing its activity,  which causes inhibition of tumor growth. Ang2 expression is upregulated in a range of human cancers,  and high levels of circulating Ang2 are associated with a poor prognosis.",high-affinity binding  (KD ~ 18 pmol/L for human Ang2),
5976,1696206,1380524,Blood group Rh(D) polypeptide other,114957,,OTHER,1,1,1,Unknown,,
5977,1392963,1121950,Insulin-like growth factor I receptor antagonist,234,,ANTAGONIST,1,1,1,Antibody binding results in endosomal degradation of IGF-1R and inhibition of receptor-mediated signaling.,,
5978,1392867,1121854,Vascular endothelial growth factor receptor 2 antagonist,10980,,ANTAGONIST,1,1,1,"CDP791 binds specifically to VEGFR-2, inhibiting activation by its ligands VEGF-A, VEGF-C, VEGF-D and therefore, blocking all signaling through this receptor. ",,
5979,1392868,1121855,Mesothelin inhibitor,114839,,INHIBITOR,1,1,1,MORAb-009 can internalize after binding mesothelin on the cell surface. MORAb-009 can exert antibody-dependent cellular cytotoxicity. MORAb-009 blocks CA125/MUC16-mesothelin interaction.,,
5980,1705901,193817,Glutamate receptor ionotropic AMPA antagonist,104825,,ANTAGONIST,1,1,1,Competitive antagonist.,,
5981,1392869,1121856,Interleukin-13 inhibitor,109782,,INHIBITOR,1,1,1,"IMA-638 allows IL-13 interaction with IL-13Ralpha1 but blocks recruitment of the IL-4Ralpha–chain to form the high-affinity receptor, inhibiting downstream signal of IL-13/IL-13Ralpha1. Anrukinzumab does not block IL-13 binding to IL-13alpha1 or IL-13alpha2. ",,
5982,1392870,1121857,Tumor necrosis factor ligand superfamily member 13B inhibitor,106137,,INHIBITOR,1,1,1,"It has high affinity and specificity for cytokines BLyS and APRIL, preventing receptor binding. Three receptors, TACI, BCMA (B-cell maturation antigen) and BAFF-R, have been identified that have unique binding affinities for BLyS and APRIL (PMID: 10898980).",,
5983,1392870,1121857,Tumor necrosis factor ligand superfamily member 13 inhibitor,115397,,INHIBITOR,1,1,1,"It has high affinity and specificity for cytokines BLyS and APRIL, preventing receptor binding. Three receptors, TACI, BCMA (B-cell maturation antigen) and BAFF-R, have been identified that have unique binding affinities for BLyS and APRIL (PMID: 10898980).",,
5984,1392872,1121859,Heterotrimeric lymphotoxin LTa1b2 inhibitor,116918,,INHIBITOR,1,1,1,"Baminercept binds to both LTBR ligands, namely, a membrane bound heterotrimeric lymphotoxin (LT) form LTalpha1beta2 and the ligand called LIGHT (TNFSF14). It is a dual pathway inhibitor blocking signaling triggered by both membrane LT and LIGHT ligands.",,
5985,1392872,1121859,Tumor necrosis factor ligand superfamily member 14 inhibitor,114875,,INHIBITOR,1,1,1,"Baminercept binds to both LTBR ligands, namely, a membrane bound heterotrimeric lymphotoxin (LT) form LTalpha1beta2 and the ligand called LIGHT (TNFSF14). It is a dual pathway inhibitor blocking signaling triggered by both membrane LT and LIGHT ligands.",,
5986,1392873,1121860,Phosphatidylserine inhibitor,116919,,INHIBITOR,1,1,1,"In most tissues, the principal target of bavituximab, phosphatidylserine (PS), is restricted to the internal surface of the cell membrane. Bavituximab binds a complex of beta2 glycoprotein 1 (beta2GP1) and PS, triggering antitumor effects via a number of mechanisms. Principally, bavituximab acts as a vascular targeting agent. The bavituximab–beta2GP1–PS complex induces host effector processes such as antibody-dependent cellular cytotoxicity, resulting in vascular destruction. ",,
5987,1392881,1121868,Mucin-1 binding agent,109790,,BINDING AGENT,1,1,1,HuC242 binds specifically to the extracellular domain of a tumor-associated carbohydrate epitope of CanAg (a novel glycoform of MUC1).  ,,
5988,1392882,1121869,Mucin-1 binding agent,109790,,BINDING AGENT,1,1,1,"Cantuzumab ravtansine is generated based on MoAb C242, which is raised against a cell surface superantigen, CA242, found in a variety of human tumor cells. Upon binding and entry, the immunoconjugate releases the maytansinoid agent DM4, which binds to tubulin, thereby affecting microtubule assembly/disassembly dynamics. ",,
5989,1392883,1121870,C-C motif chemokine 2 inhibitor,103848,,INHIBITOR,1,1,1,,,
5990,1392885,1121872,Insulin-like growth factor I receptor antagonist,234,,ANTAGONIST,1,1,1,"CIX binds IGF-1R with high affinity and blocks interaction between IGF-1R and its ligands, IGF-1 and -II, and induces internalization and degradation of IGF-1R.",,
5991,1392887,1121874,Tumor necrosis factor receptor superfamily member 10B agonist,103092,,AGONIST,1,1,1,"It binds to TNFRSF10B, activating intracellular caspases in vitro in the presence of a cross-linker.",,
5992,1392888,1121875,Beta amyloid A4 protein inhibitor,10656,,INHIBITOR,1,1,1,Binds all forms of misfolded Amyloid beta proteins to prevent Amyloid beta aggregation and promote the disaggregation of existing Amyloid beta aggregates including plaques.,,
5993,1392889,1121876,Tumor necrosis factor receptor superfamily member 5 inhibitor,103491,,INHIBITOR,1,1,1,Triggers antibody-dependent cell-mediated cytotoxicity. Mediates apoptosis.,,
5994,1392890,1121877,Insulin-like growth factor I receptor antagonist,234,,ANTAGONIST,1,1,1,"Dalotuzumab binds to membrane-bound IGF1R, preventing binding of the ligand IGF1 and the subsequent triggering of the PI3K/Akt signaling pathway.",,
5995,1392892,1121879,Tumor necrosis factor receptor superfamily member 10B agonist,103092,,AGONIST,1,1,1,Induces TNFRSF10B clustering at the cell surface and stimulates a death-inducing signaling complex containing the adaptor molecule Fas-associated death domain and the apoptosis-initiating protease caspase-8. Fc crosslinking further augmented Drozitumab's proapoptotic activity.,"Binds to TNFRSF10B, but shows no detectable binding to any of the other Apo2L/TRAIL receptors.","Binds at the junction between CRD2 and CRD3, interacting with residues in both CRD2 and CRD3."
5996,1392896,1121883,Interleukin-9 inhibitor,114893,,INHIBITOR,1,1,1,Humanized immunoglobulin (Ig) G1 mAb that neutralizes the activity of human IL-9. ,,
5997,1392898,1121885,Integrin alpha-V/beta-3 antagonist,104292,,ANTAGONIST,1,1,1,,,
5998,1392901,1121888,Interleukin-22 inhibitor,114876,,INHIBITOR,1,1,1,,,
5999,1392902,1121889,Hepatocyte growth factor inhibitor,101207,,INHIBITOR,1,1,1,"Humanized IgG1 antibody that binds the HGF ligand with high affinity and specificity, thus inhibiting c-MET/HGF biological activities. ",,
6000,1392906,1121893,Transforming growth factor beta-1 inhibitor,104258,,INHIBITOR,1,1,1,,,
6001,1392906,1121893,Transforming growth factor beta-2 inhibitor,108251,,INHIBITOR,1,1,1,,,
6002,1392906,1121893,Transforming growth factor beta-3 inhibitor,114864,,INHIBITOR,1,1,1,,,
6003,1392912,1121899,Transmembrane glycoprotein NMB binding agent,114880,,BINDING AGENT,1,1,1,"Glembatumumab vedotin is designed to be stable in the bloodstream, but to release MMAE upon internalization into gpNMB-expressing tumor cells, resulting in a targeted cell-killing effect.  Antimitotic agent monomethyl auristatin E (MMAE), which blocks tubulin polymerization.",,
6004,1392913,1121900,T-cell surface antigen CD4 inhibitor,10476,,INHIBITOR,1,1,1,"Binds CD4, the primary receptor for human immunodeficiency virus type 1 (HIV-1), and inhibits the viral entry process.",,
6005,1392914,1121901,Vascular endothelial growth factor receptor 1 antagonist,10979,,ANTAGONIST,1,1,1,"Human monoclonal antibody against vascular endothelial growth factor receptor-1 (VEGFR-1), potently inhibits ligand-dependent phosphorylation of VEGFR-1 and downstream signaling,",,
6006,1392921,1121908,Neural cell adhesion molecule 1 binding agent,114899,,BINDING AGENT,1,1,1,"Binding to the target tumor cell through NCAM1, the antibody-drug conjugate is internalized and then cleaved inside the cell, leading to localized and enhanced antitumor activity. The conjugated drug DM1 is a synthetic derivative of maytansine, an ansa macrolide that binds to tubulin at the vinca alkaloid-binding site leading to inhibition of microtubule assembly and cell proliferation and to cell death.",,
6008,1392916,1121903,Integrin alpha-V/beta-3 antagonist,104292,9801,ANTAGONIST,1,1,1,"Shown to bind to alpha-V/beta-1, beta-3, beta-5 & beta-6 integrins, but alpha-V/beta-3 and alpha-V/beta-5 involved in tumour angiogenesis",,
6009,1392916,1121903,Integrin alpha-V/beta-5 antagonist,104830,9802,ANTAGONIST,1,1,1,"Shown to bind to alpha-V/beta-1, beta-3, beta-5 & beta-6 integrins, but alpha-V/beta-3 and alpha-V/beta-5 involved in tumour angiogenesis",,
6011,1392924,1121911,HLA-DR antigens-associated invariant chain antagonist,100659,,ANTAGONIST,1,1,1,,,
6012,1392928,1121915,Granulocyte-macrophage colony-stimulating factor inhibitor,114916,,INHIBITOR,1,1,1,,,
6013,1392929,1121916,Trophoblast glycoprotein other,114895,,OTHER,1,1,1,"The therapeutic effect is associated with activation of SAg-binding T cells. The SAg-binding T lymphocytes expand, differentiate to effector cells, and infiltrate the tumor. The therapeutic efficacy is most likely related to the dual mechanism of tumor cell killing: (1) direct lysis by cytotoxic T lymphocytes of tumor cells expressing the antigen recognized by the antibody moiety of the fusion protein and (2) secretion of cytokines eliminating antigen-negative tumor cell variants. ",,
6014,1392933,1121920,Platelet-derived growth factor receptor alpha antagonist,12627,,ANTAGONIST,1,1,1,"Human immunoglobulin G subclass 1 (IgG1) monoclonal antibody that binds to PDGFRalpha and blocks the PDGF-AA, PDGF-BB, and PDGF-CC ligands from binding to the receptor. ",,
6015,1392934,1121921,Interleukin-6 inhibitor,104209,,INHIBITOR,1,1,1,"Binds to IL-6 at Site 3 and neutralizes biological activity through blocking hexamer (of two molecules each of IL6, IL6R and IL6ST/gp130) formation on the IL6ST/gp130 signaling axis.",,
6016,1392936,1121923,Epithelial cell adhesion molecule binding agent,109789,,BINDING AGENT,1,1,1,"Single chain anti-EpCAM fragment fused with Pseudomonas exotoxin. Designed to target cancer cells expressing EpCAM, which internalize the recombinant fusion protein once it is bound. Within the cell, the payload dissociates from the single chain fragment and is then able to exert its cell-killing activity.",,
6017,1392938,1121925,TNF-alpha inhibitor,185,,INHIBITOR,1,1,1,Trivalent albumin-binding nanobody that neutralizes the pro-inflammatory tumor necrosis factor alpha (TNF-alpha) as a causative agent for exacerbating rheumatoid arthritis.  It binds to serum to increase its in vivo half-life.,,
6018,1392940,1121927,TNF-beta inhibitor,195,,INHIBITOR,1,1,1,"Binds LT-alpha in both the secreted LT-alpha3 and the surface-expressed LT-alpha1beta2, blocking TNFR and LTBR signalling. Depletes LT-alpha–expressing cells by antibody-dependent cellular cytotoxicity (ADCC). ",,
6019,1392941,1121928,TNF-alpha inhibitor,185,,INHIBITOR,1,1,1,,,
6020,1392942,1121929,Beta amyloid A4 protein binding agent,10656,,BINDING AGENT,1,1,1,Amyloid clearing function. ,,Binds free carboxy terminal amino acids 30-40 of the Abeta40 peptide (PMID:22197375).
6021,1392948,1121935,Insulin-like growth factor I receptor antagonist,234,,ANTAGONIST,1,1,1,,,
6022,1392949,1121936,Blood group Rh(D) polypeptide inhibitor,114957,,INHIBITOR,1,1,1,Fully human IgG1 targeted against the human RhD antigen on RhD-positive circulating RhD-reactive B cells (RBCs).Clears of antibody-coated RhD RBCs.,,
6023,1392951,1121938,OX-2 membrane glycoprotein inhibitor,114831,,INHIBITOR,1,1,1,Blocks binding of CD200 to the CD200 receptor.  Induces Ab-dependent cellular cytotoxicity of activated T cells.,,
6024,1392957,1121944,Inhibin beta A chain inhibitor,109824,,INHIBITOR,1,1,1,"By binding activin, Sotatercept prevents activin from binding endogenous receptors and thus acts as a decoy.",,
6025,1392960,1121947,Integrin alpha-IIb/beta-3 antagonist,104685,,ANTAGONIST,1,1,1,,,
6026,1392961,1121948,Tenascin other,114817,,OTHER,1,1,1,Intended use as tumour pretargeting agent.,,
6027,1392967,1121954,T-cell surface antigen CD4 agonist,10476,,AGONIST,1,1,1,"Humanised anti-human CD4 IgG1 mAb, which selectively activates regulatory T cells (Tregs) by binding to CD4 and activatiing signalling downstream pathways. Does not induce antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity.",,Binds epitope in the IgG-like C2 type 1 domain distinct from binding region for other ligands
6028,1392969,1121956,Tumor necrosis factor receptor superfamily member 9 agonist,114818,,AGONIST,1,1,1,,,
6029,1392970,1121957,Integrin alpha-2 antagonist,101250,,ANTAGONIST,1,1,1,,,
6030,1392972,1121959,B-lymphocyte antigen CD20 binding agent,181,,BINDING AGENT,1,1,1,"Induces apoptosis,  Antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). ",,
6031,1695978,1380154,Ig epsilon chain C region inhibitor,229,,INHIBITOR,1,1,1,Humanized IgG1 monoclonal antibody against IgE that recognizes and masks an epitope in the CH3 region of IgE responsible for binding to the high-affinity Fc(epsilon) receptor on mast cells and basophils.,,
6032,1697099,1380284,Epithelial cell adhesion molecule inhibitor,109789,,INHIBITOR,1,1,1,Moderate affinity for EpCAM.,,
6033,1697110,1380295,Receptor protein-tyrosine kinase erbB-2 cross-linking agent,188,,CROSS-LINKING AGENT,1,1,1,"Immunomodulator. Trifunctional bispecific monoclonal antibody (mAb) has the capacity to enhance immunological effector functions such as antibody dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Designed to induce the formation of tri-cell-complexes consisting of Her2-positive tumor cells, CD3+ T cells, and Fcγ-receptor positive accessory cells. ",,
6034,1697110,1380295,T-cell surface glycoprotein CD3 epsilon chain cross-linking agent,233,,CROSS-LINKING AGENT,1,1,1,"Immunomodulator. Trifunctional bispecific monoclonal antibody (mAb) has the capacity to enhance immunological effector functions such as antibody dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Designed to induce the formation of tri-cell-complexes consisting of Her2-positive tumor cells, CD3+ T cells, and Fcγ-receptor positive accessory cells. ",,
6035,1697119,1380304,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,The binding of matuzumab to domain III sterically blocks the domain rearrangement that is required for high affinity ligand binding and receptor dimerization.,,
6036,1697132,1380317,Growth/differentiation factor 8 inhibitor,109584,,INHIBITOR,1,1,1,,,
6037,1696067,1380385,Interleukin-4 inhibitor,114855,,INHIBITOR,1,1,1,,,
6038,1696092,1380410,Tumor necrosis factor receptor superfamily member 5 partial agonist,103491,,PARTIAL AGONIST,1,1,1,Blocks CD154 binding to CD40 and has partial agonist properties. ,,
6039,1696115,1380433,"Amine oxidase, copper containing inhibitor",20143,,INHIBITOR,1,1,1,Inhibits lymphocyte binding to AOC3 (VAP-1) expressed in high endothelial venules (HEV).,,
6040,1696135,1380453,T-cell surface antigen CD4 inhibitor,10476,,INHIBITOR,1,1,1,,,
6041,1696196,1380514,Trophoblast glycoprotein other,114895,,OTHER,1,1,1,"Immunomodulator. Targets the superantigen with subsequent activation of cytotoxic T cells in tumor tissue. Targeting of superantigens towards tumours induces a strong, local cytotoxic T-cell attack, which directly kills tumour cells and leads to inflammation and the local accumulation of tumouricidal cytokines.",,
6042,1696230,1380636,Interleukin-2 receptor alpha chain antagonist,182,,ANTAGONIST,1,1,1,,,
6043,1696262,1380667,Intercellular adhesion molecule-1 antagonist,11088,,ANTAGONIST,1,1,1,It attenuates T cell and neutrophil emigration and tissue effector functions by blocking their adhesion to the vascular endothelium through ICAM1.,,
6044,1696292,1380697,Transforming growth factor beta-1 inhibitor,104258,,INHIBITOR,1,1,1,,,
6045,1696321,1380725,Interferon gamma inhibitor,108375,,INHIBITOR,1,1,1,,,
6046,1696337,1380741,T-cell surface antigen CD4 negative modulator,10476,,NEGATIVE MODULATOR,1,1,1,Blocks activation of T-cells. Causes depletion of CD4+ lymphocytes.,,
6047,1696352,1380755,T-cell surface antigen CD4 negative modulator,10476,,NEGATIVE MODULATOR,1,1,1,,,
6048,1696364,1380767,Carcinoembryonic antigen-related cell adhesion molecule 5 other,114842,,OTHER,1,1,1,IgG1 MAb that induces antibody-dependent cell-mediated cytotoxicity  (ADCC) in vitro.,,Binds with high affinity to the restricted A3B3 domain (Gold group 3) found on CEACAM5. 
6049,1697438,1380841,Leukocyte adhesion molecule-1 inhibitor,12721,,INHIBITOR,1,1,1,,,
6050,1697452,1380855,Interleukin-6 inhibitor,104209,,INHIBITOR,1,1,1,"It binds circulating IL-6 cytokine rather than the IL-6 receptor, blocking both classic signaling and trans-signaling.",,
6051,1697455,1380857,Interleukin-6 inhibitor,104209,,INHIBITOR,1,1,1,,,
6052,1697476,1380878,Tumor necrosis factor receptor superfamily member 8 other,106140,,OTHER,1,1,1,Antibody-dependent cell-mediated cytotoxicity (ADCC). ,,
6053,1697485,1380887,TRAIL receptor-1 agonist,12693,,AGONIST,1,1,1,"Mapatumumab, like the native ligand TRAIL, mediates apoptosis by binding to TRAIL-R1, leading to activation of the caspase cascade, cleavage of key intracellular signalling components and DNA and subsequent cell death.",,
6054,1697525,1380926,Epithelial cell adhesion molecule other,109789,,OTHER,1,1,1,"Immunomodulator. The humanized monoclonal antibody moiety of tucotuzumab celmoleukin recognizes and binds to EpCAM thereby concentrating IL2 (celmoleukin) in EpCAM-expressing tumor tissue. Subsequently, the localized IL2 moiety of this fusion protein may stimulate a cytotoxic T-cell antitumor immune response.",,
6055,1697544,1380945,Reticulon-4 inhibitor,114856,,INHIBITOR,1,1,1,,,
6056,1696487,1380986,Tumor necrosis factor ligand superfamily member 4 inhibitor,114861,,INHIBITOR,1,1,1,,,
6057,1696514,1381005,TNF-alpha inhibitor,185,,INHIBITOR,1,1,1,,,
6058,1696517,1381008,T-cell surface antigen CD2 inhibitor,196,,INHIBITOR,1,1,1,"The antibody tumor-killing action is a FcRγ-dependent mechanism presumably mediated by effector cells, including monocytes and granulocytes that express FcRγIII.",,
6059,1696522,1381013,CD40 ligand inhibitor,109787,,INHIBITOR,1,1,1,"Binds to CD154, block CD154 binding to CD40 and inhibit T cell-dependent B cell differentiation, The latter activity is independent of FcR binding.",,
6060,1696560,1381051,T-cell surface glycoprotein CD5 binding agent,114849,,BINDING AGENT,1,1,1,Immunotoxin.,,
6061,1696832,1381323,Ganglioside GD3 other,109803,,OTHER,1,1,1,"Immunostimulant. Binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells and complement-mediated cytotoxicity.",,
6062,1696870,1381361,Integrin beta-2 negative modulator,12662,,NEGATIVE MODULATOR,1,1,1,,,
6063,1696878,1381369,Eotaxin inhibitor,108379,,INHIBITOR,1,1,1,,,
6064,1696926,1381417,Immunoglobulin epsilon Fc receptor antagonist,10100,,ANTAGONIST,1,1,1,This mAb has been shown to block IgE synthesis in human B cells.,,
6065,1696999,1381490,Integrin alpha-M/beta-2 antagonist,105116,,ANTAGONIST,1,1,1,Inhibits the leukocyte’s ability to adhere to the endothelial cell and transmigrate across the endothelial cell layer.,,
6066,1696999,1381490,Integrin alpha-L/beta-2 (LFA-1) antagonist,106151,,ANTAGONIST,1,1,1,Inhibits the leukocyte’s ability to adhere to the endothelial cell and transmigrate across the endothelial cell layer. ,,
6067,1392904,1121891,T cell surface glycoprotein CD3 inhibitor,106147,,INHIBITOR,1,1,1,,,
6068,1706683,1381703,Epithelial cell adhesion molecule other,109789,,OTHER,1,1,1,Antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).,,
6069,1706689,1381707,Myeloid cell surface antigen CD33 other,81,,OTHER,1,1,1,M195 is rapidly internalized after binding to target cells. No antibody-dependent cell-mediated cytotoxicity (ADCC).,,
6070,1706694,1381711,High affinity immunoglobulin gamma Fc receptor I cross-linking agent,101161,,CROSS-LINKING AGENT,1,1,1,Immunostimulant. Antibody dependent cellular phagocytosis (ADCP) and antibody-dependent cell-mediated cytotoxicity (ADCC).,,
6071,1706694,1381711,Receptor protein-tyrosine kinase erbB-2 cross-linking agent,188,,CROSS-LINKING AGENT,1,1,1,Immunostimulant. Induces antibody dependent cellular phagocytosis (ADCP) and antibody-dependent cell-mediated cytotoxicity (ADCC). ,,
6072,1706716,1381726,B-lymphocyte antigen CD19 binding agent,109546,,BINDING AGENT,1,1,1,"The mechanism of action of SAR3419 involves binding to the cell-surface antigen, followed by internalization via endocytosis and subsequent intracellular routing to lysosomes where the huB4 antibody moiety of the ADC is degraded to yield the lysine-SPDB-DM4 metabolite. Induces antibody-dependent cell-mediated cytotoxicity (ADCC) but not complement-dependent cytotoxicity (CDC). Induces cell-cycle arrest at the G2/M phase followed by an increase in apoptotic cells. ",,
6073,1706741,1381740,Beta amyloid A4 protein binding agent,10656,,BINDING AGENT,1,1,1,Neutralises disease-relevant aggregated forms of amyloid-beta.  ,,Binds with high affinity to the Abeta N terminus (aa1-5).
6074,1706751,1381748,B-lymphocyte antigen CD19 binding agent,109546,,BINDING AGENT,1,1,1,Immunotoxin,,
6075,1706767,1381761,Endoglin inhibitor,114846,,INHIBITOR,1,1,1,Induces  antibody-dependent  cellular cytotoxicity (ADCC) and apoptosis of CD105 (Endoglin)-positive tumour cells.,,
6076,1706787,1381772,Integrin beta-2 inhibitor,12662,,INHIBITOR,1,1,1,,,
6077,1706779,1381770,Monocyte differentiation antigen CD14 inhibitor,107600,,INHIBITOR,1,1,1,Diminishes inflammatory responses induced by  i.v. injection of LPS. ,,
6078,1706790,1381774,B-lymphocyte antigen CD19 binding agent,109546,,BINDING AGENT,1,1,1,MEDI-551 binds directly to CD19 protein on the surface of the plasmablasts (produce autoantibodies called AQP4-Ab (or NMO-IgG) to the protein aquaporin-4 ) and depletes them.,,
6080,1706799,1381783,C-C chemokine receptor type 5 antagonist,10580,,ANTAGONIST,1,1,1,Viral-entry inhibitor.,,
6081,1706803,1381786,Integrin beta-2 inhibitor,12662,,INHIBITOR,1,1,1,Mediates antibody-dependent cell-mediated cytotoxicity (ADCC) (10-fold increase in ADCC than rituximab). ,,
6082,1706813,1381792,CD22 binding agent,11695,,BINDING AGENT,1,1,1,,,
6083,1706818,1381795,Insulin-like growth factor I inhibitor,108252,,INHIBITOR,1,1,1,"Selectively binds to human IGF-I and IGF-II, and inhibits their ability to trigger IGFIR (Insulin-like growth factor 1 receptor) and INSR (insulin receptor) signaling without affecting insulin activation of INSR.",,
6084,1706818,1381795,Insulin-like growth factor II inhibitor,114918,,INHIBITOR,1,1,1,"Selectively binds to human IGF-I and IGF-II, and inhibits their ability to trigger IGFIR (Insulin-like growth factor 1 receptor) and INSR (insulin receptor) signaling without affecting insulin activation of INSR.",,
6085,1706820,1381797,Insulin-like growth factor I receptor antagonist,234,,ANTAGONIST,1,1,1,Inhibits IGF-1 signalling but has no effect on insulin pathway . selectively inhibit the growth of CD45-negative human myeloma cell lines (HMCLs). ,,
6086,1706827,1381804,Mucin-1 other,109790,,OTHER,1,1,1,Immunostimulant. ,,Recognises the tandem repeat peptide sequence DTRPAP.
6087,1706833,1381807,Interleukin-2 receptor alpha chain binding agent,182,,BINDING AGENT,1,1,1,Immunotoxin. ,,
6088,1706854,1381817,Connective tissue growth factor inhibitor,114862,,INHIBITOR,1,1,1,,,
6089,1706856,1381819,C-X-C motif chemokine 10 inhibitor,114925,,INHIBITOR,1,1,1,"Bispecific antibody that targets mesothelin, a tumor associated antigen, while neutralizing the CD47 ""don't eat me"" signal. ",,
6090,1706858,1381821,Dickkopf-related protein 1 inhibitor,102660,,INHIBITOR,1,1,1,Can neutralize both human DKK1 and murine DKK1. ,,
6091,1706861,1381824,Delta-like protein 4 inhibitor,114877,,INHIBITOR,1,1,1,,,
6092,1706865,1381827,Epidermal growth factor-like protein 7 inhibitor,114933,,INHIBITOR,1,1,1,Blocks endothelial cell adhesion to the EGFL7 protein.,,
6093,1706869,1381830,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
6094,1706871,1381831,Epidermal growth factor receptor erbB1 cross-linking agent,9,,CROSS-LINKING AGENT,1,1,1,Binds to the EGFR and to the high-affinity immunoglobulin G (IgG) receptor CD64 both separately and simultaneously. Mediates antibody-dependent cell-mediated cytotoxicity (ADCC) with lysis of EGFR overexpressing cell lines.,,
6095,1706871,1381831,High affinity immunoglobulin gamma Fc receptor I cross-linking agent,101161,,CROSS-LINKING AGENT,1,1,1,Binds to the EGFR and to the high-affinity immunoglobulin G (IgG) receptor CD64 both separately and simultaneously. Mediates antibody-dependent cell-mediated cytotoxicity (ADCC) with lysis of EGFR overexpressing cell lines.,,
6096,1706875,1381833,Epidermal growth factor receptor erbB1 antagonist,9,,ANTAGONIST,1,1,1,Induces antibody-dependent cell-mediated cytotoxicity (ADCC).,,
6097,1706880,1540531,Endosialin inhibitor,114936,,INHIBITOR,1,1,1,,,
6098,1706889,1381842,Receptor tyrosine-protein kinase erbB-3 antagonist,102678,,ANTAGONIST,1,1,1,Blocks ligand-dependent activation (phosphorylation) of ErbB3.,,
6099,1706897,1381850,Coagulation factor VIII inhibitor,10210,,INHIBITOR,1,1,1,Partially  inhibits  Factor  VIII  activity  (FVIII:C). Inhibits 40% to 70% of FVIII:C in in vitro in the presence of excess antibody.,,
6100,1706900,1381852,Fibronectin other,17040,,OTHER,1,1,1,Used as radiolabelled antibody radretumab.,,Targets the ED-B domain of Fibronectin.
6101,1706905,1381857,Disialoganglioside GD2 other,109548,,OTHER,1,1,1,"APN301 is designed to localize GD2-positive tumor cells via the antibody component. The fused IL2 then stimulates the patient's immune system against the tumor by activation of both, NK and T cells, whereas the Fc portion of the antibody is designed to trigger tumor cell killing by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). ",,
6102,1706906,1381858,Disialoganglioside GD2 other,109548,,OTHER,1,1,1,Mediates cell (ADCC)- and complement (CDC)-dependent cytotoxicity of cultured human melanoma cells.,,
6103,1706909,1381861,Disialoganglioside GD2 other,109548,,OTHER,1,1,1,Mimics the GD2 glycopeptide antigen eliciting both a humoral and cellular anti-GD2 immune response. ,,
6104,1706915,1381866,Disialoganglioside GD2 inhibitor,109548,,INHIBITOR,1,1,1,Induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).,,
6105,1706916,1381867,Claudin-18 binding agent,114820,,BINDING AGENT,1,1,1,"Antibody drug conjugates (ADCs), coupled to a cytotoxic agent.",Against isoform 2 of Claudin-18.,
6106,1706919,1381869,Ganglioside GD3 other,109803,,OTHER,1,1,1,Interacts with CD16/Fc gamma RIIIa and triggers antibody-dependent cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).,,
6108,1706923,1381873,Granulocyte-macrophage colony-stimulating factor inhibitor,114916,,INHIBITOR,1,1,1,,,
6109,1706937,1381882,Envelope glycoprotein gp160 inhibitor,103744,,INHIBITOR,1,1,1,Blocking its attachment to CD4 cells. Immunoprophyaxis HIV1 infection.,,
6110,1706939,1381884,Envelope glycoprotein gp160 inhibitor,103744,,INHIBITOR,1,1,1,,,
6111,1706953,1381895,Ig epsilon chain C region inhibitor,229,,INHIBITOR,1,1,1,,,
6112,1706955,1381896,Ig epsilon chain C region inhibitor,229,,INHIBITOR,1,1,1,,,
6113,1706958,1381897,Ig epsilon chain C region inhibitor,229,,INHIBITOR,1,1,1,,,
6114,1706959,1381898,Interleukin-1 receptor antagonist,198,,ANTAGONIST,1,1,1,Binds the third immunoglobulin domain of the interleukin-1 receptor type 1 (IL-1R1) and nonselectively inhibits the activity of both forms of IL-1 (IL-1alpha and IL-1beta).,,
6115,1706962,1381900,Interleukin-10 inhibitor,114881,,INHIBITOR,1,1,1,,,
6116,1706967,1381905,Interleukin-13 inhibitor,109782,,INHIBITOR,1,1,1,,,
6117,1706969,1381907,Interleukin-15 inhibitor,114915,,INHIBITOR,1,1,1,Neutralizes IL-15 biologic activity.,,
6118,1706981,1381914,T-cell surface antigen CD4 inhibitor,10476,,INHIBITOR,1,1,1,Non-depleting.,,
6119,1706983,1381915,Tumor necrosis factor receptor superfamily member 5 inhibitor,103491,,INHIBITOR,1,1,1,"Engagement of CD40 by PG102 induces formation of a dysfunctional CD40 signaling complex characterized by altered TNFR-associated factor (TRAF) recruitment and association, with resultant ineffective induction of kinase and transcription factor activation. Importantly for potential therapeutic applications, although PG102 did not inhibit CD154–CD40 binding, it inhibited and prevented CD154-induced CD40 activation. ( Do not confuse with PG102, a water soluble extract from Actinidia arguta).",,
6120,1706986,1381918,CD40 ligand inhibitor,109787,,INHIBITOR,1,1,1,"Inhibits, dose-dependently, antigen-specific immune responses to tetanus toxoid in Cynomolgus monkeys.",,
6121,1706991,1381921,Intercellular adhesion molecule 3 inhibitor,114823,,INHIBITOR,1,1,1,,,
6122,1706993,1381922,Intercellular adhesion molecule-1 antagonist,11088,,ANTAGONIST,1,1,1,,,
6123,1706997,1381925,T-cell differentiation antigen CD6 binding agent,114814,,BINDING AGENT,1,1,1,Immunotoxin.,,
6124,1707000,1381927,P-selectin inhibitor,12723,,INHIBITOR,1,1,1,,,
6125,1707013,1381938,Killer cell immunoglobulin-like receptor 2DL2 inhibitor,116920,,INHIBITOR,1,1,1,"Acts as a checkpoint inhibitor by blocking the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands.",,
6126,1707013,1381938,Killer cell immunoglobulin-like receptor 2DL3 inhibitor,114987,,INHIBITOR,1,1,1,"Acts as a checkpoint inhibitor by blocking the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands.",,
6127,1707013,1381938,Killer cell immunoglobulin-like receptor 2DL1 inhibitor,114873,,INHIBITOR,1,1,1,"Acts as a checkpoint inhibitor by blocking the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands",,
6128,1707015,1381940,Killer cell immunoglobulin-like receptor 2DL1 inhibitor,114873,,INHIBITOR,1,1,1,"Blocks the interaction of the three main inhibitory KIR receptors (KIR2DL-1, -2, -3) with their ligands, the human leukocyte antigen-C (HLA-C) molecules.",,
6129,1707015,1381940,Killer cell immunoglobulin-like receptor 2DL2 inhibitor,116920,,INHIBITOR,1,1,1,"Blocks the interaction of the three main inhibitory KIR receptors (KIR2DL-1, -2, -3) with their ligands, the human leukocyte antigen-C (HLA-C) molecules.",,
6130,1707015,1381940,Killer cell immunoglobulin-like receptor 2DL3 inhibitor,114987,,INHIBITOR,1,1,1,"Blocks the interaction of the three main inhibitory KIR receptors (KIR2DL-1, -2, -3) with their ligands, the human leukocyte antigen-C (HLA-C) molecules.",,
6131,1707027,1381951,Mucosal addressin cell adhesion molecule-1 inhibitor,10359,,INHIBITOR,1,1,1,,,
6132,1707038,1381960,Myeloid cell surface antigen CD33 binding agent,81,,BINDING AGENT,1,1,1,Immunotoxin.,,
6133,1707039,1926921,Growth/differentiation factor 8 inhibitor,109584,,INHIBITOR,1,1,1,,,
6134,1707048,1381968,Beta-nerve growth factor inhibitor,103854,,INHIBITOR,1,1,1,,,
6135,1707051,1381970,Osteopontin inhibitor,104033,,INHIBITOR,1,1,1,,,
6136,1707062,1381979,Subtilisin/kexin type 9 inhibitor,12353,,INHIBITOR,1,1,1,"Inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) binding to hepatic low density lipoprotein receptor (LDL-r), thereby blocking PCSK9-mediated degradation of LDL-r.",,
6137,1707069,1381984,Platelet-derived growth factor receptor beta inhibitor,197,,INHIBITOR,1,1,1,,,
6138,1707080,1381995,Glutamate carboxypeptidase II other,184,,OTHER,1,1,1,"Recognizes conformational epitopes on FOLH1, mediates anti-body-dependent cellular cytotoxicity (ADCC), and is internalized.",,
6139,1707087,1382002,Parathyroid hormone-related protein inhibitor,114830,,INHIBITOR,1,1,1,,,
6140,1707106,1382013,Myelin-associated glycoprotein inhibitor,101337,,INHIBITOR,1,1,1,,,
6141,1707117,1382022,Tenascin binding agent,114817,,BINDING AGENT,1,1,1,Radioimaging and radioimmunotherapeutic activities.,,
6142,1707118,1382023,Tenascin other,114817,,OTHER,1,1,1,Immunocytokine. Immunomodulator.,,Antibody F16 specific to the alternatively spliced A1 domain of tenascin-C
6143,1707119,1382024,Tenascin binding agent,114817,,BINDING AGENT,1,1,1,To be used radiolabelled for radioimaging or radioimmunotherapeutic applications.,,A1 domain of tenascin-C.
6144,1707121,1382025,Transforming growth factor beta-1 inhibitor,104258,,INHIBITOR,1,1,1,,,
6145,1707125,1382027,TNF-alpha inhibitor,185,,INHIBITOR,1,1,1,,,
6146,1707131,1382029,Fibronectin binding agent,17040,,BINDING AGENT,1,1,1,Immunocytokine. Immunostimulant.,,Directed against the extra-domain B (ED-B) of fibronectin (L19).
6147,1707137,1382031,T-cell receptor inhibitor,109802,,INHIBITOR,1,1,1,,,
6148,1707160,1382048,Fibronectin binding agent,17040,,BINDING AGENT,1,1,1,Immunocytokine. Immunostimulant.,,
6149,1707171,1382053,Interleukin-6 inhibitor,104209,,INHIBITOR,1,1,1,,,
6150,1707178,1382056,Interleukin-8 inhibitor,10040,,INHIBITOR,1,1,1,"Blocks the binding of IL-8 to IL-8 receptors and inhibits IL-8-dependent neutrophil activation, migration, and degranulation.",,
6151,1707179,1382057,Interleukin-8 inhibitor,10040,,INHIBITOR,1,1,1,,,
6155,1702148,26851,Thromboxane-A synthase inhibitor,248,,INHIBITOR,1,1,1,"Terbogrel mode of action combines the inhibition of the thromboxane A2 (TxA2) receptor with the inhibition of thromboxane A synthase. This combination not only blocks the formation and action  of TxA2, but it also leads to an enhanced local production of antithrombotic prostaglandins. This mechanism provides potent antithrombotic action without affecting systemic haemostasis.",,
6156,2472959,1926911,Nonstructural protein 5A inhibitor,108438,,INHIBITOR,1,1,1,,,
6157,1697370,1380602,Glucagon-like peptide 1 receptor agonist,11758,,AGONIST,1,1,1,,,
6158,1697535,1380936,Toxin B inhibitor,109801,,INHIBITOR,1,1,1,,,
6159,2794243,2096419,"PARP 1, 2 and 3 inhibitor",109545,,INHIBITOR,1,1,1,In patients with BRCA mutation,,
6160,2792993,2096393,SMN2 pre-mRNA positive modulator,116819,,POSITIVE MODULATOR,1,1,1,SPINRAZA was shown to increase exon 7 inclusion in SMN2 messenger ribonucleic acid (mRNA) transcripts and production of full-length SMN protein ,,
6161,2583178,2039237,Cyclin-dependent kinase 4 inhibitor,12946,,INHIBITOR,1,1,1,,,
6162,2583178,2039237,Cyclin-dependent kinase 6 inhibitor,10480,,INHIBITOR,1,1,1,,,
6163,1702674,76760,Monoamine oxidase B inhibitor,104,,INHIBITOR,1,1,1,Highly selective and reversible MAO-B inhibitor ,,
6164,1937950,1592326,Mu opioid receptor antagonist,129,,ANTAGONIST,1,1,1,,,
6165,1702588,1377965,Tryptophan 5-hydroxylase inhibitor,116867,,INHIBITOR,1,1,1,"Prodrug, in vitro inhibitory potency of telotristat towards tryptophan hydroxylase is 29 times higher than that of telotristat ethyl",,
6166,1702930,675842,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,"Prodrug - activity due to metabolite, 21-desDFZ",,
6167,2583604,2039345,Sphingosine 1-phosphate receptor modulator,105736,,MODULATOR,1,1,1,"Amiselimod (also known as MT-1303) is another oral S1P receptor modulator, and is converted to its active metabolite amiselimod phosphate in vivo. Amiselimod showed greater affinity for S1P1 than for S1P2–5 receptors in human cells and, unlike fingolimod phosphate, had little agonistic activity at human S1P3 receptors",,
6168,2791714,2096372,Beta amyloid A4 protein inhibitor,10656,,INHIBITOR,1,1,1,,selectively binds soluble amyloid β (Aβ) protofibrils,
6169,2792318,2096381,Alpha-synuclein inhibitor,102780,,INHIBITOR,1,1,1,"Recombinant human antibody that prevents alpha-synuclein cell-to-cell transmission, and thus propagation of Lewy body pathology",,
6170,2791066,2096359,C-type lectin domain family 4 member C inhibitor,105430,,INHIBITOR,1,1,1,Humanized IgG1 mAb that specifically recognizes BDCA2 expressed exclusively on the surface ofplasmacytoid dendritic cells (pDCs). BIIB059 binding triggers BDCA2 internalization and potently inhibits TLR7/9-induced Type I IFN and other cytokines produced by pDCs,,
6171,2792319,2096382,Unknown,,,,1,1,1,May lead to replacement of myelin on damaged nerve fibres,,
6172,2792997,2096397,SOD1 mRNA inhibitor,116921,,INHIBITOR,1,1,1,Thought to reduce the production of SOD1 protein,,
6173,2791067,2283020,Beta-secretase 1 inhibitor,12252,,INHIBITOR,1,1,1,"Orally bioavailable small molecule BACE1 inhibitor, has shown robust lowering of cerebral amyloid-beta in preclinical and clinical studies",,
6174,2472696,1926771,Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 inhibitor,114926,,INHIBITOR,1,1,1,Antagonism of LINGO-1 exhibits neuroprotective effects in animal models,,
6175,1703484,430597,Human herpesvirus 1 DNA polymerase inhibitor,27,,INHIBITOR,1,1,1,,,
6176,1704048,27624,Mu opioid receptor agonist,129,,AGONIST,1,1,1,,,
6194,2583196,88648,Unknown,,,,1,1,1,"It is a component in the formulation of soaps, rinses, and shampoos, etc. It acts as a metabolic uncoupler to reduce the sludge growth in activated sludge cultures.",,
6195,1702208,40940,Unknown,,,,1,1,1,,,
6196,1699323,150722,Cyclooxygenase-1 inhibitor,96,,INHIBITOR,1,1,1,"It acts by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions.",,PDBe: 1ht8 (The 2.7 angstrom resolution model of ovine COX-1 complexed with alclofenac)
6197,1699603,83245,Translocator protein partial agonist,101532,,PARTIAL AGONIST,1,1,1,The anxiolytic and anticonvulsant properties of alpidem appear to be elicited both with a direct mechanism through the interaction with central benzodiazepine receptor (CBR) and with an indirect mechanism by the interaction with peripheral benzodiazepine receptor (PBR) as well as the stimulation of pregnenolone formation.,Alpidem binds with nanomolar affinity both peripheral benzodiazepine receptor (PBR) (Ki =0.5-7 nM) and central benzodiazepine receptor CBR (Ki =1-28 nM).,
6198,1699619,176014,Dopamine D1 and D2 receptor antagonist,105040,,ANTAGONIST,1,1,1,"Amineptine is a selective inhibitor of dopamine reuptake and its effects are selectively exerted on the mesolimbocortical system, resulting in reactivation of this system.",,
6199,1706305,60246,Unknown,,,,1,1,1,,,
6200,1702218,2366,Unknown,,,,1,1,1,"The mechanisms by which sodium amobarbital reduces both pain and sensory abnormalities are unknown. Possibly more than one mechanisms account for the observed effects. Sodium amobarbital has been shown to produce a reversible depression of the central nervous system (CNS), may exert a euphoric effect, and preferentially suppresses polysynaptic responses both at the level of the spinal cord and subcortical and cortical levels. On the peripheral nervous system, sodium amobarbital selectively depresses transmission through autonomic ganglia and reduction of choline esters nicotinic excitation. The inhibitory effects of sodium amobarbital have been reported to occur at the gamma-aminobutyric acid (GABA) sites, and at the NMDA (n-methyl d-aspartate) receptor as a non-competitive receptor antagonist. In general, sodium amobarbital enhances GABA-A inhibition in multiple peripheral and central nervous system sites and also exerts noncompetitive antagonistic effects on AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors, as well as kainate and NMDA receptors. It is possible that the noncompetitive NMDAreceptor antagonistic action of sodium amobarbital may be responsible for the substantial alteration of cutaneous (centrally mediated) hyperesthesia. (PMID: 19264049 )",,
6201,1703184,1378211,Unknown,,,,1,1,1,"The mechanisms by which sodium amobarbital reduces both pain and sensory abnormalities are unknown. Possibly more than one mechanisms account for the observed effects. Sodium amobarbital has been shown to produce a reversible depression of the central nervous system (CNS), may exert a euphoric effect, and preferentially suppresses polysynaptic responses both at the level of the spinal cord and subcortical and cortical levels. On the peripheral nervous system, sodium amobarbital selectively depresses transmission through autonomic ganglia and reduction of choline esters nicotinic excitation. The inhibitory effects of sodium amobarbital have been reported to occur at the gamma-aminobutyric acid (GABA) sites, and at the NMDA (n-methyl d-aspartate) receptor as a non-competitive receptor antagonist. In general, sodium amobarbital enhances GABA-A inhibition in multiple peripheral and central nervous system sites and also exerts noncompetitive antagonistic effects on AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors, as well as kainate and NMDA receptors. It is possible that the noncompetitive NMDAreceptor antagonistic action of sodium amobarbital may be responsible for the substantial alteration of cutaneous (centrally mediated) hyperesthesia. (PMID: 19264049 )",,
6202,1700964,1376807,Unknown,,,,1,1,1,Coronary artery dilator,,
6203,1700915,1376759,Unknown,,,,1,1,1,,,
6204,1702441,254983,Prostaglandin-H2 D-isomerase inhibitor,109622,,INHIBITOR,1,1,1,"Non-narcotic analgesic, which also has some anti-inflammatory properties",,
6205,1702757,453649,Uridine 5'-monophosphate synthase inhibitor,101114,,INHIBITOR,1,1,1,"The primary action of this compound is related to the activity of the nucleoside 6-azauridine, which is a structural analog of uridine. In mammalian systems, 6-azauridine, after its metabolic conversion to 6-azauridine-5′-phosphate, competitively inhibits intracellular pyrimidine nucleotide synthesis. The mechanism of inhibition is related to a competition beween orotidine-5'-phosphate and 6-azauridine-5'-phosphate for the enzyme orotidylate decarboxylase.",,
6206,1700598,621308,Xanthine dehydrogenase inhibitor,149,,INHIBITOR,1,1,1,"Bendazac has anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties, but its principal effect is to inhibit the denaturation of proteins. It protects lens proteins from denaturation, aggregation and precipitation in the medical treatment of senile cataract. Inhibits xanthine oxidase (XO) but not xanthine dehydrogenase (XDH). The oxidation of -SH groups near the active center, during the conversion of XDH to reversible XO, produces a conformational modification which allows bendazac to bind to reversible XO inhibiting the enzyme activity. The lysine salt is better absorbed than the parent compound after oral administration.",,
6207,1699580,418415,Acyl coenzyme A:cholesterol acyltransferase 1 inhibitor,12920,,INHIBITOR,1,1,1,"Benfluorex and its metabolite have a great affinity for hydrophobic domains such us lipid bilayers. Both compounds can be incorporated into cellular membranes and modify their physical and biological properties. As a consequence they inhibit the activity of several membrane-bound enzymes involved with lipid metabolism: Acyl Coenzyme A: cholesterol-acyltransferase , phosphatidate phosphohydrolase and diacylglycerol acyltransferase. Some in vitro experiments focusing on carbohydrate metabolism have suggested that the antihyperglycemicactivity of benfluorex results from a postinsulin binding effect(s).",High afﬁnity to 5-HT2B receptors (TID: 227 /  UniProt ID: P41595) with agonist properties on these receptors. This mechanism is responsible for the induce valvular heart disease caused by benfluorex.,
6208,1700652,219327,Arachidonate 12-lipoxygenase inhibitor,11134,,INHIBITOR,1,1,1,"It acts directly on mononuclear cells, inhibiting their chemotactic response; it inhibits the lipoxygenase enzyme which converts arachidonic acid to hydroxy derivatives and the leukotrienes; and it has a mild inhibitory action on the formation of other prostaglandins.",,
6209,1706350,898847,Unknown,,,,1,1,1,,,
6210,1706353,395946,Calmodulin inhibitor,101444,,INHIBITOR,1,1,1,"Coronary vasodilator, uricosuric agent.",,
6211,1699663,46656,Unknown,,,,1,1,1,"Anthelmintic drug that uncouples electron transport, acts on the mitochondrial respiratory chain and aids in the suppression of adenosine-5’-triphosphate (ATP) synthesis via uncoupling of oxidative phosphorylation.",,
6212,1705841,871360,Unknown,,,,1,1,1,"Anthelmintic drug that uncouples electron transport, acts on the mitochondrial respiratory chain and aids in the suppression of adenosine-5’-triphosphate (ATP) synthesis via uncoupling of oxidative phosphorylation.",,
6213,1706162,1078605,Unknown,,,,1,1,1,Antipyretic analgesic drug.,,
6214,1706375,56090,Unknown,,,,1,1,1,"Buformin delays absorption of glucose from the gastrointestinal tract, increases insulin sensitivity and glucose uptake into cells, and inhibits synthesis of glucose by the liver. Buformin and the other biguanides are not hypoglycemic, but rather antihyperglycemic agents. They do not produce hypoglycemia; instead, they reduce basal and postprandial hyperglycemia in diabetics. Biguanides may antagonize the action of glucagon, thus reducing fasting glucose levels Buformin has anti-proliferative and anti-metastatic effects in endometrial cancer cells.",,
6215,1706366,209964,Transient receptor potential cation channel subfamily V member 4 inhibitor,11847,,INHIBITOR,1,1,1,"Butamben is a pain-relieving local anesthetic. It inhibits voltage-gated channels in the sensory neurons (T-type calcium channels, Cav1.2/L-type channels, Kv4 channels). It also inhibits Transient Receptor Potential A1 (TRPA1) and Transient Receptor Potential V4 (TRPV4).",,
6216,1701128,1631832,Transient receptor potential cation channel subfamily A member 1 inhibitor,101412,,INHIBITOR,1,1,1,"Butamben is a pain-relieving local anesthetic. It inhibits voltage-gated channels in the sensory neurons (T-type calcium channels, Cav1.2/L-type channels, Kv4 channels). It also inhibits Transient Receptor Potential A1 (TRPA1) and Transient Receptor Potential V4 (TRPV4).",,
6217,1702164,887229,Mineralocorticoid receptor antagonist,48,,ANTAGONIST,1,1,1,"Canrenone specifically antagonizes aldosterone at the mineralocorticoid receptor in the kidneys, thereby increasing sodium excretion and inhibiting potassium excretion.",,
6218,1702780,705687,Sigma opioid receptor agonist,11272,,AGONIST,1,1,1,"Carbetapentane suppresses the cough reflex in the central nervous system, but the exact mechanism of action is not known with certainty. The drug acts as an agonist at sigma receptors (subtype σ1).","Binding affinity (determined by competitive binding to [3H]-pentazocine-labelled sites on guinea-pig brain membranes): 75+- 28 nM, n=3",
6219,1702845,182928,Progesterone receptor modulator,36,,MODULATOR,1,1,1,"Chlormadinone acetate (CMA) shows high affinity and activity at the progesterone receptor. It has an anti-estrogenic effect and, in contrast to natural progesterone, shows moderate anti-androgenic properties. CMA acts by blocking androgen receptors in target organs and by reducing the activity of skin 5alpha-reductase. It suppresses gonadotropin secretion and thereby reduces ovarian and adrenal androgen production.","Chlormadinone acetate has a strong affinity for the progesterone receptor, one-third higher than natural progesterone.",
6222,1702823,128555,Unknown,,,,1,1,1,Cianidanol-3 inhibits lipid peroxidation by hepatotoxic chemicals and accelerates elimination of HBsAg. (PMID: 6368355) Disrupting copper homeostasis by knockdown of either CTR-1 or ATOX-1 protein can inhibit angiogenesis in endothelial cells. Dextran-Catechin (cianidanol) generates reactive oxygen species which in turns disrupts copper homeostasis by depleting the copper importer CTR-1 and copper trafficking ATOX-1 protein. So dextran-catechin potent antiangiogenic activity is mediated by disrupting copper homeostasis. (PMID: 28794411) Cianidanol in pine needle was shown to inhibit angiotensin-converting enzyme and it could be considered as a potential cardiovascular medicine. (PMID: 28827527),,
6223,1706349,1215321,Unknown,,,,1,1,1,"Cinepazide  maleate  (CM)  is  a  calcium-channel  blocker with  vasodilator  action  that  can  increase  blood  flow  to  the brain  and  peripheral  organs,  such  as  cardiac  muscle,  skeletal  muscle,  and  kidneys. CM is  known to  potentiate the  effects  of adenosine by preventing both its degradation by deaminase and its accumulation by atrial tissue. CM was found to ameliorate diabetes exacerbated  chronic cerebral hypoperfusion induced cognitive impairment  by inhibiting astrocyte  activation, preventing damage to cholinergic neurons, and reducing  BACE1  expression  in  the  hippocampus.",,
6224,1699675,898773,Unknown,,,,1,1,1,"It was withdrawn from the market (August 31, 2007) due to its potential to induce cardiac arrhythmias by a blockade of the potassium channel coded by the human ether-a`-go-go-related gene (hERG).",,
6225,1702802,1078456,Unknown,,,,1,1,1,"Cloforex is a prodrug to chlorphentermine (see PMID: 5536739). Chlorphentermine acts by facilitating the release of catecholamines, especially noradrenaline and dopamine, from nerve terminals in the brain and also inhibits their uptake. The increase in synaptic concentrations of these catecholamines causes behavioral changes including an increase in motor activity, mental alertness and excitement, causes euphoria, and suppresses appetite.",,
6226,1700343,1376406,Unknown,,,,1,1,1,,,
6227,1706201,11685,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,Non steroidal antiinflamatory drug.,,
6228,1699671,2198,Unknown,,,,1,1,1,,,
6229,1704258,1378826,Unknown,,,,1,1,1,,,
6230,1706336,231925,Estrogen receptor modulator,104682,,MODULATOR,1,1,1,"Cyclofenil is a weak non-steroidal oestrogen which has been used to induce ovulation, and more recently to treat systemic sclerosis. It is metabolized in rats, rabbits and man to cyclofenil diphenol (bis(p-hydroxyphenyl)cyclohexylidenemethane). Both of them bind to oestrogen receptors, although with a rather lower affinity than 17 beta-oestradiol.",,
6231,1702917,82895,Retinoid X receptor alpha antagonist,275,,ANTAGONIST,1,1,1,Danthron binds to the tetrameric RXRalpha-LBD and transformed the 9cRA-induced RXRalpha-LBD dimer to tetramer. It binds to RXRalpha-LBD with a stoichimetric ratio of 1:2.,,Crystal structure of tetrameric RXRalpha-LBD complexed with danthron ( PDBe ID: 3nsq)
6232,1702985,1228462,Serotonin (5-HT) receptor agonist,104841,,AGONIST,1,1,1,"It reduces appetite by increasing the amount of extracellular serotonin in the brain. Dexfenfluramine is an anorectic agent that acts by enhancing serotonergic transmission through inhibition of 5-HT reuptake by the parent compound, and through its major circulating des-ethylated metabolite, dexnorfenfluramine, which is a 5-HT reuptake inhibitor, a 5-HT and noradrenaline releasing agent, and a potent agonist at postsynaptic 5-HT2 receptors.",,
6233,2583712,255981,Unknown,,,,1,1,1,It is not fungistatic for such organisms as Penicillium or Aspergillus but is highly effective against the pathogenic species of importance in Dermatology. Its antibacterial action was found to be negligible.,,
6234,1699726,27104,Unknown,,,,1,1,1,Desinfectant with antibacterial and antifungal activity.,,
6235,1704236,1763641,Unknown,,,,1,1,1,Antimuscarinic drug,,
6236,1704223,1677867,Bacterial 70S ribosome inhibitor,105830,9806,INHIBITOR,1,1,1,"Dihydrostreptomycin binds to a specific site on the bacterial mechanosensitive channel (MscL) and modifies its conformation, thus allowing the passage of K+ and glutamate out of, and dihydrostreptomycin into, the cell. Once it is inside the cell, It binds to the S12 protein of the 30S subunit on the ribosome, inhibits translation and can cause misreading of mRNA.",,It binds to the S12 protein of the 30S subunit on the ribosome.
6237,1703561,678116,Adrenergic receptor beta antagonist,104700,,ANTAGONIST,1,1,1,"Dilevalol is a nonselective, Beta-adrenergic receptor antagonist with, Beta 2-adrenergic receptor agonist activity. It has three to six times the activity of labetalol at the Beta-receptor, but unlike labetalol, little activity at the Alpha 1-receptor. In animal studies, it causes vasodilation even in denervated limbs, which is blocked by propranolol, suggesting that these vasodilator effects are due to Beta 2-adrenergic receptor agonism. It lowers blood pressure, both in normal and hypertensive subjects. Because the fall in blood pressure correlates with a fall in peripheral vascular resistance rather than a decrease in cardiac index, it is thought to be due to the Beta 2-adrenergic receptor agonist induced vasodilation, rather than to non-specific, Beta-adrenergic receptor antagonist effects.",,
6238,1705385,2197674,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,"The pharmacologically active dipyrone metabolite, 4-methylamino-antipyrine (MAA), targets the initiation of the catalytic reaction of both COX isoforms by reducing the higher oxidation states of COX or sequestering activating peroxides. It does not compete with arachidonic acid for the catalytic site of COX. Instead it binds to the Fe3+ in the haem. In the next step, the Fe3+ is reduced and an MAA radical is formed.",,
6240,1705412,1121342,Histamine H2 receptor antagonist,102,,ANTAGONIST,1,1,1,"Ebrotidine is the first of a new generation of H2 receptor antagonists with gastroprotective activity. It stimulates epithelial cell proliferative activity and produces beneficial physicochemical changes in the gastric mucus that contribute to its gastro-protective action against ethanol-, aspirin- or stress-induced gastric mucosal damage. The antisecretory properties of ebrotidine are similar to those of ranitidine and approximately 10-fold greater than those of cimetidine. This drug exhibits anti-Helicobacter pylori activity that is synergistic with a number of antibacterial agents; it inhibits the urease enzyme and the proteolytic and mucolytic activities of H. pylori, and counteracts the inhibitory effects of H. pylori lipo-polysaccharide.",,
6241,1703818,1378425,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,"Encainide is a class IC antiarrhythmic agent having little or no effect on action-potential duration or maximum diastolic potential but decreasing the maximum rate of phase O depolarization as well as increasing atrial and ventricular effective refractory periods. In intact animals or humans, encainide increases the AH, PR, QRS, and H-V intervals while not affecting the sinus node cycle length or JT interval. It is metabolized to O-demethyl encainide (ODE) and 3-methoxy-ODE (MODE), both of which are also antiarrhythmics with similar pharmacology to encainide.",,
6243,1699914,163172,Unknown,,,,1,1,1,"Exifone possesses potent anti-radical properties, and has beneﬁcial effects on age-related cognitive disorders.",,
6244,1699737,16521,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,"It acts by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions.",,
6245,1703786,1249052,Unknown,,,,1,1,1,,,
6246,1703880,1378487,Serotonin 1d (5-HT1d) receptor agonist,105,,AGONIST,1,1,1,"Fenfluramine (FA) reduces epileptiform activity by stimulating 5-HT2C and 5-HT1D receptors, leading to enhanced GABAergic neurotransmission, and by a σ1-antagonistic action that can reduce the excitatory neurotransmission by modulating N-methyl-D-aspartate (NMDA) responses. In addition, FA also significantly decreases the noradrenaline (NAD) brain content that might contribute to its anti-epileptic effects. Fenfluramine causes the release of serotonin (5-HT) by disrupting vesicular storage of the neurotransmitter and inhibiting its reuptake. The increased 5-HT availability in the brain results in a loss of appetite.",,
6247,1699911,49226,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,"Beta-2 adrenergic receptor stimulation in the lung causes relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial airflow.",,
6248,1702250,876580,Unknown,,,,1,1,1,It is a non-steroid antiinflammatory drug.,,
6249,1702722,418438,Unknown,,,,1,1,1,"It is a mild dopamine (DA) receptor agonist, probably not directly affecting hypothalamic and/or pituitary DA receptors but indirectly via a reduced DA re-uptake at the pre-synaptic level. Fipexide may facilitate dopamine neurotransmission by inhibition of an enkephalinergic inhibitory feed-back circuit.",,
6250,1702313,1248678,Unknown,,,,1,1,1,"Flosequinan is a potent direct-acting vasodilator agent which acts on both peripheral arterial and venous vessels, by interfering with the inositol-tri- phosphate/protein kinase C pathway.",,
6251,1703289,11715,GABA-A receptor; anion channel positive allosteric modulator,104688,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,"It binds to a specific part of the GABA-A receptor, called the benzodiazepine site, which is distinct from the GABA binding site. When bound, it enhances the effect of GABA so they shut down brain activity more effectively, which broadens their spectrum of tranquillising actions.",,
6252,1703294,244737,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,Glafenine is a nonsteroidal anti-inflammatory drug that inhibits both COX isoforms.,,
6253,1699729,228897,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,,,
6254,1699933,16580,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,,It potently inhibited serotonin (5-HT) uptake with Ki values in the low nanomolar range (2.7nM),
6255,1699932,16599,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,"It is a cyclooxygenase inhibitor. This prevents the conversion of arachidonic acid into prostaglandins, which are involved in the regulation of pain, inflammation, and fever.",,
6256,2583297,1078515,Unknown,,,,1,1,1,"Improves the outgrowth of nerve cells in culture. The biochemical mechanism suggested to explain this effect was an improvement of microtubule formation in nerve cells. Isaxonine intercalates between the polar heads of phospholipids in the membrane bilayer, thereby leading to its rigidification.",,
6257,1705266,78364,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,"It inhibits the action of cyclooxygenase enzyme (COX), which produces the pro-inflammatory prostaglandins from arachidonic acids.",,
6258,1705329,424824,Cyclooxygenase-2 inhibitor,126,,INHIBITOR,1,1,1,"Cyclooxygenase 2 (COX2) is involved in the production of prostaglandins, in response to injury or certain diseases. These prostaglandins cause pain, swelling and inflammation. When COX2 is inhibited the production of these prostaglandins is blocked, and that relieves pain and inflammation.",It has the highest COX-2 selectivity of any NSAID.,It binds to a different site on the COX-2 enzyme than other COX-2 inhibitors.
6259,1705801,1249053,Monoamine oxidase inhibitor,104789,,INHIBITOR,1,1,1,"Mebanazine, a monoamine oxidase inhibitor, when injected in vivo, reduces pituitary weight, STH and LH production, DNA, RNA and alkaline phosphatase activity.",,
6260,1703574,1093573,Mucosa-associated lymphoid tissue lymphoma translocation protein 1 inhibitor,109917,,INHIBITOR,1,1,1,"Mepazine is a small molecule inhibitor of the mucosa-associated lymphoid tissue lymphoma translocation protein-1 (MALT1). It selectively inhibits the cleavage activity of recombinant and cellular MALT1 by a noncompetitive mechanism. Consequently, it inhibits anti-apoptotic NF-kB signaling and elicits toxic effects selectively on MALT1-dependent ABC-DLBCL cells in vitro and in vivo.",,
6262,1703573,842060,Androgen Receptor agonist,56,,AGONIST,1,1,1,"Methandrostenolone binds to and activates the androgen receptor (AR) causing dramatic increases in protein synthesis, glycogenolysis, and muscle strength over a short space of time.",,
6263,1701759,1676537,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
6264,1703611,704719,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
6265,1703437,22572,GABA-A receptor; anion channel positive allosteric modulator,104688,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,"Methaqualone was demonstrated to be a positive allosteric modulator at human Alpha 1,2,3,5 Beta 2,3 Gamma 2S GABA A receptors (GABAARs) expressed in Xenopus oocytes, whereas it displayed highly diverse functionalities at the Alpha 4,6 Beta 1,2,3 Delta GABAAR subtypes, ranging from inactivity (Alpha4 Beta1 Delta), through negative (Alpha 6 Beta 1 Delta) or positive allosteric modulation (Alpha 4 Beta 2 Delta, Alpha 6 Beta 2,3 Delta), to superagonism (Alpha 4 Beta 3 Delta).",,"Proposed to act through the transmembrane beta(+)/alpha(-) subunit interface of the receptor, possibly targeting a site overlapping with that of the general anesthetic etomidate.  It doesn't interact with the benzodiazepine, barbiturate, or neurosteroid binding sites."
6266,1704539,1379099,GABA-A receptor; anion channel positive allosteric modulator,104688,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,"Methaqualone was demonstrated to be a positive allosteric modulator at human Alpha 1,2,3,5 Beta 2,3 Gamma 2S GABA A receptors (GABAARs) expressed in Xenopus oocytes, whereas it displayed highly diverse functionalities at the Alpha 4,6 Beta 1,2,3 Delta GABAAR subtypes, ranging from inactivity (Alpha4 Beta1 Delta), through negative (Alpha 6 Beta 1 Delta) or positive allosteric modulation (Alpha 4 Beta 2 Delta, Alpha 6 Beta 2,3 Delta), to superagonism (Alpha 4 Beta 3 Delta).",,"Proposed to act through the transmembrane beta(+)/alpha(-) subunit interface of the receptor, possibly targeting a site overlapping with that of the general anesthetic etomidate.  It doesn't interact with the benzodiazepine, barbiturate, or neurosteroid binding sites."
6267,1704630,1379185,Unknown,,,,1,1,1,It is an opioid analgesic drug that acts on opioid receptors to produce morphine-like effects.,,
6268,1703570,33583,Serotonin 2 (5-HT2) receptor antagonist,104686,,ANTAGONIST,1,1,1,"Minaprine binds to serotonin type 2 receptors and to dopamine D1 and D2 type receptors. It also binds to the serotonin reuptake pump. Therefore, minaprine blocks the reuptake of both dopamine and serotonin. It is also, to a slight degree, cholinomimetic. Thus it may exhibit both mood-brightening and nootropic properties. It also acts as a reversible inhibitor of monoamine oxidase. It has also been found to inhibit acetylcholinesterase in a reversible and competitive way.",IC50= 85µM on homogenized rat striatum acetylcholinesterase.,
6269,1703475,788435,Serotonin 2 (5-HT2) receptor antagonist,104686,,ANTAGONIST,1,1,1,"Minaprine binds to serotonin type 2 receptors and to dopamine D1 and D2 type receptors. It also binds to the serotonin reuptake pump. Therefore, minaprine blocks the reuptake of both dopamine and serotonin. It is also, to a slight degree, cholinomimetic. Thus it may exhibit both mood-brightening and nootropic properties. It also acts as a reversible inhibitor of monoamine oxidase. It has also been found to inhibit acetylcholinesterase in a reversible and competitive way.",IC50= 85µM on homogenized rat striatum acetylcholinesterase.,
6270,1705445,265957,Adrenergic receptor alpha antagonist,104787,,ANTAGONIST,1,1,1,"Moxisylyte reduces or blocks the response to adrenaline. Because of its alpha-blocking properties, it competitively inhibits the effects of noradrenaline without effect on beta and 5-hydroxytriptamine receptors.","Moderate specificity for alpha-1 receptors. IC50 value of 86 nM was obtained for native alpha 1A subtypes from rat submaxillary gland and an IC50 value of 39 nM for native alpha-1B subtypes from rat liver. No affinity for beta adrenoceptors, D1, 5HT1A and 5HT2 receptors and moderate affinity for H1 receptors. On the native receptor subtypes also, deacetylmoxisylyte (DAM), the main active metabolite, had the same affinity as moxisylyte (IC50=25 nM for alpha1A subtypes and 34nM for alpha1B subtypes)",
6271,1703393,1078524,Unknown,,,,1,1,1,Muzolimine produces a diuresis in the loop of Henle. It has to be metabolized to generate the active compound. It inhibits active Na+K+Cl- cotransport in the cTAL segment from the lumen side.,,
6272,1696956,1381447,Lipopolysaccharide (LPS) inhibitor,109804,,INHIBITOR,1,1,1,"It binds the lipid A moiety of endotoxin, the lipopolysaccharide (LPS) component of the gram-negative bacterial cell wall.",,
6273,1703360,705834,Monoamine oxidase inhibitor,104789,,INHIBITOR,1,1,1,"Monoamine oxidase (MAO) works by interfering with the MAO enzyme, therefore increasing the concentrations of various neurotransmitters, such as Serotonin, Epinephrine, Dopamine and Norepinephrine.",Inhibition of rat brain mono-amine oxidase in vitro (I50): 7.8+- 0.5 uM,
6274,1701036,1376877,Unknown,,,,1,1,1,"Whether it increases the sensitivity of the respiratory centre to CO2 levels, acts on the chemoreceptors of the carotid body, or simply wakens the patient to enable him to co-operate with coughing is not clear.",,
6275,1705800,1249055,Alcohol dehydrogenase inhibitor,104823,,INHIBITOR,1,1,1,,,
6276,1703586,705835,Monoamine transporter inhibitor,105759,,INHIBITOR,1,1,1,It strongly inhibits the re-uptake of dopamine as well as noradrenaline and it is a relatively weak inhibitor of serotonin uptake.,Nomifensine inhibition of norepinephrine (NA) uptake by synaptosomal fractions from rat hypothalamus (IC50 = 7.0 × 10−7 M) was similar to that of nortriptyline and protriptyline. It was found to be a powerful inhibitor of NA uptake in synaptosomes obtained from whole brain (IC50 = 9.0 × 10−8 M). Nomifensine had only a moderate effect on serotonin accumulation (IC50 = 2.8 × 10−5 M).,
6277,1703648,826568,Unknown,,,,1,1,1,Oxyphenisatin alters membrane permeability leading to electrolyte flux and net loss of water. It was also shown to inhibit the growth of transformed cells in vitro.,,
6278,1702113,757917,"Carnitine O-palmitoyltransferase 1, muscle isoform inhibitor",105495,,INHIBITOR,1,1,1,"It inhibits the mitochondrial enzyme carnitine palmitoyltransferase 1 (CPT-1) and to a lesser extent CPT-2. This causes a shift in myocardial substrate utilisation from long chain fatty acids to carbohydrates, resulting in increased glucose and lactate utilization and increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency. Perhexiline maleate was also found to inhibit the activity of Mammalian target of rapamycin complex 1 (mTORC1).","It inhibits rat heart and liver carnitine palmitoyltransferase 1 (CPT1) (IC50 = 77 and 148 µM, respectively) and rat heart CPT2 (IC50 = 79 µM). It reversibly inhibits Mammalian target of rapamycin complex 1 (mTORC1) at micromolar concentrations.",
6279,1699360,16498,Unknown,,,,1,1,1,"The mechanism of action is a combination of peripheral and central actions, neither of which involves inhibition of cyclooxygenase. Since a major portion of a dose of phenacetin is rapidly metabolised to paracetamol, it seems possible that phenacetin owes some of its therapeutic activity to its main metabolite, paracetamol.",,
6280,1706122,952723,Unknown,,,,1,1,1,Inhibitor of Complex I of the mitochondrial respiratory chain. It activates AMP-activated protein kinase (AMPK).The mechanism of activation remains uncertain.,,
6281,1705547,1249056,Monoamine oxidase inhibitor,104789,,INHIBITOR,1,1,1,Phenoxypropazine is an irreversible and non-selective monoamine oxidase inhibitor.,,
6283,1705802,1248996,Unknown,,,,1,1,1,It is a tranquilizer with a separation of the anti-emetic and tranquilizing qualities. Its action is on the medullary chemoreceptor centre.,,
6284,1705451,314827,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,Inhibits the conversion of arachidonic acid into prostaglandin E2 by prostaglandin synthase in a competitive and reversible way.,,
6285,1697024,1380209,Bile acids sequestering agent,106154,,SEQUESTERING AGENT,1,1,1,Polidexide is an anion exchange resin that forms a non-absorbable complex with bile acids in the intestine thus removing the latter from the entero-hepatic circulation and facilitating their excretion in the faeces.,,
6288,1703656,31171,Sodium channel protein type V alpha subunit blocker,11480,,BLOCKER,1,1,1,"Prenylamine is a potent sodium channel (NaCh) blocker during voltage clamp conditions in vitro and a long-acting local anesthetic (LA) when injected into rats for blockage of sciatic nerve in vivo. It interacts with calmodulin and inhibits, dose dependently, myosin light chain kinase (Ca2+-dependent protein kinase) and actomyosin( Ca2+-dependent ATPase) A nonselective inhibitor for slow Ca2+ channels, tends to prolong the cycle length to decrease the diastolic depolarization, the rate of rise of action potential, the amplitude of action potential. Prenylamine also affected several classic apoptosis-related proteins, including Bax, Bcl-2, and cytochrome c, and increased caspase-3 activity.","Binding of prenylamine to the sodium channels (NaChs) is highly voltage-dependent: The resting affinity (IC50 at -150 mV) for prenylamine in neuronal NaChs is 27.7 +- 1.3 uM, whereas the inactivated affinity (IC50 at -60 mV) is 0.75 +-0.02 uM— a 37-fold difference.",
6289,1699201,153476,Cholecystokinin receptor antagonist,104769,,ANTAGONIST,1,1,1,"Proglumide is a drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It specifically and competitively inhibits the effects and the receptor-binding of gastrin and the closely related peptide, cholecystokinin.",Inhibition was reversible and competitive in nature with a KI of 0.7 mM,
6290,1705374,18271,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,Non-selective beta blocker clinical candidate. It was never used clinically.,,
6291,1701840,1377615,Butyrylcholinesterase inhibitor,10532,,INHIBITOR,1,1,1,"Propanidid is a competitive inhibitor of serum cholinesterase, and neuromuscular plaque and brain acetylcholinesterase.  It is an intravenous anesthetic that has been used for rapid induction of anesthesia and for maintenance of anesthesia of short duration.",,
6292,1701724,1377503,Diamine oxidase activator,10664,,ACTIVATOR,1,1,1,"Proxibarbal is a non-sedative barbiturate with a specific anti-serotonin and anti-histamine effect, due to enzyme induction of serotoninase and histaminase. Its lack of unpleasant side-effects permits its use for the preventive treatment of migraine.",,
6293,1701224,1377063,Monoamine transporters; Norepinephrine & dopamine inhibitor,104870,,INHIBITOR,1,1,1,"It is an inhibitor of the transporters for certain monoamine neurotransmitters, including dopamine and norepinephrine, preventing their uptake.",,
6294,1703624,27616,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,"Remoxipride binds specifically to the D2 receptor and has little affinity for other central receptors e.g. adrenergic, muscarinic and 5-HT receptors. Therefore, the incidence of adverse effects is less than with other antipsychotics. Dopamine binding to the D2 receptor inhibits the prolactin release from the pituitary into plasma, and therefore, D2 antagonism induces its release.",,
6295,1703401,2197427,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,"Remoxipride binds specifically to the D2 receptor and has little affinity for other central receptors e.g. adrenergic, muscarinic and 5-HT receptors. Therefore, the incidence of adverse effects is less than with other antipsychotics. Dopamine binding to the D2 receptor inhibits the prolactin release from the pituitary into plasma, and therefore, D2 antagonism induces its release.",,
6296,1699368,16088,Cannabinoid CB1 receptor antagonist,87,,ANTAGONIST,1,1,1,"Rimonabant, a selective cannabinoid CB1 receptor antagonist, given systemically reduces the increase of the concentration of dopamine in the dialysate from the shell of the nucleus accumbens, which occurs when rats are exposed to novel high palatable foods.",,
6297,1699273,10813,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,"Sertindole was developed as an antipsychotic drug. It is a potent antagonist at dopamine D2, serotonin 5-HT2, and α1-adrenergic receptors with high affinity. Additionally, Sertindole suppresses potassium channel in the brain and heart. It also induces both autophagy and ROS generation in neuroblastoma cells.","It has high affinity for dopamine D2, serotonin 5-HT2, and α1-adrenergic receptors.",
6298,1701472,23417,"Endothelin receptor, ET-A/ET-B antagonist",104833,,ANTAGONIST,1,1,1,"Sitaxentan is a competitive antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors. Under normal conditions, endothelin-1 binding of ET-A or ET-B receptors causes pulmonary vasoconstriction. By blocking this interaction, Sitaxentan decreases pulmonary vascular resistance",,
6299,1702650,1378010,"Endothelin receptor, ET-A/ET-B antagonist",104833,,ANTAGONIST,1,1,1,"Sitaxentan is a competitive antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors. Under normal conditions, endothelin-1 binding of ET-A or ET-B receptors causes pulmonary vasoconstriction. By blocking this interaction, Sitaxentan decreases pulmonary vascular resistance",,
6300,1700780,110103,DNA polymerase catalytic subunit inhibitor,101616,,INHIBITOR,1,1,1,"It derives its antiviral activity from selective conversion by a specific thymidine kinase, present in certain DNA viruses, to nucleotides which in turn interfere with viral DNA synthesis. This viral thymidine kinase is different from the thymidine kinase present in mammalian cells. Sorivudine isnot a substrate for mammalian thymidine kinase, thus explaining the selectivity of this drug.","Sorivudine has antiviral activity against several viruses including varicella zoster virus, herpes simplex type 1 virus, Epstein-Barr virus.",
6301,1699451,1503088,Unknown,,,,1,1,1,It has been reported that sparteine activates acetylcholine receptors (nicotinic and muscarinic) and inhibits Na+ and K+ channels,"Sparteine has a higher affinity for muscarinic than nicotinic acetylcholine receptors (IC50s of 21 vs. 331 mM, respectively) as measured by the displacement of radiolabeled ligands. sparteine and acetylcholine also compete for a common binding site [",
6302,1699315,233553,Unknown,,,,1,1,1,Blood sugar lowering drug,,
6303,1702194,93930,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,"Bacteria and some protozoa are unable to obtain folic acid from the environment, and must synthesize it by converting PABA (para-aminobenzoate) to dihydropteroate using the enzyme dihydropteroate synthase. Sulfadimethoxine, being structurally similar to PABA, acts as a competitive inhibitor. It binds to the enzyme's active site and prevents the synthesis of folic acid from progressing. Folic acid is necessary for these organisms to produce nucleic acids, which are required for cell division. Thus, it has a microbiostatic effect rather than a microbiocidal one, and has the strongest effect in the beginning stages of an infection, when the pathogen is rapidly dividing.",,
6304,1704978,1379523,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,"Bacteria and some protozoa are unable to obtain folic acid from the environment, and must synthesize it by converting PABA (para-aminobenzoate) to dihydropteroate using the enzyme dihydropteroate synthase. Sulfadimethoxine, being structurally similar to PABA, acts as a competitive inhibitor. It binds to the enzyme's active site and prevents the synthesis of folic acid from progressing. Folic acid is necessary for these organisms to produce nucleic acids, which are required for cell division. Thus, it has a microbiostatic effect rather than a microbiocidal one, and has the strongest effect in the beginning stages of an infection, when the pathogen is rapidly dividing.",,
6305,1702152,2516,Bacterial dihydropteroate synthase inhibitor,106168,,INHIBITOR,1,1,1,"It acts as competitive inhibitor of dihydropteroate synthase, an enzyme that uses PABA as a substrate for the synthesis of folic acid.",,
6306,1702191,418491,Voltage-gated calcium channel blocker,105734,,BLOCKER,1,1,1,Suloctidil is a molecule with calcium antagonist properties and anti-ionophoretic effect. The stimulatory effect of suloctidil on the release of the platelet inhibitor PGI2 from the vascular endothelium might contribute to the known antiplatelet and antithrombotic activity of this drug. Suloctidil acts to inhibit serum TxB2 generation.,,
6307,1705552,1379765,Bacterial DNA gyrase inhibitor,105577,,INHIBITOR,1,1,1,"The bactericidal activity of temafloxacin and other fluoroquinolones is attributed to inhibition of bacterial DNA gyrase (topoisomerase II), an enzyme that regulates supercoiling and uncoiling of DNA.",,
6308,1706143,19569,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,"In humans, terfenadine is well absorbed and it is metabolized by two routes, i.e. N-dealkylation to azacyclonol and hydroxylation of the t-butyl group to form hydroxyterfenadine. Hydroxyterfenadine undergoes subsequent oxidation to the corresponding carboxylic acid, which is thought to be the biologically active antihistamine.",,
6309,1702309,551160,Muscarinic acetylcholine receptor antagonist,104691,,ANTAGONIST,1,1,1,"Terodiline has non-selective anticholinergic and calcium blocking effects within the same concentration range, the anticholinergic effect predominating at low and the calcium entry blocking action at high concentrations.",,
6310,1702027,1377797,GABA-A receptor; anion channel positive allosteric modulator,104688,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,Tetrazepam is a benzodiazepine site agonist and binds unselectively to type 1 and type 2 benzodiazepine site types as well as to peripheral benzodiazepine receptors. The muscle relaxant properties of tetrazepam are most likely due to a reduction of calcium influx.,"Tetrazepam was approximately one-seventh as potent as diazepam at the central receptor and as potent as diazepam at the peripheral binding site. Tetrazepam did not distinguish type I from type II central benzodiazepine receptors, as evidenced by comparable affinities for the cerebellar and hippocampal receptors.",
6311,1701956,1377728,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,,,
6312,1701471,2819,Unknown,,,,1,1,1,Uricosuric diuretic action,,
6313,1699174,2084,Aldose reductase inhibitor,242,,INHIBITOR,1,1,1,"It reduces the flux of glucose through the polyol pathway, inhibiting tissue accumulation of sorbitol and fructose and preventing reduction of redox potentials.","Tolrestat inhibited in dose-dependent fashion the aldose reductase from bovine lenses (IC50, 3.5 X 10(-8) mol/L) and the formation of sorbitol in human red blood cells incubated with glucose (IC50, 3 X 10(-8) mol/L)",PDBe: 2fzd
6314,2583614,1249058,Unknown,,,,1,1,1,,,
6315,1700763,27105,Unknown,,,,1,1,1,,,
6317,1705817,316600,Delta(24)-sterol reductase inhibitor,105655,,INHIBITOR,1,1,1,"Inhibits 24-dehydrocholesterol reductase, which catalyzes the final step of cholesterol biosynthesis, the conversion of desmosterol into cholesterol. This results in tissue accumulation of desmosterol, which in turn is responsible for the side effects of triparanol.",,
6319,1699327,452538,Unknown,,,,1,1,1,,,
6320,1702081,1377851,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,Induces prolactin secretion without any estrogenic or progestagenic effects.,,
6321,1702298,644928,Unknown,,,,1,1,1,"It has been used therapeutically as a vasodilator and antihypertensive agent, particularly in cerebrovascular disorders. Vincamine relaxes the smooth muscle cells within the walls of blood vessels. This increases the blood flow to the brain which subsequently improves the supply of glucose, oxygen and other important nutrients. Also, Vincamine activates the locus coeruleus (LC), which is an area in the brain responsible for various physiological processes. These include stress, attention and arousal. The LC is a wakefulness-promoting centre that regulates the levels of alertness. Therefore, when Vincamine is ingested it affects the LC which results in a higher alertnes.",,
6322,1705781,1249059,Unknown,,,,1,1,1,,,
6323,1702335,478003,Thrombin inhibitor,11,,INHIBITOR,1,1,1,"Ximelagatran is a prodrug that undergoes rapid enzymatic conversion to the active compound melagatran. Melagatran is a potent, competitive, and reversible direct inhibitor binding to the active site of soluble and clot-bound α-thrombin. It inhibits coagulation.",,"Melagatran, the active molecule, binds to the arginine side pocket of thrombin."
6324,1702154,1532522,Serotonin (5-HT) receptor antagonist,104841,,ANTAGONIST,1,1,1,"Zimelidine (ZIM) and its main active metabolite norzimelidine (NZIM) have been shown to preferentially inhibit 5-hydroxytryptamine (5-HT, serotonin) neuronal uptake both in vitro and in vivo while having much less effect on noradrenaline (NA) uptake. ZIM in vivo blocked the 5-HT uptake mechanism in the cerebral cortex, hippocampus, striatum, hypothalamus and spinal cord, thus indicating effects on both the ascending and descending 5-HT pathways. ZIM is devoid of a 5-HT releasing action, MAO-inhibitory properties and effects on dopamine (DA) uptake",,
6325,1699307,2197274,Unknown,,,,1,1,1,Nonsteroidal anti-inflammatory agent. It is an inhibitor of prostaglandin synthesis.,,
6327,1706662,1381688,Tumor necrosis factor receptor superfamily member 10B agonist,103092,,AGONIST,1,1,1,,,
6328,1976825,1626784,Hemagglutinin inhibitor,103160,,INHIBITOR,1,1,1,,,
6329,2473427,1927108,Vascular endothelial growth factor A inhibitor,187,,INHIBITOR,1,1,1,,,
6331,1706883,1381839,Receptor protein-tyrosine kinase erbB-2 binding agent,188,,BINDING AGENT,1,1,1,,,
6332,1697380,1380608,Myeloid cell surface antigen CD33 binding agent,81,,BINDING AGENT,1,1,1,,,
6333,1706768,1381762,Macrophage colony stimulating factor receptor inhibitor,12840,,INHIBITOR,1,1,1,,,
6334,1706770,1927219,Macrophage colony stimulating factor receptor inhibitor,12840,,INHIBITOR,1,1,1,,,
6335,1706948,1540525,Interferon-alpha/beta receptor alpha chain antagonist,200,,ANTAGONIST,1,1,1,,,
6336,1707077,1381992,Glutamate carboxypeptidase II binding agent,184,,BINDING AGENT,1,1,1,,,
6337,1707084,1381999,Glutamate carboxypeptidase II binding agent,184,,BINDING AGENT,1,1,1,,,
6339,1707181,1382059,Matrix protein 2 inhibitor,104398,,INHIBITOR,1,1,1,,,
6340,1706771,1381765,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
6341,1706669,1381693,T-cell surface glycoprotein CD3 epsilon chain inhibitor,233,,INHIBITOR,1,1,1,,,
6344,1707068,1540523,Platelet-derived growth factor receptor alpha inhibitor,12627,,INHIBITOR,1,1,1,,,
6345,1697399,1380625,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
6346,1706866,1381828,Epidermal growth factor receptor erbB1 antagonist,9,,ANTAGONIST,1,1,1,,,
6348,2473143,2039248,Epidermal growth factor receptor erbB1 binding agent,9,,BINDING AGENT,1,1,1,,,
6349,1706892,1626779,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
6350,1706867,1381829,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
6352,1697251,675439,B-lymphocyte antigen CD20 binding agent,181,,BINDING AGENT,1,1,1,,,
6355,1976826,1626785,Integrin alpha-4/beta-7 inhibitor,104768,,INHIBITOR,1,1,1,,,
6356,1706902,1926981,Folate receptor alpha binding agent,10103,,BINDING AGENT,1,1,1,,,
6357,1706895,1381848,Complement factor D inhibitor,105346,,INHIBITOR,1,1,1,,,
6359,1392925,1121912,C-C chemokine receptor type 4 cross-linking agent,10579,,CROSS-LINKING AGENT,1,1,1,,,
6363,1707123,1382026,Angiopoietin-1 inhibitor,108253,,INHIBITOR,1,1,1,,,
6364,1697531,1380932,CD22 inhibitor,11695,,INHIBITOR,1,1,1,,,
6365,1696265,1380670,CD22 inhibitor,11695,,INHIBITOR,1,1,1,,,
6366,1707193,1382070,Leukocyte common antigen binding agent,12088,,BINDING AGENT,1,1,1,,,
6367,1706989,1381920,Leukocyte common antigen binding agent,12088,,BINDING AGENT,1,1,1,,,
6368,1706946,1381890,Interferon gamma inhibitor,108375,,INHIBITOR,1,1,1,,,
6369,1697545,1380946,Programmed cell death protein 1 inhibitor,108437,,INHIBITOR,1,1,1,,,
6370,2473677,1927220,B-lymphocyte antigen CD19 binding agent,109546,,BINDING AGENT,1,1,1,,,
6372,1706914,1381865,Disialoganglioside GD2 inhibitor,109548,,INHIBITOR,1,1,1,,,
6373,1706908,1381860,Disialoganglioside GD2 binding agent,109548,,BINDING AGENT,1,1,1,,,
6375,1696811,1381302,Mucin-16 binding agent,109778,,BINDING AGENT,1,1,1,,,
6376,1706968,1381906,Interleukin-13 inhibitor,109782,,INHIBITOR,1,1,1,,,
6377,1707103,1382011,Sclerostin inhibitor,109783,,INHIBITOR,1,1,1,,,
6378,1707105,1382012,Sclerostin inhibitor,109783,,INHIBITOR,1,1,1,,,
6379,2473427,1927108,Angiopoietin-2 inhibitor,109785,,INHIBITOR,1,1,1,,,
6380,1707123,1382026,Angiopoietin-2 inhibitor,109785,,INHIBITOR,1,1,1,,,
6381,1706677,1381699,Epithelial cell adhesion molecule binding agent,109789,,BINDING AGENT,1,1,1,,,
6382,1696730,1381221,Epithelial cell adhesion molecule cross-linking agent,109789,,CROSS-LINKING AGENT,1,1,1,,,
6385,1707161,2096423,Interleukin-23 inhibitor,106133,9800,INHIBITOR,1,1,1,,,Alpha (p19) subunit is binding site
6386,1706757,1381753,Toxin B inhibitor,109801,,INHIBITOR,1,1,1,,,
6387,1707057,1381975,Lipopolysaccharide (LPS) inhibitor,109804,,INHIBITOR,1,1,1,,,
6388,1696956,1381447,Lipopolysaccharide (LPS) inhibitor,109804,,INHIBITOR,1,1,1,,,
6389,1706778,2039295,Tumor necrosis factor receptor superfamily member 9 agonist,114818,,AGONIST,1,1,1,,,
6391,1392871,1121858,Reticulon-4 inhibitor,114856,,INHIBITOR,1,1,1,,,
6393,1706996,1381924,Neural cell adhesion molecule 1 binding agent,114899,,BINDING AGENT,1,1,1,,,
6395,1696460,1380974,Mucin-5AC binding agent,114981,,BINDING AGENT,1,1,1,,,
6396,1392886,1763548,Mucin-5AC binding agent,114981,,BINDING AGENT,1,1,1,,,
6398,1707033,1763540,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
6399,2583420,2039299,Calcitonin gene-related peptide inhibitor,116903,,INHIBITOR,1,1,1,,,
6401,2473115,1926980,Lymphocyte differentiation antigen CD38 inhibitor,100622,,INHIBITOR,1,1,1,,,
6402,1706970,1381908,Lymphocyte differentiation antigen CD38 inhibitor,100622,,INHIBITOR,1,1,1,,,
6403,1707206,1382083,Fibroblast activation protein alpha binding agent,100186,,BINDING AGENT,1,1,1,,,
6404,1706758,1381754,Botulinum neurotoxin type A inhibitor,101110,,INHIBITOR,1,1,1,,,
6406,1707001,1381928,P-selectin antagonist,12723,,ANTAGONIST,1,1,1,,,
6408,1706879,1381836,Receptor tyrosine-protein kinase erbB-3 inhibitor,102678,,INHIBITOR,1,1,1,,,
6409,1706892,1626779,Receptor tyrosine-protein kinase erbB-3 inhibitor,102678,,INHIBITOR,1,1,1,,,
6410,1706664,1381689,ICOS ligand inhibitor,114910,,INHIBITOR,1,1,1,,,
6412,1697534,1380935,Alpha-fetoprotein binding agent,114825,,BINDING AGENT,1,1,1,,,
6413,1707008,1381934,Transferrin receptor protein 1 antagonist,114821,,ANTAGONIST,1,1,1,,,
6414,2583419,2039298,Fusion glycoprotein F0 inhibitor,116942,,INHIBITOR,1,1,1,,,
6415,1707089,1382004,Glycoprotein inhibitor,116943,,INHIBITOR,1,1,1,,,
6416,1392950,1121937,Interferon alpha inhibitor,116937,,INHIBITOR,1,1,1,,,
6417,1706867,1381829,Low affinity immunoglobulin gamma Fc region receptor III-A cross-linking agent,116938,,CROSS-LINKING AGENT,1,1,1,,,
6419,2473430,1927111,Tumor-associated calcium signal transducer 2 binding agent,116939,,BINDING AGENT,1,1,1,,,
6420,1976829,1626788,T-cell-specific surface glycoprotein CD28 antagonist,101109,,ANTAGONIST,1,1,1,,,
6421,1392923,1121910,Granulocyte-macrophage colony-stimulating factor receptor antagonist,106148,,ANTAGONIST,1,1,1,,,
6422,1706756,1381752,Toxin A inhibitor,109800,,INHIBITOR,1,1,1,,,
6423,1392922,1121909,Tumor necrosis factor receptor superfamily member 5 antagonist,103491,,ANTAGONIST,1,1,1,,,
6424,1976822,1626781,CD27 antigen agonist,115294,,AGONIST,1,1,1,,,
6425,1697537,1380938,CD70 antigen binding agent,114874,,BINDING AGENT,1,1,1,,,
6426,1697538,1380939,CD70 antigen binding agent,114874,,BINDING AGENT,1,1,1,,,
6427,1706701,1763544,B-cell antigen receptor complex-associated protein beta chain binding agent,114813,,BINDING AGENT,1,1,1,,,
6428,1707037,1381959,Cell surface glycoprotein MUC18 inhibitor,114824,,INHIBITOR,1,1,1,,,
6429,1707158,1382046,Interleukin-18 inhibitor,104029,,INHIBITOR,1,1,1,,,
6430,1697136,1380321,Clumping factor A inhibitor,116944,,INHIBITOR,1,1,1,,,
6431,1697138,1380323,Shiga toxin subunit B inhibitor,116945,,INHIBITOR,1,1,1,,,
6432,2583010,2039200,Thymic stromal lymphopoietin inhibitor,114892,,INHIBITOR,1,1,1,,,
6433,1707141,1382035,Thymic stromal lymphopoietin inhibitor,114892,,INHIBITOR,1,1,1,,,
6434,1707205,1382082,Cell surface A33 antigen binding agent,114888,,BINDING AGENT,1,1,1,,,
6435,2138985,1763542,Interleukin-20 inhibitor,115410,,INHIBITOR,1,1,1,,,
6436,1695903,1380110,Tumor necrosis factor ligand superfamily member 13B inhibitor,106137,,INHIBITOR,1,1,1,,,
6437,2473258,1927040,Angiopoietin-related protein 3 inhibitor,112446,,INHIBITOR,1,1,1,,,
6438,1706902,1926981,Tubulin inhibitor,104766,,INHIBITOR,1,1,1,,,
6439,2472667,1926759,Thioredoxin reductase 1 inhibitor,172,,INHIBITOR,1,1,1,"It inhibits thioredoxin reductase 1 (TrxR1) disulfide reductase activity and induces an NADPH oxidase activity in TrxR1, generating ROS such as superoxide and hydrogen peroxide. ",,
6440,1704365,1378930,Unknown,,,,1,1,1,"Theophylline is a bronchodilator by relaxing brochial smooth muscle, oppose the effects of many broncho-constrictor mediators, and also relaxes smooth muscle in the urinary and biliary ways.",,
6441,1699588,314587,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,"Non-steroidal anti-inflammatory drug. Acemetacin works by blocking the effect of natural substances called cyclo-oxygenase (COX) enzymes. These enzymes help to make other chemicals in the body, called prostaglandins. Some prostaglandins are produced at sites of injury or damage, and cause pain and inflammation. By blocking the effect of COX enzymes, fewer prostaglandins are produced, which means pain and inflammation are eased.",It has modest selectivity for COX-1.,
6442,2790710,754676,Unknown,,,,1,1,1,"Although its mechanism of action is not fully known, acetarsone may bind to protein-containing sulfhydryl groups located in the parasite, thereby forming lethal As-S bonds. This may prevent their functioning and eventually kill the parasite.",,
6443,2791014,1078496,Unknown,,,,1,1,1,"L-Acetylcarnitine is an acetic acid ester of carnitine that facilitates movement of acetyl CoA into the matrices of mammalian mitochondria during the oxidation of fatty acids. In addition to its metabolic role, acetyl-L-carnitine posses unique neuroprotective, neuromodulatory, and neurotrophic properties that may play an important role in counteracting various disease processes. It is able to cross the bloodbrain barrier and enter the blood circulation in the brain. It shows a nicotinic action, principally at the neuromuscular junction, blocking the transmission. It has been demonstrated that acetate moieties of acetyl-L-carnitine play a role in increasing the potency of cholinergic and anticholinergic actions by reacting with the electrophilic or cationic site of the cholinergic receptor. It has also been reported that acetylcarnitine inhibits alcohol dehydrogenase competitively. (Acetylcarnitine competes with NAD+ (Ki = 135 mumol.L-1))",,
6444,1706283,255548,Unknown,,,,1,1,1,"Acipimox is a hypolipidemic agent. It has special application for the treatment of hyperlipidemia in non-insulin-dependent diabetic patients. Acipimox acts on the niacin receptor 1, inhibiting the enzyme triglyceride lipase. This reduces the concentration of fatty acids in the blood plasma and their inflow into the liver. Consequently, VLDL cholesterol production in the liver is reduced, which leads indirectly to a reduction in LDL and increase in HDL cholesterol (Wikipedia).",,
6445,1699350,8209,Melatonin receptor agonist,104733,,AGONIST,1,1,1,Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors.,"Melatonin receptor MT1, Ki=0.1nM / MT2, Ki=0.12nM 5-HT2C receptor, Ki=631nM",
6446,2794665,1767956,Muscarinic acetylcholine receptor M2 positive allosteric modulator,47,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,Alcuronium binds to cardiac muscarinic receptors simultaneously with their specific antagonist [3H]methyl-N-scopolamine ([3H]NMS) and allosterically increases their affinity to this ligand.,,
6447,1702349,1025553,Vitamin D receptor agonist,64,,AGONIST,1,1,1,Alfacalcidol is a vitamin D analog and is used for supplementation in humans and as a poultry feed additive.,,
6448,1702350,1377888,Estrogen receptor agonist,104682,,AGONIST,1,1,1,"Allylestrenol has the same function as Progesterone, it prepares the uterus for receiving the fertilised ovum and suppresses uterine motility. Progesterone binds to the progesterone and estrogen receptors. Once bound to the receptor, it will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge.",,
6449,2791418,657667,Unknown,,,,1,1,1,Almitrine is a respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep.,,
6450,1703216,1378242,Unknown,,,,1,1,1,It is a muscarinic antagonist. It is a potent parasympatholytic agent with antisecretory and spasmolytic actions on the gastrointestinal tract.,,
6452,1702809,389011,Serotonin (5-HT) receptor antagonist,104841,,ANTAGONIST,1,1,1,"Amisulpride blocks pre- and post synaptic dopamine D2, D3 receptors as well as the 5-HT7a receptor.","The chemical structure of amisulpride contains a chiral center and, thus, is a mixture of two optical isomers: (S)-amisulpride and (R)-amisulpride. The enantiomers bind at dopamine D2/3 and α2- adrenoceptors in a stereoselective manner with marked differences in affinity: (S)-amisulpride displays high affinity binding at both D2 and D3 receptors. On the other hand, the isomers display reversed stereoselectivity (but weaker affinity) at α2-adrenoceptors.",
6455,1706195,2580,DNA topoisomerase II inhibitor,104727,,INHIBITOR,1,1,1,"Amsacrine may intercalate into DNA and inhibit topoisomerase II, resulting in DNA double-strand breaks, arrest of the S/G2 phase of the cell cycle, and cell death. This agent's cytotoxicity is maximal during the S phase of the cell cycle when topoisomerase levels are greatest. In addition, amsacrine may induce transcription of tumor promoter p53 protein and block p53 ubiquitination and proteasomal degradation, resulting in p53-dependent tumor cell apoptosis.",,
6456,2792847,2096390,Unknown,,,,1,1,1,Amyl nitrite cause direct vasorelaxation through vascular generation of nitric oxide (NO) and relaxation via a cyclic guanosine monophosphate-dependent process.,,
6457,1706301,936561,Unknown,,,,1,1,1,"Amylmetacresol has antivial, antibactericidal, and local anesthetic properties. It is one of the two core active ingredients of throat lozenges (amylmetacresol 0.6 mg and 2,4-dichlorobenzyl alcohol 1.2mg)",,
6458,1696198,1380516,Plasminogen activator,12,,ACTIVATOR,1,1,1,"Anistreplase is an acylated form of the streptokinase-plasminogen complex. Acylation makes the complex temporarily inactive but protects it from neutralization by plasmin inhibitors. After deacylation, which begins immediately after injection, the streptokinase-plasminogen complex promotes thrombolysis by speeding the conversion of plasminogen to plasmin.",,
6459,1706327,66687,Unknown,,,,1,1,1,"The mode of action of anthralin is thought to be either through its effect on DNA, probably mitochondrial DNA, which reduces cell turnover, or through its effects on various enzyme systems, including those of polyamine synthesis and respiration.  Anthralin has been found to inhibit proliferation of keratinocytes in vivo. Oxidation of anthralin under physiological conditions results in the formation of 9-anthron-10-yl radical, a key intermediate, as well as superoxide and hydroxyl radicals. Anthralin free radicals destroy the DNA of cells and inactivate enzymes associated with cell proliferation and inflammation.",,
6460,1702788,26820,Cyclooxygenase-1 inhibitor,96,,INHIBITOR,1,1,1,"Antipyrine inhibits a brain COX isoform, COX-3. COX-3 is a COX-1 variant that retains intron 1 in its mRNA.",IC50 uM values for Antipyrine inhibition of COX enzymes: COX-1 : >1000 COX-2 : > 1000 COX-3 : 863,"Antipyrine inhibits a brain COX isoform, COX-3. COX-3 is a COX-1 variant that retains intron 1 in its mRNA."
6461,1699589,989360,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,Apazone is a non-steroidal antiinflammatory drug that has a weak anti-cyclooxygenase-1 and anti-cyclooxygenase-2 activity.,Apazone has a weak anti-cyclooxygenase-1 and anti-cyclooxygenase-2 activity.,
6462,1696761,1381252,Vasopressin receptor agonist,105773,,AGONIST,1,1,1,"Argipressin is the endogenous ligand for the known subtypes of the vasopressin receptors, V1a, V1b (V3), and V2, and could also act on the oxytocin receptor at high concentrations. V1a receptor and V2 receptor are the principal subtypes mediating the physiological function.",,
6463,2791731,1531962,Thioredoxin reductase 1 inhibitor,172,,INHIBITOR,1,1,1,,IC50 = 65 nm,
6464,2793956,1308753,Unknown,,,,1,1,1,"Bamethan exerts its beneficial effect through peripheral vasodilation, there by decreasing peripheral resistance and increasing blood flow and volume in the extremities.",,
6465,2790476,2096352,Unknown,,,,1,1,1,"Barbexaclone is a potent antiepileptic. It is a salt compound of phenobarbital and propylhexedrine. While barbexaclone has sedative properties, propylhexedrine has psychostimulant properties intended to offset these sedative effects.",,
6466,1699344,99581,Unknown,,,,1,1,1,Beclamide is a drug that possesses anticonvulsant activity.,,
6467,1696609,1381100,Unknown,,,,1,1,1,"Scientific evidence to recommend the use of A. belladonna in its natural form for any condition is insufficient, although some of its components, in particular l-atropine, which was purified from belladonna in the 1830s, have accepted medical uses. Donnatal is a pharmaceutical prescription, approved in the United States by the FDA, that combines natural belladonna alkaloids (atropine and scopolamine) in a specific, fixed ratio with phenobarbital to provide peripheral anticholinergic/antispasmodic action and mild sedation. According to its labeling, it is possibly effective for use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.",,
6468,1696581,1381072,Antithrombin-III activator,16,,ACTIVATOR,1,1,1,"Bemiparin binds to antithrombin III (AT), causing a conformational change that results in its activation. The activated AT then inactivates factor Xa and, to a lesser extent, factor II.",,
6469,1699559,270986,Unknown,,,,1,1,1,Benorilate is an ester-linked codrug of aspirin with paracetamol.,,
6470,1702775,627070,DOPA decarboxylase inhibitor,83,,INHIBITOR,1,1,1,"Benserazide has little therapeutic effect on its own, and its effect occurs synergically in combination with levodopa. Levodopa is a precursor to the neurotransmitter dopamine which is administered to increase its levels in the central nervous system. However, most levodopa is decarboxylated to dopamine before it reaches the brain, and since dopamine is unable to cross the blood–brain barrier, this translates to little therapeutic gain with strong peripheral side effects. Benserazide, a DOPA decarboxylase inhibitor, prevents the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. Benserazide cannot cross the blood–brain barrier.",,
6472,1706348,374182,Solute carrier family 22 member 12 inhibitor,102767,,INHIBITOR,1,1,1,Benzbromarone acts by suppressing uric acid reabsorption via inhibition of the uric acid transporter 1 (URAT1) in renal tubular cells. Benzbromarone (BBR) is an inhibitor of Fatty acid-binding protein 4 (FABP4). This indicates that BBR might be a new potential therapeutic agent for type 2 diabetes. Benzbromarone is a very potent inhibitor of CYP2C9.,,"Molecular docking and point mutations studies revealed that Ser55, Asp76, and Arg126 are the key residues of Fatty acid-binding protein 4 (FABP4) that bind with benzbromarone."
6473,1702937,15890,Unknown,,,,1,1,1,"Benznidazole inhibits the synthesis of DNA, RNA, and proteins within the T. cruzi parasite. Studies suggest that benznidazole is reduced by a Type I nitroreductase (NTR) enzyme of T. cruzi producing a series of short-lived intermediates that may promote damage to several macromolecules including DNA. In mammalian cells, however, benznidazole is metabolized by reduction of the nitro group to an amino group by a Type II NTR enzyme. The precise mechanism of action is not known.",,
6474,1700668,16735,Unknown,,,,1,1,1,"Benzocaine is a surface anesthetic that acts by preventing transmission of impulses along nerve fibers and at nerve endings. It binds to the sodium channel and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions. Depolarization of the neuronal membrane is inhibited, thereby blocking the initiation and conduction of nerve impulses.",,
6475,1702962,13371,Unknown,,,,1,1,1,Benzoic acid is a fungistatic compound that is widely used as a food preservative. It is a constituent of Whitfield's ointment which is used for the treatment of fungal skin diseases.,,
6476,2793356,9913,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,"Benzydamine is a nonsteroidal anti-inflammatory drug that acts partly through an inhibitory effect on the phospholipase A2 by diminishing the liberation of arachidonic acid from phospholipids, and partly as a weak inhibitor of prostaglandin G/H synthase 1 and 2 by reducing the production of prostaglandins.",Weak inhibitotor of COX-1 and COX-2,
6477,1705846,952018,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,"Benzydamine is a nonsteroidal anti-inflammatory drug that acts partly through an inhibitory effect on the phospholipase A2 by diminishing the liberation of arachidonic acid from phospholipids, and partly as a weak inhibitor of prostaglandin G/H synthase 1 and 2 by reducing the production of prostaglandins.",Weak inhibitotor of COX-1 and COX-2.,
6478,2795485,915190,Unknown,,,,1,1,1,Its pharmaceutical activity is based on depressing of thyroid hormones formation.,,
6479,2792699,32459,Histamine H3 receptor antagonist,10280,,ANTAGONIST,1,1,1,"Betahistine has a very strong affinity as an antagonist for histamine H3 receptors and a weak affinity as an agonist for histamine H1 receptors. Its efficacy can be explained by mechanisms targeting these histamine receptors (HRs) at three different levels: the vascular tree, with an increase of cochlear and vestibular blood flow involving the H1R; the central nervous system, with an increase of histamine turnover implicating the H3R, and the peripheral labyrinth, with a decrease of vestibular input implying the H3R/H4R.",Betahistine is a strong Histamine H3 receptor antagonist and a weak Histamine H1 agonist.,
6480,1702821,57488,Peroxisome proliferator-activated receptor agonist,109738,,AGONIST,1,1,1,"Bezafibrate is a peroxisome proliferator-activated receptor agonist that acts on all three receptor subtypes (alpha, delta and gamma). Bezafibrate simultaneously targets atherogenic dyslipidemia and insulin resistance without development of overweight; it reduces plasma triglycerides and glucose levels, increases HDL-C and decreases the prevalence of small, dense LDL particles.",,
6482,1699703,1121294,Histamine H1 receptor inverse agonist,127,,INVERSE AGONIST,1,1,1,"Bilastine is an H1 receptor inverse agonist. The biological effects of histamine in the allergic reaction are mediated through H1 receptors that coexist in active and inactive forms of g-protein-coupled receptors which balance each other. Histamine works as an agonist that pushes the balance to the active side leading to effects such as muscular contraction, bronchospasms, upregulation of endothelial permeability, and stimulation of sensory nerves and cough receptors. H1 antihistamines, like Bilastine, work as inverse agonists that drive the balance toward the inactive side and suppress the effects of histamine. In vitro data have also shown that bilastine exerts antiinflammatory activity by inhibiting the release of histamine, IL-4 and tumor necrosis factor (TNF)-α from human mast cells and granulocytes. It has limited penetration across the blood-brain barrier.","Bilastine has high specificity for H1-receptors while has negligible affinity for 30 other receptors (serotonin, bradykinin, leukotriene-D4, muscarinic M3-receptors, α1-adrenoceptors, β2-adrenoceptors, and H2- and H3-histamine receptors).",
6483,2790761,1015985,Coagulation factor XII activator,11288,,ACTIVATOR,1,1,1,Bismuth subgallate activates factor XII (Hageman factor) and therefore accelerates the coagulation cascade thus promoting rapid haemostasis.,,
6484,1699684,16960,GABA receptor alpha-2 subunit positive allosteric modulator,12770,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,Bromozepan acts in one of the allosteric sites of the GABA-A receptors by increasing the opening frequency of gamma-aminobutyric acid activated cloride channels.,,
6485,1696802,1381293,Unknown,,,,1,1,1,"The antiedematous, antiinflammatory, antithrombotic and fibrinolytic efficacy of bromelain suggests that several mechanisms of action are involved on different levels (see PMID: 11577981)",,
6486,2795256,418419,Unknown,,,,1,1,1,"Bromhexine is a secretolytic agent, increasing the production of serous mucus in the respiratory tract and makes the phlegm thinner and less viscous. This contributes to a secretomotoric effect by helping the cilia transport the phlegm out of the lungs. Its mechanism of action is complex and remains incompletely explored.",,
6487,1700627,34949,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,"Bromperidol has potent antagonistic effects for dopamine D2 receptors in contrast to very weak affinity for other receptors such as dopamine D1, 5-HT2, norepinephrine, and acetylcholine. It was also reported to be bactericidal and greatly enhanced the activities of several antibiotics and drug combinations against M. tuberculosis. (PMID:21576426)",,
6488,1706364,153408,Unknown,,,,1,1,1,"The exact mechanism of the anti-inflammatory role of bufexamac is still unclear. In-vitro, Bufexamac was shown to act as an inhibitor of prostaglandin synthesis and a stabiliser of rat liver lysosomes. Which of these properties is of importance in-vivo is not clarified. Bufexamac induces tubulin hyperacetylation in drug concentrations matching its antiinflammatory effect. Therefore, inhibition of histone deacetylase 6 (HDAC6) may contribute to the clinical efficacy of bufexamac. Bufexamac is a selective inhibitor of leukotriene A4 hydrolase (LTA4H), a crucial enzyme in the leukotriene B4 (LTB4) biosynthesis pathway.",,
6489,2791700,1383264,Gonadotropin-releasing hormone receptor agonist,118,,AGONIST,1,1,1,"Buserelin, a gonadotropin-releasing hormone (GnRH) agonist, is a therapeutic drug suppressing the release of Luteinizing hormone (LH) and Follicle-stimulating hormone (FSH). Initial interaction of buserelin with the GnRH receptor induces release of FSH and LH by gonadotrophes. Long-term exposure to constant levels of buserelin, rather than endogenous pulses, leads to downregulation of the GnRH receptors and subsequent suppression of the pituitary release of LH and FSH.",,
6490,2794906,1383256,Unknown,,,,1,1,1,"In vitro, butriptyline is a strong antihistamine and anticholinergic, moderate 5-HT2 and α1-adrenergic receptor antagonist, and very weak or negligible monoamine reuptake inhibitor.",(null),
6491,1696713,1381204,Unknown,,,,1,1,1,"Cadexomer iodine is an effective palliative dressing for wounds in chronic critical limb ischemia (CCLI). The antimicrobial effect of iodine prevents wet gangrene. The absorptive capacity of cadexomer beads dries necrotic tissue facilitating dry gangrene and auto-amputation without desiccating viable tissue. Cadexomer iodine enhances autolytic debridement, mitigates inflammation beyond the antimicrobial effects of iodine, and encourages granulation and epithelialization even in severely hypoperfused wounds. Cadexomer iodine delays proximal limb amputation in CCLI and may facilitate healing in some ischemic wounds.",,
6492,2794327,2197297,Unknown,,,,1,1,1,"Calamine works by its counter-irritant effect. After application to the skin the calamine evaporates, which produces a cooling effect that helps distract you from the itch. This sensation also helps relieve sunburn. Calamine lotions and creams also contain the active ingredient zinc oxide, which has soothing effect and also has antiseptic properties that help prevent infection from scratching.",,
6493,1705291,549033,Adrenergic receptor alpha-1 antagonist,104723,,ANTAGONIST,1,1,1,"Isoxsuprine is a beta-adrenoreceptor agonist and an alpha-adrenoreceptor antagonist, with both characteristics contributing to vasodilation and uterine relaxation.","Isoxsuprine has a higher affinity of α1-adrenoreceptors (Kd=59+-15nM, adrenoreceptors in rat vas deferens) than for β2-adrenoceptors ( Kd=3900+-500nM adrenoreceptors in rat vas deferens).",
6494,1706236,422175,Cytochrome P450 17A1 inhibitor,12949,,INHIBITOR,1,1,1,"Abiraterone is converted by an enzyme to the more active Δ4-abiraterone (D4A). D4A inhibits 17α-hydroxylase/17,20-lyase (CYP17A1), 3β-hydroxysteroid dehydrogenase (3βHSD) and steroid-5α-reductase (SRD5A), which are required for 5α-dihydrotestosterone (DHT) synthesis. DHT promotes signaling by the androgen receptor and the development of castration-resistant prostate cancer. D4A also antagonizes the androgen receptor.",,
6495,1706253,393440,Unknown,,,,1,1,1,"Diosmin (diosmetin 7-O-rutinoside), is a natural flavone glycoside which is indicated for the treatment of hemorrhoids, lymphedema and varicose veins. It is well known to possess antiinflammatory, antioxidant, antimutagenic and anti-hyperlipidemic properties. It has been reported that diosmin significantly increased the transport of digoxin and cellular accumulation of rhodamine-123 in Caco-2 cells by inhibition of P-gp-mediated efflux. It has also been reported a protective mechanisms on LPS-induced lung injury through inhibition of T cell receptors, pro-inflammatory cytokines and NF-kB activation.",,
6562,1697251,675439,B-lymphocyte antigen CD20 binding agent,181,,BINDING AGENT,1,1,1,"One way to enhance the effectiveness of monoclonal antibodies is to chelate radionuclides, such as yttrium-90 ((90)Y), to the antibody. (90)Y is a high-energy, beta-emitting radioisotope that delivers most of its radiation over a path length of 2 to 5 mm. Therefore, the antibody, Ibritumomab, binds to the CD20 antigen, found on the surface of normal and malignant B cells, and delivers or targets the radiation only to CD20+ cells, sparing normal cells (and B cell precursors) from the radiation.",,
6646,1706036,2197638,Calcitonin receptor agonist,119,,AGONIST,1,1,1,"Calcitonin acts to reduce blood calcium (Ca2+), opposing the effects of parathyroid hormone (PTH). More specifically, calcitonin lowers blood Ca2+ levels in two ways: Major effect: Inhibits osteoclast activity in bones. Minor effect: Inhibits renal tubular cell reabsorption of Ca2+ and phosphate, allowing them to be excreted in the urine.",,
6648,1699709,445067,Unknown,,,,1,1,1,"Camphor has been pharmaceutically applied as an analgesic, antipruritic, antispasmodic, anti-inflammatory rubefacient. In addition, camphor has been used as an antiseptic, contraceptive, aphrodisiac, and lactation suppressant. Because camphor has mild expectant, nasal decongestant, and cough-suppressant effects, camphor in ointments, oils, and inhalants has been widely used as a home treatment for colds.",,
6649,1702914,795084,Mineralocorticoid receptor antagonist,48,,ANTAGONIST,1,1,1,,,
6651,1706316,66028,Acetylcholinesterase inhibitor,105700,,INHIBITOR,1,1,1,"Carbaryl is a reversible inhibitor of the enzyme acetylcholinesterase. It resembles acetylcholine, but the carbamoylated enzyme undergoes the final hydrolysis step very slowly (minutes) compared with the acetylated enzyme generated by acetylcholine (microseconds). It interferes with the cholinergic nervous system and causes death because the effects of the neurotransmitter acetylcholine cannot be terminated by carbamoylated acetylcholinesterase.",,
6652,2793379,454298,11-beta-hydroxysteroid dehydrogenase inhibitor,109696,,INHIBITOR,1,1,1,"Carbenoxolone is an inhibitor of the steroid dehydrogenase enzymes 11 β-hydroxysteroid dehydrogenase (human) and 3α, 20 β-hydroxysteroid dehydrogenase (bacterial). It is often used as a gap junction inhibitor in neuroscience research.",,
6653,1704079,1763639,Oxytocin receptor agonist,116,,AGONIST,1,1,1,"Carbetocin is a long-acting synthetic octapeptide analogue of oxytocin with agonist properties. Like oxytocin, carbetocin binds to oxytocin receptors present on the smooth musculature of the uterus, resulting in rhythmic contractions of the uterus, increased frequency of existing contractions and increased uterine tone.",,
6654,1699629,517099,Thyroid peroxidase inhibitor,40,,INHIBITOR,1,1,1,"Carbimazole is a prodrug as after absorption it is converted to the active form, methimazole. Methimazole prevents thyroid peroxidase enzyme from coupling and iodinating the tyrosine residues on thyroglobulin, hence reducing the production of the thyroid hormones T3 and T4.",,
6655,1706329,397731,Unknown,,,,1,1,1,"Carbocisteine is a mucolytic that reduces the viscosity of sputum and so can be used to help relieve the symptoms of chronic obstructive pulmonary disorder (COPD) and bronchiectasis by allowing the sufferer to bring up sputum more easily. Carbocisteine reportedly scavenged H2O2, HOCl, OH+ and ONOO– in cell-free medium, inhibited ROS production in rat neutrophils, promoted GSH and HO-1 expression in cigarette smoke-exposed bronchial epithelial cells, and ameliorated oxidant-induced 16HBE cell apoptosis. Furthermore, carbocisteine was capable of attenuating the synthesis of pro-inflammatory cytokines following rhinovirus or respiratory syncytial virus infection. It was speculated that the efficacy of carbocisteine in COPD was more closely associated with its anti-oxidant and anti-inflammatory effects, than with mucolytic activity.",,
6656,1697444,1380847,T cell surface glycoprotein CD3 cross-linking agent,106147,,CROSS-LINKING AGENT,1,1,1,"Catumaxomab is a trifunctional bispecific monoclonal antibody with potential antineoplastic activity. Catumaxomab has two antigen-recognition sites: one for human CD3, a T cell surface antigen; and one for human epithelial cell adhesion molecule (EpCAM), a cell surface antigen expressed by a variety of epithelial tumor cells. In addition, the modified Fc portion of this antibody binds Fc receptors on antingen presenting cells (APCs) such as macrophages and dendritic cells (DCs). Catumaxomab brings T cells, EpCAM-expressing epithelial tumor cells and APCs together into tricellular complexes, which may result in a potent cytotoxic T-lymphocyte (CTL) response against EpCAM-expressing epithelial tumor cells. Fc-mediated binding of APCs in the tricellular complex potentiates EpCAM antigen presentation to T cells and the activation of anti-tumor cytotoxic T cell functions.",,
6657,1706300,180228,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,"Cefamandole is a broad-spectrum cephalosporin antibiotic which belong to a class of beta-lactam antibiotics. β-lactams disrupt bacterial cell wall biosynthesis by irreversibly inhibiting the D,D-transpeptidases that are responsible for cross-linking the pentapeptide components of polymerized peptidoglycan precursors via specific peptide linkages. This results in the weakening of the bacterial cell wall and causes cell lysis.",,
6658,1700594,1503084,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,"Cefodizime is a 3rd generation cephalosporin antibiotic with broad spectrum activity against aerobic gram positive and gram negative bacteria. It targets penicillin-binding proteins (PBPs) 1A/B, 2, and 3 resulting in the eventual death of the bacterial cell.",,
6659,2793534,104846,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,"Cefpirome is a fourth-generation cephalosporin. Cefpirome is considered highly active against Gram-negative bacteria, including Pseudomonas aeruginosa, and Gram-positive bacteria. It binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Cefpirome is a zwitterion with a net charge of zero at physiological pH that penetrates the outer membrane of Gram negative pathogens more rapidly than ceftazidime.",,
6660,2792102,1799684,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,"Cefsulodin is a semi-synthetic, third-generation cephalosporin antibiotic with a narrow spectrum of activity. It has activity against Pseudomonas aeruginosa and Staphylococcus aureus but little activity against other bacteria. It binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Cefsulodin inhibits PBP 1a and 1b.",,
6661,2792101,36502,Beta-2 adrenergic receptor partial agonist,43,,PARTIAL AGONIST,1,1,1,"Celiprolol was developed as a third-generation β-adrenoceptor antagonist with selective β1-antagonist, partial β2-agonist, and mild α2-antagonist actions. Given this combination of effects, celiprolol may be better described as a selective adrenoreceptor modulator. It has antihypertensive and antianginal properties.",,
6662,1696216,1380534,Unknown,,,,1,1,1,Oxidised cellulose dressings work to stop bleeding by accelerating blood platelet aggregation and helping the blood clotting process to start. The fibres are able to absorb up to seven times their own volume in blood.  When saturated the oxidised cellulose swells into a gelatinous mass. Oxidised cellulose is naturally acidic and it is this acid that starts to break down the blood cells triggering the clotting process in the body.  The oxidised cellulose also lowers the pH within the wound due to its acidity. This creates a hostile environment for most bacteria and also gives it antimicrobial benefit.,,
6663,1706333,182325,Unknown,,,,1,1,1,Cetrimide is a quaternary ammonium compound and a cationic detergent that is effective against many Gram-positive and Gram-negative bacteria. It has the capacity to decrease the biofilm’s mechanical stability.,,
6664,2791449,114108,Unknown,,,,1,1,1,"Cetylpyridinium chloride (CPC) in a high bioactive mouth rinse matrix. CPC acts primarily by penetrating the bacterial cell membrane that causes leakage of cell components, disruption of bacterial metabolism, inhibition of cell growth, and finally cell death.",,
6665,2792480,2096386,Unknown,,,,1,1,1,"Chloral betaine is a sedative-hypnotic drug. It is a betaine complex with chloral hydrate, which acts as an extended-acting formulation of chloral hydrate which is then metabolized into trichloroethanol, which is responsible for most or all of its effects. Chloral hydrate mechanism of action is still unknown, but it is believed that its sedative effect is mediated by the Gamma Aminobutyric Acid-A receptors.",,
6666,1702796,453652,Unknown,,,,1,1,1,"Chloral hydrate is converted to the active compound trichloroethanol by hepatic alcohol dehydrogenase. The agent interacts with various neurotransmitter-operated ion channels, thereby enhancing gamma-aminobutyric acid (GABA)-A receptor mediated chloride currents and inhibiting amino acid receptor-activated ion currents. In addition, chloral hydrate enhances the agonistic effects of glycine receptors, inhibits AMPA-induced calcium influx in cortical neurons, and facilitates 5-HT 3 receptor-mediated currents in ganglionic neurons. Overall, this results in a depressive effect on the central nervous system.",,
6667,1699504,863857,Unknown,,,,1,1,1,"Chlorobutanol is a chemical preservative, sedative hypnotic and weak local anaesthetic similar in nature to chloral hydrate. It has antibacterial and antifungal properties.",,
6668,1705496,419430,Unknown,,,,1,1,1,Chloroxylenol is an antiseptic and disinfectant which is used for skin disinfection and cleaning surgical instruments. Chloroxylenol is most effective against Gram-positive bacteria. It works by disruption of the cell wall and stopping the function of enzymes.,,
6669,2793346,1383214,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,Chlorphenoxamine is an antihistamine and anticholinergic used as an antipruritic and antiparkinsonian agent.,,
6670,1705813,373953,Unknown,,,,1,1,1,"Local anti-infective agent used for skin, gastrointestinal, and vaginal infections with fungi, protozoa, and certain bacteria.",,
6673,1700302,1376365,Unknown,,,,1,1,1,Choline salicylate is a non-steroidal anti-inflammatory drug.,,
6674,1706354,453655,Angiotensin-converting enzyme inhibitor,69,,INHIBITOR,1,1,1,"Cilazapril is a prodrug which is hydrolysed to the active angiotensin converting enzyme (ACE) inhibitor cilazaprilat after absorption. It prevents conversion of angiotensin I into angiotensin II causing an increase in plasma renin activity and a decrease in plasma angiotensin II and aldosterone concentrations. Most data support the hypothesis that the beneficial haemodynamic effects of cilazapril result from ACE inhibition and the consequent reduction of angiotensin II levels, which either directly or indirectly causes dilatation of peripheral vessels and reduction of vascular resistance. It prevents the reabsorption of sodium and water from renal tubules and decreases the heart flow rate.",,
6676,1702842,563655,Peroxisome proliferator-activated receptor alpha agonist,163,,AGONIST,1,1,1,"Ciprofibrate, a PPARα activator, is used to treat hyperlipidaemia and was found to be beneficial in the prevention of ischemic heart disease in individuals with elevated levels of LDL cholesterol. In addition ciprofibrate is also found to modestly decrease elevated fibrinogen and plasminogen activator inhibitor-1 levels and elevate level of plasma HDL cholesterol.",,
6677,1702161,182814,Serotonin 4 (5-HT4) receptor agonist,168,,AGONIST,1,1,1,"Clebopride, a D-2 dopamine antagonist with antiemetic and prokinetic properties, can improve the bowel cleansing efficacy. Clebopride also stimulates peripheral 5-HT4 receptors and shortens intestinal transit time.","A receptor binding assay revealed that clebopride bound to the D2 dopamine receptor with a high affinity and to the alpha-2 adrenoceptor and 5-HT2 serotonin receptor with relatively lower affinity, and not to D1 dopamine, alpha-1 adrenergic, muscarinic acetylcholine, H1 histamine, or opioid receptor.",
6678,1704068,74690,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,"Clenbuterol is a β2-adrenergic receptor agonist that causes relaxation of airway smooth muscle by binding to the receptor and activating adenylyl cyclase. Activation of adenylyl cyclase leads to an increase in intracellular concentrations of cyclic adenosine monophosphate (cAMP) and ultimately activation of protein kinase A (PKA). In the airways this inhibits smooth muscle contraction by opening K+ channels and down-regulating myosin light chain kinase activity. In addition, evidence indicates that clenbuterol induces production of neurotrophic factors, and promotes anti-inflammatory and neuroprotective effects.",Clenbuterol is a moderately selective β2-adrenergic receptor agonist.,
6679,1704058,1508315,Unknown,,,,1,1,1,"Clobetasone butyrate is a glucocorticosteroid used in dermatology for treating skin inflammation and also in ophthalmology. It helps to reduce the itchiness and erythema associated with eczema and dermatitis. In ophthalmology, clobetasone is effective in the treatment of dry eyes in Sjögren's Syndrome.",,
6680,1699649,139608,GABA-A receptor; anion channel positive allosteric modulator,104688,2618,POSITIVE ALLOSTERIC MODULATOR,1,1,1,Chlomethiazole allosterically enhances GABAA receptor conductance and has been shown to be neuroprotective in animal models of both global and focal ischemia.,,Barbiturate site
6681,1699681,103542,Serotonin 2 (5-HT2) receptor antagonist,104784,,ANTAGONIST,1,1,1,Clotiapine affects multiple receptors. It blocks 5HT3-receptors and downregulates cortical 5HT2- receptors. It has high affinity for the 5HT-6 and 5HT-7 receptors and acts as an antagonist of the D-4 receptors.,,
6682,1696133,1380451,Follicle stimulating hormone receptor agonist,99,,AGONIST,1,1,1,"Corifollitropin alfa is a recombinant long-acting follicle-stimulating hormone (FSH) agonist for the treatment of infertility. It is similar to FSH, a natural hormone in the body that stimulates the production of eggs in the ovaries. The β subunit of clorifollitropin alfa contains the carboxy-terminal peptide of human chorionic gonadotropin to prolong its activity in the body. As a result a single dose of the medicine can be given to stimulate egg production for seven days, thereby replacing daily injections that would be required with other FSH medicines.",,
6683,1703080,1378112,Glucocorticoid receptor agonist,25,,AGONIST,1,1,1,"Structurally, cortivazol possesses the unique feature of a bulky phenylpyrazole structure fused at carbon atoms 2 and 3 to the A ring of the steroid moiety. This pyrazoloid structure imparts a significant increase in potency to the molecule and results in unusual two-site binding kinetics with the glucocorticoid receptor. Cortivazol induces the nuclear translocation and transactivation function of the glucocorticoid receptor, but not of the mineralocorticoid receptor.",Cortivazol has high affinity for the glucocorticoid receptor (GR) (10–20 times greater affinity for the GR than dexamethasone),"Cortivazol binds to the glucocorticoid receptor in the cytosol from CEM C7 cells (a human acute lymphoblastic leukemia line) in a fashion consistent with interaction with at least two sites. In mutant leukemia cells derived from CEM C7, resistant to kill by 10-4 M dexamethasone and deficient in standard glucocorticoid binding sites, cortivazol still finds a binding site and kills the cells. In wild-type leukemia cells, the binding sites of cortivazol, those with both higher (Kd ~5 x 10-10 M) and lower (Kd ~1 X 10-8 M) affinity appear to be on forms of the glucocorticoid receptor itself, and not on two different classes of molecules. Cortivazol interacts with the distinct portion of the ligand binding domain (LBD) and differentially modulates the ligand-dependent interaction between transcription intermediary factor 2 and the LBD when compared with cortisol, dexamethasone and aldosterone."
6684,1706320,1256,Unknown,,,,1,1,1,Coumarin induces proteolysis of high-molecular-weight proteins present in lymphedema. Small-size protein fragments can then be more easily drained via the lymphatics. The oncotic pressure drops and edema lessens.,,
6686,1705847,904871,Unknown,,,,1,1,1,"Cyclandelate is a vasodilating agent that acts directly on the smooth muscles of blood vessels. It produces clinical effects in cerebral as well as peripheral vascular diseases. Cyclandelate inhibits the aggregation patterns of blood platelets stimulated with a variety of agonists such as adenosine diphosphate, thrombin, collagen, adrenaline (epinephrine) and platelet activating factor. It maintains red cell deformability by inhibiting calcium entry through the red cell membrane.",,
6687,1703516,797138,Unknown,,,,1,1,1,Cyclopenthiazide is a thiazide diuretic used in the treatment of heart failure and hypertension.,,
6688,1702935,236019,Androgen Receptor antagonist,56,,ANTAGONIST,1,1,1,Cyproterone acetate has been shown to compete with dihydrotestosterone for binding to the androgen receptor and to exhibit progestogenic activities. Cyproterone also suppresses the secretion of gonadotropins and thus interferes with testosterone production. Cyproterone acetate is a potent glucocorticoid receptor antagonist.,"Cyproterone acetate is known to possess the following pharmacological activity: Androgen receptor antagonist/very weak partial agonist (IC50 = 57 nM) Progesterone receptor agonist (Kd = 15 nM; IC50 = 79 nM) Glucocorticoid receptor antagonist (Kd = 45 nM; IC50 = 360 nM) Weak inhibitor of 3β-hydroxysteroid dehydrogenase, 17α-hydroxylase/17,20-lyase, and 21-hydroxylase",
6689,2792053,1383340,Serotonin transporter inhibitor,121,,INHIBITOR,1,1,1,"Dapoxetine is a selective serotonin reuptake inhibitor (SSRI). It blocks axonal re-uptake of serotonin (5-HT) from the synapse by 5-HT transporters, resulting in enhanced 5-HT neurotransmission, stimulation of post-synaptic membrane 5-HT2C receptors and ejaculatory delay.","Dapoxetine is a potent selective serotonin reuptake inhibitor (SSRI) (pKi = 8 nM). Equilibrium radioligand binding studies using human cells demonstrate that dapoxetine binds to serotonin (5-HT), norepinephrine (NE) and dopamine (DA) reuptake transporters and inhibits uptake in the following order of potency: NE<5-HT>>DA.",
6690,2791057,282577,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,"Debrisoquin is an adrenergic neuron-blocking drug. It acts at the sympathetic neuroeffector junction by inhibiting or interfering with the release and/or distribution of norepinephrine (NE), rather than acting at the effector cell by inhibiting the association of norepinephrine with its receptors. It is taken up by norepinephrine transporters. It becomes concentrated in NE transmitter vesicles, replacing NE in these vesicles. This leads to a gradual depletion of NE stores in the nerve endings. Once inside the terminal it blocks the release of noradrenaline in response to arrival of an action potential. In contrast to ganglionic blocking agents, debrisoquin suppresses equally the responses mediated by alpha-and beta-adrenergic receptors but does not produce parasympathetic blockade. Since sympathetic blockade results in modest decreases in peripheral resistance and cardiac output, debrisoquin lowers blood pressure in the supine position. It further reduces blood pressure by decreasing the degree of vasoconstriction that normally results from reflex sympathetic nervous activity upon assumption of the upright posture, thus reducing venous return and cardiac output more.",,
6691,2792058,192290,Unknown,,,,1,1,1,"Dequalinium chloride (DQC) has a broad spectrum against gram-positive and -negative bacteria, yeasts, and protozoa. The antimicrobial activity of DQC is primarily based on their ability to increase cell permeability with subsequent loss of enzyme activity. The mechanism of action of DQC is based on the following actions: Adsorption on the cell surface and diffusion through the cell wall disturbing the cell permeability. Denaturation of proteins and discontinuation of synthesis in ribosomes. Loss of enzymatic activity. Precipitation of nucleic acid. Its multiple mode of action is thought to reduce the risk of resistance of pathogens.",,
6692,1702999,117758,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,"Ketoprofen is a non-steroidal anti-inﬂammatory drug. It is a racemic mixture and its analgesic efﬁcacy is due to the (S)-enantiomer, dexketoprofen. The analgesic action of the (R)-enantiomer is considered to be less signiﬁcant, but causes the majority of adverse effects, that is gastric mucosa irritation. Its mechanism of action is the non-selective inhibition of cyclooxygenase-1 and cyclooxygenase-2.",Dexketoprofen was found to be a potent inhibitor of the prostaglandin F2 alpha (PGF2 alpha) production in rat brain (IC50 = 6.2 nM),
6693,1696149,1380467,Unknown,,,,1,1,1,"Dextranomer exerts its effect by a capillary action which absorbs wound exudate, as well as wound debris and microorganisms, into the dextranomer beads or into the spaces between the beads, thus removing such products from the wound surface. Dextranomer is an aid to wound or ulcer management, and does not directly affect tissue repair in such ulcers, but the removal of debris (and possibly microorganisms) from the wound could be expected to promote natural healing.",,
6694,2795308,2096440,Opioid receptors; mu/kappa/delta agonist,104765,,AGONIST,1,1,1,Dextromoramide is a powerful opioid analgesic approximately three times more potent than morphine but shorter acting.,,
6695,2792081,866306,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,"Dibenzepin is a tricyclic antidepressant (TCA). It acts as a selective norepinephrine reuptake inhibitor (NRI). It is also a potent antihistamine (H1 receptor). The drug has weak or negligible effects on serotonin and dopamine reuptake. Unlike many other TCAs, dibenzepin has no antiadrenergic (α1, α2), antiserotonergic (5-HT1A, 5-HT2A), or antidopaminergic effects and has few or no anticholinergic (mACh) effects.",Inhibitory effect on the uptake of noradrenaline (59 nM) by the perfused rabbit heart: 44.8 mM (ID50) Ki = 23 nM for H1 receptors.,
6698,1703003,454305,Unknown,,,,1,1,1,"Diflucortolone valerate (DFV) is a potent glucocorticosteroidal molecule which is commonly used in the treatment of skin disorders. According to the corticosteroidal classification system, DFV is classified as a high potent steroid for the available formulations of ointments and creams.",,
6700,1706381,758744,Unknown,,,,1,1,1,"Diloxanide furoate (DF) is a luminal amoebicide that destroys trophozoites of E. histolytica and prevents amoebic cyst formation. DF is converted to the active molecule, Diloxanide, by hydrolytic degradation in the colon, mediated by colonic microflora. The exact mechanism of diloxanide is unknown. Diloxanide is structurally related to chloramphenicol and may act in a similar fashion by blocking protein synthesis. It acts on the organisms in the intestinal lumen but is not effective against organisms in tissue.",,
6701,1696148,1380466,Unknown,,,,1,1,1,"Dimethicone is used variously in the cosmetic industry. It is used widely in skin-moisturizing lotions where it is listed as an active ingredient whose purpose is ""skin protection"". It can be used in the treatment of head lice on the scalp.",,
6702,2791438,26443,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,"Dimetindene is an antihistamine/anticholinergic drug. It is a selective histamine H1 antagonist and binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. As dimetindene only minimally passes across the blood-brain barrier, it is classified as a second generation antihistamine.",,
6736,1699628,394206,Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor,224,,INHIBITOR,1,1,1,"Inhibits the reduction of vitamin K by vitamin K epoxide reductase. This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, XI and X, and interferes with coagulation.",,
6737,1699507,332615,Oxytocin receptor antagonist,116,,ANTAGONIST,1,1,1,"Atosiban is a synthetic peptide which acts as a competitive antagonist of oxytocin (and vasopressin) at human uterine oxytocin receptors. Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. As a result there is a rapid inhibition of uterine contractility. In addition, atosiban suppresses oxytocin-mediated release of prostaglandin E and F from the decidua.",,
6745,1705257,61717,Unknown,,,,1,1,1,"Diacerein is a prodrug that is metabolized to rhein. It is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also been shown to have protective effects against subchondral bone remodelling. The principal mechanism of action of diacerein is to inhibit the interleukin-1 beta (IL-1beta) system and related downstream signalling. Diacerein has been shown to impact the activation of IL-1beta via a reduced production of IL-1 converting enzyme, as well as to affect the sensitivity to IL-1 by decreasing IL-1 receptor levels on the cell surface of chondrocytes and by indirectly increasing IL-1 receptor antagonist production.",,
6748,1696170,1380488,Cyclooxygenase inhibitor,104725,,INHIBITOR,1,1,1,"Acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation.",,"Aspirin inhibits COX1 by acetylation of the hydroxyl group of Ser 530, thereby excluding access for arachidonic acid to Tyr 385 by steric hindrance. Aspirin also acetylates serine 516 in COX-2, but due to the larger size of the catalytic channel, arachidonic acid is able to “squeeze past” the acetylated structure and form 15-R-hydroxyeicosatetraenoic acid."
6751,1696162,1380480,Alpha-galactosidase A activator,10693,,ACTIVATOR,1,1,1,"Agalsidase alfa catalyses the hydrolysis of globotriaosylceramide (Gb3), cleaving a terminal galactose residue from the molecule. It counteracts the deficient activity of the lysosomal enzyme alpha-galactosidase A in the Fabry disease. Treatment with the enzyme has been shown to reduce accumulation of Gb3 in many cell types including endothelial and parenchymal cells.",,
6752,2792306,418413,Serotonin 1a (5-HT1a) receptor antagonist,51,,ANTAGONIST,1,1,1,"Alverine has been shown to bind to 5-HT1A receptors thereby acting as an antagonist that reduces the visceral pronociceptive effect of 5-HT. Alverine acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasms which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. It has also been reported that Alverine acts as HNF4α activator.",,
6754,1695900,675404,Coagulation factor X inhibitor,194,,INHIBITOR,1,1,1,"Antithrombin (AT) is a serine protease inhibitor that is the principal inhibitor of the blood coagulation serine proteases thrombin and Factor Xa, and to a lesser extent, Factors IXa, XIa, XIIa, trypsin, plasmin, and kallikrein. AT neutralizes the activity of thrombin and other serine proteases by forming a complex between enzyme and inhibitor. This complex is rapidly cleared from the circulation by internalization into liver cells. In the absence of heparin, complex formation occurs at a relatively slow rate. When heparin or heparin sulfate on the vessel wall is present, however, it binds to lysyl residues on AT and dramatically accelerates the rate of complex formation.",,
6755,1699561,2256,Unknown,,,,1,1,1,Barbital is a long-acting barbiturate that depresses most metabolic processes at high doses. It is used as a hypnotic and sedative and may induce dependence. Barbital is also used in veterinary practice for central nervous system depression.,,
6756,1699566,65455,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,"Benperidol is a butyrophenone derivative and a specific dopamine antagonist, selective for the D2 receptor. It also binds to serotonin receptors but to a lesser extent. In high doses it has anti histaminergic and alpha-adrenergic properties but its anticholinergic effects are small.",,Benperidol has high affinity and selectivity for binding to central D2-like specific binding sites.
6758,2791272,1070837,Unknown,,,,1,1,1,Bephenium hydroxynaphthoate is an anthelmintic agent formerly used in the treatment of hookworm infections and ascariasis.,,
6760,1706328,150585,Cyclooxygenase-2 inhibitor,126,,INHIBITOR,1,1,1,"Aceclofenac works by inhibiting the action of cyclooxygenase 2 (with minimal inhibition of COX1) involved in the production of prostaglandins which is accountable for pain, swelling, inflammation and fever. Aceclofenac has shown stimulatory effects on cartilage matrix synthesis that may be linked to the ability of the drug to inhibit the suppression by IL-1β of various growth factors.","Data from human whole blood assays show inhibition of COX-2 (with minimal effects on COX-1) by both the parent compound and 4′-hydroxyaceclofenac: IC50 values for COX-1 and COX-2, respectively, were >100 and 0.8 for aceclofenac and >100 and 36 for 4′- hydroxyaceclofenac.",
6782,2794605,624269,Unknown,,,,1,1,1,"Following absorption, carbenicillin phenyl sodium is rapidly hydrolyzed to the active carbenicillin, which binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall, thereby preventing the cross-linkage of peptidoglycans, which are critical components of the bacterial cell wall. This leads to a weakening of the bacterial cell wall, eventually causing bacterial cell lysis.",,
6783,1696776,1381267,Unknown,,,,1,1,1,"Carboxymethylcellulose sodium is used for the temporary relief of burning, irritation and discomfort due to dryness of the eye or exposure to wind or sun.",,
6785,1705821,66311,Voltage-gated L-type calcium channel blocker,104801,,BLOCKER,1,1,1,"Cinnarizine is an antihistaminic, a not competitive antagonist of the H1 receptors that, probably, also acts as sedative. Specifically, its mechanism of action seems to be double: 1) the block of the passage of Ionian Calcium from endolymph to the vestibular sensory cells, suppressing their function, 2) the vasodilatation, which ameliorates the blood flow and the metabolic availability in the vestibular nuclei, with the global result of a vestibular depression.",,
6786,1702880,1078501,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,"Clotiazepam binds to the benzodiazepine site of the GABAA receptor where it acts as a full agonist; this action results in an enhanced GABA inhibitory effect at the GABAA receptor. It has anxiolytic, sedative, and anticonvulsant properties.",,Benzodiazepine site
6787,1696706,1381197,Asparagine hydrolytic enzyme,106202,,HYDROLYTIC ENZYME,1,1,1,"Crisantaspase (or Asparaginase) takes advantage of the fact that acute lymphoblastic leukemia cells and some other suspected tumor cells are unable to synthesize the non-essential amino acid asparagine, whereas normal cells are able to make their own asparagine; thus leukemic cells require high amount of asparagine. These leukemic cells depend on circulating asparagine. Asparaginase, however, catalyzes the conversion of L-asparagine to aspartic acid and ammonia. This deprives the leukemic cell of circulating asparagine, which leads to cell death.",,
6789,1704066,515105,Unknown,,,,1,1,1,"Dehydrocholic acid is a synthetic bile acid, manufactured by the oxidation of cholic acid. It acts as a hydrocholeretic, increasing bile output to clear increased bile acid load.",,
6790,2794864,1673728,Sodium channel alpha subunit blocker,105639,,BLOCKER,1,1,1,"Dichlorobenzyl alcohol is a mild antiseptic, able to kill bacteria and viruses associated with mouth and throat infections. It is a common ingredient in throat lozenges such as Strepsils, Lorsept, and Gorpils. A low-pH throat lozenge containing dichlorobenzyl alcohol (1.2 mg) and amylmetacresol (0.6 mg) has been found to deactivate respiratory syncytial virus and SARS-Cov, but not adenovirus or rhinovirus. Dichlorobenzyl alcohol acts as a local anaesthetic and blocks voltage-gated Na channels in a local anaesthetic-like manner.",,
6791,1703988,1533212,Vitamin D receptor agonist,64,,AGONIST,1,1,1,"Dihydrotachysterol (DHT) is a synthetic vitamin D analog. Once hydroxylated to 25-hydroxydihydrotachysterol, the modified drug binds to the vitamin D receptor. The bound form of the vitamin D receptor serves as a transcriptional regulator of bone matrix proteins, inducing the expression of osteocalcin and suppressing synthesis of type I collagen. Vitamin D (when bound to the vitamin D receptor)stimulates the expression of a number of proteins involved in transporting calcium from the lumen of the intestine, across the epithelial cells and into blood. This stimulates intestinal calcium absorption and increases renal phosphate excretion.",,
6848,1699467,1352913,"Troponin, cardiac muscle positive modulator",104786,,POSITIVE MODULATOR,1,1,1,"It is a Ca2+ sensitizer. It acts through direct binding with troponin-C thereby increasing the affinity of troponin-C for Ca2+ in a Ca2+ dependent manner. It has phosphodiesterase-III inhibitory properties. It also has a vasodilatory effect, by opening adenosine triphosphate (ATP)-sensitive potassium channels in vascular smooth muscle to cause smooth muscle relaxation.",,Binding site on cardiac troponin C (cTnC) has been localized to a hydrophobic region of its N-domain near the so-called D/E linker region.
6849,1700027,23430,Matrix metalloproteinase-1 inhibitor,13000,,INHIBITOR,1,1,1,Inhibits matrix metalloproteinase (MMP) activity by specifically interacting with the Zn2+ in their catalytic site. This compound inhibits MMPs potently and specifically with 50% inhibitory concentrations (IC50S) against most members of the MMP family in the nanomolar range.,,
6850,1700027,23430,Matrix metalloproteinase 12 inhibitor,11871,,INHIBITOR,1,1,1,Inhibits matrix metalloproteinase (MMP) activity by specifically interacting with the Zn2+ in their catalytic site. This compound inhibits MMPs potently and specifically with 50% inhibitory concentrations (IC50S) against most members of the MMP family in the nanomolar range.,,
6851,1700027,23430,Matrix metalloproteinase-2 inhibitor,13001,,INHIBITOR,1,1,1,Inhibits matrix metalloproteinase (MMP) activity by specifically interacting with the Zn2+ in their catalytic site. This compound inhibits MMPs potently and specifically with 50% inhibitory concentrations (IC50S) against most members of the MMP family in the nanomolar range.,,
6852,1700027,23430,Matrix metalloproteinase 3 inhibitor,11109,,INHIBITOR,1,1,1,Inhibits matrix metalloproteinase (MMP) activity by specifically interacting with the Zn2+ in their catalytic site. This compound inhibits MMPs potently and specifically with 50% inhibitory concentrations (IC50S) against most members of the MMP family in the nanomolar range.,,
6853,1700027,23430,Matrix metalloproteinase 7 inhibitor,12738,,INHIBITOR,1,1,1,Inhibits matrix metalloproteinase (MMP) activity by specifically interacting with the Zn2+ in their catalytic site. This compound inhibits MMPs potently and specifically with 50% inhibitory concentrations (IC50S) against most members of the MMP family in the nanomolar range.,,
6854,2472667,1926759,Ribonucleoside-diphosphate reductase RR1 inhibitor,104791,,INHIBITOR,1,1,1,Inhibition of ribonucleotide reductase will block DNA synthesis and repair and cellular growth.,,
6855,1701128,1631832,Transient receptor potential cation channel subfamily V member 4 inhibitor,11847,,INHIBITOR,1,1,1,"Butamben is a pain-relieving local anesthetic. It inhibits voltage-gated channels in the sensory neurons (T-type calcium channels, Cav1.2/L-type channels, Kv4 channels). It also inhibits Transient Receptor Potential A1 (TRPA1) and Transient Receptor Potential V4 (TRPV4).",,
6856,1706366,209964,Transient receptor potential cation channel subfamily A member 1 inhibitor,101412,,INHIBITOR,1,1,1,"Butamben is a pain-relieving local anesthetic. It inhibits voltage-gated channels in the sensory neurons (T-type calcium channels, Cav1.2/L-type channels, Kv4 channels). It also inhibits Transient Receptor Potential A1 (TRPA1) and Transient Receptor Potential V4 (TRPV4).",,
6857,1703880,1378487,Serotonin 2c (5-HT2c) receptor agonist,108,,AGONIST,1,1,1,"Fenfluramine (FA) reduces epileptiform activity by stimulating 5-HT2C and 5-HT1D receptors, leading to enhanced GABAergic neurotransmission, and by a σ1-antagonistic action that can reduce the excitatory neurotransmission by modulating N-methyl-D-aspartate (NMDA) responses. In addition, FA also significantly decreases the noradrenaline (NAD) brain content that might contribute to its anti-epileptic effects. Fenfluramine causes the release of serotonin (5-HT) by disrupting vesicular storage of the neurotransmitter and inhibiting its reuptake. The increased 5-HT availability in the brain results in a loss of appetite.",,
6858,1703880,1378487,Sigma opioid receptor antagonist,11272,,ANTAGONIST,1,1,1,"Fenfluramine (FA) reduces epileptiform activity by stimulating 5-HT2C and 5-HT1D receptors, leading to enhanced GABAergic neurotransmission, and by a σ1-antagonistic action that can reduce the excitatory neurotransmission by modulating N-methyl-D-aspartate (NMDA) responses. In addition, FA also significantly decreases the noradrenaline (NAD) brain content that might contribute to its anti-epileptic effects. Fenfluramine causes the release of serotonin (5-HT) by disrupting vesicular storage of the neurotransmitter and inhibiting its reuptake. The increased 5-HT availability in the brain results in a loss of appetite.",,
6859,1701840,1377615,Acetylcholinesterase inhibitor,93,,INHIBITOR,1,1,1,"Propanidid is a competitive inhibitor of serum cholinesterase, and neuromuscular plaque and brain acetylcholinesterase.  It is an intravenous anesthetic that has been used for rapid induction of anesthesia and for maintenance of anesthesia of short duration.",,
6860,1702113,757917,Carnitine palmitoyltransferase 2 inhibitor,10765,,INHIBITOR,1,1,1,"It inhibits the mitochondrial enzyme carnitine palmitoyltransferase 1 (CPT-1) and to a lesser extent CPT-2. This causes a shift in myocardial substrate utilisation from long chain fatty acids to carbohydrates, resulting in increased glucose and lactate utilization and increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency. Perhexiline maleate was also found to inhibit the activity of Mammalian target of rapamycin complex 1 (mTORC1).","It inhibits rat heart and liver carnitine palmitoyltransferase 1 (CPT1) (IC50 = 77 and 148 µM, respectively) and rat heart CPT2 (IC50 = 79 µM). It reversibly inhibits Mammalian target of rapamycin complex 1 (mTORC1) at micromolar concentrations.",
6861,1702113,757917,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,"It inhibits the mitochondrial enzyme carnitine palmitoyltransferase 1 (CPT-1) and to a lesser extent CPT-2. This causes a shift in myocardial substrate utilisation from long chain fatty acids to carbohydrates, resulting in increased glucose and lactate utilization and increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency. Perhexiline maleate was also found to inhibit the activity of Mammalian target of rapamycin complex 1 (mTORC1).","It inhibits rat heart and liver carnitine palmitoyltransferase 1 (CPT1) (IC50 = 77 and 148 µM, respectively) and rat heart CPT2 (IC50 = 79 µM). It reversibly inhibits Mammalian target of rapamycin complex 1 (mTORC1) at micromolar concentrations.",
6862,1703656,31171,Calmodulin inhibitor,101444,,INHIBITOR,1,1,1,"Prenylamine is a potent sodium channel (NaCh) blocker during voltage clamp conditions in vitro and a long-acting local anesthetic (LA) when injected into rats for blockage of sciatic nerve in vivo. It interacts with calmodulin and inhibits, dose dependently, myosin light chain kinase (Ca2+-dependent protein kinase) and actomyosin( Ca2+-dependent ATPase) A nonselective inhibitor for slow Ca2+ channels, tends to prolong the cycle length to decrease the diastolic depolarization, the rate of rise of action potential, the amplitude of action potential. Prenylamine also affected several classic apoptosis-related proteins, including Bax, Bcl-2, and cytochrome c, and increased caspase-3 activity.","Binding of prenylamine to the sodium channels (NaChs) is highly voltage-dependent: The resting affinity (IC50 at -150 mV) for prenylamine in neuronal NaChs is 27.7 +- 1.3 uM, whereas the inactivated affinity (IC50 at -60 mV) is 0.75 +-0.02 uM— a 37-fold difference.",
6863,1705412,1121342,Urease inhibitor,100923,,INHIBITOR,1,1,1,"Ebrotidine is the first of a new generation of H2 receptor antagonists with gastroprotective activity. It stimulates epithelial cell proliferative activity and produces beneficial physicochemical changes in the gastric mucus that contribute to its gastro-protective action against ethanol-, aspirin- or stress-induced gastric mucosal damage. The antisecretory properties of ebrotidine are similar to those of ranitidine and approximately 10-fold greater than those of cimetidine. This drug exhibits anti-Helicobacter pylori activity that is synergistic with a number of antibacterial agents; it inhibits the urease enzyme and the proteolytic and mucolytic activities of H. pylori, and counteracts the inhibitory effects of H. pylori lipo-polysaccharide.",,
6864,1701724,1377503,Monoamine oxidase A activator,86,,ACTIVATOR,1,1,1,"Proxibarbal is a non-sedative barbiturate with a specific anti-serotonin and anti-histamine effect, due to enzyme induction of serotoninase and histaminase. Its lack of unpleasant side-effects permits its use for the preventive treatment of migraine.",,
6865,1699273,10813,Adrenergic receptor alpha-1 antagonist,104723,,ANTAGONIST,1,1,1,"Sertindole was developed as an antipsychotic drug. It is a potent antagonist at dopamine D2, serotonin 5-HT2, and α1-adrenergic receptors with high affinity. Additionally, Sertindole suppresses potassium channel in the brain and heart. It also induces both autophagy and ROS generation in neuroblastoma cells.","It has high affinity for dopamine D2, serotonin 5-HT2, and α1-adrenergic receptors.",
6866,1699273,10813,Serotonin 2 receptors; 5-HT2a & 5-HT2c antagonist,104817,,ANTAGONIST,1,1,1,"Sertindole was developed as an antipsychotic drug. It is a potent antagonist at dopamine D2, serotonin 5-HT2, and α1-adrenergic receptors with high affinity. Additionally, Sertindole suppresses potassium channel in the brain and heart. It also induces both autophagy and ROS generation in neuroblastoma cells.","It has high affinity for dopamine D2, serotonin 5-HT2, and α1-adrenergic receptors.",
6867,1702309,551160,Voltage-gated calcium channel blocker,105734,,BLOCKER,1,1,1,"Terodiline has non-selective anticholinergic and calcium blocking effects within the same concentration range, the anticholinergic effect predominating at low and the calcium entry blocking action at high concentrations.","It was reported that the drug inhibits guinea-pig bladder L-type Ca2+ current (ICa,L) with an IC50 of 1.7 uM.",
6868,1703475,788435,Acetylcholinesterase inhibitor,93,,INHIBITOR,1,1,1,"Minaprine binds to serotonin type 2 receptors and to dopamine D1 and D2 type receptors. It also binds to the serotonin reuptake pump. Therefore, minaprine blocks the reuptake of both dopamine and serotonin. It is also, to a slight degree, cholinomimetic. Thus it may exhibit both mood-brightening and nootropic properties. It also acts as a reversible inhibitor of monoamine oxidase. It has also been found to inhibit acetylcholinesterase in a reversible and competitive way.",IC50= 85µM on homogenized rat striatum acetylcholinesterase.,
6869,1703475,788435,Dopamine D1 and D2 receptor agonist,105040,,AGONIST,1,1,1,"Minaprine binds to serotonin type 2 receptors and to dopamine D1 and D2 type receptors. It also binds to the serotonin reuptake pump. Therefore, minaprine blocks the reuptake of both dopamine and serotonin. It is also, to a slight degree, cholinomimetic. Thus it may exhibit both mood-brightening and nootropic properties. It also acts as a reversible inhibitor of monoamine oxidase. It has also been found to inhibit acetylcholinesterase in a reversible and competitive way.",IC50= 85µM on homogenized rat striatum acetylcholinesterase.,
6870,1703475,788435,Monoamine oxidase A inhibitor,86,,INHIBITOR,1,1,1,"Minaprine binds to serotonin type 2 receptors and to dopamine D1 and D2 type receptors. It also binds to the serotonin reuptake pump. Therefore, minaprine blocks the reuptake of both dopamine and serotonin. It is also, to a slight degree, cholinomimetic. Thus it may exhibit both mood-brightening and nootropic properties. It also acts as a reversible inhibitor of monoamine oxidase. It has also been found to inhibit acetylcholinesterase in a reversible and competitive way.",IC50= 85µM on homogenized rat striatum acetylcholinesterase.,
6871,1703475,788435,Muscarinic acetylcholine receptor M1 agonist,61,,AGONIST,1,1,1,"Minaprine binds to serotonin type 2 receptors and to dopamine D1 and D2 type receptors. It also binds to the serotonin reuptake pump. Therefore, minaprine blocks the reuptake of both dopamine and serotonin. It is also, to a slight degree, cholinomimetic. Thus it may exhibit both mood-brightening and nootropic properties. It also acts as a reversible inhibitor of monoamine oxidase. It has also been found to inhibit acetylcholinesterase in a reversible and competitive way.",IC50= 85µM on homogenized rat striatum acetylcholinesterase.,
6872,1703570,33583,Acetylcholinesterase inhibitor,93,,INHIBITOR,1,1,1,"Minaprine binds to serotonin type 2 receptors and to dopamine D1 and D2 type receptors. It also binds to the serotonin reuptake pump. Therefore, minaprine blocks the reuptake of both dopamine and serotonin. It is also, to a slight degree, cholinomimetic. Thus it may exhibit both mood-brightening and nootropic properties. It also acts as a reversible inhibitor of monoamine oxidase. It has also been found to inhibit acetylcholinesterase in a reversible and competitive way.",IC50= 85µM on homogenized rat striatum acetylcholinesterase.,
6873,1703570,33583,Dopamine D1 and D2 receptor agonist,105040,,AGONIST,1,1,1,"Minaprine binds to serotonin type 2 receptors and to dopamine D1 and D2 type receptors. It also binds to the serotonin reuptake pump. Therefore, minaprine blocks the reuptake of both dopamine and serotonin. It is also, to a slight degree, cholinomimetic. Thus it may exhibit both mood-brightening and nootropic properties. It also acts as a reversible inhibitor of monoamine oxidase. It has also been found to inhibit acetylcholinesterase in a reversible and competitive way.",IC50= 85µM on homogenized rat striatum acetylcholinesterase.,
6874,1703570,33583,Monoamine oxidase A inhibitor,86,,INHIBITOR,1,1,1,"Minaprine binds to serotonin type 2 receptors and to dopamine D1 and D2 type receptors. It also binds to the serotonin reuptake pump. Therefore, minaprine blocks the reuptake of both dopamine and serotonin. It is also, to a slight degree, cholinomimetic. Thus it may exhibit both mood-brightening and nootropic properties. It also acts as a reversible inhibitor of monoamine oxidase. It has also been found to inhibit acetylcholinesterase in a reversible and competitive way.",IC50= 85µM on homogenized rat striatum acetylcholinesterase.,
6875,1703570,33583,Muscarinic acetylcholine receptor M1 agonist,61,,AGONIST,1,1,1,"Minaprine binds to serotonin type 2 receptors and to dopamine D1 and D2 type receptors. It also binds to the serotonin reuptake pump. Therefore, minaprine blocks the reuptake of both dopamine and serotonin. It is also, to a slight degree, cholinomimetic. Thus it may exhibit both mood-brightening and nootropic properties. It also acts as a reversible inhibitor of monoamine oxidase. It has also been found to inhibit acetylcholinesterase in a reversible and competitive way.",IC50= 85µM on homogenized rat striatum acetylcholinesterase.,
6876,1703561,678116,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,"Dilevalol is a nonselective, Beta-adrenergic receptor antagonist with, Beta 2-adrenergic receptor agonist activity. It has three to six times the activity of labetalol at the Beta-receptor, but unlike labetalol, little activity at the Alpha 1-receptor. In animal studies, it causes vasodilation even in denervated limbs, which is blocked by propranolol, suggesting that these vasodilator effects are due to Beta 2-adrenergic receptor agonism. It lowers blood pressure, both in normal and hypertensive subjects. Because the fall in blood pressure correlates with a fall in peripheral vascular resistance rather than a decrease in cardiac index, it is thought to be due to the Beta 2-adrenergic receptor agonist induced vasodilation, rather than to non-specific, Beta-adrenergic receptor antagonist effects.",,
6877,2792081,866306,Norepinephrine transporter inhibitor,100,,INHIBITOR,1,1,1,"Dibenzepin is a tricyclic antidepressant (TCA). It acts as a selective norepinephrine reuptake inhibitor (NRI). It is also a potent antihistamine (H1 receptor). The drug has weak or negligible effects on serotonin and dopamine reuptake. Unlike many other TCAs, dibenzepin has no antiadrenergic (α1, α2), antiserotonergic (5-HT1A, 5-HT2A), or antidopaminergic effects and has few or no anticholinergic (mACh) effects.",Inhibitory effect on the uptake of noradrenaline (59 nM) by the perfused rabbit heart: 44.8 mM (ID50) Ki = 23 nM for H1 receptors.,
6878,2792101,36502,Adrenergic receptor alpha-2 antagonist,104743,,ANTAGONIST,1,1,1,"Celiprolol was developed as a third-generation β-adrenoceptor antagonist with selective β1-antagonist, partial β2-agonist, and mild α2-antagonist actions. Given this combination of effects, celiprolol may be better described as a selective adrenoreceptor modulator. It has antihypertensive and antianginal properties.",Weak antagonist.,
6879,2792101,36502,Beta-1 adrenergic receptor antagonist,50,,ANTAGONIST,1,1,1,"Celiprolol was developed as a third-generation β-adrenoceptor antagonist with selective β1-antagonist, partial β2-agonist, and mild α2-antagonist actions. Given this combination of effects, celiprolol may be better described as a selective adrenoreceptor modulator. It has antihypertensive and antianginal properties.",,
6880,2792306,418413,Hepatocyte nuclear factor 4-alpha activator,101173,,ACTIVATOR,1,1,1,"Alverine has been shown to bind to 5-HT1A receptors thereby acting as an antagonist that reduces the visceral pronociceptive effect of 5-HT. Alverine acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasms which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. It has also been reported that Alverine acts as HNF4α activator.",,
6881,2792699,32459,Histamine H1 receptor agonist,127,,AGONIST,1,1,1,"Betahistine has a very strong affinity as an antagonist for histamine H3 receptors and a weak affinity as an agonist for histamine H1 receptors. Its efficacy can be explained by mechanisms targeting these histamine receptors (HRs) at three different levels: the vascular tree, with an increase of cochlear and vestibular blood flow involving the H1R; the central nervous system, with an increase of histamine turnover implicating the H3R, and the peripheral labyrinth, with a decrease of vestibular input implying the H3R/H4R.",Betahistine is a strong Histamine H3 receptor antagonist and a weak Histamine H1 agonist.,
6882,1697444,1380847,Epithelial cell adhesion molecule cross-linking agent,109789,,CROSS-LINKING AGENT,1,1,1,"Catumaxomab is a trifunctional bispecific monoclonal antibody with potential antineoplastic activity. Catumaxomab has two antigen-recognition sites: one for human CD3, a T cell surface antigen; and one for human epithelial cell adhesion molecule (EpCAM), a cell surface antigen expressed by a variety of epithelial tumor cells. In addition, the modified Fc portion of this antibody binds Fc receptors on antingen presenting cells (APCs) such as macrophages and dendritic cells (DCs). Catumaxomab brings T cells, EpCAM-expressing epithelial tumor cells and APCs together into tricellular complexes, which may result in a potent cytotoxic T-lymphocyte (CTL) response against EpCAM-expressing epithelial tumor cells. Fc-mediated binding of APCs in the tricellular complex potentiates EpCAM antigen presentation to T cells and the activation of anti-tumor cytotoxic T cell functions.",,
6883,1702350,1377888,Progesterone receptor agonist,36,,AGONIST,1,1,1,"Allylestrenol has the same function as Progesterone, it prepares the uterus for receiving the fertilised ovum and suppresses uterine motility. Progesterone binds to the progesterone and estrogen receptors. Once bound to the receptor, it will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge.",,
6884,1706236,422175,Androgen Receptor antagonist,56,,ANTAGONIST,1,1,1,"Abiraterone is converted by an enzyme to the more active Δ4-abiraterone (D4A). D4A inhibits 17α-hydroxylase/17,20-lyase (CYP17A1), 3β-hydroxysteroid dehydrogenase (3βHSD) and steroid-5α-reductase (SRD5A), which are required for 5α-dihydrotestosterone (DHT) synthesis. DHT promotes signaling by the androgen receptor and the development of castration-resistant prostate cancer. D4A also antagonizes the androgen receptor.",,
6885,1706236,422175,Steroid 5-alpha-reductase inhibitor,105770,,INHIBITOR,1,1,1,"Abiraterone is converted by an enzyme to the more active Δ4-abiraterone (D4A). D4A inhibits 17α-hydroxylase/17,20-lyase (CYP17A1), 3β-hydroxysteroid dehydrogenase (3βHSD) and steroid-5α-reductase (SRD5A), which are required for 5α-dihydrotestosterone (DHT) synthesis. DHT promotes signaling by the androgen receptor and the development of castration-resistant prostate cancer. D4A also antagonizes the androgen receptor.",,
6886,1699350,8209,Serotonin 2c (5-HT2c) receptor antagonist,108,,ANTAGONIST,1,1,1,Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors.,"Melatonin receptor MT1, Ki=0.1nM / MT2, Ki=0.12nM 5-HT2C receptor, Ki=631nM",
6887,1705291,549033,Beta-2 adrenergic receptor agonist,43,,AGONIST,1,1,1,"Isoxsuprine is a beta-adrenoreceptor agonist and an alpha-adrenoreceptor antagonist, with both characteristics contributing to vasodilation and uterine relaxation.","Isoxsuprine has a higher affinity of α1-adrenoreceptors (Kd=59+-15nM, adrenoreceptors in rat vas deferens) than for β2-adrenoceptors ( Kd=3900+-500nM adrenoreceptors in rat vas deferens).",
6888,1705821,66311,Histamine H1 receptor antagonist,127,,ANTAGONIST,1,1,1,"Cinnarizine is an antihistaminic, a not competitive antagonist of the H1 receptors that, probably, also acts as sedative. Specifically, its mechanism of action seems to be double: 1) the block of the passage of Ionian Calcium from endolymph to the vestibular sensory cells, suppressing their function, 2) the vasodilatation, which ameliorates the blood flow and the metabolic availability in the vestibular nuclei, with the global result of a vestibular depression.",,
6889,1702809,389011,Dopamine receptors; D2 & D3 antagonist,104754,,ANTAGONIST,1,1,1,"Amisulpride blocks pre- and post synaptic dopamine D2, D3 receptors as well as the 5-HT7a receptor.","The chemical structure of amisulpride contains a chiral center and, thus, is a mixture of two optical isomers: (S)-amisulpride and (R)-amisulpride. The enantiomers bind at dopamine D2/3 and α2- adrenoceptors in a stereoselective manner with marked differences in affinity: (S)-amisulpride displays high affinity binding at both D2 and D3 receptors. On the other hand, the isomers display reversed stereoselectivity (but weaker affinity) at α2-adrenoceptors.",
6890,1702161,182814,Dopamine D2 receptor antagonist,72,,ANTAGONIST,1,1,1,"Clebopride, a D-2 dopamine antagonist with antiemetic and prokinetic properties, can improve the bowel cleansing efficacy. Clebopride also stimulates peripheral 5-HT4 receptors and shortens intestinal transit time.","A receptor binding assay revealed that clebopride bound to the D2 dopamine receptor with a high affinity and to the alpha-2 adrenoceptor and 5-HT2 serotonin receptor with relatively lower affinity, and not to D1 dopamine, alpha-1 adrenergic, muscarinic acetylcholine, H1 histamine, or opioid receptor.",
6891,1699681,103542,Dopamine D4 receptor antagonist,90,,ANTAGONIST,1,1,1,Clotiapine affects multiple receptors. It blocks 5HT3-receptors and downregulates cortical 5HT2- receptors. It has high affinity for the 5HT-6 and 5HT-7 receptors and acts as an antagonist of the D-4 receptors.,,
6892,1699681,103542,Serotonin 3 (5-HT3) receptor antagonist,104714,,ANTAGONIST,1,1,1,Clotiapine affects multiple receptors. It blocks 5HT3-receptors and downregulates cortical 5HT2- receptors. It has high affinity for the 5HT-6 and 5HT-7 receptors and acts as an antagonist of the D-4 receptors.,,
6893,1695900,675404,Thrombin inhibitor,11,,INHIBITOR,1,1,1,"Antithrombin (AT) is a serine protease inhibitor that is the principal inhibitor of the blood coagulation serine proteases thrombin and Factor Xa, and to a lesser extent, Factors IXa, XIa, XIIa, trypsin, plasmin, and kallikrein. AT neutralizes the activity of thrombin and other serine proteases by forming a complex between enzyme and inhibitor. This complex is rapidly cleared from the circulation by internalization into liver cells. In the absence of heparin, complex formation occurs at a relatively slow rate. When heparin or heparin sulfate on the vessel wall is present, however, it binds to lysyl residues on AT and dramatically accelerates the rate of complex formation.",,
6894,1702935,236019,Glucocorticoid receptor antagonist,25,,ANTAGONIST,1,1,1,Cyproterone acetate has been shown to compete with dihydrotestosterone for binding to the androgen receptor and to exhibit progestogenic activities. Cyproterone also suppresses the secretion of gonadotropins and thus interferes with testosterone production. Cyproterone acetate is a potent glucocorticoid receptor antagonist.,"Cyproterone acetate is known to possess the following pharmacological activity: Androgen receptor antagonist/very weak partial agonist (IC50 = 57 nM) Progesterone receptor agonist (Kd = 15 nM; IC50 = 79 nM) Glucocorticoid receptor antagonist (Kd = 45 nM; IC50 = 360 nM) Weak inhibitor of 3β-hydroxysteroid dehydrogenase, 17α-hydroxylase/17,20-lyase, and 21-hydroxylase",
6895,1702935,236019,Progesterone receptor agonist,36,,AGONIST,1,1,1,Cyproterone acetate has been shown to compete with dihydrotestosterone for binding to the androgen receptor and to exhibit progestogenic activities. Cyproterone also suppresses the secretion of gonadotropins and thus interferes with testosterone production. Cyproterone acetate is a potent glucocorticoid receptor antagonist.,"Cyproterone acetate is known to possess the following pharmacological activity: Androgen receptor antagonist/very weak partial agonist (IC50 = 57 nM) Progesterone receptor agonist (Kd = 15 nM; IC50 = 79 nM) Glucocorticoid receptor antagonist (Kd = 45 nM; IC50 = 360 nM) Weak inhibitor of 3β-hydroxysteroid dehydrogenase, 17α-hydroxylase/17,20-lyase, and 21-hydroxylase",
6896,1700780,110103,DNA polymerase inhibitor,100303,,INHIBITOR,1,1,1,"It derives its antiviral activity from selective conversion by a specific thymidine kinase, present in certain DNA viruses, to nucleotides which in turn interfere with viral DNA synthesis. This viral thymidine kinase is different from the thymidine kinase present in mammalian cells. Sorivudine isnot a substrate for mammalian thymidine kinase, thus explaining the selectivity of this drug.","Sorivudine has antiviral activity against several viruses including varicella zoster virus, herpes simplex type 1 virus, Epstein-Barr virus.",
6897,1705374,18271,Beta-2 adrenergic receptor antagonist,43,,ANTAGONIST,1,1,1,Non-selective beta blocker clinical candidate. It was never used clinically.,,
6898,2138986,1763543,Parathyroid hormone receptor agonist,160,,AGONIST,1,1,1,,,
6899,2473051,2039319,Tyrosine-protein kinase BTK inhibitor,100097,,INHIBITOR,1,1,1,,,
6901,1703778,1378389,Mineral supplement,,,,1,1,1,,,
6902,2472970,1926917,PI3-kinase p110-alpha subunit inhibitor,11362,,INHIBITOR,1,1,1,,,
6903,2792891,336913,DNA inhibitor,105574,,INHIBITOR,1,1,1,,,
6904,1702485,1377908,Bacterial DNA gyrase inhibitor,105577,,INHIBITOR,1,1,1,,,
6905,1976760,1626757,Synaptic vesicular amine transporter inhibitor,162,,INHIBITOR,1,1,1,,,
6906,1699948,60371,Unknown,,,,1,1,1,,,
6907,2973287,2197802,"Isocitrate dehydrogenase [NADP], mitochondrial inhibitor",117303,,INHIBITOR,1,1,1,,,
6908,2473661,1927212,"Hepatitis C virus serine protease, NS3/NS4A inhibitor",104803,,INHIBITOR,1,1,1,,,
6909,1343279,85305,Unknown,,,,1,1,1,L-glutamine may improve the NAD redox potential in sickle RBCs through increasing the availability of reduced glutathione ,,
6910,2139007,701175,DNA terminase inhibitor,117302,,INHIBITOR,1,1,1,,,
6913,2473099,1926972,Nonstructural protein 5A inhibitor,108438,,INHIBITOR,1,1,1,,,
6914,2973279,2197794,HMG-CoA reductase inhibitor,24,,INHIBITOR,1,1,1,,,
6915,2973276,2197791,HMG-CoA reductase inhibitor,24,,INHIBITOR,1,1,1,,,
6916,1706105,497784,DNA inhibitor,106020,,INHIBITOR,1,1,1,Enters bacterial cell as an inactive prodrug where the nitro group is reduced by bacterial enzymes to radical anions. It is believed that these radical anions interfere with bacterial DNA synthesis,,
6917,2973122,1797574,Tryptophan 5-hydroxylase inhibitor,116867,,INHIBITOR,1,1,1,,,
6918,2973234,1782496,Carbepenem-hydrolyzing beta-lactamase KPC inhibitor,101457,,INHIBITOR,1,1,1,,,
6919,2583090,2039219,Synaptic vesicular amine transporter inhibitor,162,,INHIBITOR,1,1,1,,,
6920,2583602,2039343,"Hepatitis C virus serine protease, NS3/NS4A inhibitor",104803,,INHIBITOR,1,1,1,,,
6921,2973289,2197803,Type-1 angiotensin II receptor agonist,115,,AGONIST,1,1,1,,,
6922,2472695,1926770,Polypeptides proteolytic enzyme,106160,,PROTEOLYTIC ENZYME,1,1,1,Cerliponase alfa is activated in the lysosome and the activated proteolytic form of rhTPP1 cleaves tripeptides from the N-terminus of proteins ,,
6923,1879140,1540489,Ghrelin receptor agonist,11536,,AGONIST,1,1,1,,,
6924,2473106,1926975,Rho-associated protein kinase inhibitor,104981,,INHIBITOR,1,1,1,,,
6925,2973406,2197918,DNA gyrase inhibitor,117304,,INHIBITOR,1,1,1,,,
6926,2973407,2197919,Glycosaminoglycans hydrolytic enzyme,117301,,HYDROLYTIC ENZYME,1,1,1,,,
6927,2794874,2197737,Human immunodeficiency virus type 1 integrase inhibitor,12456,,INHIBITOR,1,1,1,HIV-1 integrase strand transfer inhibitor,,
6929,3131784,2197795,Somatostatin receptor binding agent,104951,,BINDING AGENT,1,1,1,,Highest affinity for SSTR2,
6930,1706454,1380095,Human immunodeficiency virus type 1 reverse transcriptase inhibitor,228,,INHIBITOR,1,1,1,,,
6931,1706437,178290,Alpha-galactosidase A stabiliser,10693,,STABILISER,1,1,1,,,
6932,2138977,1763534,SMN2 pre-mRNA positive modulator,116819,,POSITIVE MODULATOR,1,1,1,SPINRAZA was shown to increase exon 7 inclusion in SMN2 messenger ribonucleic acid (mRNA) transcripts and production of full-length SMN protein ,,
7029,1706832,1381806,Interleukin-2 receptor alpha chain binding agent,182,,BINDING AGENT,1,1,1,,,
7030,1706705,1381722,Endothelin receptor ET-B binding agent,247,,BINDING AGENT,1,1,1,,,
7031,1706950,1381892,Ig epsilon chain C region inhibitor,229,,INHIBITOR,1,1,1,,,
7032,1706687,1381706,Myeloid cell surface antigen CD33 binding agent,81,,BINDING AGENT,1,1,1,,,
7033,1706769,1381763,Macrophage colony stimulating factor receptor inhibitor,12840,,INHIBITOR,1,1,1,,,
7034,1706878,1381835,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,,,
7035,1707085,1382117,Glutamate carboxypeptidase II binding agent,184,,BINDING AGENT,1,1,1,,,
7036,1707081,1381996,Glutamate carboxypeptidase II binding agent,184,,BINDING AGENT,1,1,1,,,
7037,1707086,1382118,Glutamate carboxypeptidase II binding agent,184,,BINDING AGENT,1,1,1,,,
7038,1707079,1381993,Glutamate carboxypeptidase II binding agent,184,,BINDING AGENT,1,1,1,,,
7039,1696110,1380428,Major surface antigen inhibitor,183,,INHIBITOR,1,1,1,,,
7040,1706798,1381782,C-C chemokine receptor type 5 inhibitor,10580,,INHIBITOR,1,1,1,,,
7041,1706797,1381781,C-C chemokine receptor type 5 inhibitor,10580,,INHIBITOR,1,1,1,,,
7042,1707153,1382042,Vascular endothelial growth factor receptor 3 inhibitor,11752,,INHIBITOR,1,1,1,,,
7043,1706819,1381796,Insulin-like growth factor I receptor inhibitor,234,,INHIBITOR,1,1,1,,,
7044,1707159,1382047,Interleukin-1 receptor inhibitor,198,,INHIBITOR,1,1,1,,,
7045,1706777,1381768,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
7046,2583192,2039249,Glucagon receptor inhibitor,146,,INHIBITOR,1,1,1,,,
7047,2473256,1927038,Plasma kallikrein inhibitor,23,,INHIBITOR,1,1,1,,,
7048,1706675,1381697,Vascular endothelial growth factor receptor 2 inhibitor,10980,,INHIBITOR,1,1,1,,,
7049,1706709,1381723,Fibrinogen beta chain binding agent,11181,,BINDING AGENT,1,1,1,,,
7050,1697300,1380551,Prostate specific antigen binding agent,10373,,BINDING AGENT,1,1,1,,,
7051,1938040,1592361,C-X-C chemokine receptor type 4 inhibitor,10473,,INHIBITOR,1,1,1,,,
7052,2473259,1927041,Folate receptor alpha binding agent,10103,,BINDING AGENT,1,1,1,,,
7053,1707023,1381948,CD22 binding agent,11695,,BINDING AGENT,1,1,1,,,
7054,1697397,1380623,CD22 binding agent,11695,,BINDING AGENT,1,1,1,,,
7055,1696592,1381083,CD22 binding agent,11695,,BINDING AGENT,1,1,1,,,
7056,2138990,1763547,CD22 binding agent,11695,,BINDING AGENT,1,1,1,,,
7057,1706817,1381794,CD22 binding agent,11695,,BINDING AGENT,1,1,1,,,
7058,1706775,1381766,Interleukin-2 receptor beta chain inhibitor,10770,,INHIBITOR,1,1,1,,,
7059,1707164,1382050,Interleukin-2 receptor beta chain inhibitor,10770,,INHIBITOR,1,1,1,,,
7060,1392930,1121917,Macrophage-stimulating protein receptor inhibitor,11379,,INHIBITOR,1,1,1,,,
7061,1706899,1381851,Fibroblast growth factor receptor 3 inhibitor,11926,,INHIBITOR,1,1,1,,,
7062,1976827,1626786,Subtilisin/kexin type 9 inhibitor,12353,,INHIBITOR,1,1,1,,,
7063,1392953,1121940,Interferon alpha inhibitor,116937,,INHIBITOR,1,1,1,,,
7064,1696865,1381356,Intercellular adhesion molecule-1 inhibitor,11088,,INHIBITOR,1,1,1,,,
7065,1392944,1121931,Fibronectin binding agent,17040,,BINDING AGENT,1,1,1,,,
7066,1707050,1381969,Fibronectin binding agent,17040,,BINDING AGENT,1,1,1,,,
7067,1706901,1381853,Fibronectin binding agent,17040,,BINDING AGENT,1,1,1,,,
7068,1707136,1382030,Tumor necrosis factor receptor R1 inhibitor,10806,,INHIBITOR,1,1,1,,,
7069,1706941,1381886,Envelope polyprotein GP160 inhibitor,14044,,INHIBITOR,1,1,1,,,
7070,1706938,1381883,Envelope polyprotein GP160 inhibitor,14044,,INHIBITOR,1,1,1,,,
7071,1706940,1381885,Envelope polyprotein GP160 inhibitor,14044,,INHIBITOR,1,1,1,,,
7072,1707011,1381936,Integrin beta-2 inhibitor,12662,,INHIBITOR,1,1,1,,,
7073,1707196,1382073,Vitronectin receptor alpha binding agent,12661,,BINDING AGENT,1,1,1,,,
7074,2583009,2039199,C-C chemokine receptor type 2 inhibitor,11575,,INHIBITOR,1,1,1,,,
7076,1696657,1381148,Fibroblast activation protein alpha binding agent,100186,,BINDING AGENT,1,1,1,,,
7077,1706882,1381838,Ephrin type-A receptor 3 inhibitor,30009,,INHIBITOR,1,1,1,,,
7078,1392973,1121960,Neuropilin-1 inhibitor,100781,,INHIBITOR,1,1,1,,,
7079,1706665,1381690,T-cell-specific surface glycoprotein CD28 agonist,101109,,AGONIST,1,1,1,,,
7080,1706746,1381744,Protective antigen inhibitor,101164,,INHIBITOR,1,1,1,,,
7081,1706745,1381743,Protective antigen inhibitor,101164,,INHIBITOR,1,1,1,,,
7082,1392920,1121907,Tumor necrosis factor receptor superfamily member 10B agonist,103092,,AGONIST,1,1,1,,,
7083,1706661,1381687,Tumor necrosis factor receptor superfamily member 10B agonist,103092,,AGONIST,1,1,1,,,
7084,2473559,1927166,Myelin-associated glycoprotein inhibitor,101337,,INHIBITOR,1,1,1,,,
7085,2472981,1926920,Receptor tyrosine-protein kinase erbB-3 inhibitor,102678,,INHIBITOR,1,1,1,,,
7086,1706935,2039375,Receptor tyrosine-protein kinase erbB-3 inhibitor,102678,,INHIBITOR,1,1,1,,,
7087,1706888,1381841,Receptor tyrosine-protein kinase erbB-3 inhibitor,102678,,INHIBITOR,1,1,1,,,
7089,1707156,1382044,Interleukin-18 cross-linking agent,104029,,CROSS-LINKING AGENT,1,1,1,,,
7090,1707045,1381966,Beta-nerve growth factor inhibitor,103854,,INHIBITOR,1,1,1,,,
7091,1707046,1381967,Beta-nerve growth factor inhibitor,103854,,INHIBITOR,1,1,1,,,
7092,1706985,1381917,Tumor necrosis factor receptor superfamily member 5 agonist,103491,,AGONIST,1,1,1,,,
7093,1707025,1381949,Tumor necrosis factor receptor superfamily member 3 agonist,103493,,AGONIST,1,1,1,,,
7094,1707070,1381985,Placenta growth factor inhibitor,103950,,INHIBITOR,1,1,1,,,
7095,1706961,1381899,Interleukin-1 beta inhibitor,104335,,INHIBITOR,1,1,1,,,
7097,1707175,1382055,Interleukin-6 inhibitor,104209,,INHIBITOR,1,1,1,,,
7098,1707172,1382054,Interleukin-6 inhibitor,104209,,INHIBITOR,1,1,1,,,
7099,1706934,1381880,Hepcidin inhibitor,117296,,INHIBITOR,1,1,1,,,
7100,1707029,1381953,Macrophage colony-stimulating factor 1 inhibitor,117297,,INHIBITOR,1,1,1,,,
7101,1707028,1381952,Macrophage colony-stimulating factor 1 inhibitor,117297,,INHIBITOR,1,1,1,,,
7102,1707053,1381971,Tumor necrosis factor receptor superfamily member 4 agonist,117298,,AGONIST,1,1,1,,,
7103,1707056,1381974,Cadherin-3 inhibitor,117299,,INHIBITOR,1,1,1,,,
7104,1707071,1381986,Poly-N-acetylglucosamine binding agent,117300,,BINDING AGENT,1,1,1,,,
7105,1706673,1381695,Tumor necrosis factor receptor superfamily member 8 binding agent,106140,,BINDING AGENT,1,1,1,,,
7106,1707199,1382076,Complement C5 inhibitor,106142,,INHIBITOR,1,1,1,,,
7107,1707095,1382007,Fusion glycoprotein F0 inhibitor,106144,,INHIBITOR,1,1,1,,,
7108,1707094,1382006,Fusion glycoprotein F0 inhibitor,106144,,INHIBITOR,1,1,1,,,
7109,1706988,1381919,CD44 antigen inhibitor,108280,,INHIBITOR,1,1,1,,,
7110,1706718,1381728,CD44 antigen binding agent,108280,,BINDING AGENT,1,1,1,,Specific to variant exon 6-containing CD44,
7111,1696274,1380679,CD44 antigen binding agent,108280,,BINDING AGENT,1,1,1,,Specific to variant exon 6-containing CD44,
7112,1706998,1381926,Selectin E inhibitor,11517,,INHIBITOR,1,1,1,,,
7113,1707139,1382033,Tumor susceptibility gene 101 protein inhibitor,102788,,INHIBITOR,1,1,1,,,
7115,1706846,1381812,T-cell surface glycoprotein CD3 epsilon chain cross-linking agent,233,,CROSS-LINKING AGENT,1,1,1,,,
7116,2790728,2096355,B-lymphocyte antigen CD20 binding agent,181,,BINDING AGENT,1,1,1,,,
7117,1707228,1382105,B-lymphocyte antigen CD20 binding agent,181,,BINDING AGENT,1,1,1,"Acts through engagement of immune effector cells, directly activating intracellular death signaling pathways and/or activation of the complement cascade.",,
7118,1706809,1381788,B-lymphocyte antigen CD20 binding agent,181,,BINDING AGENT,1,1,1,,,
7119,1706812,1381791,B-lymphocyte antigen CD20 cross-linking agent,181,,CROSS-LINKING AGENT,1,1,1,,,
7120,1706928,1381877,Proheparin-binding EGF-like growth factor inhibitor,108372,,INHIBITOR,1,1,1,,,
7121,1707185,1382062,Fibronectin receptor alpha inhibitor,11789,,INHIBITOR,1,1,1,,,
7122,2472842,1926841,B-lymphocyte antigen CD19 binding agent,109546,,BINDING AGENT,1,1,1,,,
7123,1706793,1381777,B-lymphocyte antigen CD19 binding agent,109546,,BINDING AGENT,1,1,1,,,
7124,1706794,1381778,B-lymphocyte antigen CD19 binding agent,109546,,BINDING AGENT,1,1,1,,,
7125,1706971,1381909,Interleukin 17A inhibitor,109547,,INHIBITOR,1,1,1,,,
7126,1706972,1381910,Interleukin 17A inhibitor,109547,,INHIBITOR,1,1,1,,,
7127,1706904,1381856,Disialoganglioside GD2 cross-linking agent,109548,,CROSS-LINKING AGENT,1,1,1,,,
7128,1706684,1381704,T cell surface glycoprotein CD3 cross-linking agent,106147,,CROSS-LINKING AGENT,1,1,1,,,
7129,1706924,1381874,T cell surface glycoprotein CD3 cross-linking agent,106147,,CROSS-LINKING AGENT,1,1,1,,,
7130,1706812,1381791,T cell surface glycoprotein CD3 cross-linking agent,106147,,CROSS-LINKING AGENT,1,1,1,,,
7131,1706700,1927221,Mucin-16 binding agent,109778,,BINDING AGENT,1,1,1,,,
7132,2473429,1927110,Neurogenic locus notch homolog protein 1 inhibitor,105173,,INHIBITOR,1,1,1,,,
7133,2792994,2096394,Interleukin-6 receptor alpha subunit inhibitor,106134,,INHIBITOR,1,1,1,,,
7134,1697536,1380937,Toxin A inhibitor,109800,,INHIBITOR,1,1,1,,,
7135,1696336,1380740,T-cell receptor inhibitor,109802,,INHIBITOR,1,1,1,,,
7136,2473558,1927165,Platelet-derived growth factor subunit B inhibitor,107993,,INHIBITOR,1,1,1,,,
7137,2138993,1763550,Neurogenic locus notch homolog protein 3 inhibitor,109578,,INHIBITOR,1,1,1,,,
7138,2138993,1763550,Neurogenic locus notch homolog protein 2 inhibitor,109579,,INHIBITOR,1,1,1,,,
7139,1697539,1380940,Growth/differentiation factor 8 inhibitor,109584,,INHIBITOR,1,1,1,,,
7141,1707040,1381962,Growth/differentiation factor 8 inhibitor,109584,,INHIBITOR,1,1,1,,,
7142,2472841,1926840,Growth/differentiation factor 8 inhibitor,109584,,INHIBITOR,1,1,1,,,
7143,1707208,1927223,Growth/differentiation factor 8 inhibitor,109584,,INHIBITOR,1,1,1,,,
7144,1706966,1381904,Interleukin-13 inhibitor,109782,,INHIBITOR,1,1,1,,,
7145,1706738,1381738,Angiopoietin-2 inhibitor,109785,,INHIBITOR,1,1,1,,,
7146,1696559,1381050,Basigin inhibitor,109788,,INHIBITOR,1,1,1,,,
7147,1706684,1381704,Epithelial cell adhesion molecule cross-linking agent,109789,,CROSS-LINKING AGENT,1,1,1,,,
7150,1706685,1381705,Epithelial cell adhesion molecule binding agent,109789,,BINDING AGENT,1,1,1,,,
7151,1707198,1382075,Mucin-1 binding agent,109790,,BINDING AGENT,1,1,1,,,
7152,1706830,1381805,Mucin-1 binding agent,109790,,BINDING AGENT,1,1,1,,,
7153,1697456,1380858,Mucin-1 binding agent,109790,,BINDING AGENT,1,1,1,,,
7154,1696264,1380669,Mucin-1 binding agent,109790,,BINDING AGENT,1,1,1,,,
7155,1706710,1381724,Mucin-1 binding agent,109790,,BINDING AGENT,1,1,1,,,
7156,1706823,1381800,Mucin-1 binding agent,109790,,BINDING AGENT,1,1,1,,,
7159,1392939,1121926,Lipopolysaccharide (LPS) inhibitor,109804,,INHIBITOR,1,1,1,,,
7160,1706932,1381878,Genome polyprotein inhibitor,109949,,INHIBITOR,1,1,1,,,
7161,1392917,1121904,T-cell differentiation antigen CD6 inhibitor,114814,,INHIBITOR,1,1,1,,,
7162,1707032,1381956,Mesothelin binding agent,114839,,BINDING AGENT,1,1,1,,,
7163,1706704,1381721,Mesothelin binding agent,114839,,BINDING AGENT,1,1,1,,,
7164,1707192,1382069,Mesothelin binding agent,114839,,BINDING AGENT,1,1,1,,,
7165,1706753,1381750,CD276 antigen binding agent,114840,,BINDING AGENT,1,1,1,,,
7166,2473679,1927222,CD276 antigen cross-linking agent,114840,,CROSS-LINKING AGENT,1,1,1,,,
7167,1938044,1592357,Leukocyte antigen CD37 binding agent,114841,,BINDING AGENT,1,1,1,,,
7168,1706690,1381708,Leukocyte antigen CD37 binding agent,114841,,BINDING AGENT,1,1,1,,,
7169,2472698,1926772,Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent,114842,,BINDING AGENT,1,1,1,,,
7170,1696593,1381084,Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent,114842,,BINDING AGENT,1,1,1,,,
7171,1707004,1381931,Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent,114842,,BINDING AGENT,1,1,1,,,
7172,1696201,1380519,Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent,114842,,BINDING AGENT,1,1,1,,,
7173,1706844,1381810,Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent,114842,,BINDING AGENT,1,1,1,,,
7174,1706846,1381812,Carcinoembryonic antigen-related cell adhesion molecule 5 cross-linking agent,114842,,CROSS-LINKING AGENT,1,1,1,,,
7175,1706841,1381809,Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent,114842,,BINDING AGENT,1,1,1,,,
7176,1696565,1381056,T-cell surface glycoprotein CD5 binding agent,114849,,BINDING AGENT,1,1,1,,,
7177,1392915,1121902,Syndecan-1 binding agent,114859,,BINDING AGENT,1,1,1,,,
7178,1707005,1381932,CD70 antigen cross-linking agent,114874,,CROSS-LINKING AGENT,1,1,1,,,
7179,1706862,1381825,Delta-like protein 4 inhibitor,114877,,INHIBITOR,1,1,1,,,
7180,1696459,1380973,Transmembrane glycoprotein NMB binding agent,114880,,BINDING AGENT,1,1,1,,,
7181,1706731,1381733,Cell surface A33 antigen binding agent,114888,,BINDING AGENT,1,1,1,,,
7182,1706927,1381875,Cell surface A33 antigen binding agent,114888,,BINDING AGENT,1,1,1,,,
7183,1707044,1763551,Nectin-4 binding agent,114889,,BINDING AGENT,1,1,1,,,
7184,1696099,1380417,Trophoblast glycoprotein cross-linking agent,114895,,CROSS-LINKING AGENT,1,1,1,,,
7185,1706945,1381889,Inducible T-cell costimulator inhibitor,114914,,INHIBITOR,1,1,1,,,
7187,1706920,1381870,Granulocyte-macrophage colony-stimulating factor inhibitor,114916,,INHIBITOR,1,1,1,,,
7188,2583417,2039296,Granulocyte-macrophage colony-stimulating factor inhibitor,114916,,INHIBITOR,1,1,1,,,
7189,1706699,2096357,Metalloreductase STEAP1 binding agent,114917,,BINDING AGENT,1,1,1,,,
7190,1707073,1381988,Prostate stem cell antigen inhibitor,114922,,INHIBITOR,1,1,1,,,
7191,1707227,1382104,C-X-C motif chemokine 10 inhibitor,114925,,INHIBITOR,1,1,1,,,
7192,1706776,1381767,Interleukin-3 receptor subunit alpha inhibitor,114948,,INHIBITOR,1,1,1,,,
7193,1706924,1381874,Melanocyte protein PMEL cross-linking agent,114949,,CROSS-LINKING AGENT,1,1,1,,,
7194,1706918,1381868,Tumor necrosis factor receptor superfamily member 18 agonist,114956,,AGONIST,1,1,1,,,
7195,1696913,1381404,Blood group Rh(D) polypeptide inhibitor,114957,,INHIBITOR,1,1,1,,,
7196,1706752,1381749,Programmed cell death 1 ligand 2 cross-linking agent,114967,,CROSS-LINKING AGENT,1,1,1,,,
7197,1696268,1380673,Interferon alpha-1/13 binding agent,114968,,BINDING AGENT,1,1,1,,,
7198,1707107,1382014,Choline transporter-like protein 4 binding agent,114975,,BINDING AGENT,1,1,1,,,
7199,1707146,1382040,Tumor necrosis factor ligand superfamily member 12 inhibitor,114984,,INHIBITOR,1,1,1,,,
7201,1707144,1382038,Tumor necrosis factor ligand superfamily member 12 inhibitor,114984,,INHIBITOR,1,1,1,,,
7202,1707108,1382015,Teratocarcinoma-derived growth factor 1 binding agent,114986,,BINDING AGENT,1,1,1,,,
7203,1706826,1381803,Lactadherin binding agent,115304,,BINDING AGENT,1,1,1,,,
7204,1697121,1380306,Complement receptor type 1 inhibitor,115604,,INHIBITOR,1,1,1,,,
7205,1707009,1381935,Transferrin receptor inhibitor,117225,,INHIBITOR,1,1,1,,,
7206,1707058,1381976,Low calcium response locus protein V inhibitor,117226,,INHIBITOR,1,1,1,,,
7207,1392945,1121932,Glycoprotein inhibitor,117227,,INHIBITOR,1,1,1,,,
7208,1392905,1121892,Glycoprotein inhibitor,117227,,INHIBITOR,1,1,1,,,
7209,1695970,1380146,Envelope glycoprotein B inhibitor,117228,,INHIBITOR,1,1,1,,,
7210,1696656,1381147,Envelope glycoprotein H inhibitor,117229,,INHIBITOR,1,1,1,,,
7211,1706849,1381814,Collagen alpha-4(IV) chain inhibitor,117230,,INHIBITOR,1,1,1,,,
7212,1707188,1382065,E protein inhibitor,117231,,INHIBITOR,1,1,1,,,
7213,1696899,1381390,80S Ribosome inhibitor,117219,,INHIBITOR,1,1,1,,,
7214,1707097,1382008,Fusion glycoprotein F0 inhibitor,116942,,INHIBITOR,1,1,1,,,
7215,1696876,1381367,Fusion glycoprotein F0 inhibitor,116942,,INHIBITOR,1,1,1,,,
7216,1696200,1380518,Human leukocyte antigen DR beta chain inhibitor,117240,,INHIBITOR,1,1,1,,,
7217,2792996,2096396,Light chain aggregates inhibitor,117232,,INHIBITOR,1,1,1,,,
7218,1706743,1381742,Light chain aggregates inhibitor,117232,,INHIBITOR,1,1,1,,,
7219,1707111,1382120,Tumor-associated antigen 72 binding agent,117233,,BINDING AGENT,1,1,1,,,
7220,1707110,1382119,Tumor-associated antigen 72 binding agent,117233,,BINDING AGENT,1,1,1,,,
7221,1707109,1382016,Tumor-associated antigen 72 inhibitor,117233,,INHIBITOR,1,1,1,,,
7222,1696571,1381062,Tumor-associated antigen 72 binding agent,117233,,BINDING AGENT,1,1,1,,,
7223,1707031,1381954,Melanin binding agent,117234,,BINDING AGENT,1,1,1,,,
7224,1707088,1382003,RAAG12 inhibitor,117235,,INHIBITOR,1,1,1,,,
7225,1697123,1380308,Lipoteichoic acid inhibitor,117236,,INHIBITOR,1,1,1,,,
7226,1707055,1381973,Oxidized LDL inhibitor,117237,,INHIBITOR,1,1,1,,,
7227,1707072,1381987,Proteoglycan chondroitin sulfate-associated protein binding agent,117238,,BINDING AGENT,1,1,1,,,
7228,1707100,1382009,ABC transporter GrfA inhibitor,117239,,INHIBITOR,1,1,1,,,
7229,1707017,1381942,Lewis Y antigen binding agent,117220,,BINDING AGENT,1,1,1,,,
7230,1706749,1381746,Lewis Y antigen binding agent,117220,,BINDING AGENT,1,1,1,,,
7231,1707021,1381946,Lewis Y antigen binding agent,117220,,BINDING AGENT,1,1,1,,,
7233,1707018,1381943,Lewis Y antigen binding agent,117220,,BINDING AGENT,1,1,1,,,
7234,1706750,1381747,Lewis Y antigen binding agent,117220,,BINDING AGENT,1,1,1,,,
7235,1707016,1381941,Lewis Y antigen binding agent,117220,,BINDING AGENT,1,1,1,,,
7236,1707020,1381944,Lewis Y antigen binding agent,117220,,BINDING AGENT,1,1,1,,,
7237,1707207,1382084,DNA-histone H1 complex binding agent,117223,,BINDING AGENT,1,1,1,,,
7238,1706863,1381826,DNA-histone H1 complex binding agent,117223,,BINDING AGENT,1,1,1,,,
7239,1707102,1382010,Sphingosine 1-phosphate inhibitor,117224,,INHIBITOR,1,1,1,,,
7240,1392943,1121930,Ganglioside GM3 (NeuGcGM3) inhibitor,116872,,INHIBITOR,1,1,1,,,
7241,1707041,1381963,Unknown,,,,1,1,1,,,
7242,1706859,1381822,Unknown,,,,1,1,1,,,
7243,1706760,1381755,Unknown,,,,1,1,1,,,
7244,1707209,1382086,Unknown,,,,1,1,1,,,
7245,1707210,1382087,Unknown,,,,1,1,1,,,
7246,1707211,1382088,Unknown,,,,1,1,1,,,
7247,1707212,1382089,Unknown,,,,1,1,1,,,
7248,1706702,1381719,Unknown,,,,1,1,1,,,
7249,1696860,1381351,Unknown,,,,1,1,1,,,
7250,1697111,1380296,Unknown,,,,1,1,1,,,
7251,1697480,1380882,Unknown,,,,1,1,1,,,
7252,2792891,336913,DNA topoisomerase II alpha inhibitor,63,,INHIBITOR,1,1,1,,,
7253,2472970,1926917,PI3-kinase p110-delta subunit inhibitor,11177,,INHIBITOR,1,1,1,,,
7254,1702485,1377908,Topoisomerase IV inhibitor,105771,,INHIBITOR,1,1,1,,,
7255,2973406,2197918,Topoisomerase IV inhibitor,107934,,INHIBITOR,1,1,1,,,
7256,2973406,2197918,DNA gyrase inhibitor,107908,,INHIBITOR,1,1,1,,,
7257,2973406,2197918,DNA topoisomerase IV inhibitor,117305,,INHIBITOR,1,1,1,,,
7258,1344207,674650,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
7259,1344600,2197611,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,,,16s RRNA
7260,3132606,1519923,Serine/threonine-protein kinase AKT inhibitor,105106,,INHIBITOR,1,1,1,Part of Astra Zeneca's Open Innovation program,,
7261,2973270,2197785,Hepatocyte growth factor receptor inhibitor,11451,,INHIBITOR,1,1,1,,,
7262,2973270,2197785,Macrophage-stimulating protein receptor inhibitor,11379,,INHIBITOR,1,1,1,,,
7263,2973270,2197785,Vascular endothelial growth factor receptor inhibitor,104799,,INHIBITOR,1,1,1,,,
7264,2973270,2197785,Tyrosine-protein kinase TIE-2 inhibitor,12913,,INHIBITOR,1,1,1,,,
7265,2973157,1525993,Serine/threonine-protein kinase mTOR inhibitor,11400,,INHIBITOR,1,1,1,ATP-competitive mTORC1/mTORC2 inhibitor,,
7267,1706050,441579,Sodium/glucose cotransporter 2 inhibitor,20092,,INHIBITOR,1,1,1,,,
7273,2139017,448872,Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker,103531,,BLOCKER,1,1,1,,,
7277,1702339,447955,,,,,1,1,1,,,
7279,1703605,1153672,Histamine H2 receptor antagonist,102,,ANTAGONIST,1,1,1,,,
7284,2791623,27611,GABA-A receptor; anion channel positive allosteric modulator,104688,2617,POSITIVE ALLOSTERIC MODULATOR,1,1,1,,,Benzodiazepine site
7285,1702394,195106,,,,,1,1,1,,,
7286,2792696,160056,Betaine-homocysteine S-methyltransferase substrate,109554,,SUBSTRATE,1,1,1,,,
7295,1344341,1379830,,,,,1,1,1,,,
7297,2583085,2039214,,,,,1,1,1,,,
7299,1976727,1626741,,,,,1,1,1,,,
7300,3130064,1248760,Unknown,,,,1,1,1,"Provides a DHFR-independent source of folate, counteracting methotrexate toxicity. Can enhance toxic effects of fluoropyrimidines in cancer therapy through conversion to 5,10-methylenetetrahydrofolate, stabilising binding of 5-fluoro-2'-deoxyuridine-5'-monophosphate to thymidylate synthase",,
7306,1706401,1038730,,,,,1,1,1,,,
7311,1976777,282661,Voltage-gated potassium channel blocker,105708,,BLOCKER,1,1,1,Mechanism for therapeutic effect not fully elucidated. ,Broad spectrum potassium channel blocker,
7312,2794983,1330340,,,,,1,1,1,,,
7329,3130663,43261,Renal dipeptidase inhibitor,245,,INHIBITOR,1,1,1,,,
7332,1697328,1380570,,,,,1,1,1,,,
7333,3133606,2335926,,,,,1,1,1,,,
7334,3133128,2335520,,,,,1,1,1,,,
7335,3133123,2335516,,,,,1,1,1,,,
7336,1699977,3059,,,,,1,1,1,,,
7337,3132267,622408,,,,,1,1,1,,,
7338,2973345,2197858,,,,,1,1,1,,,
7339,3133450,2335790,,,,,1,1,1,,,
7340,3133674,2335981,,,,,1,1,1,,,
7341,2583611,2039353,,,,,1,1,1,,,
7342,3133822,2336097,,,,,1,1,1,,,
7346,2139023,1763573,Voltage-gated potassium channel blocker,105708,,BLOCKER,1,1,1,Mechanism for therapeutic effect not fully elucidated. ,Broad spectrum potassium channel blocker,
7347,1702680,1378028,Thrombopoietin receptor agonist,265,,AGONIST,1,1,1,Stimulates megakaryocyte production resulting in increased platelets.,,The binding site is distinct from the thrombopoietin binding site.
7348,1879126,1540480,Reverse transcriptase negative allosteric modulator,106660,,NEGATIVE ALLOSTERIC MODULATOR,1,1,1,Inhibits reverse transcriptase and viral replication.,Does not inhibit human cellular DNA polymerases alpha and beta or mitochondrial DNA polymerase gamma. Active against a range of HIV-1 isolates from different groups. ,NNRTI binding site
7349,1702497,2197387,Tyrosine-protein kinase SYK inhibitor,10906,,INHIBITOR,1,1,1,Inhibits signalling in FC-activating and B-cell receptors.,,"Catalytic domain of SYK, ATP-competitive inhibitor"
7350,2139013,1763565,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,Inhibits FLT3 signalling and proliferation and induces apoptosis in leukemia cells expressing FLT3-ITD.,Inhibits multiple receptor tyrosine kinases. Active against FLT3 and certain FLT3 variants.,ATP-binding site
7351,3133112,2335505,Smoothened homolog antagonist,101400,,ANTAGONIST,1,1,1,Inhibits smoothened which is involved in hedgehog pathway signalling and inhibited tumor growth in a mouse model.,,
7352,2973316,2197829,Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor,104483,,INHIBITOR,1,1,1,Inhibits isocitrate dehydrogenase 1 resulting in decreased 2-hydroxyglutarate levels and induced myloid differentiation.,Active against Isocitrate dehydrogenase 1 and certain mutations that increase 2-hydroxyglutarate levels (most commonly R132 mutant forms). ,
7353,1706463,1380101,Thrombopoietin receptor agonist,265,,AGONIST,1,1,1,Interacts with TPO receptors on megakaryocytes inducing proliferation and differentiation of megakaryocyte progenitor cells. Upregulates platelet production.,,Binds the transmembrane domain of the TPO receptor.
7354,1700838,1376685,Unknown,,,,1,1,1,"Antihelmintic. Based on other nematode studies, the mechanism may be through binding glutamate-gate chloride channels, GABA receptors and/or ABC transporters impacting cell permeability, polarisation and parasite motility.",Active against Onchocerca volvulus microfilariae.,
7355,1702666,1378018,Serotonin 4 (5-HT4) receptor agonist,168,,AGONIST,1,1,1,Facilitates acetylcholine release and stimulates colonic peristalsis.,Selective for 5-HT4.,
7356,2791711,2096370,Muscarinic acetylcholine receptor M3 antagonist,219,,ANTAGONIST,1,1,1,Inhibits the muscarinic M3 receptor leading to bronchodilation.,Similar affinity for muscarinic receptors M1-M5 but bronchodilation mediated via receptor M3.,
7357,1879159,1540505,Unknown,,,,1,1,1,"Inhibits protein synthesis, target unconfirmed. ",,
7358,2138995,1763554,Potassium chelating agent,109707,,CHELATING AGENT,1,1,1,"Potassium binder, exchanges potassium for hydrogen and sodium and lowers potassium levels.",High affinity for potassium,
7359,2973275,2197790,Neurokinin 1 receptor antagonist,250,,ANTAGONIST,1,1,1,"Inhibits substance P mediated activation of NK1 receptors, activation is linked to delayed emesis.",,
7360,3133113,2335506,Supplement,,,,1,1,1,Provides a source of calories and fatty acids. Fatty acids are an essential component of cellular structures and bioactive molecules.,,
7361,3133114,2335507,Transthyretin mRNA RNAi inhibitor,118393,,RNAI INHIBITOR,1,1,1,Short interfering RNA (siRNA) which binds the 3-UTR region of wild-type and mutant transthyretin mRNA leading to degradation and reduced TTR protein levels. ,,
7362,3133072,2335474,Polymerase acidic protein inhibitor,103467,,INHIBITOR,1,1,1,Inhibits viral replication. PA is one component of the viral RNA polymerase complex. ,"Higher activity against Influenza A (IC50 1.4-3.1 nM) versus Influenza B (4.5-8.9 nM). Active in cell culture against subtypes A/H1N1, A/H3N2, A/H7N9 and Type B.",CAP-dependent endonuclease
7363,3133155,2335544,Interleukin-3 receptor subunit alpha binding agent,114948,,BINDING AGENT,1,1,1,CD123 directed cytotoxin. ,,
7364,2973344,2197857,Complement C5 inhibitor,106142,,INHIBITOR,1,1,1,Prevents cleavage of complement protein C5 into the C5a proinflammatory anaphylatoxin and the C5b subunit of the terminal complement complex C5b-9 ultimately preventing hemolysis.,High affinity for the complement protein C5.,
7365,3133072,2335474,Polymerase acidic protein inhibitor,104525,,INHIBITOR,1,1,1,Inhibits viral replication. PA is one component of the viral RNA polymerase complex. ,"Higher activity against Influenza A (IC50 1.4-3.1 nM) versus Influenza B (4.5-8.9 nM). Active in cell culture against subtypes A/H1N1, A/H3N2, A/H7N9 and Type B.",CAP-dependent endonuclease
7366,2973242,348726,GABA-A receptor; anion channel positive allosteric modulator,104688,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,"Mechanism of action not fully elucidated. Activity against alpha-1/beta-2/gamma-2, alpha-4/beta-3/delta and alpha-6/beta-3/delta in vitro.",,Binding site distinct from benzodiazepine site
7367,1701985,1304641,Unknown,,,,1,1,1,"Possible effects include GABA receptor modulation, L-lactate dehydrogenase inhibition or cytochrome P450 inhibition (resulting in increased levels of co-administered clobazam).",,
7368,1703295,1151796,Adrenergic receptor alpha-2 agonist,104743,,AGONIST,1,1,1,Reduces norepinephrine release and decreases synmpathetic tone.,,
7369,2973384,2197897,2'-deoxyadenosine hydrolytic enzyme,106156,,HYDROLYTIC ENZYME,1,1,1,Complements a deficiency of adenosine deaminase.,,
7370,2583398,1757351,ALK tyrosine kinase receptor inhibitor,100417,,INHIBITOR,1,1,1,"Active against ALK-driven tumors, inhibits ALK phosphorylation.","Active against other kinases: ROS1, TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK, FAK2, ACK.  Active against some ALK variants.",
7371,3133490,2335823,Neurotrophic tyrosine kinase receptor agonist,109739,,AGONIST,1,1,1,Acts through nerve growth factor receptors in the eye to support nerve integrity.,,
7372,2583398,1757351,EML4-ALK  inhibitor,117043,,INHIBITOR,1,1,1,"Active against ALK-driven tumors, inhibits ALK phosphorylation.","Active against other kinases: ROS1, TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK, FAK2, ACK.  Active against some ALK variants.",
7373,1763602,1449218,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,Inhibits bacterial protein synthesis.,"Indicated for infections caused by Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens, Bacteroides species and Parabacteroides distasonis. Active in vitro against additional organisms but clinical signficance unknown. ",30S subunit
7374,1879161,1540507,Unknown,,,,1,1,1,Hypothesized that redox cycling of the drug and oxidation of the redox product generates reactive oxygen species that provide the killing effect.  ,Active against the pre-erythrocytic and erythrocytic stages.,
7375,1706070,706068,Envelope phospholipase F13 (p37) inhibitor,118391,,INHIBITOR,1,1,1,Antiviral inhibiting the orthopoxvirus envelope wrapping protein VP37 and preventing its interaction with cellular components and the subsequent production of virion particles.,,
7376,3133155,2335544,Elongation factor 2 inhibitor,104188,,INHIBITOR,1,1,1,CD123 directed cytotoxin. ,,
7377,1702570,1377950,DNA-directed RNA polymerase inhibitor,118390,9799,INHIBITOR,1,1,1,Binds to the beta subunit of RNA polymerase inhibiting bacterial RNA synthesis.,Active against enterotoxigenic and enteroaggregative E coli involved in traveller's diarrhea.,Beta subunit RpoB
7379,2473682,1927225,Fibroblast growth factor receptor inhibitor,104793,,INHIBITOR,1,1,1,Inhibits FGFR phosphorylation and signalling which decreases viability in cells with abnormal FGFR. ,"Active against FGFR1, FGFR2, FGFR3 and FGFR4. Also binds to RET, CSF1R, PDGFRA, PDGFRB, FLT4, KIT and VEGFR2. ",
7380,1702249,630539,Unknown,,,,1,1,1,"Not fully elucidated. Triclabendazole and the active sulfoxide and sulfone metabolites are absorbed by worms which decreases resting membrane potential, inhibits tubulin function and impacts protein/enzyme synthesis.",Antihelmintic active against Fasciola species (Fasciola hepatica and Fasciola gigantica).,
7381,2973387,2197900,Interleukin-23 inhibitor,106133,9800,INHIBITOR,1,1,1,Selectively binds the p19 subunit of human interleukin-23 inhibiting it's interaction with the receptor and the subsequent release of pro-inflammatory cytokines and chemokines.,Selective for human interleukin-23.,Alpha (p19) subunit is binding site
7382,3132776,2335183,Unknown,,,,1,1,1,Not fully elucidated. Known to function as a dopamine and norepinephrine reuptake inhibitor and has low affinity for the dopamine transporter (Ki 14.2 uM) and norepinephrine transporter (Ki 3.7 uM). ,"Does not inhibit serotonin reuptake (IC50 > 100 uM). No binding to the dopamine, serotonin, norepinephrine, GABA, adenosine, histamine, orexin, benzodiazepine, muscarininc acetylcholine or nicotinic acetylcholine receptors. ",
7383,3133848,2336121,Sphingosine 1-phosphate receptor Edg-1 agonist,11631,,AGONIST,1,1,1,Siponimod reduces lymphocyte numbers in peripheral blood by blocking their release from the lymph nodes. The mechanism of theraputic effects in MS are unknown.,High binding affinity for S1P receptors 1 and 5. ,
7384,3132794,2335200,Synaptosomal-associated protein 25 proteolytic enzyme,106138,,PROTEOLYTIC ENZYME,1,1,1,"Binds to and is taken up by nerves that use acetylcholine. Once internalised, the catalytic domain of PrabotulinumtoxinA cleaves SNAP-25, a SNARE protein, preventing membrane fusion and release of acetlycholine required for nerve signalling. ",Toxin A is selective for SNAP-25.,Cleaves the C-terminal SNARE motif
7385,2583286,2197738,Human immunodeficiency virus type 1 integrase inhibitor,12456,,INHIBITOR,1,1,1,Inhibition of the integrase prevents viral integration into the host DNA which is required for propagation.,Active against a range of clinical HIV-1 isolates across different groups and subgroups. Also displayed activity against an HIV-2 strain included in the assay (EC50 1.1nM).,Active site
7386,2973297,2197810,Neurotrophic tyrosine kinase receptor inhibitor,109739,,INHIBITOR,1,1,1,"Fusions between the neurotrophic kinase receptor (NTKR) genes can result in their constitutive activation which promotes tumor growth, larotrectinib inhibits these targets. ","Lower level affinity for TNK2. Limited activity against TRKA resistance variants with point mutation G595R or against TRKC with point mutations G623R, G696A or F617L.",ATP-binding site
7387,3133111,2335504,Melanocortin receptor 4 agonist,10142,,AGONIST,1,1,1,"Alpha-MSH analogue. Binds MC1R, MC3R, MC4R and MC5R but most potent against MC1R and MC4R. MC4R is expressed on neurons in the central nervous system and likely to be involved in efficacy. MC3R may also be involved, but role poorly understood.","Active against melanocortin receptors. In order of potency: MC1R, MC4R, MC3R, MC5R, MC2R. MCR1R & MC4R are most relevant at therapeutic doses. ",
7388,3133800,2336081,Supplement,,,,1,1,1,Iron replacement product that delivers iron for intestinal uptake which is then transferred to ferritin and transferrin.,,
7389,2973331,2197844,Macrophage colony stimulating factor receptor inhibitor,12840,,INHIBITOR,1,1,1,Overexpression of the CSF1R ligand promotes tumor cell proliferation which is inhibited by pexidartinib in CSF1R-dependent tumors. Pexidartinib inhibited a CSF1R dependent cell line in vivo.,,
7390,1706701,1763544,Tubulin inhibitor,104766,2627,INHIBITOR,1,1,1,"The antibody binds to the B-cells, is internalised, and the linker proteolytically cleaved to release the small molecule which binds to microtubules inhibiting cell division and inducing apoptosis.",,
7391,2139015,1763567,Beta-lactamase SHV-1 inhibitor,101068,,INHIBITOR,1,1,1,Relebactam is used in combination with the beta-lactam antibacterial imipenem and protects imipenem from degradation by certain bacterial beta-lactamases. Relebactam itself has no antibacterial activity.,"Inhibits serine beta lactamases (SHV, TEM, CTX-M type and Enterobacter cloacae P99, Pseudomonase derived cephalosporinase PDC and Klebsiella pneumoniae carbapenemase KPC). Not active against MBLs, some oxacillinases and certain GES allelles. Can restore the activity of imipenem/cilastatin combinations against KPC-producing Enterobacteriaceae and PDC-producing Pseudomonas aeruginosa.",
7392,1705094,1379625,Alpha-galactosidase A stabiliser,10693,,STABILISER,1,1,1,"Migalastat binds to the active site of alpha-galactosidase A, deficient in Fabry disease, stabilising the protein or protein variant enabling trafficking to the lysosome and enzyme activity. ",Binds alpha-galactosidase A and variants.,Active site
7393,1699848,1376124,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,Inhibits bacterial protein synthesis.,"Active against gram-positives expressing tetracycline resistance proteins tetK, tetL, tetM.",30S subunit
7394,1879148,1540495,Bacterial 70S ribosome inhibitor,105830,2620,INHIBITOR,1,1,1,Inhibits bacterial protein synthesis.,"Indicated for Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae. Activity against (but not indicated for) Pseudomonas aeruginosa, Citrobacter freundii, Citrobacter koseri, Enterobacter aerogenes, Klebsiella oxytoca, Morganella morganii, Proteus vulgaris, Providencia stuartii and Serratia marcescens.",30S subunit
7395,2583606,2039348,Progesterone receptor agonist,36,,AGONIST,1,1,1,Suppresses ovulation.,,
7396,3133115,2335508,Transthyretin mRNA antisense inhibitor,118393,,ANTISENSE INHIBITOR,1,1,1,Binds wild-type and mutant TTR mRNA which is subsequently degraded reducing TTR protein levels.,,
7397,3133336,2335694,Programmed cell death protein 1 inhibitor,108437,,INHIBITOR,1,1,1,Binds to the T-cell PD-1 receptor preventing it's interaction with the PD-L1 and PD-L2 ligands and removing inhibition of immune response. ,,
7398,3133377,2335727,Calcitonin gene-related peptide antagonist,116903,,ANTAGONIST,1,1,1,Binds to calcitonin gene-related peptide blocking binding to it's receptor.,,
7399,3133432,2335773,Phenylalanine hydrolytic enzyme,118392,,HYDROLYTIC ENZYME,1,1,1,Substitutes for deficient phenylalanine hydroxylase. Hydrolyses phenylalanine to reduce blood concentrations.,,
7400,2973335,2197848,Interferon gamma inhibitor,108375,,INHIBITOR,1,1,1,IFNgamma is neutralised by emapalumab reducing the concentration of CXCL9 chemokine (induced by IFNgamma).,,
7401,1696500,1380994,Asparagine hydrolytic enzyme,106202,,HYDROLYTIC ENZYME,1,1,1,Hydrolyses L-asparagine which is required by leukemic cells which have low level expression of L-asparagine synthetase.,,
7402,2973384,2197897,Adenosine hydrolytic enzyme,106157,,HYDROLYTIC ENZYME,1,1,1,Complements a deficiency of adenosine deaminase.,,
7403,1702488,515206,Gonadotropin-releasing hormone receptor antagonist,118,,ANTAGONIST,1,1,1,Reduces GnRH signalling and ultimately decreases levels of the ovarian sex hormones.,,
7404,2139015,1763567,Bacterial beta-lactamase TEM inhibitor,106170,,INHIBITOR,1,1,1,Relebactam is used in combination with the beta-lactam antibacterial imipenem and protects imipenem from degradation by certain bacterial beta-lactamases. Relebactam itself has no antibacterial activity.,"Inhibits serine beta lactamases (SHV, TEM, CTX-M type and Enterobacter cloacae P99, Pseudomonase derived cephalosporinase PDC and Klebsiella pneumoniae carbapenemase KPC). Not active against MBLs, some oxacillinases and certain GES allelles. Can restore the activity of imipenem/cilastatin combinations against KPC-producing Enterobacteriaceae and PDC-producing Pseudomonas aeruginosa.",
7405,2139015,1763567,Beta-lactamase inhibitor,18040,,INHIBITOR,1,1,1,Relebactam is used in combination with the beta-lactam antibacterial imipenem and protects imipenem from degradation by certain bacterial beta-lactamases. Relebactam itself has no antibacterial activity.,"Inhibits serine beta lactamases (SHV, TEM, CTX-M type and Enterobacter cloacae P99, Pseudomonase derived cephalosporinase PDC and Klebsiella pneumoniae carbapenemase KPC). Not active against MBLs, some oxacillinases and certain GES allelles. Can restore the activity of imipenem/cilastatin combinations against KPC-producing Enterobacteriaceae and PDC-producing Pseudomonas aeruginosa.",
7406,2139015,1763567,Beta-lactamase inhibitor,12802,,INHIBITOR,1,1,1,Relebactam is used in combination with the beta-lactam antibacterial imipenem and protects imipenem from degradation by certain bacterial beta-lactamases. Relebactam itself has no antibacterial activity.,"Inhibits serine beta lactamases (SHV, TEM, CTX-M type and Enterobacter cloacae P99, Pseudomonase derived cephalosporinase PDC and Klebsiella pneumoniae carbapenemase KPC). Not active against MBLs, some oxacillinases and certain GES allelles. Can restore the activity of imipenem/cilastatin combinations against KPC-producing Enterobacteriaceae and PDC-producing Pseudomonas aeruginosa.",
7407,2139015,1763567,Carbapenem-hydrolyzing beta-lactamase KPC inhibitor,109776,,INHIBITOR,1,1,1,Relebactam is used in combination with the beta-lactam antibacterial imipenem and protects imipenem from degradation by certain bacterial beta-lactamases. Relebactam itself has no antibacterial activity.,"Inhibits serine beta lactamases (SHV, TEM, CTX-M type and Enterobacter cloacae P99, Pseudomonase derived cephalosporinase PDC and Klebsiella pneumoniae carbapenemase KPC). Not active against MBLs, some oxacillinases and certain GES allelles. Can restore the activity of imipenem/cilastatin combinations against KPC-producing Enterobacteriaceae and PDC-producing Pseudomonas aeruginosa.",
7408,2139015,1763567,Beta-lactamase CTX-M inhibitor,101456,,INHIBITOR,1,1,1,Relebactam is used in combination with the beta-lactam antibacterial imipenem and protects imipenem from degradation by certain bacterial beta-lactamases. Relebactam itself has no antibacterial activity.,"Inhibits serine beta lactamases (SHV, TEM, CTX-M type and Enterobacter cloacae P99, Pseudomonase derived cephalosporinase PDC and Klebsiella pneumoniae carbapenemase KPC). Not active against MBLs, some oxacillinases and certain GES allelles. Can restore the activity of imipenem/cilastatin combinations against KPC-producing Enterobacteriaceae and PDC-producing Pseudomonas aeruginosa.",
7409,1392927,1121914,Elongation factor 2 inhibitor,104188,,INHIBITOR,1,1,1,"The Fv at the amino terminus binds to CD22 present on the B-cell malignancy being targeted, and the carboxyl terminal lysine residue at position 613 is rapidly removed by plasma carboxypeptidase, generating a protein ending in REDL. Very soon after binding, the recombinant immunotoxin-CD22 complex is internalized through clathrin-coated pits into the endocytic compartment, where 2 steps occur: (i) reduction of the disulfide bond in domain II, and (ii) a furin-catalyzed cleavage in the middle of ",,
7410,1344615,1369655,Dihydrofolate reductase inhibitor,102873,,INHIBITOR,1,1,1,"PAS is incorporated into the folate pathway by dihydropteroate synthase (DHPS) and dihydrofolate synthase (DHFS) to generate a hydroxyl dihydrofolate antimetabolite, which in turn inhibits DHFR enzymatic activity. Mechanism in Crohn's disease/ulcerative colitis may be through PPAR-gamma/NF-kappa-B inhibition",,
7411,1344403,674535,Dihydrofolate reductase inhibitor,102873,,INHIBITOR,1,1,1,"PAS is incorporated into the folate pathway by dihydropteroate synthase (DHPS) and dihydrofolate synthase (DHFS) to generate a hydroxyl dihydrofolate antimetabolite, which in turn inhibits DHFR enzymatic activity. Mechanism in Crohn's disease/ulcerative colitis may be through PPAR-gamma/NF-kappa-B inhibition",,
7412,2473104,1724957,PI3-kinase p110-alpha subunit inhibitor,11362,,INHIBITOR,1,1,1,,,
7413,2473104,1724957,PI3-kinase p110-delta subunit inhibitor,11177,,INHIBITOR,1,1,1,,,
7415,2473074,1383172,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,Dacomitinib is an irreversible pan-ERBB inhibitor.,,
7416,2473074,1383172,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,Dacomitinib is an irreversible pan-ERBB inhibitor.,,
7417,2473074,1383172,Receptor protein-tyrosine kinase erbB-4 inhibitor,12699,,INHIBITOR,1,1,1,Dacomitinib is an irreversible pan-ERBB inhibitor.,,
7418,2139013,1763565,Tyrosine-protein kinase receptor UFO inhibitor,100410,,INHIBITOR,1,1,1,,,
7419,2473359,364875,Interleukin-8 receptor A antagonist,11574,,ANTAGONIST,1,1,1,,High selectivity for CXCR2 over CXCR1,
7420,1706035,299120,Receptor protein-tyrosine kinase erbB-4 inhibitor,12699,,INHIBITOR,1,1,1,Neratinib is an irreversible pan-HER tyrosine kinase inhibitor.,,
7421,2973277,2197792,Receptor protein-tyrosine kinase erbB-2 inhibitor,188,,INHIBITOR,1,1,1,Neratinib is an irreversible pan-HER tyrosine kinase inhibitor.,,
7422,2973277,2197792,Epidermal growth factor receptor erbB1 inhibitor,9,,INHIBITOR,1,1,1,Neratinib is an irreversible pan-HER tyrosine kinase inhibitor.,,
7423,2973277,2197792,Receptor protein-tyrosine kinase erbB-4 inhibitor,12699,,INHIBITOR,1,1,1,Neratinib is an irreversible pan-HER tyrosine kinase inhibitor.,,
7424,2973278,2197793,Poly [ADP-ribose] polymerase 2 inhibitor,100933,,INHIBITOR,1,1,1,,IC(50) inhibition PARP2 (2.1 nM),
7425,2973278,2197793,Poly [ADP-ribose] polymerase-1 inhibitor,11663,,INHIBITOR,1,1,1,,IC(50) inhibition PARP1 (3.8 nM) ,
7426,2973331,2197844,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,,,
7427,2973331,2197844,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,,,
7428,2582996,1947706,Bromodomain and extra-terminal motif (BET) inhibitor,118688,,INHIBITOR,1,1,1,,,
7429,3132165,694811,Bromodomain and extra-terminal motif (BET) inhibitor,118688,,INHIBITOR,1,1,1,,,
7430,3132564,2225368,Tyrosine-protein kinase JAK3 inhibitor,10849,,INHIBITOR,1,1,1,,,
7431,3132564,2225368,TEC family kinase inhibitor,118691,,INHIBITOR,1,1,1,,,
7432,3133026,2335429,Bromodomain and extra-terminal motif (BET) inhibitor,118688,,INHIBITOR,1,1,1,,,
7433,2791710,1566719,Bromodomain and extra-terminal motif (BET) inhibitor,118688,,INHIBITOR,1,1,1,,,
7434,3132991,2335394,Bromodomain and extra-terminal motif (BET) inhibitor,118688,,INHIBITOR,1,1,1,,,
7438,3133172,2335552,Huntingtin mRNA antisense inhibitor,118690,,ANTISENSE INHIBITOR,1,1,1,,,
7439,3132569,573017,Liver X receptor agonist,109979,,AGONIST,1,1,1,,May be selective for LXR beta,
7440,3133383,2335731,5-aminolevulinate synthase mRNA RNAi inhibitor,118694,,RNAI INHIBITOR,1,1,1,"The double stranded RNA interferes with aminolevulinate synthase 1 mRNA in the liver, leading to it's degradation and therefore reduces levels of toxic metabolites (aminolevulinic acid and porphobilinogen) that would otherwise be produced by functional ALAS1.",,
7441,2973307,2197820,GABA-A receptor; anion channel positive allosteric modulator,104688,,POSITIVE ALLOSTERIC MODULATOR,1,1,1,The precise mechanism in seizures is unknown. ,,
7442,2973307,2197820,Sodium channel alpha subunit inhibitor,105639,,INHIBITOR,1,1,1,"The precise mechanism in seizures is unknown. 
Reduces neuronal firing associated with sodium currents and increases the activity of the GABA-A channels. 
It appears to inhibit the non-inactivated, persistent (repetitive) component of sodium currents that may be associated with epilepsy.  ",,
7443,3132668,2241718,Hemoglobin HbA positive modulator,104753,,POSITIVE MODULATOR,1,1,1,"Haemoglobin A is an oxygen-transporting metalloprotein complex in blood (composed of two alpha and two beta subunits). 
In sickle cell disease, a single mutation is found in the beta subunit and the and this form of the protein complex is referred to as Haemoglobin S. 
Haemoglobin S forms an abnormal cell shape (sickles) and polymerises in the absence of oxygen.
Voxelotor binds Haemoglobin S and increases the oxygen affinity of Haemoglobin S which reduces sickling, Voxelotor inhibits HbS polymerisation.",,
7444,3132778,2335184,Melanocortin receptor 1 agonist,11869,,AGONIST,1,1,1,"Structural analog of α-melanocyte stimulating hormone (α-MSH), increases production of eumelanin in the skin.",Binds predominantly to MCR-1.,
7445,2583404,2039284,Retinoic acid receptor gamma agonist,240,,AGONIST,1,1,1,"Activation of RAR has downstream effects including anti-inflammatory effects. However, the precise role in alleviating acne is unknown.
The gamma subtype is most relevant to acne.","Most active at the gamma subtype, > 20-fold selectivity over RAR alpha and RAR beta.",
7446,1938038,1592363,Transforming growth factor beta inhibitor,117291,,INHIBITOR,1,1,1,"Erythroid maturation agent.
Luspatercept is a recombinant protein that mimics the human activin receptor type IIB and sequesters its TGF-beta ligands. 
This reduces the interaction between TGF-beta ligands and the native TGF-beta receptor reducing downstream Smad2/3 signaling with the overall result of increased erythroid maturation.",,
7447,2473540,1927158,Bacterial 70S ribosome inhibitor,105830,2621,INHIBITOR,1,1,1,Antibacterial. Interacts with the bacterial ribosome and functions as a bacterial protein synthesis inhibitor.,"Indicated for infections caused by Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
Also active against Staphylococcus aureus (methicillin-resistant isolates) Streptococcus agalactiae, Streptococcus anginosus, Streptococcus mitis, Streptococcus pyogenes, Streptococcus salivarius, Haemophilus parainfluenzae and Moraxella catarrhalis but not validated for these bacteria in clinical trials.",23s rRNA (interacts with the A- and P-sites).
7448,1937976,1592344,Serotonin 1f (5-HT1f) receptor agonist,279,,AGONIST,1,1,1,The prescise mechanism is unknown but is thought to be neuronal.,High affinity for the 5-HT1F receptor.,
7449,2791030,1966507,Janus Kinase (JAK) inhibitor,105757,,INHIBITOR,1,1,1,JAKs transmit signals that impact downstream cellular functions such as immune cell function.,"In vitro, higher activity against JAK1 and JAK2 relative to JAK3 and TYK2. 
Greater inhibition of JAK1 and JAK1/JAK3 mediated signalling compared to JAK2/JAK2 but the therapeutic relevance of this is unknown.
",
7450,2973332,2197845,Bacterial penicillin-binding protein inhibitor,105683,,INHIBITOR,1,1,1,"Antibacterial.
Cefiderocol is a siderophore conjugated to a cephalosporin.
Cephalosporins bind to penicillin binding proteins disrupting bacterial cell wall biosynthesis. Siderophores (ferric iron binding compound) are taken up into bacterial cells both passively and also through dedicated siderophore import mechanisms. 
Conjugation of the active compound to a siderophore facilitates uptake.","Active against Gram-negative bacteria. No relevant activity against Gram-positives and anaerobes. 
Indicated for Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.

Also active against (but not necessarily indicated for) certain S. maltophilia, meropenem­resistant Enterobacteriaceae, P. aeruginosa, and A. baumannii isolates. This includes some meropenem, ciprofloxacin, and amikacin-resistant isolates including some isolates with genetically confirmed resistance genes. 
Also displays in vitro against the following bacteria but the clinical relevance is unknown - Acinetobacter baumannii, Citrobacter freundii complex, Citrobacter koseri, Klebsiella aerogenes, Klebsiella oxytoca, Morganella morganii, Proteus vulgaris, Providencia rettgeri, Serratia marcescens, Stenotrophomonas maltophilia.",
7451,3132781,2335187,Tyrosine-protein kinase JAK2 inhibitor,10938,,INHIBITOR,1,1,1,"Active against wild-type Jak2 and FLT3 and mutationally activated forms (e.g. JAK2V617F and FLT3ITD).
Mutant Jak2 is implicated in myeloproliferative neoplasms (MPNs). 
In cell models, fedratinib reduced signalling associated with these mutant kinases with the overall effect of decreasing cell proliferation and inducing apoptosis.
In animal models, fedratinib improved survival.","Higher selectivity for JAK2 over family members JAK1, JAK3 and TYK2.",
7452,3132781,2335187,Tyrosine-protein kinase receptor FLT3 inhibitor,12670,,INHIBITOR,1,1,1,"Active against wild-type Jak2 and FLT3 and mutationally activated forms (e.g. JAK2V617F and FLT3ITD).
Mutant Jak2 is implicated in myeloproliferative neoplasms (MPNs). 
In cell models, fedratinib reduced signalling associated with these mutant kinases with the overall effect of decreasing cell proliferation and inducing apoptosis.
In animal models, fedratinib improved survival.",,
7453,3133350,2335705,P-selectin blocker,12723,,BLOCKER,1,1,1,"Binds P-selectin on the surface of the activated endothelium and platelets and blocks it's interaction with ligands on other cells, this reduces cell adhesion. ",,
7454,2473436,1304559,Neurotrophic tyrosine kinase receptor inhibitor,109739,,INHIBITOR,1,1,1,"TRK, ROS1, or ALK kinase fusion proteins can cause abherrent signalling and cell proliferation. 
Entrectinib demonstrated in vitro and in vivo inhibition of cancer cell lines harboring NTRK, ROS1, and ALK fusion genes. ","Inhibits the TRK, ROS1 and ALK kinases at 0.1 to 2 nM. Active against the JAK2 and TNK2 kinases with IC50 values > 5 nM.",
7455,2473436,1304559,Proto-oncogene tyrosine-protein kinase ROS inhibitor,101019,,INHIBITOR,1,1,1,"TRK, ROS1, or ALK kinase fusion proteins can cause abherrent signalling and cell proliferation. 
Entrectinib demonstrated in vitro and in vivo inhibition of cancer cell lines harboring NTRK, ROS1, and ALK fusion genes. ","Inhibits the TRK, ROS1 and ALK kinases at 0.1 to 2 nM. Active against the JAK2 and TNK2 kinases with IC50 values > 5 nM.",
7456,2473436,1304559,ALK tyrosine kinase receptor inhibitor,100417,,INHIBITOR,1,1,1,"TRK, ROS1, or ALK kinase fusion proteins can cause abherrent signalling and cell proliferation. 
Entrectinib demonstrated in vitro and in vivo inhibition of cancer cell lines harboring NTRK, ROS1, and ALK fusion genes. ","Inhibits the TRK, ROS1 and ALK kinases at 0.1 to 2 nM. Active against the JAK2 and TNK2 kinases with IC50 values > 5 nM.",
7457,3133825,2336099,Cystic fibrosis transmembrane conductance regulator positive modulator,11540,,POSITIVE MODULATOR,1,1,1,"Facilitates processing and trafficking of CFTR mutants to increase the amount of mature protein at the cell surface. 
Has an additive effect with IVACAFTOR AND TEZACAFTOR on functional CFTR.",,
7458,3132670,2146132,Tyrosine-protein kinase BTK inhibitor,100097,,INHIBITOR,1,1,1,Forms an active site covalent bond with the target kinase. Inhibition of BTK on B-cells impacts downstream signalling effects such as B-cell proliferation.,,
7459,3132749,2267090,Histamine H3 receptor inverse agonist,10280,,INVERSE AGONIST,1,1,1,Therapeutic effect unclear. Possibly mediated by activity against the Histamine H3 receptor which enhances histaminergic neuron activity linked to wakefulness. ,"High affinity for Histamine H3 receptors (Ki = 1nM) with minimal binding at other histamine receptors (H1, H2, or H4 receptors; Ki >10 μM).",
7460,1976741,378216,Unknown,,,,1,1,1,"Antimycobacterial.
Potentially a dual mechanism, the molecular target is not fully elucidated. 
In the bacterial cell, pretomanid undergoes nitro-reduction catalysed by the bacterial enyzyme Ddn. The nitro-reduction step is dependent on the reduced cofactor F420 which is produced by the bacterial enzyme Fgd1. 
Under aerobic conditions, in actively respiring bacteria, the active compound is proposed to inhibit mycolic acid biosynthesis. 
Under anaerobic conditions, in non-respiring bacteria, the NO released by Ddn processing is proposed to act as a respiratory poison.
Alternatively, it has been suggested that both active and non-respiring bacteria are targeted through disrupted sugar phosphate metabolism and toxic methylglyoxal accumulation.",,
7461,3133387,2335733,Dystrophin pre-mRNA positive modulator,116818,,POSITIVE MODULATOR,1,1,1,"In Duchenne muscular dystrophy, deletion of exon 53 prevents synthesis of a functional dystrophin protein. Golodirsen is a 'molecular patch' that allows skipping of exon 53 and the assembly of remaining exons (54 onwards) to produce an internally truncated but functional dystrophin protein (that is missing exons 52/53).",,
7465,2583698,2039364,Cytochrome P450 11B1 inhibitor,76,,INHIBITOR,1,1,1,"Inhibits 11beta-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland (IC50 2.5 ± 0.1 nM in a cell-line assay).",,
7466,2583089,2039217,Sphingosine 1-phosphate receptor Edg-1 modulator,11631,,MODULATOR,1,1,1,The mechanism by which ozanimod exerts therapeutic effects in multiple sclerosis is unknown but Ozanimod treatment reduces lymphocytes in peripheral blood and their migration into the central nervous system,Binds with high affinity to S1P receptors 1 and 5.,
7467,1697174,699375,Prostatic acid phosphatase binding agent,10824,,BINDING AGENT,1,1,1,"Immunotherapy. Precise mechanism of action is unknown. Patient-derived antigen presenting cells are exposed to recombinant human prostatic acid phosphatase, an antigen expressed in prostate cancer tissue, linked to an immune cell activator and may help direct the immune response to cancer cells.",,
7468,2973347,2197860,B-lymphocyte antigen CD19 binding agent,109546,,BINDING AGENT,1,1,1,T cell immunotherapy. A patients T cells are extracted and modified with a vector that encodes an anti-CD19 chimeric antigen receptor (CAR) to bind and eliminate CD19-expressing cancer cells and normal B cell. The CAR is fused to domains that enhance T-cell activity.,,
7469,3132806,2335211,Survival motor neuron protein positive modulator,103665,,POSITIVE MODULATOR,1,1,1,Virus vector-based gene therapy that provides a correct copy of the human SMN1 gene.,,
7470,1343938,20881,Glutathione precursor,,,,1,1,1,"Antidote for acetaminophen overdose. Upon overdose, significant amounts of a reactive intermediate are formed which reacts with glutathione, depleting hepatic glutathione stores, and then reacts with hepatocyte proteins. Acetylcysteine provides an alternative substrate for conjugation with the reactive intermediate potentially restoring glutathione levels.",,
7471,1343938,20881,Mycolytic,,,,1,1,1,"Mucolytic agent, cleaves disulfide linkages reducing mucous viscosity. May also have a role in managing the oxidant burden.",,
7472,1343064,443348,Supplement,,,,1,1,1,Provides a source of ascorbic acid and restores depleted ascorbic acid resources.,,
7473,3133330,2335688,Heat shock protein HSP90 inhibitor,104750,,INHIBITOR,1,1,1,"Components of injured cells (Danger-Associated Molecular Patterns, or DAMPs) activate the immune system. CD24 is a biological immunomodulator that can interact with DAMPs inhibiting their stimulation of the immune response. CD24Fc augments endogenous CD24 to potentially suppress severe immune response. ",,
7474,3133330,2335688,Heat shock 70 kDa protein 1A/1B inhibitor,117129,,INHIBITOR,1,1,1,"Components of injured cells (Danger-Associated Molecular Patterns, or DAMPs) activate the immune system. CD24 is a biological immunomodulator that can interact with DAMPs inhibiting their stimulation of the immune response. CD24Fc augments endogenous CD24 to potentially suppress severe immune response. ",,
7475,3133330,2335688,High mobility group protein B1 inhibitor,105589,,INHIBITOR,1,1,1,"Components of injured cells (Danger-Associated Molecular Patterns, or DAMPs) activate the immune system. CD24 is a biological immunomodulator that can interact with DAMPs inhibiting their stimulation of the immune response. CD24Fc augments endogenous CD24 to potentially suppress severe immune response. ",,Box B
7476,3133330,2335688,Sialic acid-binding Ig-like lectin 10 modulator,118696,,MODULATOR,1,1,1,Siglec receptors negatively regulate the immune system. CD24 interacts with Siglec 10 to selectively regulate host responses to stimulation by Danger-Associated Molecular Patterns. Recombinant CD24Fc augments endogenous CD24 to suppress a severe immune response.,,
7477,2792671,673430,Antiseptic,,,,1,1,1,Antiseptic,,
7478,1702656,1064694,Cyclophilin A inhibitor,180,,INHIBITOR,1,1,1,,Also displays activity against CypD,
7479,1700046,84575,Cytochrome P450 51 inhibitor,58,,INHIBITOR,1,1,1,"Not elucidated, potentially comparable to similar antifungal agents.",Antifungal activity.,
7480,2473549,1927162,ATP-citrate synthase inhibitor,12028,,INHIBITOR,1,1,1,"Bempedoic acid is activated to a CoA-ester that inhibits ACL. ACL is upstream of HMG-CoA, an enzyme involved in the cholesterol biosynthesis pathway. Overall, bempedoic acid lowers low-density lipoprotein cholesterol by inhibition of cholesterol synthesis in the liver.",,
7481,3132636,2205527,RNA-directed RNA polymerase L inhibitor,118697,,INHIBITOR,1,1,1,Remdesivir is intracellularly converted to the pharmacologically active ingredient GS-443902 which competes with adenosine triphosphate (ATP) and is incorporated into viral RNA causing delayed chain termination.,"Broad spectrum activity against filoviruses (eg, EBOV, MARV), CoVs (eg, SARS-CoV, MERS-CoV), and paramyxoviruses (eg, respiratory syncytial virus [RSV], Nipah virus [NiV], and Hendra virus). Inhibits RNA-dependent RNA polymerase from MERS-CoV.",
7482,3132601,2282945,Stem cell growth factor receptor inhibitor,238,,INHIBITOR,1,1,1,"Receptor tyrosine kinases have a role in cell proliferation and are targeted by cancer chemotherapy. Avapritinib inhibits autophosphorylation in KIT D816V and PDGFRA D842V mutants (IC50 of 4 nM and 30 nM, respectively) in vitro and was active in a mouse xenograft model.","Active against PDGFRA and PDGFRA D842 and multiple KIT exon 11, 11/17 and 17 mutants (IC50s < 25 nM). Other potential targets: wild-type KIT, PDGFRB, CSFR1.",
7483,3132601,2282945,Platelet-derived growth factor receptor alpha inhibitor,12627,,INHIBITOR,1,1,1,"Receptor tyrosine kinases have a role in cell proliferation and are targeted by cancer chemotherapy. Avapritinib inhibits autophosphorylation in KIT D816V and PDGFRA D842V mutants (IC50 of 4 nM and 30 nM, respectively) in vitro and was active in a mouse xenograft model.","Active against PDGFRA and PDGFRA D842 and multiple KIT exon 11, 11/17 and 17 mutants (IC50s < 25 nM). Other potential targets: wild-type KIT, PDGFRB, CSFR1.",
7484,3133876,2336148,Histone-lysine N-methyltransferase EZH2 inhibitor,105440,,INHIBITOR,1,1,1,,Inhibits some EZH2 mutants including Y646X and A687V and inhibits EZH1 at an IC50 of 392 nM (36 x higher than for EZH2). ,
7485,1699095,497330,Osmotic agent,,,,1,1,1,Osmotic agent with a laxative effect in the colon. ,,
7486,1879155,1540501,Calcitonin gene-related peptide type 1 receptor antagonist,19904,,ANTAGONIST,1,1,1,Therapeutic mechanism not fully elucidated.,,
7487,1705360,149457,Unknown,,,,1,1,1,Not fully established. Prasterone is an inactive endogenous steroid that is converted to active estrogens and androgens. ,,
7488,1703640,563451,Reducing agent,,,,1,1,1,Non-enyzmatic (oxidation-reduction agent): methylene blue is first metabolised to leucomethylene blue via NADPH reductase which then reduces the ferric iron of metHb to the ferrous state of normal hemoglobin. ,,
7489,2472830,2096368,Supplement,,,,1,1,1,Iron replacement product,,
7490,3133480,2335815,Receptor protein-tyrosine kinase erbB-2 binding agent,188,,BINDING AGENT,1,1,1,"The antibody binds to HER2-expressing tumor cells, is internalised and the small molecule DXd is released. DXd causes DNA damage and apoptotic cell death. Approval based on tumor response rate and duration of response.",,
7491,3133480,2335815,DNA topoisomerase I inhibitor,62,,INHIBITOR,1,1,1,"The antibody binds to HER2-expressing tumor cells, is internalised and the small molecule DXd is released. DXd causes DNA damage and apoptotic cell death. Approval based on tumor response rate and duration of response.",,
7492,2138979,1763536,B-lymphocyte antigen CD19 binding agent,109546,,BINDING AGENT,1,1,1,T-cell immunotherapy. A patients T-cells are extracted and modified with a vector encoding an anti-CD19 chimeric antigen receptor (CAR) to eliminate CD19-expressing malignant and normal cells. The CAR is fused to intracellular signaling domains that initiate and enhance T-cell activity. ,,
7493,2583189,2039246,Retinoid isomerohydrolase positive modulator,116832,,POSITIVE MODULATOR,1,1,1,Virus vector-based gene therapy that provides a correct copy of the human RPE65 gene.,,
7494,1702954,947848,Adrenergic receptor agonist,105670,,AGONIST,1,1,1,"Alpha and beta-adrenergic receptor agonist with direct effects that increase arterial pressures, cardiac output, and peripheral resistance. Indirectly causes release of norepinephrine from sympathetic neurons.",,
7495,3133879,2336151,Unknown,,,,1,1,1,Anal fistulas display inflammation and release cytokines. Expanded adipose stem cells have immunomodulatory and anti-inflammatory effects that may promote healing.,,
7496,1702909,114423,Reverse transcriptase inhibitor,106660,,INHIBITOR,1,1,1,,,
7497,1702965,565387,Phosphodiesterase 4 inhibitor,104679,,INHIBITOR,1,1,1,Inhibits phosphodiesterase 4 leading to a decrease in cyclic AMP and a reduction in calcium ions which dilates muscles/blood vessesl contributing to it's spasmolytic and vasodilating action.,,
7498,3132586,1677677,Probable protein-cysteine N-palmitoyltransferase porcupine inhibitor,103574,,INHIBITOR,1,1,1,,,
7499,1706019,61337,"Hepatitis C virus serine protease, NS3/NS4A inhibitor",104803,,INHIBITOR,1,1,1,,,
7500,1702670,1378020,"Hepatitis C virus serine protease, NS3/NS4A inhibitor",104803,,INHIBITOR,1,1,1,,,
7501,1879167,1334241,"Hepatitis C virus serine protease, NS3/NS4A inhibitor",104803,,INHIBITOR,1,1,1,,,
7502,3133254,2335618,"Hepatitis C virus serine protease, NS3/NS4A inhibitor",104803,,INHIBITOR,1,1,1,,,
7503,1699830,704872,"Hepatitis C virus serine protease, NS3/NS4A inhibitor",104803,,INHIBITOR,1,1,1,,,
7504,1702643,1378005,"Hepatitis C virus serine protease, NS3/NS4A inhibitor",104803,,INHIBITOR,1,1,1,,,
7505,1706420,597302,"Hepatitis C virus serine protease, NS3/NS4A inhibitor",104803,,INHIBITOR,1,1,1,,,
7506,1706426,345157,HIV-1 protease inhibitor,118439,,INHIBITOR,1,1,1,,,
7507,1699213,161350,HIV-1 protease inhibitor,118439,,INHIBITOR,1,1,1,,,
7508,1706046,431125,"Hepatitis C virus serine protease, NS3/NS4A inhibitor",104803,,INHIBITOR,1,1,1,,,
7509,2794860,686453,Hemagglutinin negative modulator,109717,,NEGATIVE MODULATOR,1,1,1,Binds and stabilises viral hemagglutin preventing rearrangements required for membrane fusion and entry into the host cell.,Broad-spectrum antiviral,Hydrophobic cavity in the HA trimer stem at the interface between two protomers. 
7510,1703699,1378311,Adrenergic receptor alpha antagonist,104787,,ANTAGONIST,1,1,1,Smooth muscle relaxant,,
